DESCRIPTION		CHARGE
Fine needle aspiration; without imaging guidance	\$	286.00
Fine needle aspiration; without imaging guidance	\$	607.00
Fine needle aspiration; with imaging guidance	\$	1,691.00
Fine needle aspiration; with imaging guidance	\$	2,218.00
Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst), soft tissue (eg, extremity, abdominal wall, neck), percutaneous	\$	657.00
Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst), soft tissue (eg, extremity, abdominal wall, neck), percutaneous	\$	1,272.00
Placement of soft tissue localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous, including imaging guidance; first lesion	\$	1,979.00
Placement of soft tissue localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous, including imaging guidance; each additional lesion (List separately in addition to code for primary procedure)	\$	1,385.00
Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or subcutaneous abscess, cyst, furuncle, or paronychia); simple or single	\$	657.00
Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or subcutaneous abscess, cyst, furuncle, or paronychia); simple or single	\$	657.00
Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or subcutaneous abscess, cyst, furuncle, or paronychia); complicated or multiple	\$	657.00
Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or subcutaneous abscess, cyst, furuncle, or paronychia); complicated or multiple	\$	657.00
Incision and drainage of pilonidal cyst; simple	\$	657.00
Incision and drainage of pilonidal cyst; complicated	\$	3,726.00
Incision and removal of foreign body, subcutaneous tissues; simple	\$	1,129.00
Incision and removal of foreign body, subcutaneous tissues; simple	\$	1,129.00
Incision and removal of foreign body, subcutaneous tissues; complicated	\$	4,710.00
Incision and drainage of hematoma, seroma or fluid collection	\$	3,470.00
Incision and drainage of hematoma, seroma or fluid collection	\$	3,470.00
Puncture aspiration of abscess, hematoma, bulla, or cyst	\$	657.00
Puncture aspiration of abscess, hematoma, bulla, or cyst	\$	657.00
Puncture aspiration of abscess, hematoma, bulla, or cyst	\$	657.00
Puncture aspiration of abscess, hematoma, bulla, or cyst	\$	1,272.00
Incision and drainage, complex, postoperative wound infection	\$	6,446.00
Debridement, subcutaneous tissue (includes epidermis and dermis, if performed); first 20 sq cm or less	\$	1,129.00
Debridement, subcutaneous tissue (includes epidermis and dermis, if performed); first 20 sq cm or less	\$	1,129.00
Debridement, muscle and/or fascia (includes epidermis, dermis, and subcutaneous tissue, if performed); first 20 sq cm or less	\$	867.00
Debridement, muscle and/or fascia (includes epidermis, dermis, and subcutaneous tissue, if performed); first 20 sq cm or less	\$	1,129.00
Debridement, bone (includes epidermis, dermis, subcutaneous tissue, muscle and/or fascia, if performed); first 20 sq cm or less	\$	2,633.00
Debridement, subcutaneous tissue (includes epidermis and dermis, if performed); each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)	\$	697.00
Debridement, muscle and/or fascia (includes epidermis, dermis, and subcutaneous tissue, if performed); each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)	\$	697.00
Debridement, bone (includes epidermis, dermis, subcutaneous tissue, muscle and/or fascia, if performed); each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)	\$	1,945.00
Paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); single lesion	\$	345.00
Paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); single lesion	\$	345.00
Paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); 2 to 4 lesions	\$	345.00
Paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); more than 4 lesions	\$	605.00
Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion	\$	605.00
Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion	\$	605.00
Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; each separate/additional lesion (List	\$	189.00
separately in addition to code for primary procedure)	_	
Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 0.5 cm or less	\$	1,310.00
Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 1.1 to 2.0 cm	\$	2,161.00
Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 2.1 to 3.0 cm	\$	2,633.00
Debridement of nail(s) by any method(s); 1 to 5	\$	250.00
Debridement of nail(s) by any method(s); 6 or more	\$	250.00
Avulsion of nail plate, partial or complete, simple; single	\$	605.00
Avulsion of nail plate, partial or complete, simple; single	\$	605.00
Avulsion of nail plate, partial or complete, simple; each additional nail plate (List separately in addition to code for primary procedure)	\$	149.00
Evacuation of subungual hematoma	\$	250.00
Evacuation of subungual hematoma	\$	250.00
Excision of nail and nail matrix, partial or complete (eg, ingrown or deformed nail), for permanent removal	\$	1,310.00
Excision of nail and nail matrix, partial or complete (eg, ingrown or deformed nail), for permanent removal	\$	1,310.00

DESCRIPTION		CHARGE
Repair of nail bed	\$	818.00
Wedge excision of skin of nail fold (eg, for ingrown toenail)	\$	629.00
Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 2.5 cm or less	\$	345.00
Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 2.5 cm or less	\$	445.00
Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 2.6 cm to 7.5 cm	\$	345.00
Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 2.6 cm to 7.5 cm	\$	445.00
Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 7.6 cm to 12.5 cm	\$	345.00
Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 7.6 cm to 12.5 cm	\$	445.00
Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 12.6 cm to 20.0 cm	\$	345.00
Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 20.1 cm to 30.0 cm	\$	486.00
Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); over 30.0 cm	\$	345.00
Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); over 30.0 cm	\$	345.00
Simple repair of superficial wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 2.5 cm or less	\$	345.00
Simple repair of superficial wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 2.6 cm to 5.0 cm	\$	345.00
Simple repair of superficial wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 5.1 cm to 7.5 cm	\$	345.00
Simple repair of superficial wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 7.6 cm to 12.5 cm	\$	345.00
Simple repair of superficial wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 12.6 cm to 20.0 cm	\$	345.00
Treatment of superficial wound dehiscence; simple closure	\$	1,764.00
Treatment of superficial wound dehiscence; simple closure	\$	1,683.00
Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); 2.5 cm or less	\$	818.00
Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); 2.6 cm to 7.5 cm	\$	818.00
Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); 7.6 cm to 12.5 cm	\$	818.00
Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); 12.6 cm to 20.0 cm	\$	1,683.00
Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); 20.1 cm to 30.0 cm	\$	1,683.00
Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); over 30.0 cm	\$	1,683.00
Repair, intermediate, wounds of neck, hands, feet and/or external genitalia; 2.5 cm or less	\$	818.00
Repair, intermediate, wounds of neck, hands, feet and/or external genitalia; 2.6 cm to 7.5 cm	\$	818.00
Repair, intermediate, wounds of neck, hands, feet and/or external genitalia; 7.6 cm to 12.5 cm	\$	818.00
Repair, intermediate, wounds of neck, hands, feet and/or external genitalia; 12.6 cm to 20.0 cm	\$	818.00
Repair, intermediate, wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 2.5 cm or less	\$	818.00
Repair, intermediate, wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 2.6 cm to 5.0 cm	\$	818.00
Repair, intermediate, wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 5.1 cm to 7.5 cm	\$	818.00
Repair, intermediate, wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 7.6 cm to 12.5 cm	\$	818.00
Repair, intermediate, wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 12.6 cm to 20.0 cm	\$	818.00
Repair, complex, trunk; 2.6 cm to 7.5 cm	\$	1,683.00
Repair, complex, scalp, arms, and/or legs; 1.1 cm to 2.5 cm	\$	818.00
Repair, complex, scalp, arms, and/or legs; 2.6 cm to 7.5 cm	\$	1,683.00
Repair, complex, scalp, arms, and/or legs; each additional 5 cm or less (List separately in addition to code for primary procedure)	\$	1,636.00
Repair, complex, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; 1.1 cm to 2.5 cm	\$	818.00
Repair, complex, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; 2.6 cm to 7.5 cm	\$	1,683.00
Repair, complex, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; each additional 5 cm or less (List separately in addition to code for	\$	1,636.00
primary procedure) Repair, complex, eyelids, nose, ears and/or lips; 1.1 cm to 2.5 cm	\$	1,683.00
Repair, complex, eyelids, nose, ears and/or lips; 2.6 cm to 7.5 cm	\$	1,683.00
Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area	\$	5,633.00
Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (List separately in addition to code for primary procedure)	1	5,633.00
Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children	\$	9,286.00
Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)	\$	9,286.00
Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area	\$	5,633.00
Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (List separately in addition to code for primary procedure)	\$	5,633.00
Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children	\$	5,633.00
Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)	\$	5,633.00

DESCRIPTION	CHARGE
Dressings and/or debridement of partial-thickness burns, initial or subsequent; small (less than 5% total body surface area)	\$ 605.00
Dressings and/or debridement of partial-thickness burns, initial or subsequent; small (less than 5% total body surface area)	\$ 605.00
Dressings and/or debridement of partial-thickness burns, initial or subsequent; medium (eg, whole face or whole extremity, or 5% to 10% total body surface area)	\$ 605.00
Dressings and/or debridement of partial-thickness burns, initial or subsequent; medium (eg, whole face or whole extremity, or 5% to 10% total body surface area)	\$ 605.00
Dressings and/or debridement of partial-thickness burns, initial or subsequent; large (eg, more than 1 extremity, or greater than 10% total body surface area)	\$ 605.00
Dressings and/or debridement of partial-thickness burns, initial or subsequent; large (eg, more than 1 extremity, or greater than 10% total body surface area)	\$ 605.00
Chemical cauterization of granulation tissue (ie, proud flesh)	\$ 605.00
Unlisted procedure, skin, mucous membrane and subcutaneous tissue	\$ 250.00
Unlisted procedure, skin, mucous membrane and subcutaneous tissue	\$ 250.00
Puncture aspiration of cyst of breast	\$ 1,691.00
Puncture aspiration of cyst of breast; each additional cyst (List separately in addition to code for primary procedure)	\$ 124.00
Injection procedure only for mammary ductogram or galactogram	\$ 80.00
Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including stereotactic guidance	\$ 4,941.00
Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including stereotactic guidance (List separately in addition to code for primary procedure)	\$ 4,857.00
Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including ultrasound guidance	\$ 6,058.00
Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including ultrasound guidance (List separately in addition to code for primary procedure)	\$ 3,030.00
Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including magnetic resonance guidance	\$ 5,829.00
Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including magnetic resonance guidance (List separately in addition to code for primary procedure)	\$ 5,829.00
Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including mammographic guidance	\$ 560.00
Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; each additional lesion, including mammographic guidance (List separately in addition to code for primary procedure)	\$ 560.00
Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including ultrasound guidance	\$ 848.00
Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; each additional lesion, including ultrasound guidance (List separately in addition to code for primary procedure)	\$ 848.00
Placement of breast localization device(s) (eg clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including magnetic resonance guidance	\$ 816.00
Placement of breast localization device(s) (eg clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; each additional lesion, including magnetic resonance guidance (List separately in addition to code for primary procedure)	\$ 816.00
Biopsy, muscle, percutaneous needle	\$ 3,387.00
Biopsy, muscle, percutaneous needle	\$ 5,671.00
Biopsy, bone, trocar, or needle; superficial (eg, ilium, sternum, spinous process, ribs)	\$ 3,135.00
Biopsy, bone, trocar, or needle; superficial (eg, ilium, sternum, spinous process, ribs)	\$ 3,877.00
Biopsy, bone, trocar, or needle; deep (eg, vertebral body, femur)	\$ 5,496.00
Biopsy, bone, open; superficial (eg, sternum, spinous process, rib, patella, olecranon process, calcaneus, tarsal, metatarsal, carpal, metacarpal, phalanx)	\$ 7,132.00
Injection of sinus tract; diagnostic (sinogram)	\$ 63.00
Injection(s); single tendon sheath, or ligament, aponeurosis (eg, plantar 'fascia')	\$ 902.00
Injection(s); single tendon sheath, or ligament, aponeurosis (eg, plantar 'fascia')	\$ 831.00
Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s)	\$ 922.00
Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s)	\$ 922.00
Injection(s); single or multiple trigger point(s), 3 or more muscles	\$ 922.00
Arthrocentesis, aspiration and/or injection, small joint or bursa (eg, fingers, toes); without ultrasound guidance	\$ 831.00
Arthrocentesis, aspiration and/or injection, small joint or bursa (eg, fingers, toes); without ultrasound guidance	\$ 831.00
Arthrocentesis, aspiration and/or injection, intermediate joint or bursa (eg, temporomandibular, acromioclavicular, wrist, elbow or ankle, olecranon bursa); without ultrasound guidance	\$ 831.00
Arthrocentesis, aspiration and/or injection, intermediate joint or bursa (eg, temporomandibular, acromioclavicular, wrist, elbow or ankle, olecranon bursa); without ultrasound guidance	\$ 831.00
Arthrocentesis, aspiration and/or injection, intermediate joint or bursa (eg, temporomandibular, acromioclavicular, wrist, elbow or ankle, olecranon bursa); without ultrasound guidance	\$ 759.00
Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); without ultrasound guidance	\$ 831.00
Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); without ultrasound guidance	\$ 831.00

DESCRIPTION		CHARGE
Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); without ultrasound guidance	\$	831.00
Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); with ultrasound guidance, with permanent	\$	909.00
recording and reporting		
Aspiration and injection for treatment of bone cyst	\$	2,410.00
Insertion of wire or pin with application of skeletal traction, including removal (separate procedure)	\$	10,581.00
Closed treatment of temporomandibular dislocation; initial or subsequent	\$	346.00
Biopsy, soft tissue of neck or thorax	\$	5,236.00
Injection procedure for shoulder arthrography or enhanced CT/MRI shoulder arthrography	\$	93.00
Closed treatment of clavicular fracture; without manipulation	\$	445.00
Closed treatment of clavicular fracture; with manipulation Closed treatment of newinal humoral (curraical or anatomical post) fracture; without manipulation	\$ \$	1,845.00 712.00
Closed treatment of proximal humeral (surgical or anatomical neck) fracture; without manipulation Closed treatment of proximal humeral (surgical or anatomical neck) fracture; with manipulation, with or without skeletal traction	\$	5,144.00
Closed treatment of greater humeral tuberosity fracture; without manipulation	\$	445.00
Closed treatment of greater humeral tuberosity fracture; with manipulation	\$	5,144.00
Closed treatment of shoulder dislocation, with manipulation; without anesthesia	\$	712.00
Closed treatment of shoulder dislocation, with manipulation; requiring anesthesia	\$	4,742.00
Injection procedure for elbow arthrography	\$	93.00
Closed treatment of humeral shaft fracture; with manipulation, with or without skeletal traction	\$	4,513.00
Closed treatment of supracondylar or transcondylar humeral fracture, with or without intercondylar extension; with manipulation, with or without skin or	\$	4,879.00
skeletal traction		
Closed treatment of humeral epicondylar fracture, medial or lateral; without manipulation	\$	445.00
Closed treatment of humeral epicondylar fracture, medial or lateral; with manipulation	\$	712.00
Treatment of closed elbow dislocation; without anesthesia	\$	712.00
Treatment of closed elbow dislocation; requiring anesthesia	\$	2,709.00
Closed treatment of radial head subluxation in child, nursemaid elbow, with manipulation	\$	712.00
Closed treatment of radial head or neck fracture; without manipulation	\$	712.00
Closed treatment of radial head or neck fracture; with manipulation	\$	712.00
Closed treatment of ulnar fracture, proximal end (eg, olecranon or coronoid process[es]); without manipulation	\$	445.00
Closed treatment of ulnar fracture, proximal end (eg, olecranon or coronoid process[es]); with manipulation	\$	712.00
Injection procedure for wrist arthrography	\$	93.00
Closed treatment of radial shaft fracture; without manipulation	\$	445.00
Closed treatment of radial shaft fracture; with manipulation	\$	1,845.00
Closed treatment of ulnar shaft fracture; with manipulation Closed treatment of radial and ulnar shaft fractures; without manipulation	\$ \$	712.00 445.00
Closed treatment of radial and ulnar shaft fractures; with manipulation	\$	712.00
Closed treatment of distal radial fracture (eg, Colles or Smith type) or epiphyseal separation, includes closed treatment of fracture of ulnar styloid, when	\$	712.00
performed; without manipulation	Ŷ	/12/00
Closed treatment of distal radial fracture (eg, Colles or Smith type) or epiphyseal separation, includes closed treatment of fracture of ulnar styloid, when	\$	1,845.00
performed; with manipulation	· ·	,
Drainage of finger abscess; simple	\$	657.00
Closed treatment of metacarpal fracture, single; without manipulation, each bone	\$	445.00
Closed treatment of metacarpal fracture, single; with manipulation, each bone	\$	712.00
Closed treatment of metacarpophalangeal dislocation, single, with manipulation; without anesthesia	\$	712.00
Closed treatment of phalangeal shaft fracture, proximal or middle phalanx, finger or thumb; without manipulation, each	\$	445.00
Closed treatment of phalangeal shaft fracture, proximal or middle phalanx, finger or thumb; with manipulation, with or without skin or skeletal traction, each	\$	712.00
Closed treatment of articular fracture, involving metacarpophalangeal or interphalangeal joint; with manipulation, each	\$	4,513.00
Closed treatment of distal phalangeal fracture, finger or thumb; without manipulation, each	\$	445.00
Closed treatment of distal phalangeal fracture, finger or thumb; with manipulation, each	\$	712.00
Closed treatment of interphalangeal joint dislocation, single, with manipulation; without anesthesia	\$	445.00
Closed treatment of interphalangeal joint dislocation, single, with manipulation; requiring anesthesia	\$	712.00
Amputation, finger or thumb, primary or secondary, any joint or phalanx, single, including neurectomies; with local advancement flaps (V-Y, hood)	\$	5,137.00
Injection procedure for hip arthrography; without anesthesia	\$ ¢	93.00
Injection procedure for hip arthrography; with anesthesia Closed treatment of hip dielection, traumatic; without anesthesia	\$ \$	93.00 921.00
Closed treatment of hip dislocation, traumatic; without anesthesia Closed treatment of post hip arthroplasty dislocation; without anesthesia	\$	712.00
Closed treatment of post hip arthroplasty dislocation; without anestnesia	\$	4,742.00
Incision and drainage, deep abscess, bursa, or hematoma, thigh or knee region	\$	7,063.00
Injection of contrast for knee arthrography	\$	93.00
Closed treatment of femoral fracture, proximal end, neck; with manipulation, with or without skeletal traction	\$	5,593.00
Closed treatment of femoral fracture, distal end, medial or lateral condyle, without manipulation	\$	712.00
Closed treatment of femoral fracture, distal end, medial or lateral condyle, with manipulation	\$	712.00
Closed treatment of patellar fracture, without manipulation	\$	712.00

DESCRIPTION	1	CHARGE
Closed treatment of tibial fracture, proximal (plateau); without manipulation	\$	712.00
Closed treatment of tibial fracture, proximal (plateau); with or without manipulation, with skeletal traction	\$	5,144.00
Closed treatment of knee dislocation; without anesthesia	\$	977.00
Closed treatment of patellar dislocation; without anesthesia	\$	445.00
Biopsy, soft tissue of leg or ankle area; superficial	\$	3,135.00
Biopsy, soft tissue of leg or ankle area; deep (subfascial or intramuscular)	\$	7,635.00
Injection procedure for ankle arthrography	\$	93.00
Closed treatment of tibial shaft fracture (with or without fibular fracture); without manipulation	\$	712.00
Closed treatment of tibial shaft fracture (with or without fibular fracture); with manipulation, with or without skeletal traction	\$	5,144.00
Closed treatment of medial malleolus fracture; without manipulation	\$	712.00
Closed treatment of medial malleolus fracture; with manipulation, with or without skin or skeletal traction	\$	5,144.00
Closed treatment of distal fibular fracture (lateral malleolus); without manipulation	\$	712.00
Closed treatment of distal fibular fracture (lateral maleolus); with manipulation	\$	712.00
Closed treatment of bimalleolar ankle fracture (eg, lateral and medial malleoli, or lateral and posterior malleoli or medial and posterior malleoli); without	\$	712.00
manipulation	ډ	/12.00
	Lċ	1.945.00
Closed treatment of bimalleolar ankle fracture (eg, lateral and medial malleoli, or lateral and posterior malleoli or medial and posterior malleoli); with manipulation	\$	1,845.00
Closed treatment of trimalleolar ankle fracture; without manipulation	\$	712.00
Closed treatment of trimalleolar ankle fracture; with manipulation	\$	1,845.00
Closed treatment of fracture of weight bearing articular portion of distal tibia (eg, pilon or tibial plafond), with or without anesthesia; with skeletal traction	\$	5,144.00
and/or requiring manipulation		
Closed treatment of ankle dislocation; without anesthesia	\$	677.00
Removal of foreign body, foot; subcutaneous	\$	2,633.00
Closed treatment of calcaneal fracture; without manipulation	\$	712.00
Closed treatment of calcaneal fracture; with manipulation	\$	1,845.00
Closed treatment of metatarsal fracture; with manipulation, each	\$	735.00
Closed treatment of fracture great toe, phalanx or phalanges; without manipulation	\$	445.00
Closed treatment of fracture great toe, phalanx or phalanges; with manipulation	\$	905.00
Closed treatment of fracture, phalanx or phalanges, other than great toe; without manipulation, each	\$	445.00
Closed treatment of fracture, phalanx or phalanges, other than great toe; with manipulation, each	\$	712.00
Closed treatment of metatarsophalangeal joint dislocation; without anesthesia	\$	710.00
Closed treatment of interphalangeal joint dislocation; without anesthesia	\$	445.00
Amputation, toe; interphalangeal joint	\$	6,918.00
Application of long arm splint (shoulder to hand)	\$	413.00
Application of short arm splint (forearm to hand); static	\$	413.00
Application of finger splint; static	\$	229.00
Application of rigid total contact leg cast	\$	916.00
Application of long leg splint (thigh to ankle or toes)	\$	413.00
Application of short leg splint (calf to foot)	\$	413.00
Strapping; Unna boot	\$	
		569.00
Application of multi-layer compression system; leg (below knee), including ankle and foot	\$	413.00
Application of multi-layer compression system; upper arm, forearm, hand, and fingers	\$	229.00
Removal or bivalving; gauntlet, boot or body cast	\$	525.00
Drainage abscess or hematoma, nasal, internal approach	\$	533.00
Removal foreign body, intranasal; office type procedure	\$	404.00
Control nasal hemorrhage, anterior, simple (limited cautery and/or packing) any method	\$	346.00
Control nasal hemorrhage, anterior, complex (extensive cautery and/or packing) any method	\$	346.00
Control nasal hemorrhage, posterior, with posterior nasal packs and/or cautery, any method; initial	\$	574.00
Intubation, endotracheal, emergency procedure	\$	609.00
Intubation, endotracheal, emergency procedure	\$	657.00
Intubation, endotracheal, emergency procedure	\$	640.00
Tracheotomy tube change prior to establishment of fistula tract	\$	533.00
Laryngoscopy, flexible; with removal of foreign body(s)	\$	5,089.00
Laryngoscopy, flexible; diagnostic	\$	618.00
Laryngoscopy, flexible; diagnostic	\$	618.00
Laryngoscopy, flexible; diagnostic	\$	618.00
Tracheostomy, planned (separate procedure)	\$	674.00
Tracheostomy, emergency procedure; cricothyroid membrane	\$	1,774.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; diagnostic, with cell washing, when performed (separate procedure)	\$	1,333.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with brushing or protected brushings	\$	3,910.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage	\$	3,910.00

DESCRIPTION	С	HARGE
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial or endobronchial biopsy(s), single or multiple sites	\$	3,910.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial needle aspiration biopsy(s), trachea, main stem and/or lobar bronchus(i)	\$	8,218.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), each additional lobe (List separately in addition to code for primary procedure)	\$	327.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial needle aspiration biopsy(s), each additional lobe (List separately in addition to code for primary procedure)	\$	327.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with removal of foreign body	\$	3,910.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with placement of catheter(s) for intracavitary radioelement application	\$	2,148.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), one or two mediastinal and/or hilar lymph node stations or structures	\$	8,199.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), one or two mediastinal and/or hilar lymph node stations or structures	\$	8,199.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), 3 or more mediastinal and/or hilar lymph node stations or structures	\$	8,199.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), 3 or more mediastinal and/or hilar lymph node stations or structures	\$	8,199.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transendoscopic endobronchial ultrasound (EBUS) during bronchoscopic diagnostic or therapeutic intervention(s) for peripheral lesion(s) (List separately in addition to code for primary procedure[s])	\$	406.00
Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transendoscopic endobronchial ultrasound (EBUS) during bronchoscopic diagnostic or therapeutic intervention(s) for peripheral lesion(s) (List separately in addition to code for primary procedure[s])	\$	406.00
Catheter aspiration (separate procedure); nasotracheal	\$	51.00
Transtracheal (percutaneous) introduction of needle wire dilator/stent or indwelling tube for oxygen therapy	\$	674.00
Biopsy, pleura, percutaneous needle	\$	2,203.00
Biopsy, pleura, percutaneous needle	\$	6,502.00
Biopsy, lung or mediastinum, percutaneous needle	\$ \$	4,314.00
Insertion of indwelling tunneled pleural catheter with cuff Tube thoracostomy, includes connection to drainage system (eg, water seal), when performed, open (separate procedure)	\$ \$	6,874.00 1,993.00
Removal of indwelling tunneled pleural catheter with cuff	\$	354.00
Thoracentesis, needle or catheter, aspiration of the pleural space; without imaging guidance	\$	490.00
Thoracentesis, needle or catheter, aspiration of the pleural space; without imaging guidance	\$	1,993.00
Thoracentesis, needle or catheter, aspiration of the pleural space; with imaging guidance	\$	1,993.00
Thoracentesis, needle or catheter, aspiration of the pleural space; with imaging guidance	\$	2,415.00
Thoracentesis, needle or catheter, aspiration of the pleural space; with imaging guidance	\$	825.00
Pleural drainage, percutaneous, with insertion of indwelling catheter; with imaging guidance	\$	1,993.00
Pleural drainage, percutaneous, with insertion of indwelling catheter; with imaging guidance	\$	2,609.00
Unlisted procedure, lungs and pleura	\$	2,522.00
Pericardiocentesis; initial	\$	1,993.00
Insertion or replacement of temporary transvenous single chamber cardiac electrode or pacemaker catheter (separate procedure)	\$	28,158.00
Implantation of patient-activated cardiac event recorder	\$	28,158.00
Removal of an implantable, patient-activated cardiac event recorder	\$ ¢	3,557.00
Injection procedures (eg, thrombin) for percutaneous treatment of extremity pseudoaneurysm Injection procedures (eg, thrombin) for percutaneous treatment of extremity pseudoaneurysm	\$ \$	785.00 785.00
Venipuncture, age 3 years or older, necessitating the skill of a physician or other qualified health care professional (separate procedure), for diagnostic or	\$ \$	20.00
therapeutic purposes (not to be used for routine venipuncture)	Ļ	20.00
Collection of venous blood by venipuncture	\$	20.00
Collection of venous blood by venipuncture	\$	18.00
Collection of venous blood by venipuncture	\$	18.00
Collection of venous blood by venipuncture	\$	18.00
Collection of venous blood by venipuncture	\$	18.00
Collection of venous blood by venipuncture	\$	18.00
Collection of venous blood by venipuncture	\$	18.00
Collection of venous blood by venipuncture	\$	18.00
Collection of venous blood by venipuncture	\$	18.00
Collection of venous blood by venipuncture	\$	20.00
Collection of venous blood by venipuncture	\$	20.00
Collection of capillary blood specimen (eg, finger, heel, ear stick)	\$	32.00
Collection of capillary blood specimen (eg, finger, heel, ear stick)	\$ ¢	32.00
Collection of capillary blood specimen (eg, finger, heel, ear stick) Collection of capillary blood specimen (eg, finger, heel, ear stick)	\$ \$	32.00 32.00
Collection of capillary blood specimen (eg, finger, heel, ear stick)	\$ \$	32.00

DESCRIPTION		CHARGE
Collection of capillary blood specimen (eg, finger, heel, ear stick)	\$	32.00
Collection of capillary blood specimen (eg, finger, heel, ear stick)	\$	32.00
Transfusion, blood or blood components	\$	1,172.00
Transfusion, blood or blood components	\$	1,172.00
Transfusion, blood or blood components	\$	1,172.00
Transfusion, blood or blood components	\$	1,172.00
Transfusion, blood or blood components	\$	1,233.00
Transfusion, blood or blood components	\$	1,172.00
Transfusion, blood or blood components	\$	1,172.00
Transfusion, blood or blood components	\$	1,233.00
Insertion of non-tunneled centrally inserted central venous catheter; younger than 5 years of age	\$	3,504.00
Insertion of non-tunneled centrally inserted central venous catheter; younger than 5 years of age	\$	3,492.00
Insertion of non-tunneled centrally inserted central venous catheter; younger than 5 years of age	\$	3,504.00
Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older	\$ \$	3,492.00
Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older	\$	3,504.00 3,492.00
Insertion of non-tunneled centrally inserted central venous catheter; age 5 years of older	\$	3,504.00
Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump; age 5 years or older	\$	3,651.00
Insertion of peripherally inserted central venous catheter (FICC), without subcutaneous port of pump, age 5 years of older	\$	3,651.00
Collection of blood specimen from a completely implantable venous access device	\$	347.00
Collection of blood specimen from a completely implantable venous access device	\$	347.00
Collection of blood specimen from a completely implantable venous access device	\$	333.00
Collection of blood specimen from a completely implantable venous access device	\$	347.00
Collection of blood specimen using established central or peripheral catheter, venous, not otherwise specified	\$	333.00
Collection of blood specimen using established central or peripheral catheter, venous, not otherwise specified	\$	333.00
Collection of blood specimen using established central or peripheral catheter, venous, not otherwise specified	\$	347.00
Collection of blood specimen using established central or peripheral catheter, venous, not otherwise specified	\$	347.00
Collection of blood specimen using established central or peripheral catheter, venous, not otherwise specified	\$	347.00
Declotting by thrombolytic agent of implanted vascular access device or catheter	\$	755.00
Declotting by thrombolytic agent of implanted vascular access device or catheter	\$	755.00
Declotting by thrombolytic agent of implanted vascular access device or catheter	\$	755.00
Declotting by thrombolytic agent of implanted vascular access device or catheter	\$	755.00
Declotting by thrombolytic agent of implanted vascular access device or catheter	\$	769.00
Declotting by thrombolytic agent of implanted vascular access device or catheter	\$	769.00
Declotting by thrombolytic agent of implanted vascular access device or catheter	\$	769.00
Arterial puncture, withdrawal of blood for diagnosis	\$	404.00
Arterial puncture, withdrawal of blood for diagnosis	\$	404.00
Arterial puncture, withdrawal of blood for diagnosis	\$	404.00
Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous	\$	36.00
Placement of needle for intraosseous infusion	\$	388.00
Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage	\$	1,279.00
Bone marrow; aspiration only	\$	3,692.00
Bone marrow; biopsy, needle or trocar Bone marrow; biopsy, needle or trocar	\$	5,543.00 203.00
Diagnostic bone marrow; biopsy(ies) and aspiration(s)	\$	1,310.00
Diagnostic bone marrow; biopsylies) and aspiration(s)	\$	1,310.00
Biopsy or excision of lymph node(s); by needle, superficial (eg, cervical, inguinal, axillary)	\$	2,886.00
Biopsy or excision of lymph node(s); by needle, superficial (eg, cervical, inguinal, axillary) Biopsy or excision of lymph node(s); by needle, superficial (eg, cervical, inguinal, axillary)	\$	3,412.00
Injection procedure; radioactive tracer for identification of sentinel node	\$	1,059.00
Unlisted procedure, hemic or lymphatic system	\$	1,218.00
Repair of laceration 2.5 cm or less; floor of mouth and/or anterior two-thirds of tongue	\$	375.00
Drainage of abscess, cyst, hematoma from dentoalveolar structures	\$	657.00
Biopsy of salivary gland; needle	\$	3,412.00
Biopsy of salivary gland; incisional	\$	8,165.00
Incision and drainage abscess; peritonsillar	\$	1,073.00
Biopsy; nasopharynx, survey for unknown primary lesion	\$	8,165.00
Removal of foreign body from pharynx	\$	1,389.00
Esophagoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	\$	2,755.00
Esophagoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	\$	2,755.00
Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance	\$	4,163.00
Esophagoscopy, flexible, transoral; with biopsy, single or multiple	\$	2,755.00
Esophagoscopy, flexible, transoral; with injection sclerosis of esophageal varices	\$	2,755.00
Esophagoscopy, flexible, transoral; with band ligation of esophageal varices	\$	4,163.00

DESCRIPTION		CHARGE
Esophagoscopy, flexible, transoral; with optical endomicroscopy	\$	4,163.00
Esophagoscopy, flexible, transoral; with endoscopic mucosal resection	\$	2,755.00
Esophagoscopy, flexible, transoral; with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed)	\$	9,742.00
Esophagoscopy, flexible, transoral; with dilation of esophagus, by balloon or dilator, retrograde (includes fluoroscopic guidance, when performed)	\$	4,163.00
Esophagoscopy, flexible, transoral; with dilation of esophagus with balloon (30 mm diameter or larger) (includes fluoroscopic guidance, when performed)	\$	4,163.00
Esophagoscopy, flexible, transoral; with removal of foreign body(s)	\$	4,163.00
Esophagoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique	\$	4,163.00
Esophagoscopy, flexible, transoral; with transendoscopic balloon dilation (less than 30 mm diameter)	\$	4,163.00
Esophagoscopy, flexible, transoral; with insertion of guide wire followed by passage of dilator(s) over guide wire Esophagoscopy, flexible, transoral; with control of bleeding, any method	\$ \$	4,163.00 4,163.00
Esophagoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)	\$	8,088.00
Esophagoscopy, flexible, transoral; with endoscopic ultrasound examination	\$	4,163.00
Esophagoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s)	\$	4,163.00
Esophagogastroduodenoscopy, flexible, transoral; with dilation of esophagus with balloon (30 mm diameter or larger) (includes fluoroscopic guidance, when performed)	\$	4,163.00
Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	\$	2,755.00
Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance	\$	2,755.00
Esophagogastroduodenoscopy, flexible, transoral; with endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent	\$	4,163.00
structures Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures)	\$	4,163.00
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	ć	2,755.00
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	\$ \$	2,755.00
Esophagogastroducterioscopy, nextore, transoral, with biopsy, single of multiple Esophagogastroducterioscopy, flexible, transoral; with transmural drainage of pseudocyst (includes placement of transmural drainage catheter[s]/stent[s], when performed, and endoscopic ultrasound, when performed)	\$	4,163.00
Esophagogastroduodenoscopy, flexible, transoral; with insertion of intraluminal tube or catheter	\$	2,755.00
Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal	\$	4,163.00
to the anastomosis)	<u> </u>	2 755 00
Esophagogastroduodenoscopy, flexible, transoral; with injection sclerosis of esophageal/gastric varices	\$ c	2,755.00
Esophagogastroduodenoscopy, flexible, transoral; with band ligation of esophageal/gastric varices	\$	4,163.00
Esophagogastroduodenoscopy, flexible, transoral; with dilation of gastric/duodenal stricture(s) (eg, balloon, bougie) Esophagogastroduodenoscopy, flexible, transoral; with directed placement of percutaneous gastrostomy tube	\$ ¢	4,163.00 4,163.00
Esophagogastroduodenoscopy, flexible, transoral; with directed placement of percutaneous gastrostomy tube	\$ \$	4,163.00
Esophagogastroduodenoscopy, flexible, transoral, with removal of foreign body(s)	\$	2,755.00
Esophagogastroduodenoscopy, flexible, transoral; with removal of foreign body(s) Esophagogastroduodenoscopy, flexible, transoral; with insertion of guide wire followed by passage of dilator(s) through esophagus over guide wire	\$	2,755.00
Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic balloon dilation of esophagus (less than 30 mm diameter)	\$	4,163.00
Esophagogastroduodenoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps	Ś	4,163.00
Esophagogastroduodenoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique	\$	4,163.00
Esophagogastroduodenoscopy, flexible, transoral; with optical endomicroscopy	\$	4,163.00
Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided transmural injection of diagnostic or therapeutic substance(s) (eg, anesthetic, neurolytic agent) or fiducial marker(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis)	\$	4,163.00
Esophagogastroduodenoscopy, flexible, transoral; with endoscopic mucosal resection	\$	2,755.00
Esophagogastroduodenoscopy, flexible, transoral; with control of bleeding, any method	\$	4,163.00
Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease	\$	8,088.00
Esophagogastroduodenoscopy, flexible, transoral; with endoscopic ultrasound examination, including the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis	\$	4,163.00
Endoscopic retrograde cholangiopancreatography (ERCP); diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	\$	7,944.00
Endoscopic retrograde cholangiopancreatography (ERCP); with biopsy, single or multiple	\$	7,944.00
Endoscopic retrograde cholangiopancreatography (ERCP); with sphincterotomy/papillotomy	\$	7,944.00
Endoscopic retrograde cholangiopancreatography (ERCP); with pressure measurement of sphincter of Oddi	\$	7,944.00
Endoscopic retrograde cholangiopancreatography (ERCP); with removal of calculi/debris from biliary/pancreatic duct(s)	\$	7,944.00
Endoscopic retrograde cholangiopancreatography (ERCP); with destruction of calculi, any method (eg, mechanical, electrohydraulic, lithotripsy)	\$	7,944.00
Esophagogastroduodenoscopy, flexible, transoral; with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed)	\$	9,742.00
Esophagogastroduodenoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)	\$	4,163.00

DESCRIPTION		CHARGE
Endoscopic cannulation of papilla with direct visualization of pancreatic/common bile duct(s) (List separately in addition to code(s) for primary procedure)	\$	7,944.00
Endoscopic retrograde cholangiopancreatography (ERCP); with placement of endoscopic stent into biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent	\$	7,944.00
Endoscopic retrograde cholangiopancreatography (ERCP); with removal of foreign body(s) or stent(s) from biliary/pancreatic duct(s)	\$	7,944.00
Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation	\$	7,944.00
and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchanged	l l	
Endoscopic retrograde cholangiopancreatography (ERCP); with trans-endoscopic balloon dilation of biliary/pancreatic duct(s) or of ampulla (sphincteroplasty), including sphincterotomy, when performed, each duct	\$	7,944.00
Endoscopic retrograde cholangiopancreatography (ERCP); with ablation of tumor(s), polyp(s), or other lesion(s), including pre- and post-dilation and guide wire passage, when performed	\$	7,944.00
Ligation, direct, esophageal varices	\$	2,949.00
Dilation of esophagus, by unguided sound or bougie, single or multiple passes	\$	2,755.00
Dilation of esophagus, over guide wire	\$	4,163.00
Naso- or oro-gastric tube placement, requiring physician's skill and fluoroscopic guidance (includes fluoroscopy, image documentation and report)	\$	622.00
Gastric intubation and aspiration(s) therapeutic, necessitating physician's skill (eg, for gastrointestinal hemorrhage), including lavage if performed	\$	404.00
Gastric intubation and aspiration(s) therapeutic, necessitating physician's skill (eg, for gastrointestinal hemorrhage), including lavage if performed	\$	404.00
Gastric intubation and aspiration, diagnostic; single specimen (eg, acid analysis)	\$	404.00
Gastric intubation and aspiration, diagnostic; collection of multiple fractional specimens with gastric stimulation, single or double lumen tube (gastric secretory study) (eg, histamine, insulin, pentagastrin, calcium, secretin), includes drug administration	\$	538.00
Duodenal intubation and aspiration, diagnostic, includes image guidance; single specimen (eg, bile study for crystals or afferent loop culture)	\$	643.00
Duodenal intubation and aspiration, diagnostic, includes image guidance; collection of multiple fractional specimens with pancreatic or gallbladder stimulation, single or double lumen tube, includes drug administration	\$	643.00
Change of gastrostomy tube, percutaneous, without imaging or endoscopic guidance	\$	755.00
Repositioning of a naso- or oro-gastric feeding tube, through the duodenum for enteric nutrition	\$	2,755.00
Repositioning of a naso- or oro-gastric feeding tube, through the duodenum for enteric nutrition	\$	2,892.00
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	\$	2,755.00
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; with biopsy, single or multiple	\$	3,439.00
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; with removal of foreign body(s)	\$	3,439.00
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; with removal of tumor(s), polyp(s), or other lesion(s) by	\$	5,066.00
snare technique	Ŧ	-,
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery	\$	5,066.00
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; with control of bleeding (eg, injection, bipolar cautery, unipolar cautery, laser, heater probe, stapler, plasma coagulator)	\$	5,066.00
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique	\$	5,066.00
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; with transendoscopic stent placement (includes predilation)	\$	9,742.00
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; with placement of percutaneous jejunostomy tube	\$	5,066.00
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; with conversion of percutaneous gastrostomy tube to percutaneous jejunostomy tube	\$	5,066.00
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, including ileum; diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure)	\$	3,439.00
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, including ileum; with biopsy, single or multiple	\$	5,066.00
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, including ileum; with control of bleeding (eg, injection, bipolar cautery, unipolar cautery, laser, heater probe, stapler, plasma coagulator)	\$	5,066.00
Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, including ileum; with transendoscopic stent placement (includes predilation)	\$	9,742.00
lleoscopy, through stoma; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure) lleoscopy, through stoma; with biopsy, single or multiple	\$ \$	3,439.00 3,439.00
lleoscopy, through stoma, with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed)	\$	9,742.00
Endoscopic evaluation of small intestinal pouch (eg, Kock pouch, ileal reservoir [S or J]); diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	\$	3,028.00
Endoscopic evaluation of small intestinal pouch (eg, Kock pouch, ileal reservoir [S or J]); with biopsy, single or multiple	\$	3,028.00
Colonoscopy through stoma; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	\$	3,028.00
Colonoscopy through stoma; with biopsy, single or multiple	\$	3,028.00
Colonoscopy through stoma; with control of bleeding, any method	\$	3,028.00
Colonoscopy through stoma; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps	\$	3,028.00
Colonoscopy through stoma; with removal of tumor(s), polyp(s), or other lesion(s) by not clossy force polymer stoma; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique	\$	3,028.00
Colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre-and post-dilation and guide wire passage, when performed)	\$	3,028.00

DESCRIPTION		CHARGE
Introduction of long gastrointestinal tube (eg, Miller-Abbott) (separate procedure)	\$	2,012.00
Unlisted procedure, small intestine	\$	2,805.00
Proctosigmoidoscopy, rigid; diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure)	\$	1,895.00
Sigmoidoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	\$	1,895.00
Sigmoidoscopy, flexible; with biopsy, single or multiple	\$	1,895.00
Sigmoidoscopy, flexible; with removal of foreign body(s)	\$	3,202.00
Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps	\$	1,895.00
Sigmoidoscopy, flexible; with control of bleeding, any method	\$	3,202.00
Sigmoidoscopy, flexible; with directed submucosal injection(s), any substance	\$	1,895.00
Sigmoidoscopy, flexible; with decompression (for pathologic distention) (eg, volvulus, megacolon), including placement of decompression tube, when performed	\$	3,202.00
Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique	\$	3,202.00
Sigmoidoscopy, flexible; with transendoscopic balloon dilation	\$	3,202.00
Sigmoidoscopy, flexible; with endoscopic ultrasound examination	\$	3,202.00
Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s)	\$	3,202.00
Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)	\$	3,202.00
Sigmoidoscopy, flexible; with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed)	\$	9,742.00
Colonoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	\$	3,028.00
Colonoscopy, flexible; with removal of foreign body(s)	\$	3,028.00
Colonoscopy, flexible; with biopsy, single or multiple	\$	3,028.00
Colonoscopy, flexible; with directed submucosal injection(s), any substance	\$	3,028.00
Colonoscopy, flexible; with control of bleeding, any method	\$	3,028.00
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps	\$	3,028.00
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique	\$	3,028.00
Colonoscopy, flexible; with transendoscopic balloon dilation	\$	3,028.00
Colonoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)	\$	3,028.00
Colonoscopy, flexible; with endoscopic stent placement (includes pre- and post-dilation and guide wire passage, when performed)	\$	9,742.00
Colonoscopy, flexible; with endoscopic mucosal resection	\$	2,951.00
Colonoscopy, flexible; with endoscopic ultrasound examination limited to the rectum, sigmoid, descending, transverse, or ascending colon and cecum, and	\$	3,028.00
adjacent structures Colonoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s), includes endoscopic ultrasound	\$	3,028.00
examination limited to the rectum, sigmoid, descending, transverse, or ascending colon and cecum, and adjacent structures Colonoscopy, flexible; with decompression (for pathologic distention) (eg, volvulus, megacolon), including placement of decompression tube, when performed	\$	3,238.00
	Ć	2 200 00
Unlisted procedure, colon	\$ c	3,399.00
Perirectal injection of sclerosing solution for prolapse Removal of fecal impaction or foreign body (separate procedure) under anesthesia	\$ \$	605.00
Incision and drainage of ischiorectal and/or perirectal abscess (separate procedure)	\$	5,834.00 5,834.00
Incision and drainage of ischiorectal and/or perirectal abscess (separate procedure)	\$	5,834.00
Incision and drainage of ischolectar and/or perificial	\$	1,813.00
Incision of thrombosed hemorrhoid, external	\$	867.00
Excision of thrombosed hemorrhoid, external	\$	3,518.00
Anoscopy; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	\$	404.00
Biopsy of liver, needle; percutaneous	\$	3,616.00
Biopsy of liver, needle; percutaneous	\$	4,314.00
Unlisted procedure, liver	\$	2,161.00
Cholecystostomy, percutaneous, complete procedure, including imaging guidance, catheter placement, cholecystogram when performed, and radiological supervision	\$	8,961.00
Injection procedure for cholangiography, percutaneous, complete diagnostic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision ; existing access	\$	1,449.00
Placement of biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or	\$	8,961.00
fluoroscopy), and all associated radiological supervision ; external	I •	
Endoluminal biopsy(ies) of biliary tree, percutaneous, any method(s) (eg, brush, forceps, and/or needle), including imaging guidance (eg, fluoroscopy), and all associated radiological supervision, single or multiple (List separately in addition to code for primary procedure)	\$	4,029.00
Biopsy of pancreas, percutaneous needle	\$	3,616.00
Biopsy of pancreas, percutaneous needle	\$	3,877.00
Abdominal paracentesis (diagnostic or therapeutic); without imaging guidance	\$	1,993.00
Abdominal paracentesis (diagnostic or therapeutic); with imaging guidance	\$	2,107.00
Abdominal paracentesis (diagnostic or therapeutic); with imaging guidance	\$	2,576.00
Abdominal paracentesis (diagnostic or therapeutic); with imaging guidance	\$	490.00
Biopsy, abdominal or retroperitoneal mass, percutaneous needle	\$	4,314.00

DESCRIPTION		CHARGE
Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); visceral (eg, kidney, liver, spleen, lung/mediastinum), percutaneous	\$	5,026.0
Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); visceral (eg, kidney, liver, spleen, lung/mediastinum),	\$	5,641.0
percutaneous Jeaga guided fluid collection drainage hu catheter (og abscess homatema serema lumphesele, sust), peritoneal er retroporitoneal, persutaneous	\$	E 026 0
Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, percutaneous	\$	5,026.0
Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, percutaneous	1	5,641.0
Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphocele, cyst); peritoneal or retroperitoneal, transvaginal or	\$	3,113.0
transrectal Evebande of providusly placed abscess or syst draipage satisfater under radiological guidance (constate presedure)	ć	E 090 0
Exchange of previously placed abscess or cyst drainage catheter under radiological guidance (separate procedure)	\$	5,980.0
Replacement of gastrostomy or cecostomy (or other colonic) tube, percutaneous, under fluoroscopic guidance including contrast injection(s), image documentation and report	\$	2,012.0
Contrast injection(s) for radiological evaluation of existing gastrostomy, duodenostomy, jejunostomy, gastro-jejunostomy, or cecostomy (or other colonic) tube, from a percutaneous approach including image documentation and report	\$	653.0
Renal biopsy; percutaneous, by trocar or needle	\$	3,616.0
Renal biopsy; percutaneous, by trocar or needle	\$	5,821.0
Injection procedure for antegrade nephrostogram and/or ureterogram, complete diagnostic procedure including imaging guidance (eg, ultrasound and	\$	2,159.0
fluoroscopy) and all associated radiological supervision ; existing access		,
Placement of nephrostomy catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision	\$	7,323.0
Change of ureterostomy tube or externally accessible ureteral stent via ileal conduit	\$	4,971.0
Injection procedure for cystography or voiding urethrocystography	\$	4,971.0
Bladder irrigation, simple, lavage and/or instillation	\$	867.0
Bladder inrigation, simple, lavage and/or institution Bladder irrigation, simple, lavage and/or instillation	\$	
Bladder inrigation, simple, lavage and/or institution Bladder irrigation, simple, lavage and/or institution	\$	867.0 869.0
	\$	
Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)	\$	404.0
Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)		404.0
Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)		443.0
Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)	\$	404.0
Insertion of temporary indwelling bladder catheter; simple (eg, Foley)	\$	404.0
Insertion of temporary indwelling bladder catheter; simple (eg, Foley)	\$	404.0
Insertion of temporary indwelling bladder catheter; simple (eg, Foley)	\$	404.00
Insertion of temporary indwelling bladder catheter; simple (eg, Foley)	\$	404.0
Insertion of temporary indwelling bladder catheter; complicated (eg, altered anatomy, fractured catheter/balloon)	\$	867.00
Change of cystostomy tube; simple	\$	877.00
Bladder instillation of anticarcinogenic agent (including retention time)	\$	993.00
Bladder instillation of anticarcinogenic agent (including retention time) Needle electromyography studies (EMG) of anal or urethral sphincter, any technique	\$ \$	993.0 867.0
	1	
Circumcision, using clamp or other device with regional dorsal penile or ring block	\$	49.0
Irrigation of corpora cavernosa for priapism	\$	851.00
Drainage of scrotal wall abscess	\$ \$	3,726.0
Biopsy, prostate; needle or punch, single or multiple, any approach		836.0
Biopsy, prostate; needle or punch, single or multiple, any approach	\$	4,362.0
Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), prostate (via needle, any approach), single or multiple	\$	2,554.0
Incision and drainage of vulva or perineal abscess	\$	973.0
Incision and drainage of Bartholin's gland abscess	\$	537.0
Insertion of uterine tandem and/or vaginal ovoids for clinical brachytherapy	\$	5,648.0
Insertion of a vaginal radiation afterloading apparatus for clinical brachytherapy	\$	779.0
Removal of intrauterine device (IUD)	\$	927.0
Catheterization and introduction of saline or contrast material for saline infusion sonohysterography (SIS) or hysterosalpingography	\$	189.0
Catheterization and introduction of saline or contrast material for saline infusion sonohysterography (SIS) or hysterosalpingography	\$	189.0
Amniocentesis; diagnostic	\$	1,518.0
Fetal non-stress test	\$	520.0
Unlisted procedure, maternity care and delivery	\$	447.0
Biopsy thyroid, percutaneous core needle	\$	2,192.0
Aspiration and/or injection, thyroid cyst	\$	1,691.0
Cisternal or lateral cervical (C1-C2) puncture; without injection (separate procedure)	\$	3,810.0
Cisternal or lateral cervical (C1-C2) puncture; with injection of medication or other substance for diagnosis or treatment	\$	2,890.0
Percutaneous aspiration within the nucleus pulposus, intervertebral disc, or paravertebral tissue for diagnostic purposes	\$	3,877.0
Spinal puncture, lumbar, diagnostic	\$	2,409.0
Spinal puncture, lumbar, diagnostic	\$	1,455.0
Spinal puncture, lumbar, diagnostic	\$	1,455.0
njection, epidural, of blood or clot patch	\$	2,753.0

DESCRIPTION		CHARGE
Myelography via lumbar injection, including radiological supervision ; cervical	\$	2,643.00
Myelography via lumbar injection, including radiological supervision ; thoracic	\$	2,643.00
Myelography via lumbar injection, including radiological supervision ; lumbosacral	\$	2,643.00
Myelography via lumbar injection, including radiological supervision ; 2 or more regions (eg, lumbar/thoracic, cervical/thoracic, lumbar/cervical, lumbar/thoracic/cervical)	\$	2,643.00
Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance	\$	2,033.00
Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances,	\$	2,033.00
including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance (ie, fluoroscopy or CT)	Ŧ	_,
Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance (ie, fluoroscopy or CT)	\$	2,033.00
Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance	\$	2,033.00
Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (ie, fluoroscopy or CT)	\$	2,033.00
Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (ie, fluoroscopy or CT)	\$	2,033.00
Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance	\$	2,560.00
Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic,	\$	2,560.00
antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging		
guidance (ie, fluoroscopy or CT)	~	000.00
Injection, anesthetic agent; trigeminal nerve, any division or branch	\$	909.00
Injection, anesthetic agent; facial nerve	\$	404.00
Injection, anesthetic agent; greater occipital nerve	\$	922.00
Injection, anesthetic agent; brachial plexus, single	\$ ¢	3,384.00
Injection, anesthetic agent; brachial plexus, continuous infusion by catheter (including catheter placement)	\$	3,384.00
Injection, anesthetic agent; ilioinguinal, iliohypogastric nerves Injection, anesthetic agent; sciatic nerve, single	\$ \$	2,409.00 2,409.00
Injection, anesthetic agent, sciatic nerve, continuous infusion by catheter (including catheter placement)	\$ \$	3,384.00
Injection, anesthetic agent, scialic nerve, continuous infusion by catheter (including catheter placement)	\$	2,409.00
Injection, anesthetic agent; femoral nerve, continuous infusion by catheter (including catheter placement)	\$	3,384.00
Injection, anesthetic agent; lemoral neve, continuous infusion by catheter (including catheter placement)	\$	3,384.00
Injection, anesthetic agent; talhoar prevas, posterior approach, continuous infusion by catheter (including catheter pracement)	\$	922.00
Injection, anesthetic agent; other peripheral nerve or branch	\$	1,455.00
Injection, anesthetic agent; other peripheral nerve or branch	\$	1,455.00
Injection(s), anesthetic agent and/or steroid, transforaminal epidural, with imaging guidance (fluoroscopy or CT); cervical or thoracic, single level	Ś	2,409.00
Injection, anesthetic agent; stellate ganglion (cervical sympathetic)	\$	2,409.00
Injection, anesthetic agent; lumbar or thoracic (paravertebral sympathetic)	\$	2,409.00
Injection, anesthetic agent; lumbar or thoracic (paravertebral sympathetic)	\$	2,409.00
Application of surface (transcutaneous) neurostimulator	\$	116.00
Unlisted procedure, nervous system	\$	922.00
Removal of foreign body, external eye; conjunctival superficial	\$	355.00
Removal of foreign body, external eye; corneal, without slit lamp	\$	319.00
Removal of foreign body, external eye; corneal, with slit lamp	\$	319.00
Drainage external ear, abscess or hematoma; simple	\$	664.00
Removal foreign body from external auditory canal; without general anesthesia	\$	221.00
Removal impacted cerumen using irrigation/lavage, unilateral	\$	230.00
Removal impacted cerumen requiring instrumentation, unilateral	\$	221.00
Cisternography, positive contrast, radiological supervision	\$	2,577.00
Radiologic examination, eye, for detection of foreign body	\$	237.00
Radiologic examination, eye, for detection of foreign body	\$	237.00
Radiologic examination, eye, for detection of foreign body	\$	237.00
Radiologic examination, mandible; partial, less than 4 views	\$	275.00
Radiologic examination, mandible; partial, less than 4 views	\$	275.00
Radiologic examination, mandible; partial, less than 4 views	\$	275.00
Radiologic examination, mandible; complete, minimum of 4 views	\$	392.00
Radiologic examination, mandible; complete, minimum of 4 views	\$	392.00
Radiologic examination, mandible; complete, minimum of 4 views	\$	392.00

DESCRIPTION		CHARGE
Radiologic examination, mastoids; less than 3 views per side	\$	248.00
Radiologic examination, mastoids; less than 3 views per side	\$	237.00
Radiologic examination, mastoids; less than 3 views per side	\$	248.00
Radiologic examination, mastoids; complete, minimum of 3 views per side	\$	372.00
Radiologic examination, mastoids; complete, minimum of 3 views per side	\$	372.00
Radiologic examination, mastoids; complete, minimum of 3 views per side	\$	372.00
Radiologic examination, internal auditory meati, complete	\$	248.00
Radiologic examination, internal auditory meati, complete	\$	237.00
Radiologic examination, internal auditory meati, complete	\$	248.00
Radiologic examination, facial bones; less than 3 views	\$	248.00
Radiologic examination, facial bones; less than 3 views	\$	237.00
Radiologic examination, facial bones; less than 3 views	\$	248.00
Radiologic examination, facial bones; complete, minimum of 3 views	\$	374.00
Radiologic examination, facial bones; complete, minimum of 3 views	\$	373.00
Radiologic examination, facial bones; complete, minimum of 3 views	\$	374.00
Radiologic examination, nasal bones, complete, minimum of 3 views	\$	237.00
Radiologic examination, nasal bones, complete, minimum of 3 views	\$	237.00
Radiologic examination, nasal bones, complete, minimum of 3 views	\$	237.00
Radiologic examination; optic foramina	\$	237.00
Radiologic examination; optic foramina	\$ \$	248.00
Radiologic examination; optic foramina	\$ \$	237.00
	\$	339.00
Radiologic examination; orbits, complete, minimum of 4 views		
Radiologic examination; orbits, complete, minimum of 4 views	\$	339.00
Radiologic examination; orbits, complete, minimum of 4 views	\$	339.00
Radiologic examination, sinuses, paranasal, less than 3 views	\$	237.00
Radiologic examination, sinuses, paranasal, less than 3 views	\$	237.00
Radiologic examination, sinuses, paranasal, less than 3 views	\$	237.00
Radiologic examination, sinuses, paranasal, complete, minimum of 3 views	\$	262.00
Radiologic examination, sinuses, paranasal, complete, minimum of 3 views	\$	262.00
Radiologic examination, sinuses, paranasal, complete, minimum of 3 views	\$	262.00
Radiologic examination, sella turcica	\$	248.00
Radiologic examination, sella turcica	\$	237.00
Radiologic examination, sella turcica	\$	248.00
Radiologic examination, skull; less than 4 views	\$	237.00
Radiologic examination, skull; less than 4 views	\$	237.00
Radiologic examination, skull; less than 4 views	\$	237.00
Radiologic examination, skull; complete, minimum of 4 views	\$	373.00
Radiologic examination, skull; complete, minimum of 4 views	\$	373.00
Radiologic examination, skull; complete, minimum of 4 views	\$	373.00
Radiologic examination, temporomandibular joint, open and closed mouth; bilateral	\$	246.00
Radiologic examination, temporomandibular joint, open and closed mouth; bilateral	\$	246.00
Radiologic examination, temporomandibular joint, open and closed mouth; bilateral	\$	246.00
Temporomandibular joint arthrography, radiological supervision	\$	1,463.00
Magnetic resonance (eg, proton) imaging, temporomandibular joint(s)	\$	2,267.00
Magnetic resonance (eg, proton) imaging, temporomandibular joint(s)	\$	2,267.00
Magnetic resonance (eg, proton) imaging, temporomandibular joint(s)	\$	2,267.00
Magnetic resonance (eg, proton) imaging, temporomandibular joint(s)	\$	2,312.00
Magnetic resonance (eg, proton) imaging, temporomandibular joint(s)	\$	2,312.00
Magnetic resonance (eg, proton) imaging, temporomandibular joint(s)	\$	2,312.00
Radiologic examination; neck, soft tissue	\$	238.00
Radiologic examination; neck, soft tissue	\$	238.00
Radiologic examination; neck, soft tissue	\$	238.00
Radiologic examination, solvary gland for calculus	\$	238.00
Radiologic examination, salivary gland for calculus	\$	238.00
Radiologic examination, salivary gland for calculus		238.00
Sialography, radiological supervision	\$ \$	1,306.00
Computed tomography, head or brain; without contrast material		1,306.00
	\$ \$	
Computed tomography, head or brain; with contrast material		1,479.00
Computed tomography, head or brain; with contrast material(s)	\$ ¢	1,628.00
Computed tomography, head or brain; with contrast material(s)	\$	1,628.00
Computed tomography, head or brain; without contrast material, followed by contrast material(s) and further sections	\$	2,013.00
Computed tomography, head or brain; without contrast material, followed by contrast material(s) and further sections	\$	2,013.00
Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material	\$	793.00

DESCRIPTION	CHARGE
Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material	\$ 793.00
Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; with contrast material(s)	\$ 1,134.00
Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; with contrast material(s)	\$ 1,134.00
Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material, followed by contrast material(s) and further sections	\$ 1,335.00
Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material, followed by contrast material(s) and further sections	\$ 1,335.00
Computed tomography, maxillofacial area; without contrast material	\$ 1,431.00
Computed tomography, maxillofacial area; without contrast material	\$ 1,431.00
Computed tomography, maxillofacial area; with contrast material(s)	\$ 1,491.00
Computed tomography, maxillofacial area; with contrast material(s)	\$ 1,491.00
Computed tomography, maxillofacial area; without contrast material, followed by contrast material(s) and further sections	\$ 2,187.00
Computed tomography, maxillofacial area; without contrast material, followed by contrast material(s) and further sections	\$ 2,187.00
Computed tomography, soft tissue neck; without contrast material	\$ 1,591.00
Computed tomography, soft tissue neck; without contrast material	\$ 1,591.00
Computed tomography, soft tissue neck; with contrast material(s)	\$ 1,745.00
Computed tomography, soft tissue neck; with contrast material(s)	\$ 1,745.00
Computed tomography, soft tissue neck; without contrast material followed by contrast material(s) and further sections	\$ 2,493.00
Computed tomography, soft tissue neck; without contrast material followed by contrast material(s) and further sections	\$ 2,493.00
Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image postprocessing	\$ 5,148.00
Computed tomographic angiography, neck, with contrast material(s), including noncontrast images, if performed, and image postprocessing	\$ 5,148.00
Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s)	\$ 2,412.00
Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s)	\$ 2,460.00
Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; with contrast material(s)	\$ 2,412.00
Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; with contrast material(s)	\$ 2,460.00
Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s), followed by contrast material(s) and further sequences	\$ 2,412.00
Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s), followed by contrast material(s) and further sequences	\$ 2,460.00
Magnetic resonance angiography, head; without contrast material(s)	\$ 1,774.00
Magnetic resonance angiography, head; without contrast material(s)	\$ 1,808.00
Magnetic resonance angiography, head; with contrast material(s)	\$ 2,019.00
Magnetic resonance angiography, head; with contrast material(s)	\$ 2,057.00
Magnetic resonance angiography, head; without contrast material(s), followed by contrast material(s) and further sequences	\$ 1,987.00
Magnetic resonance angiography, head; without contrast material(s), followed by contrast material(s) and further sequences	\$ 2,025.00
Magnetic resonance angiography, neck; without contrast material(s)	\$ 1,774.00
Magnetic resonance angiography, neck; without contrast material(s)	\$ 1,808.00
Magnetic resonance angiography, neck; with contrast material(s)	\$ 2,019.00
Magnetic resonance angiography, neck; with contrast material(s)	\$ 2,057.00
Magnetic resonance angiography, neck; without contrast material(s), followed by contrast material(s) and further sequences	\$ 2,019.00
Magnetic resonance angiography, neck; without contrast material(s), followed by contrast material(s) and further sequences	\$ 2,057.00
Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material	\$ 2,119.00
Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material	\$ 2,160.00
Magnetic resonance (eg, proton) imaging, brain (including brain stem); with contrast material(s)	\$ 2,412.00
Magnetic resonance (eg, proton) imaging, brain (including brain stem); with contrast material(s)	\$ 2,460.00
Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences	\$ 2,412.00
Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences	\$ 2,460.00
Radiologic examination, chest; single view	\$ 237.00
Radiologic examination, chest; single view	\$ 237.00
Radiologic examination, chest; single view	\$ 237.00
Radiologic examination, chest; 2 views	\$ 279.00
Radiologic examination, chest; 2 views	\$ 279.00
Radiologic examination, chest; 2 views	\$ 279.00
Radiologic examination, chest; 3 views	\$ 321.00
Radiologic examination, chest; 3 views	\$ 321.00
Radiologic examination, chest; 3 views	\$ 321.00
Radiologic examination, chest; 4 or more views	\$ 373.00
Radiologic examination, chest; 4 or more views	\$ 373.00
Radiologic examination, chest; 4 or more views	\$ 373.00
Radiologic examination, ribs, unilateral; 2 views	\$ 262.00
Radiologic examination, ribs, unilateral; 2 views	\$ 262.00

DESCRIPTION		CHARGE
Radiologic examination, ribs, unilateral; 2 views	\$	262.00
Radiologic examination, ribs, unilateral; including posteroanterior chest, minimum of 3 views	\$	480.00
Radiologic examination, ribs, unilateral; including posteroanterior chest, minimum of 3 views	\$	480.00
Radiologic examination, ribs, unilateral; including posteroanterior chest, minimum of 3 views	\$	480.00
Radiologic examination, ribs, bilateral; 3 views	\$	392.00
Radiologic examination, ribs, bilateral; 3 views	\$	373.00
Radiologic examination, ribs, bilateral; 3 views	\$	392.00
Radiologic examination, ribs, bilateral; including posteroanterior chest, minimum of 4 views	\$	1,172.00
Radiologic examination, ribs, bilateral; including posteroanterior chest, minimum of 4 views	\$	1,172.00
Radiologic examination, ribs, bilateral; including posteroanterior chest, minimum of 4 views	\$	1,172.00
Radiologic examination; sternum, minimum of 2 views	\$	237.00
Radiologic examination; sternum, minimum of 2 views	\$	237.00
Radiologic examination; sternum, minimum of 2 views	\$	237.00
Radiologic examination; sternoclavicular joint or joints, minimum of 3 views	\$	278.00
Radiologic examination; sternoclavicular joint or joints, minimum of 3 views	\$	278.00
Radiologic examination; sternoclavicular joint or joints, minimum of 3 views	\$	278.00
Computed tomography, thorax; without contrast material	\$	1,798.00
Computed tomography, thorax; without contrast material	\$	1,798.00
Computed tomography, thorax; with contrast material(s)	\$	1,902.00
Computed tomography, thorax; with contrast material(s)	\$	1,902.00
Computed tomography, thorax; without contrast material, followed by contrast material(s) and further sections	\$	2,801.00
Computed tomography, thorax; without contrast material, followed by contrast material(s) and further sections	\$	2,801.00
Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing	\$	5,148.00
Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing	\$	5,148.00
Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal lymphadenopathy); without contrast material(s)	\$	2,063.00
Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal lymphadenopathy); without contrast material(s)	\$	2,102.00
Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal lymphadenopathy); with contrast material(s)	\$	2,356.00
Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal lymphadenopathy); with contrast material(s)	\$	2,402.00
Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal lymphadenopathy); without contrast material(s), followed by contrast material(s) and further sequences	\$	2,356.00
Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal lymphadenopathy); without contrast material(s), followed by	\$	2,402.00
contrast material(s) and further sequences	l ¢	227.00
Radiologic examination, spine, single view, specify level Radiologic examination, spine, single view, specify level	\$ \$	237.00
Radiologic examination, spine, single view, specify level	\$	237.00 237.00
Radiologic examination, spine, cervical; 2 or 3 views	\$	237.00
Radiologic examination, spine, cervical; 2 or 3 views	\$	237.00
Radiologic examination, spine, cervical; 2 or 3 views	\$	237.00
Radiologic examination, spine, cervical; 4 or 5 views	Ś	372.00
Radiologic examination, spine, cervical; 4 or 5 views	\$	372.00
Radiologic examination, spine, cervical; 4 or 5 views	\$	372.00
Radiologic examination, spine, cervical; 6 or more views	\$	419.00
Radiologic examination, spine, cervical; 6 or more views	\$	419.00
Radiologic examination, spine, cervical; 6 or more views	\$	419.00
Radiologic examination, spine; thoracic, 2 views	\$	237.00
Radiologic examination, spine; thoracic, 2 views	\$	237.00
Radiologic examination, spine; thoracic, 2 views	\$	237.00
Radiologic examination, spine; thoracic, 3 views	\$	373.00
Radiologic examination, spine; thoracic, 3 views	\$	373.00
Radiologic examination, spine; thoracic, 3 views	\$	373.00
Radiologic examination, spine; thoracic, minimum of 4 views	\$	248.00
Radiologic examination, spine; thoracic, minimum of 4 views	\$	237.00
Radiologic examination, spine; thoracic, minimum of 4 views	\$	248.00
Radiologic examination, spine; thoracolumbar junction, minimum of 2 views	\$	373.00
Radiologic examination, spine; thoracolumbar junction, minimum of 2 views	\$	237.00
Radiologic examination, spine; thoracolumbar junction, minimum of 2 views	\$	373.00
Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); one view	\$	250.00
Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); one view	\$	250.00

DESCRIPTION		CHARGE
Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); one view	\$	250.00
Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); 2 or 3 views	\$	415.00
Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); 2 or 3 views	\$	415.00
Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); 2 or 3 views	\$	415.00
Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); 4 or 5 views	\$	791.00
Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); 4 or 5 views	\$	791.00
Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); 4 or 5 views	\$	791.00
Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); minimum of 6 views	\$	791.00
Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); minimum of 6 views	\$	791.00
Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); minimum of 6 views	\$	791.00
Radiologic examination, spine, lumbosacral; 2 or 3 views	\$	237.00
Radiologic examination, spine, lumbosacral; 2 or 3 views	\$	237.00
Radiologic examination, spine, lumbosacral; 2 or 3 views	\$	237.00
Radiologic examination, spine, lumbosacral; minimum of 4 views	\$	391.00
Radiologic examination, spine, lumbosacral; minimum of 4 views	\$	391.00
Radiologic examination, spine, lumbosacral; minimum of 4 views	\$	391.00
Radiologic examination, spine, lumbosacral; complete, including bending views, minimum of 6 views	\$	373.00
Radiologic examination, spine, lumbosacral; complete, including bending views, minimum of 6 views	\$	373.00
Radiologic examination, spine, lumbosacral; complete, including bending views, minimum of 6 views	\$	373.00
Radiologic examination, spine, lumbosacral; bending views only, 2 or 3 views	\$	373.00
Radiologic examination, spine, lumbosacral; bending views only, 2 or 3 views	\$	373.00
Radiologic examination, spine, lumbosacral; bending views only, 2 or 3 views	\$	373.00
Computed tomography, cervical spine; without contrast material	\$	1,638.00
Computed tomography, cervical spine; without contrast material	\$	1,638.00
Computed tomography, cervical spine, with contrast material	\$	1,697.00
Computed tomography, cervical spine, with contrast material	\$	1,697.00
Computed tomography, cervical spine, with contrast material, followed by contrast material(s) and further sections	\$	5,148.00
	•	
Computed tomography, cervical spine; without contrast material, followed by contrast material(s) and further sections	\$	5,148.00
Computed tomography, thoracic spine; without contrast material	\$	1,740.00
Computed tomography, thoracic spine; without contrast material	\$	1,740.00
Computed tomography, thoracic spine; with contrast material	\$	1,901.00
Computed tomography, thoracic spine; with contrast material	\$	1,901.00
Computed tomography, thoracic spine; without contrast material, followed by contrast material(s) and further sections	\$	2,616.00
Computed tomography, thoracic spine; without contrast material, followed by contrast material(s) and further sections	\$	2,616.00
Computed tomography, lumbar spine; without contrast material	\$	1,638.00
Computed tomography, lumbar spine; without contrast material	\$	1,638.00
Computed tomography, lumbar spine; with contrast material	\$	1,697.00
Computed tomography, lumbar spine; with contrast material	\$	1,697.00
Computed tomography, lumbar spine; without contrast material, followed by contrast material(s) and further sections	\$	2,493.00
Computed tomography, lumbar spine; without contrast material, followed by contrast material(s) and further sections	\$	2,493.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; without contrast material	\$	2,412.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; without contrast material	\$	2,460.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; with contrast material(s)	\$	2,706.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; with contrast material(s)	\$	2,758.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic; without contrast material	\$	2,412.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic; without contrast material	\$	2,460.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic; with contrast material(s)	\$	2,706.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic; with contrast material(s)	\$	2,758.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast material	\$	2,412.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast material	\$	2,460.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; with contrast material(s)	\$	2,706.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; with contrast material(s)	\$	2,758.00

DESCRIPTION		CHARGE
Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical	\$	2,706.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical	\$	2,758.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic	\$	2,706.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic	\$	2,758.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar	\$	2,706.00
Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar	\$	2,758.00
Radiologic examination, pelvis; 1 or 2 views	\$	237.00
Radiologic examination, pelvis; 1 or 2 views	\$	237.00
Radiologic examination, pelvis; 1 or 2 views	\$	237.00
Radiologic examination, pelvis; complete, minimum of 3 views	\$	723.00
Radiologic examination, pelvis; complete, minimum of 3 views	\$	723.00
Radiologic examination, pelvis; complete, minimum of 3 views	\$	723.00
Computed tomographic angiography, pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing	\$	5,148.00
Computed tomography, pelvis; without contrast material	\$	1,199.00
Computed tomography, pelvis; without contrast material	\$	1,199.00
Computed tomography, pelvis; with contrast material(s)	\$	1,305.00
Computed tomography, pelvis; with contrast material(s)	\$	259.00
Computed tomography, pelvis; with contrast material(s)	\$	1,305.00
Computed tomography, pelvis, with contrast material, followed by contrast material(s) and further sections	\$	1,902.00
Computed tomography, pelvis, without contrast material, followed by contrast material(s) and further sections	\$	1,902.00
Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s)	\$	2,412.00
Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s) Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s)	\$	2,460.00
	ې \$	2,400.00
Magnetic resonance (eg, proton) imaging, pelvis; with contrast material(s)	\$ \$	
Magnetic resonance (eg, proton) imaging, pelvis; with contrast material(s)		2,758.00
Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences	\$	2,706.00
Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences	\$	2,758.00
Radiologic examination, sacroiliac joints; 3 or more views	\$	237.00
Radiologic examination, sacroiliac joints; 3 or more views	\$	237.00
Radiologic examination, sacroiliac joints; 3 or more views	\$	237.00
Radiologic examination, sacrum and coccyx, minimum of 2 views	\$	237.00
Radiologic examination, sacrum and coccyx, minimum of 2 views	\$	237.00
Radiologic examination, sacrum and coccyx, minimum of 2 views	\$	237.00
Myelography, cervical, radiological supervision	\$	2,537.00
Myelography, thoracic, radiological supervision	\$	2,537.00
Myelography, lumbosacral, radiological supervision	\$	2,537.00
Myelography, 2 or more regions (eg, lumbar/thoracic, cervical/thoracic, lumbar/cervical, lumbar/thoracic/cervical), radiological supervision	\$	2,537.00
Discography, lumbar, radiological supervision	\$	11,343.00
Radiologic examination; clavicle, complete	\$	366.00
Radiologic examination; clavicle, complete	\$	366.00
Radiologic examination; clavicle, complete	\$	366.00
Radiologic examination; scapula, complete	\$	455.00
Radiologic examination; scapula, complete	\$	455.00
Radiologic examination; scapula, complete	\$	455.00
Radiologic examination, shoulder; 1 view	\$	272.00
Radiologic examination, shoulder; 1 view	\$	272.00
Radiologic examination, shoulder; 1 view	\$	272.00
Radiologic examination, shoulder; complete, minimum of 2 views	\$	437.00
Radiologic examination, shoulder; complete, minimum of 2 views	\$	437.00
Radiologic examination, shoulder; complete, minimum of 2 views	\$	437.00
Radiologic examination, shoulder, arthrography, radiological supervision	\$	1,394.00
Radiologic examination; acromioclavicular joints, bilateral, with or without weighted distraction	\$	300.00
Radiologic examination; acromioclavicular joints, bilateral, with or without weighted distraction	\$	300.00
Radiologic examination; acromioclavicular joints, bilateral, with or without weighted distraction	\$	300.00
Radiologic examination; humerus, minimum of 2 views	\$	455.00
Radiologic examination; humerus, minimum of 2 views	\$	455.00
Radiologic examination; humerus, minimum of 2 views	\$	455.00
Radiologic examination, elbow; 2 views	\$	279.00

DESCRIPTION		CHARGE
Radiologic examination, elbow; 2 views	\$	279.00
Radiologic examination, elbow; 2 views	\$	279.00
Radiologic examination, elbow; complete, minimum of 3 views	\$	262.00
Radiologic examination, elbow; complete, minimum of 3 views	\$	262.00
Radiologic examination, elbow; complete, minimum of 3 views	\$	262.00
Radiologic examination, elbow, arthrography, radiological supervision	\$	1,394.00
Radiologic examination; forearm, 2 views	\$	237.00
Radiologic examination; forearm, 2 views	\$	237.00
Radiologic examination; forearm, 2 views	\$	237.00
Radiologic examination; upper extremity, infant, minimum of 2 views	\$	373.00
Radiologic examination; upper extremity, infant, minimum of 2 views	\$	373.00
Radiologic examination; upper extremity, infant, minimum of 2 views	\$	373.00
Radiologic examination, wrist; 2 views	\$	237.00
Radiologic examination, wrist; 2 views	\$	237.00
Radiologic examination, wrist; 2 views	\$	237.00
Radiologic examination, wrist; complete, minimum of 3 views	\$	302.00
Radiologic examination, wrist; complete, minimum of 3 views Radiologic examination, wrist; complete, minimum of 3 views	\$ \$	302.00
Radiologic examination, wrist, complete, minimum of s views Radiologic examination, wrist, arthrography, radiological supervision	\$	302.00 466.00
Radiologic examination, whist, a through a phy, radiological supervision	\$	248.00
Radiologic examination, hand; 2 views	\$	248.00
Radiologic examination, hand; 2 views	\$	248.00
Radiologic examination, hand; 2 views Radiologic examination, hand; minimum of 3 views	\$	288.00
Radiologic examination, hand; minimum of 3 views	\$	288.00
Radiologic examination, hand; minimum of 3 views	\$	288.00
Radiologic examination, finger(s), minimum of 2 views	\$	248.00
Radiologic examination, finger(s), minimum of 2 views	\$	248.00
Radiologic examination, finger(s), minimum of 2 views	\$	248.00
Computed tomography, upper extremity; without contrast material	\$	1,087.00
Computed tomography, upper extremity; without contrast material	\$	1,087.00
Computed tomography, upper extremity; with contrast material(s)	\$	1,193.00
Computed tomography, upper extremity; with contrast material(s)	\$	1,193.00
Computed tomography, upper extremity; without contrast material, followed by contrast material(s) and further sections	\$	1,740.00
Computed tomography, upper extremity; without contrast material, followed by contrast material(s) and further sections	\$	1,740.00
Computed tomographic angiography, upper extremity, with contrast material(s), including noncontrast images, if performed, and image postprocessing	\$	5,148.00
Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast material(s)	\$	4,535.00
Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast material(s)	\$	4,624.00
Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; with contrast material(s)	\$	5,120.00
Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; with contrast material(s)	\$	5,220.00
Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast material(s), followed by contrast material(s) and further sequences	\$	5,120.00
Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast material(s), followed by contrast material(s) and further sequences	\$	5,220.00
Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s)	\$	2,561.00
Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s)	\$	2,611.00
Magnetic resonance (eg, proton) imaging, any joint of upper extremity; with contrast material(s)	\$	5,120.00
Magnetic resonance (eg, proton) imaging, any joint of upper extremity; with contrast material(s)	\$	5,220.00
Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s), followed by contrast material(s) and further sequences	\$	5,120.00
Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s), followed by contrast material(s) and further sequences	\$	5,220.00
Radiologic examination, hip, unilateral, with pelvis when performed; 1 view	\$	250.00
Radiologic examination, hip, unilateral, with period when performed; 1 view	\$	250.00
Radiologic examination, hip, unilateral, with period when performed; 1 view	\$	250.00
Radiologic examination, hip, unilateral, with period when performed; 2-3 views	\$	250.00
Radiologic examination, hip, unilateral, with period when performed; 2-3 views	\$	250.00
Radiologic examination, hip, unilateral, with period when performed; 2-3 views	\$	250.00
Radiologic examination, hip, unilateral, with period when performed; 2 5 views	\$	415.00
Radiologic examination, hip, unilateral, with pelvis when performed; minimum of 4 views	\$	415.00
Radiologic examination, hip, unilateral, with period when performed; minimum of 4 views	\$	415.00
Radiologic examination, hips, bilateral, with pelvis when performed; 2 views	\$	415.00
	\$	

DESCRIPTION	CHARGE
Radiologic examination, hips, bilateral, with pelvis when performed; 2 views	\$ 415.00
Radiologic examination, hips, bilateral, with pelvis when performed; 3-4 views	\$ 415.00
Radiologic examination, hips, bilateral, with pelvis when performed; 3-4 views	\$ 415.00
Radiologic examination, hips, bilateral, with pelvis when performed; 3-4 views	\$ 415.00
Radiologic examination, hips, bilateral, with pelvis when performed; minimum of 5 views	\$ 791.00
Radiologic examination, hips, bilateral, with pelvis when performed; minimum of 5 views	\$ 791.00
Radiologic examination, hips, bilateral, with pelvis when performed; minimum of 5 views	\$ 791.00
Radiologic examination, hip, arthrography, radiological supervision	\$ 1,394.00
Radiologic examination, femur; 1 view	\$ 250.00
Radiologic examination, femur; 1 view	\$ 250.00
Radiologic examination, femur; 1 view	\$ 250.00
Radiologic examination, femur; minimum 2 views	\$ 250.00
Radiologic examination, femur; minimum 2 views	\$ 250.00
Radiologic examination, femur; minimum 2 views	\$ 250.00
Radiologic examination, knee; 1 or 2 views	\$ 387.00
Radiologic examination, knee; 1 or 2 views	\$ 387.00
Radiologic examination, knee; 1 or 2 views	\$ 387.00
Radiologic examination, knee; 3 views	\$ 530.00
Radiologic examination, knee; 3 views	\$ 530.00
Radiologic examination, knee; 3 views	\$ 530.00
Radiologic examination, knee; complete, 4 or more views	\$ 697.00
Radiologic examination, knee; complete, 4 or more views	\$ 697.00
Radiologic examination, knee; complete, 4 or more views	\$ 697.00
Radiologic examination, knee; both knees, standing, anteroposterior	\$ 237.00
Radiologic examination, knee; both knees, standing, anteroposterior	\$ 237.00
Radiologic examination, knee; both knees, standing, anteroposterior	\$ 237.00
Radiologic examination, knee, arthrography, radiological supervision	\$ 1,394.00
Radiologic examination; tibia and fibula, 2 views	\$ 288.00
Radiologic examination; tibia and fibula, 2 views	\$ 288.00
Radiologic examination; tibia and fibula, 2 views	\$ 288.00
Radiologic examination; lower extremity, infant, minimum of 2 views	\$ 241.00
Radiologic examination; lower extremity, infant, minimum of 2 views	\$ 241.00
Radiologic examination; lower extremity, infant, minimum of 2 views	\$ 241.00
Radiologic examination, ankle; 2 views	\$ 288.00
Radiologic examination, ankle; 2 views	\$ 288.00
Radiologic examination, ankle; 2 views	\$ 288.00
Radiologic examination, ankle; complete, minimum of 3 views	\$ 533.00
Radiologic examination, ankle; complete, minimum of 3 views	\$ 533.00
Radiologic examination, ankle; complete, minimum of 3 views	\$ 533.00
Radiologic examination, ankle, arthrography, radiological supervision	\$ 1,463.00
Radiologic examination, foot; 2 views	\$ 237.00
Radiologic examination, foot; 2 views	\$ 237.00
Radiologic examination, foot; 2 views	\$ 237.00
Radiologic examination, foot; complete, minimum of 3 views	\$ 455.00
Radiologic examination, foot; complete, minimum of 3 views	\$ 455.00
Radiologic examination, foot; complete, minimum of 3 views	\$ 455.00
Radiologic examination; calcaneus, minimum of 2 views	\$ 354.00
Radiologic examination; calcaneus, minimum of 2 views	\$ 354.00
Radiologic examination; calcaneus, minimum of 2 views	\$ 354.00
Radiologic examination; toe(s), minimum of 2 views	\$ 279.00
Radiologic examination; toe(s), minimum of 2 views	\$ 279.00
Radiologic examination; toe(s), minimum of 2 views	\$ 279.00
Computed tomography, lower extremity; without contrast material	\$ 1,151.00
Computed tomography, lower extremity; without contrast material	\$ 1,151.00
Computed tomography, lower extremity; with contrast material(s)	\$ 1,225.00
Computed tomography, lower extremity; with contrast material(s)	\$ 1,225.00
Computed tomography, lower extremity; without contrast material, followed by contrast material(s) and further sections	\$ 1,872.00
Computed tomography, lower extremity; without contrast material, followed by contrast material(s) and further sections	\$ 1,872.00
Computed tomographic angiography, lower extremity, with contrast material(s), including noncontrast images, if performed, and image postprocessing	\$ 5,148.00
Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s)	\$ 4,536.00
Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s)	\$ 4,625.00
Magnetic resonance (eg, proton) imaging, lower extremity other than joint; with contrast material(s)	\$ 5,120.00

DESCRIPTION		CHARGE
Magnetic resonance (eg, proton) imaging, lower extremity other than joint; with contrast material(s)	\$	5,220.00
Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s), followed by contrast material(s) and further sequences	\$	5,120.00
Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s), followed by contrast material(s) and further sequences	\$	5,220.00
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material	\$	4,536.00
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material	\$	4,625.00
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; with contrast material(s)	\$	5,120.00
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; with contrast material(s)	\$	5,220.00
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material(s), followed by contrast material(s) and further sequences	\$	5,120.00
Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material(s), followed by contrast material(s) and further sequences	\$	5,220.00
Radiologic examination, abdomen; 1 view	\$	237.00
Radiologic examination, abdomen; 1 view	\$	237.00
Radiologic examination, abdomen; 1 view	\$	237.00
Radiologic examination, abdomen; 2 views	\$	279.00
Radiologic examination, abdomen; 2 views	\$	279.00
Radiologic examination, abdomen; 2 views	\$	279.00
Radiologic examination, abdomen; 3 or more views	\$	321.00
Radiologic examination, abdomen; 3 or more views	\$	321.00
Radiologic examination, abdomen; 3 or more views	\$	321.00
Radiologic examination, abdomen; complete acute abdomen series, including supine, erect, and/or decubitus views, single view chest	\$	373.00
Radiologic examination, abdomen; complete acute abdomen series, including supine, erect, and/or decubitus views, single view chest	\$	373.00
Radiologic examination, abdomen; complete acute abdomen series, including supine, erect, and/or decubitus views, single view chest	\$	373.00
Computed tomography, abdomen; without contrast material	\$	1,824.00
Computed tomography, abdomen; with contrast material	\$ ¢	1,824.00 1,305.00
Computed tomography, abdomen; with contrast material(s) Computed tomography, abdomen; with contrast material(s)	\$ \$	1,305.00
Computed tomography, abdomen; with contrast material, followed by contrast material(s) and further sections	\$	1,798.00
Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections	\$	1,798.00
Computed tomographic angiography, abdomen and pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing	\$	2,019.00
Computed tomographic angiography, abdomen and pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing	\$	2,019.00
Computed tomographic angiography, abdomen, with contrast material(s), including noncontrast images, if performed, and image postprocessing	\$	5,148.00
Computed tomography, abdomen and pelvis; without contrast material	\$	3,020.00
Computed tomography, abdomen and pelvis; without contrast material	\$	3,020.00
Computed tomography, abdomen and pelvis; with contrast material(s)	\$	3,073.00
Computed tomography, abdomen and pelvis; with contrast material(s)	\$	3,073.00
Computed tomography, abdomen and pelvis; without contrast material in one or both body regions, followed by contrast material(s) and further sections in one or both body regions	\$	4,574.00
Computed tomography, abdomen and pelvis; without contrast material in one or both body regions, followed by contrast material(s) and further sections in one or both body regions	\$	4,574.00
Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s)	\$	2,356.00
Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s)	\$	2,402.00
Magnetic resonance (eg, proton) imaging, abdomen; with contrast material(s) Magnetic resonance (eg, proton) imaging, abdomen; with contrast material(s)	\$	2,649.00
Magnetic resonance (eg, proton) imaging, abdomen; with contrast material(s) Magnetic resonance (eg, proton) imaging, abdomen; with contrast material(s)	\$	2,700.00
Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences	\$	2,649.00
Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences	\$	2,700.00
Radiologic examination; pharynx and/or cervical esophagus	\$	439.00
Radiologic examination; esophagus	\$	292.00
Swallowing function, with cineradiography/videoradiography	\$	418.00
Radiologic examination, gastrointestinal tract, upper; with or without delayed images, without KUB	\$	693.00
Radiologic examination, gastrointestinal tract, upper; with or without delayed images, with KUB	\$	690.00
Radiologic examination, gastrointestinal tract, upper; with small intestine, includes multiple serial images	\$	782.00
Radiological examination, gastrointestinal tract, upper, air contrast, with specific high density barium, effervescent agent, with or without glucagon; with or without delayed images, without KUB	\$	726.00
Radiological examination, gastrointestinal tract, upper, air contrast, with specific high density barium, effervescent agent, with or without glucagon; with or without delayed images, with KUB	\$	722.00
Radiological examination, gastrointestinal tract, upper, air contrast, with specific high density barium, effervescent agent, with or without glucagon; with small intestine follow-through	\$	722.00
Radiologic examination, small intestine, includes multiple serial images	\$	418.00

DESCRIPTION		CHARGE
Radiologic examination, small intestine, includes multiple serial images; via enteroclysis tube	\$	642.00
Computed tomographic (CT) colonography, diagnostic, including image postprocessing; without contrast material	\$	519.00
Computed tomographic (CT) colonography, diagnostic, including image postprocessing; with contrast material(s) including non-contrast images, if performed	\$	1,128.00
Radiologic examination, colon; contrast (eg, barium) enema, with or without KUB	\$	649.00
Radiologic examination, colon; air contrast with specific high density barium, with or without glucagon	\$	675.00
Therapeutic enema, contrast or air, for reduction of intussusception or other intraluminal obstruction (eg, meconium ileus)	\$	622.00
Cholecystography, oral contrast	\$	418.00
Cholangiography and/or pancreatography; intraoperative, radiological supervision	\$	317.00
Combined endoscopic catheterization of the biliary and pancreatic ductal systems, radiological supervision	\$	599.00
Urography (pyelography), intravenous, with or without KUB, with or without tomography	\$	1,060.00
Urography, infusion, drip technique and/or bolus technique; with nephrotomography	\$	1,060.00
Urography, retrograde, with or without KUB	\$ \$	1,060.00
Urography, antegrade (pyelostogram, nephrostogram, loopogram), radiological supervision		1,060.00 1,060.00
Cystography, minimum of 3 views, radiological supervision Urethrocystography, retrograde, radiological supervision	\$ \$	1,060.00
Urethrocystography, reitograde, radiological supervision	\$	1,060.00
Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; single or first gestation	\$	1,127.00
Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; single or first gestation	\$	1,127.00
Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal perior maging when performed; each additional gestation (List separately in	\$	1,127.00
addition to code for primary procedure)	Ŷ	1)11/100
Magnetic resonance (eg, proton) imaging, fetal, including placental and maternal pelvic imaging when performed; each additional gestation (List separately in addition to code for primary procedure)	\$	1,127.00
Hysterosalpingography, radiological supervision	\$	1,441.00
Perineogram (eg, vaginogram, for sex determination or extent of anomalies)	\$	1,441.00
Computed tomography, heart, without contrast material, with quantitative evaluation of coronary calcium	\$	92.00
Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)	\$	1,018.00
Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including	\$	1,018.00
3D image postprocessing, assessment of LV cardiac function, RV structure and function and evaluation of venous structures, if performed)	Ş	1,018.00
Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3D image postprocessing (including evaluation of cardiac structures, if performed)	\$	1,018.00
Computed tomographic angiography, abdominal aorta and bilateral iliofemoral lower extremity runoff, with contrast material(s), including noncontrast images, if performed, and image postprocessing	\$	5,148.00
Venography, extremity, unilateral, radiological supervision	\$	3,398.00
Venography, extremity, bilateral, radiological supervision	\$	3,035.00
Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision	\$	1,795.00
Change of percutaneous tube or drainage catheter with contrast monitoring (eg, genitourinary system, abscess), radiological supervision	\$	613.00
Radiological guidance (ie, fluoroscopy, ultrasound, or computed tomography), for percutaneous drainage (eg, abscess, specimen collection), with placement of catheter, radiological supervision	\$	370.00
Radiological guidance (ie, fluoroscopy, ultrasound, or computed tomography), for percutaneous drainage (eg, abscess, specimen collection), with placement of	\$	1,557.00
catheter, radiological supervision		
Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time, other than 71023 or 71034 (eg, cardiac fluoroscopy)	\$	942.00
Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time, other than 71023 or 71034 (eg, cardiac fluoroscopy)	\$	643.00
Fluoroscopy, physician or other qualified health care professional time more than 1 hour, assisting a nonradiologic physician or other qualified health care professional (eg, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy)	\$	643.00
Fluoroscopy, physician or other qualified health care professional time more than 1 hour, assisting a nonradiologic physician or other qualified health care	\$	643.00
professional (eg, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy) Fluoroscopy, physician or other qualified health care professional time more than 1 hour, assisting a nonradiologic physician or other qualified health care	\$	965.00
professional (eg, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy)		
Fluoroscopy, physician or other qualified health care professional time more than 1 hour, assisting a nonradiologic physician or other qualified health care professional (eg, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy)	\$	1,448.00
Fluoroscopy, physician or other qualified health care professional time more than 1 hour, assisting a nonradiologic physician or other qualified health care professional (eg, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy)	\$	1,806.00
Fluoroscopy, physician or other qualified health care professional time more than 1 hour, assisting a nonradiologic physician or other qualified health care professional (eg, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy)	\$	2,171.00
Fluoroscopy, physician or other qualified health care professional time more than 1 hour, assisting a nonradiologic physician or other qualified health care	\$	2,530.00
professional (eg, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy) Fluoroscopy, physician or other qualified health care professional time more than 1 hour, assisting a nonradiologic physician or other qualified health care	\$	2,893.00
professional (eg, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy)		

DESCRIPTION		CHARGE
Fluoroscopy, physician or other qualified health care professional time more than 1 hour, assisting a nonradiologic physician or other qualified health care	\$	3,257.00
professional (eg, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy)	L	
Fluoroscopy, physician or other qualified health care professional time more than 1 hour, assisting a nonradiologic physician or other qualified health care	\$	3,619.00
professional (eg, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy) Radiologic examination from nose to rectum for foreign body, single view, child	\$	237.00
Radiologic examination from nose to rectum for foreign body, single view, child	\$	237.00
Radiologic examination from nose to rectum for foreign body, single view, child	\$	237.00
Radiologic examination, abscess, fistula or sinus tract study, radiological supervision	\$	1,306.00
Radiological examination, surgical specimen	\$	1,306.00
Radiologic examination, single plane body section (eg, tomography), other than with urography	\$	622.00
3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; not requiring image postprocessing on an independent workstation	\$	487.00
3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstation	\$	618.00
3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstation	\$	470.00
3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing on an independent workstation	\$	480.00
3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image	\$	480.00
postprocessing under concurrent supervision; requiring image postprocessing on an independent workstation		
3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstation	\$	480.00
Computed tomography, limited or localized follow-up study	\$	710.00
Computed tomography, limited or localized follow-up study	\$	710.00
Unlisted computed tomography procedure (eg, diagnostic, interventional)	\$	412.00
Unlisted magnetic resonance procedure (eg, diagnostic, interventional)	\$ c	1,188.00
Echoencephalography, real time with image documentation (gray scale) (for determination of ventricular size, delineation of cerebral contents, and detection of fluid masses or other intracranial abnormalities), including A-mode encephalography as secondary component where indicated	\$	554.00
Echoencephalography, real time with image documentation (gray scale) (for determination of ventricular size, delineation of cerebral contents, and detection of fluid masses or other intracranial abnormalities), including A-mode encephalography as secondary component where indicated	\$	554.00
Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation	\$	554.00
Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation	\$	554.00
Ultrasound, chest (includes mediastinum), real time with image documentation	\$	796.00
Ultrasound, chest (includes mediastinum), real time with image documentation	\$ ¢	796.00
Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; complete Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited	\$ \$	395.00 395.00
Ultrasound, abdominal, real time with image documentation; complete	\$	554.00
Ultrasound, abdominal, real time with image documentation; complete	\$	554.00
Ultrasound, abdominal, real time with image documentation; limited (eg, single organ, quadrant, follow-up)	\$	554.00
Ultrasound, abdominal, real time with image documentation; limited (eg, single organ, quadrant, follow-up)	\$	554.00
Ultrasound, abdominal aorta, real time with image documentation, screening study for abdominal aortic aneurysm (AAA)	\$	389.00
Ultrasound, abdominal aorta, real time with image documentation, screening study for abdominal aortic aneurysm (AAA)	\$	389.00
Ultrasound, abdominal aorta, real time with image documentation, screening study for abdominal aortic aneurysm (AAA)	\$	389.00
Ultrasound, abdominal aorta, real time with image documentation, screening study for abdominal aortic aneurysm (AAA)	\$	389.00
Ultrasound, abdominal aorta, real time with image documentation, screening study for abdominal aortic aneurysm (AAA)	\$	389.00
Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete	\$	554.00
Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete	\$	554.00
Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; limited Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; limited	\$ c	554.00
Ultrasound, transplanted kidney, real time and duplex Doppler with image documentation.	\$ \$	554.00 554.00
Ultrasound, transplanted kidney, real time and duplex Doppler with image documentation	\$	554.00
Ultrasound, spinal canal and contents	\$	456.00
Ultrasound, spinal canal and contents	\$	456.00
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks 0 days), transabdominal approach; single or first gestation	\$	554.00
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks 0 days), transabdominal	\$	554.00
approach; single or first gestation Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks 0 days), transabdominal	\$	785.00
approach; each additional gestation (List separately in addition to code for primary procedure) Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks 0 days), transabdominal	\$	785.00
approach; each additional gestation (List separately in addition to code for primary procedure) Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> or = 14 weeks 0 days), transabdominal	\$	554.00
approach; single or first gestation		

DESCRIPTION		CHARGE
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> or = 14 weeks 0 days), transabdominal	\$	554.00
approach; single or first gestation		
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> or = 14 weeks 0 days), transabdominal approach; each additional gestation (List separately in addition to code for primary procedure)	\$	1,015.00
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> or = 14 weeks 0 days), transabdominal approach; each additional gestation (List separately in addition to code for primary procedure)	\$	1,015.00
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation	\$	785.00
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation	\$	785.00
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal	\$	241.00
approach; each additional gestation (List separately in addition to code for primary procedure) Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal	\$	241.00
approach; each additional gestation (List separately in addition to code for primary procedure)		
Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses	\$	554.00
Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses	\$	554.00
Ultrasound, pregnant uterus, real time with image documentation, follow-up (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), transabdominal approach, per fetus	\$	370.00
Ultrasound, pregnant uterus, real time with image documentation, follow-up (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), transabdominal approach, per fetus	\$	370.00
Ultrasound, pregnant uterus, real time with image documentation, transvaginal	\$	554.00
Ultrasound, pregnant uterus, real time with image documentation, transvaginal	\$	554.00
Fetal biophysical profile; without non-stress testing	\$	580.00
Doppler velocimetry, fetal; umbilical artery	\$	370.00
Doppler velocimetry, fetal; umbilical artery	\$	370.00
Doppler velocimetry, fetal; middle cerebral artery	\$	370.00
Doppler velocimetry, fetal; middle cerebral artery	\$	370.00
Ultrasound, transvaginal	\$	748.00
Ultrasound, transvaginal Salina infusion consultatorgraphy (SIS), including solar flow Dappler, when performed	\$ ¢	748.00 785.00
Saline infusion sonohysterography (SIS), including color flow Doppler, when performed Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	\$ \$	554.00
Ultrasound, pelvic (nonobstetric), real time with image documentation, complete	\$	554.00
Ultrasound, pelvic (nonobstetric), real time with image documentation; limited or follow-up (eg, for follicles)	\$	411.00
Ultrasound, pelvic (nonobstetric), real time with image documentation; limited or follow-up (eg, for follicles)	\$	411.00
Ultrasound, scrotum and contents	\$	554.00
Ultrasound, scrotum and contents	\$	554.00
Ultrasound, transrectal	\$	1,602.00
Ultrasound, extremity, nonvascular, real-time with image documentation; complete	\$	900.00
Ultrasound, extremity, nonvascular, real-time with image documentation; complete	\$	900.00
Ultrasound, extremity, nonvascular, real-time with image documentation; limited, anatomic specific	\$	470.00
Ultrasound, extremity, nonvascular, real-time with image documentation; limited, anatomic specific	\$	470.00
Ultrasound, infant hips, real time with imaging documentation; dynamic (requiring physician or other qualified health care professional manipulation)	\$	435.00
Ultrasound, infant hips, real time with imaging documentation; dynamic (requiring physician or other qualified health care professional manipulation)	\$	435.00
Ultrasound, infant hips, real time with imaging documentation; limited, static (not requiring physician or other qualified health care professional manipulation)	\$	435.00
Ultrasound, infant hips, real time with imaging documentation; limited, static (not requiring physician or other qualified health care professional manipulation)	\$	435.00
Ultrasound guided compression repair of arterial pseudoaneurysm or arteriovenous fistulae (includes diagnostic ultrasound evaluation, compression of lesion and imaging)	\$	744.00
Ultrasound guided compression repair of arterial pseudoaneurysm or arteriovenous fistulae (includes diagnostic ultrasound evaluation, compression of lesion and imaging)	\$	781.00
Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (List separately in addition to code for primary procedure)	\$	70.00
Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (List separately in addition to code for primary procedure)	\$	70.00
Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision	\$	184.00
		· · · · · · · · · · · · · · · · · · ·

DESCRIPTION		CHARGE
Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision	\$	333.00
Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision	\$	184.00
Ultrasonic guidance, intraoperative	\$	514.00
Unlisted ultrasound procedure (eg, diagnostic, interventional)	\$	370.00
Unlisted ultrasound procedure (eg, diagnostic, interventional)	\$	370.00
Fluoroscopic guidance for needle placement (eg, biopsy, aspiration, injection, localization device) (List separately in addition to code for primary procedure)	\$	330.00
Fluoroscopic guidance and localization of needle or catheter tip for spine or paraspinous diagnostic or therapeutic injection procedures (epidural or subarachnoid) (List separately in addition to code for primary procedure)	\$	372.00
Computed tomography guidance for needle placement (eg, biopsy, aspiration, injection, localization device), radiological supervision	\$	2,186.00
Computed tomography guidance for needle placement (eg, biopsy, aspiration, injection, localization device), radiological supervision	\$	2,186.00
Computed tomography guidance for placement of radiation therapy fields	\$	363.00
Mammary ductogram or galactogram, single duct, radiological supervision	\$	903.00
Screening digital breast tomosynthesis, bilateral (List separately in addition to code for primary procedure)	\$	93.00
Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral	\$	431.00
Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral	\$	431.00
Diagnostic mammography, including computer-aided detection (CAD) when performed; bilateral	\$	467.00
Diagnostic mammography, including computer-aided detection (CAD) when performed; bilateral	\$	467.00
Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed	\$	431.00
Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed	\$	431.00
Bone age studies	\$	237.00
Bone age studies	\$	237.00
Bone age studies	\$	237.00
Bone length studies (orthoroentgenogram, scanogram)	\$	283.00
Bone length studies (orthoroentgenogram, scanogram) Bone length studies (orthoroentgenogram, scanogram)	\$	283.00
Bone length studies (orthoroentgenogram, scanogram) Bone length studies (orthoroentgenogram, scanogram)	\$	283.00
Radiologic examination, osseous survey; limited (eg, for metastases)	\$	493.00
Radiologic examination, osseous survey, limited (eg, for metastases)	\$	493.00
		493.00
Radiologic examination, osseous survey; limited (eg, for metastases)	\$ ¢	
Radiologic examination, osseous survey; complete (axial and appendicular skeleton)	\$	1,013.00
Radiologic examination, osseous survey; complete (axial and appendicular skeleton)	\$	1,013.00
Radiologic examination, osseous survey; complete (axial and appendicular skeleton)	\$	1,013.00
Radiologic examination, osseous survey, infant	\$	1,013.00
Radiologic examination, osseous survey, infant	\$	1,013.00
Radiologic examination, osseous survey, infant	\$	1,013.00
Computed tomography, bone mineral density study, 1 or more sites, axial skeleton (eg, hips, pelvis, spine)	\$	371.00
Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine)	\$	349.00
Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; appendicular skeleton (peripheral) (eg, radius, wrist, heel)	\$	210.00
Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine), including vertebral fracture assessment	\$	410.00
Vertebral fracture assessment via dual-energy X-ray absorptiometry (DXA)	\$	150.00
Therapeutic radiology simulation-aided field setting; simple	\$	756.00
Therapeutic radiology simulation-aided field setting; intermediate	\$	1,279.00
Therapeutic radiology simulation-aided field setting; complex	\$	1,479.00
Respiratory motion management simulation (List separately in addition to code for primary procedure)	\$	384.00
3-dimensional radiotherapy plan, including dose-volume histograms	\$	4,257.00
Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, only when prescribed by the treating physician	\$	470.00
Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications	\$	4,257.00
Teletherapy isodose plan; simple (1 or 2 unmodified ports directed to a single area of interest), includes basic dosimetry calculation(s)	\$	489.00
Teletherapy isodose plan; complex (multiple treatment areas, tangential ports, the use of wedges, blocking, rotational beam, or special beam considerations),	\$	1,279.00
includes basic dosimetry calculation(s)		_,_, 5.00
Brachytherapy isodose plan; simple (calculation[s] made from 1 to 4 sources, or remote afterloading brachytherapy, 1 channel), includes basic dosimetry calculation(s)	\$	470.00
Brachytherapy isodose plan; intermediate (calculation[s] made from 5 to 10 sources, or remote afterloading brachytherapy, 2-12 channels), includes basic dosimetry calculation(s)	\$	1,279.00
Special teletherapy port plan, particles, hemibody, total body	\$	1,279.00
Special dosimetry (eg, TLD, microdosimetry) (specify), only when prescribed by the treating physician	\$	470.00
Treatment devices, design and construction; simple (simple block, simple bolus)	\$	877.00
Treatment devices, design and construction; intermediate (multiple blocks, stents, bite blocks, special bolus)	\$	877.00
Treatment devices, design and construction; complex (irregular blocks, special shields, compensators, wedges, molds or casts)	\$	877.00

DESCRIPTION		CHARGE
Continuing medical physics consultation, including assessment of treatment parameters, quality assurance of dose delivery, and review of patient treatment	\$	500.00
documentation in support of the radiation oncologist, reported per week of therapy		
Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan	\$	1,279.00
Special medical radiation physics consultation	\$	583.00
Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of cranial lesion(s) consisting of 1 session; linear accelerator based	\$	14,753.00
Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions	\$	7,893.00
Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple	\$	2,097.00
Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex	\$	2,097.00
Guidance for localization of target volume for delivery of radiation treatment delivery, includes intrafraction tracking, when performed	\$	363.00
Guidance for localization of target volume for delivery of radiation treatment delivery, includes intrafraction tracking, when performed	\$	460.00
Radiation treatment delivery, >/=1 MeV; simple	\$	429.00
Radiation treatment delivery, >/=1 MeV; simple	\$	429.00
Radiation treatment delivery, >/=1 MeV; intermediate	\$	791.00
Radiation treatment delivery, >/=1 MeV; intermediate	\$	432.00
Radiation treatment delivery, >/=1 MeV; complex	\$	791.00
Radiation treatment delivery, >/=1 MeV; complex	\$	791.00
Radiation treatment delivery, >/=1 MeV; complex	\$	791.00
Therapeutic radiology port image(s)	\$	96.00
Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)	\$	2,383.00
Infusion or instillation of radioelement solution (includes 3-month follow-up care)	\$	1,042.00
Intracavitary radiation source application; simple Intracavitary radiation source application; intermediate	\$ \$	1,484.00 1,484.00
	1	1,484.00
Intracavitary radiation source application; complex Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel	\$ \$	4,278.00
Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed, 1 channels	\$	4,278.00
Remote alterioading high dose rate radionacide interstitian of intracavitary bracitytherapy, includes basic dosinietry, when performed, 2-12 channels	Ļ	4,278.00
Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; over 12 channels	\$	4,278.00
Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed	\$	5,537.00
Supervision, handling, loading of radiation source	\$	272.00
Supervision, handling, loading of radiation source	\$	272.00
Thyroid uptake, single or multiple quantitative measurement(s) (including stimulation, suppression, or discharge, when performed)	\$	577.00
Thyroid imaging (including vascular flow, when performed)	\$	754.00
Thyroid imaging (including vascular flow, when performed); with single or multiple uptake(s) quantitative measurement(s) (including stimulation, suppression, or discharge, when performed)	\$	1,181.00
Thyroid carcinoma metastases imaging; limited area (eg, neck and chest only)	\$	1,573.00
Thyroid carcinoma metastases imaging; whole body	\$	1,573.00
Parathyroid planar imaging (including subtraction, when performed)	\$	1,181.00
Parathyroid planar imaging (including subtraction, when performed); with tomographic (SPECT)	\$	3,035.00
Parathyroid planar imaging (including subtraction, when performed); with tomographic (SPECT), and concurrently acquired computed tomography (CT) for anatomical localization	\$	4,740.00
Bone marrow imaging; limited area	\$	1,423.00
Whole blood volume determination, including separate measurement of plasma volume and red cell volume (radiopharmaceutical volume-dilution technique)	\$	2,325.00
Lymphatics and lymph nodes imaging	\$	1,423.00
Liver imaging; static only	\$	1,530.00
Liver imaging (SPECT)	\$	1,530.00
Liver imaging (SPECT); with vascular flow	\$	1,530.00
Liver and spleen imaging; static only	\$	1,530.00
Liver and spleen imaging; with vascular flow	\$	1,530.00
Hepatobiliary system imaging, including gallbladder when present	\$	1,530.00
Hepatobiliary system imaging, including gallbladder when present; with pharmacologic intervention, including quantitative measurement(s) when performed	\$	1,530.00
Salivary gland function study	\$	1,330.00
Gastroesophageal reflux study	\$	1,330.00
Gastric emptying imaging study (eg, solid, liquid, or both);	\$	1,330.00
Acute gastrointestinal blood loss imaging	\$	1,330.00
Intestine imaging (eg, ectopic gastric mucosa, Meckel's localization, volvulus)	\$	1,330.00

DESCRIPTION		CHARGE
Peritoneal-venous shunt patency test (eg, for LeVeen, Denver shunt)	\$	1,330.00
Unlisted gastrointestinal procedure, diagnostic nuclear medicine	\$	1,330.00
Bone and/or joint imaging; limited area	\$	1,332.00
Bone and/or joint imaging; whole body	\$	1,332.00
Bone and/or joint imaging; 3 phase study	\$	1,332.00
Bone and/or joint imaging; tomographic (SPECT)	\$	1,332.00
Non-cardiac vascular flow imaging (ie, angiography, venography)	\$	1,306.00
Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic)	\$	4,740.00
Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection	\$	5,420.00
Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic)	\$	4,740.00
Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection	\$	4,740.00
Acute venous thrombosis imaging, peptide	\$	3,035.00
Venous thrombosis imaging, venogram; unilateral	\$	1,306.00
Venous thrombosis imaging, venogram; bilateral	\$	1,306.00
Myocardial imaging, positron emission tomography (PET), metabolic evaluation	\$	8,038.00
Myocardial imaging, positron emission tomography (PET), metabolic evaluation	\$	8,038.00
Myocardial imaging, infarct avid, planar; qualitative or quantitative	\$	1,574.00
Cardiac blood pool imaging, gated equilibrium; planar, single study at rest or stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without additional quantitative processing	\$	1,574.00
Cardiac blood pool imaging, gated equilibrium, SPECT, at rest, wall motion study plus ejection fraction, with or without quantitative processing	\$	1,574.00
Pulmonary ventilation imaging (eg, aerosol or gas)	\$	1,257.00
Pulmonary perfusion imaging (eg, particulate)	\$	1,257.00
Pulmonary ventilation (eg, aerosol or gas) and perfusion imaging	\$	1,770.00
Quantitative differential pulmonary perfusion, including imaging when performed	\$	1,257.00
Quantitative differential pulmonary perfusion and ventilation (eg, aerosol or gas), including imaging when performed	\$	1,770.00
Brain imaging, less than 4 static views; with vascular flow	\$	2,191.00
Brain imaging, minimum 4 static views; with vascular flow	\$	2,191.00
Brain imaging, tomographic (SPECT)	\$	4,755.00
Brain imaging, positron emission tomography (PET); metabolic evaluation	\$	8,038.00
Brain imaging, positron emission tomography (PET); metabolic evaluation	\$	8,038.00
Cerebrospinal fluid flow, imaging (not including introduction of material); cisternography	\$	2,191.00
Cerebrospinal fluid flow, imaging (not including introduction of material); shunt evaluation	\$	2,191.00
Cerebrospinal fluid leakage detection and localization	\$	2,191.00
Kidney imaging morphology	\$	1,713.00
Kidney imaging morphology; with vascular flow	\$	1,713.00
Kidney imaging morphology; with vascular flow and function, single study without pharmacological intervention	\$	1,713.00
Kidney imaging morphology; with vascular flow and function, single study without pharmacological intervention Kidney imaging morphology; with vascular flow and function, single study, with pharmacological intervention (eg, angiotensin converting enzyme inhibitor	\$ \$	965.00 1,713.00
and/or diuretic) Kidney imaging morphology; with vascular flow and function, multiple studies, with and without pharmacological intervention (eg, angiotensin converting	\$	1,713.00
enzyme inhibitor and/or diuretic)		
Kidney imaging morphology; tomographic (SPECT)	\$	1,713.00
Kidney function study, non-imaging radioisotopic study	\$	1,084.00
Ureteral reflux study (radiopharmaceutical voiding cystogram)	\$	1,713.00
Testicular imaging with vascular flow	\$	1,713.00
Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); limited area	\$	1,573.00
Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); multiple areas	\$	1,573.00
Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); whole body, single day imaging Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); tomographic (SPECT)	\$ \$	2,699.00 2,699.00
Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); whole body, requiring 2 or more days imaging	\$	4,755.00
Radiopharmaceutical localization of inflammatory process; limited area	\$	2,699.00
Radiopharmaceutical localization of inflammatory process; whole body	\$	2,699.00
Radiopharmaceutical localization of inflammatory process; tomographic (SPECT)	\$	2,699.00
Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)	\$	5,384.00
Positron emission tomography (PET) imaging; skull base to mid-thigh	\$	5,384.00
Positron emission tomography (PET) imaging; whole body	\$	8,038.00

DESCRIPTION		CHARGE
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging;	\$	8,038.00
limited area (eg, chest, head/neck)	¢	0 000 00
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh	\$	8,038.00
Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging;	\$	8,038.00
whole body		
Radiopharmaceutical therapy, by oral administration	\$	1,052.00
Radiopharmaceutical therapy, by intra-arterial particulate administration	\$	1,052.00
Basic metabolic panel (Calcium, ionized) This panel must include the following: Calcium, ionized (82330) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea Nitrogen (BUN) (84520)	\$	296.00
Basic metabolic panel (Calcium, ionized) This panel must include the following: Calcium, ionized (82330) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea Nitrogen (BUN) (84520)	\$	296.00
Basic metabolic panel (Calcium, total) This panel must include the following: Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea nitrogen (BUN) (84520)	\$	184.00
Electrolyte panel This panel must include the following: Carbon dioxide (bicarbonate) (82374) Chloride (82435) Potassium (84132) Sodium (84295)	\$	92.00
Comprehensive metabolic panel This panel must include the following: Albumin (82040) Bilirubin, total (82247) Calcium, total (82310) Carbon dioxide	\$	322.00
(bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Phosphatase, alkaline (84075) Potassium (84132) Protein, total (84155) Sodium (84295) Transferase, alanine amino (ALT) (SGPT) (84460) Transferase, aspartate amino (AST) (SGOT) (84450) Urea nitrogen (BUN) (84520)	Ŷ	512.00
Comprehensive metabolic panel This panel must include the following: Albumin (82040) Bilirubin, total (82247) Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Phosphatase, alkaline (84075) Potassium (84132) Protein, total (84155) Sodium (84295) Transferase, alanine amino (ALT) (SGPT) (84460) Transferase, aspartate amino (AST) (SGOT) (84450) Urea nitrogen (BUN) (84520)	\$	322.00
Lipid panel This panel must include the following: Cholesterol, serum, total (82465) Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718) Triglycerides (84478)	\$	148.00
Lipid panel This panel must include the following: Cholesterol, serum, total (82465) Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718) Triglycerides (84478)	\$	148.00
Lipid panel This panel must include the following: Cholesterol, serum, total (82465) Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718) Triglycerides (84478)	\$	142.00
Lipid panel This panel must include the following: Cholesterol, serum, total (82465) Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718) Triglycerides (84478)	\$	179.00
Renal function panel This panel must include the following: Albumin (82040) Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Phosphorus inorganic (phosphate) (84100) Potassium (84132) Sodium (84295) Urea nitrogen (BUN) (84520)	\$	230.00
Acute hepatitis panel This panel must include the following: Hepatitis A antibody (HAAb), IgM antibody (86709) Hepatitis B core antibody (HBcAb), IgM antibody (86705) Hepatitis B surface antigen (HBsAg) (87340) Hepatitis C antibody (86803)	\$	356.00
Hepatic function panel This panel must include the following: Albumin (82040) Bilirubin, total (82247) Bilirubin, direct (82248) Phosphatase, alkaline (84075)	\$	161.00
Protein, total (84155) Transferase, alanine amino (ALT) (SGPT) (84460) Transferase, aspartate amino (AST) (SGOT) (84450)		
Amikacin	\$	63.00
Amikacin	\$	63.00
Amikacin Caffeine	\$	62.00
	\$ \$	137.00 176.00
Carbamazepine; total Carbamazepine; total		202.00
Carbanazepine, fota	\$ \$	193.00
Cyclosporine	\$	107.00
Cyclosporine	\$	88.00
Clozapine	\$	34.00
Digoxin; total	\$	144.00
Valproic acid (dipropylacetic acid); total	\$	203.00
Valproic acid (dipropylacetic acid); free	\$	177.00
Ethosuximide	\$	52.00
Everolimus	\$	433.00
Gentamicin	\$	206.00
Gentamicin	\$	206.00
Gentamicin	\$	206.00
Gabapentin, whole blood, serum, or plasma	\$	54.00
Haloperidol	\$	82.00
Lamotrigine	\$	217.00
Lidocaine	\$	141.00
Lidocaine	\$	52.00
Levetiracetam	\$	79.00
Lithium	\$	71.00
	\$	357.00

DESCRIPTION		CHARGE
Oxcarbazepine	\$	150.00
Phenobarbital	\$	157.00
Phenobarbital	\$	157.00
Phenytoin; total	\$	149.00
Phenytoin; free	\$	133.00
Phenytoin; free	\$	74.00
Primidone	\$	167.00
Primidone	\$	41.00
Primidone	\$	40.00
Procainamide; with metabolites (eg, n-acetyl procainamide)	\$	164.00
Procainamide; with metabolites (eg, n-acetyl procainamide)	\$	46.00
Quinidine	\$	180.00
Quinidine	\$	38.00
Sirolimus - various dosages	\$	311.00
Tacrolimus	\$	435.00
	1	435.00
Theophylline	\$	
Tobramycin	\$ ¢	178.00
Tobramycin	\$	180.00
Tobramycin	\$	178.00
Topiramate	\$	167.00
Vancomycin	\$	217.00
Vancomycin	\$	217.00
Vancomycin	\$	217.00
Zonisamide	\$	158.00
Quantitation of therapeutic drug, not elsewhere specified	\$	135.00
Quantitation of therapeutic drug, not elsewhere specified	\$	42.00
Quantitation of therapeutic drug, not elsewhere specified	\$	348.00
Quantitation of therapeutic drug, not elsewhere specified	\$	76.00
Quantitation of therapeutic drug, not elsewhere specified	\$	15.00
Quantitation of therapeutic drug, not elsewhere specified	\$	802.00
Quantitation of therapeutic drug, not elsewhere specified	\$	201.00
Quantitation of therapeutic drug, not elsewhere specified	\$	615.00
Quantitation of therapeutic drug, not elsewhere specified	\$	570.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures (eg, immunoassay); capable of being read by direct optical	\$	294.00
observation only (eg, dipsticks, cups, cards, cartridges) includes sample validation when performed, per date of service		
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$	432.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$	432.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$	432.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$	432.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$	432.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$	432.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$	437.00

DESCRIPTION	CHARGE
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 115.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 437.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 437.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 437.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 437.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 437.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 437.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 437.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 437.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 437.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 432.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 437.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 432.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 437.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/LC-MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 432.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 432.00

DESCRIPTION	CHARGE
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 437.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 437.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 431.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 431.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 436.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 436.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/LC-MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 436.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 436.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 436.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 431.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 436.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 36.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 501.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 38.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 204.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$ 431.00

DESCRIPTION		CHARGE
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$	436.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$	436.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$	653.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$	629.00
Drug test(s), presumptive, any number of drug classes, any number of devices or procedures, by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC- MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service	\$	674.00
Alcohols	\$	257.00
Drug screening Fentanyl	\$	179.00
Drug screening Fentanyl	\$	179.00
Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number	\$	20.00
of these constituents; non-automated, with microscopy Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy	\$	19.00
Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy	\$	68.00
Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy	\$	68.00
Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy	\$	68.00
Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy	\$	16.00
Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy	\$	16.00
Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy	\$	45.00
Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy	\$	45.00
Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy	\$	44.00
Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy	\$	45.00
Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy	\$	45.00
Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy	\$	44.00
Urinalysis; qualitative or semiquantitative, except immunoassays	\$	14.00
Urinalysis; qualitative or semiquantitative, except immunoassays	\$	39.00
Urinalysis; microscopic only	\$	80.00
Urinalysis; microscopic only Urinalysis; microscopic only	\$ \$	80.00 80.00
Urinalysis; microscopic only Urine pregnancy test, by visual color comparison methods	\$ \$	80.00 69.00
Urine pregnancy test, by visual color comparison methods Urine pregnancy test, by visual color comparison methods	\$	68.00
Urine pregnancy test, by visual color comparison methods	\$	69.00
Volume measurement for timed collection, each	\$	32.00
Human Platelet Antigen 1 genotyping (HPA-1), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-1a/b (L33P)	\$	1,218.00
ASPA (aspartoacylase) (eg, Canavan disease) gene analysis, common variants (eg, E285A, Y231X)	\$	609.00
APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; full gene sequence	\$	38.00
APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; full gene sequence APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; full gene sequence	\$ \$	3,954.00 4,228.00

DESCRIPTION	c	HARGE
APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants	\$	690.00
APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; duplication/deletion variants	\$	7,908.00
APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; duplication/deletion variants	\$	4,228.00
BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative	\$	980.00
BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative	\$	969.00
BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative	\$	1,827.00
BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative	\$	436.00
BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; major breakpoint, qualitative or quantitative	\$	436.00
BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative	\$	867.00
BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative	\$	857.00
BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis; minor breakpoint, qualitative or quantitative	\$	433.00
BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, V600 variant(s)	\$	1,274.00
BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, V600 variant(s)	\$	1,420.00
BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, V600 variant(s)	\$	720.00
BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion	\$	12,882.00
variants in BRCA1 (ie, exon 13 del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb)		·
BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants in BRCA1 (ie, exon 13 del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb)	\$	3,666.00
BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants	\$	2,218.00
BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; uncommon duplication/deletion variants	\$	2,700.00
BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants (ie, exon 13	\$	38.00
del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb)	Ŷ	50.00
BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants (ie, exon 13 del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb)	\$	7,105.00
BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant	\$	1,138.00
BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis	\$	38.00
BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis	\$	8,487.00
BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis, how sequence analysis BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant	\$	21.00
CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon 9	\$ \$	1,081.00
	\$ \$	426.00
CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; common variants (eg, ACMG/ACOG guidelines)		
CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; common variants (eg, ACMG/ACOG guidelines)	\$	426.00
CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; full gene sequence	\$	2,074.00
CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)	\$	1,220.00
Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, bacterial artificial chromosome	\$	5,257.00
[BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis)		
Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, bacterial artificial chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis)	\$	4,010.00
Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, bacterial artificial chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis)	\$	4,010.00
Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, bacterial artificial chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis)	\$	3,708.00
Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP)	\$	5,257.00
variants for chromosomal abnormalities		
Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities	\$	2,258.00
EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (eg, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)	\$	1,656.00
F2 (prothrombin, coagulation factor II) (eg, hereditary hypercoagulability) gene analysis, 20210G>A variant	\$	454.00
F5 (coagulation factor V) (eg, hereditary hypercoagulability) gene analysis, Leiden variant	\$	363.00
FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles	\$	365.00
FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles	\$	688.00
FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles	\$	183.00
FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)	\$	101.00
FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)	\$	184.00
GBA (glucosidase, beta, acid) (eg, Gaucher disease) gene analysis, common variants (eg, N370S, 84GG, L444P, IVS2+1G>A)	\$	119.00
HFE (hemochromatosis) (eg, hereditary hemochromatosis) gene analysis, common variants (eg, C282Y, H63D)	\$	388.00
HFE (hemochromatosis) (eg, hereditary hemochromatosis) gene analysis, common variants (eg, C2821, HosD) HFE (hemochromatosis) (eg, hereditary hemochromatosis) gene analysis, common variants (eg, C2821, HosD)	\$ \$	260.00
IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein) (eg, familial dysautonomia) gene analysis, common	\$ \$	93.00
variants (eg, 2507+6T>C, R696P) IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s);	\$	41.00
amplified methodology (eg, polymerase chain reaction)		
IGH@ (Immunoglobulin heavy chain locus) (eg, leukemia and lymphoma, B-cell), variable region somatic mutation analysis	\$	1,251.00

DESCRIPTION		CHARGE
Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative specimen (eg, pre-transplant recipient and donor germline testing,	\$	1,287.00
post-transplant non-hematopoietic recipient germline [eg, buccal swab or other germline tissue sample] and donor testing, twin zygosity testing, or maternal		
cell contamination of fetal cells)		
Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative specimen (eg, pre-transplant recipient and donor germline testing,	\$	2,643.00
post-transplant non-hematopoietic recipient germline [eg, buccal swab or other germline tissue sample] and donor testing, twin zygosity testing, or maternal		
cell contamination of fetal cells)	L ć	45.00
Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline	\$	15.00
analyses; without cell selection Chimorian (operational) analysis, post transplantation specimen (op. homotopointic storn coll), includes comparison to provinusly performed baseline	ć	1 672 00
Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline analyses; without cell selection	\$	1,673.00
Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline	\$	2,220.00
analyses; with cell selection (eg, CD3, CD33), each cell type	Ş	2,220.00
Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline	\$	2,220.00
analyses; with cell selection (eg, CD3, CD33), each cell type	Ŷ	2,220.00
Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline	\$	2,220.00
analyses; with cell selection (eg, CD3, CD33), each cell type	-	_,
Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline	\$	2,220.00
analyses; with cell selection (eg, CD3, CD33), each cell type		,
Chimerism (engraftment) analysis, post transplantation specimen (eg, hematopoietic stem cell), includes comparison to previously performed baseline	\$	2,220.00
analyses; with cell selection (eg, CD3, CD33), each cell type		
HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; duplication/deletion	\$	1,522.00
variants		
JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant	\$	1,486.00
JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant	\$	1,164.00
KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, gastrointestinal stromal tumor [GIST], acute myeloid leukemia, melanoma), gene	\$	561.00
analysis, targeted sequence analysis (eg, exons 8, 11, 13, 17, 18)		
KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; variants in exon 2 (eg, codons 12 and 13)	\$	877.00
KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; variants in exon 2 (eg, codons 12 and 13)	\$	792.00
MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)	\$	696.00
MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)	\$	704.00
MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)	\$	704.00
MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)	\$	696.00
MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)	\$	259.00
MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)	\$	502.00
MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence	\$	15.00
analysis		
MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence	\$	1,519.00
analysis		20.00
MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence	\$	38.00
analysis MULI (mut) homolog 1. colon cancer, nonnolynocic type 2) (og, hereditary non nolynocic colorectal cancer, lynch syndrome) gene analysic;	\$	264.00
MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants	Ş	204.00
MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis;	\$	1,519.00
duplication/deletion variants	Ļ	1,515.00
MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence	\$	1,052.00
analysis	, Ý	1,052.00
MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence	\$	1,519.00
analysis		,
MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence	\$	38.00
analysis		
MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis;	\$	1,052.00
duplication/deletion variants		
MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis;	\$	1,519.00
duplication/deletion variants		
MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis	\$	1,151.00
MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis	\$	1,519.00
MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis	\$	38.00
MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants	\$	41.00
MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants	\$	4,060.00
MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion variants	\$	1,519.00
NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg,	\$	571.00
codon 61)		
NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog) (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg,	\$	1,188.00
codon 61)		

DESCRIPTION		CHARGE
PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence	\$	1,519.00
analysis	ć	20.00
PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis	\$	38.00
PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; duplication/deletion	Ś	1,519.00
variants	Ŷ	1,515.00
PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis	\$	38.00
PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant	\$	323.00
PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion	\$	2,031.00
analysis		
SMPD1(sphingomyelin phosphodiesterase 1, acid lysosomal) (eg, Niemann-Pick disease, Type A) gene analysis, common variants (eg, R496L, L302P, fsP330)	\$	2,074.00
SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (eg, Prader-Willi syndrome and/or Angelman syndrome),	\$	646.00
methylation analysis	ļ	040.00
SERPINA1 (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase, antitrypsin, member 1) (eg, alpha-1-antitrypsin deficiency), gene analysis, common	\$	303.00
variants (eg, *S and *Z)		
SERPINA1 (serpin peptidase inhibitor, clade A, alpha-1 antiproteinase, antitrypsin, member 1) (eg, alpha-1-antitrypsin deficiency), gene analysis, common	\$	2,076.00
variants (eg, *S and *Z)		
TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)	\$	1,379.00
HLA Class I and II typing, low resolution (eg, antigen equivalents); HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1	\$	4,571.00
HLA class I and II typing, low resolution (eg, antigen equivalents), HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1	\$	2,411.00
HLA Class I and II typing, low resolution (eg, antigen equivalents); HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1	\$	2,849.00
HLA Class I typing, low resolution (eg, antigen equivalents); complete (ie, HLA-A, -B, and -C)	\$	836.00
HLA Class I typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-A, -B, or -C), each	\$	2,999.00
HLA Class I typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-A, -B, or -C), each	\$	1,052.00
HLA Class I typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-A, -B, or -C), each	\$	1,052.00
HLA Class I typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-A, -B, or -C), each	\$	1,052.00
HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each	\$	933.00
HLA Class I typing, low resolution (eg, antigen equivalents); one antigen equivalent (eg, B*27), each HLA Class II typing, low resolution (eg, antigen equivalents); HLA-DRB1/3/4/5 and -DQB1	\$ \$	407.00 573.00
HLA Class II typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$	733.00
HLA Class II typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$	733.00
HLA Class II typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$	646.00
HLA Class II typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$	2,099.00
HLA Class II typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$	2,099.00
HLA Class II typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQB1, -DPB1, or -DPA1), each	\$	698.00
HLA Class II typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each HLA Class II typing, low resolution (eg, antigen equivalents); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$ \$	873.00 873.00
HLA Class II typing, low resolution (eg, antigen equivalents), one locus (eg, hLA-DKB1, -DKB5, 4/5, -DQB1, -DQA1, -DFB1, of -DFA1), each HLA Class II typing, low resolution (eg, antigen equivalents); one antigen equivalent, each	\$	1,299.00
HLA Class II typing, low resolution (eg, antigen equivalents); one antigen equivalent, each	\$	268.00
HLA Class II typing, low resolution (eg, antigen equivalents); one antigen equivalent, each	\$	145.00
HLA Class II typing, low resolution (eg, antigen equivalents); one antigen equivalent, each	\$	145.00
HLA Class I and II typing, high resolution (ie, alleles or allele groups), HLA-A, -B, -C, and -DRB1	\$	3,625.00
HLA Class I typing, high resolution (ie, alleles or allele groups); complete (ie, HLA-A, -B, and -C)	\$	2,739.00
HLA Class I typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-A, -B, or -C), each	\$	1,138.00
HLA Class I typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-A, -B, or -C), each HLA Class I typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, B*57:01P), each	\$ \$	916.00
HLA Class I typing, high resolution (ie, alleles of allele groups); one allele of allele group (eg, B 57.01P), each	\$ \$	1,138.00 565.00
HLA class I typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DPB1, or -DPA1), each	\$	743.00
HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$	743.00
HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$	646.00
HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$	21.00
HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$	1,344.00
HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$	741.00
HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$ ¢	741.00
HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$ \$	705.00 1,314.00
HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$ \$	1,314.00
HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each	\$	1,314.00
HLA Class II typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, HLA-DQB1*06:02P), each	\$	268.00
HLA Class II typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, HLA-DQB1*06:02P), each	\$	268.00
HLA Class II typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, HLA-DQB1*06:02P), each	\$	145.00

DESCRIPTION	CHARGE
HLA Class II typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, HLA-DQB1*06:02P), each	\$ 145.00
HLA Class II typing, high resolution (ie, alleles or allele groups); one allele or allele group (eg, HLA-DQB1*06:02P), each	\$ 462.00
Molecular pathology procedure, Level 1 (eg, identification of single germline variant [eg, SNP] by techniques such as restriction enzyme digestion or melt curve	\$ 122.00
analysis) ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (eg, medium chain acyl dehydrogenase deficiency), K304E variant ACE	
(angiotensin converting enzyme) (eg, hereditary blood pressure regulation), insertion/deletion variant AGTR1 (angiotensin II receptor, type 1) (eg, essential	
hypertension), 1166A>C variant BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease, type 1A), Y438N	
variant CCR5 (chemokine C-C motif receptor 5) (eg, HIV resistance), 32-bp deletion mutation/794 825del32 deletion CLRN1 (clarin 1) (eg, Usher syndrome, type	
3), N48K variant DPYD (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-FU and capecitabine drug metabolism), IVS14+1G>A variant F2 (coagulation	
factor 2) (eg, hereditary hypercoagulability), 1199G>A variant F5 (coagulation factor V) (eg, hereditary hypercoagulability), HR2 variant F7 (coagulation factor	
VII [serum prothrombin conversion accelerator]) (eg, hereditary hypercoagulability), R353Q variant F13B (coagulation factor XIII, B polypeptide) (eg, hereditary	
hypercoagulability), V34L variant FGB (fibrinogen beta chain) (eg, hereditary ischemic heart disease), -455G>A variant FGFR1 (fibroblast growth factor receptor	
1) (eg, Pfeiffer syndrome type 1, craniosynostosis), P252R variant FGFR3 (fibroblast growth factor receptor 3) (eg, Muenke syndrome), P250R variant FKTN	
(fukutin) (eg, Fukuyama congenital muscular dystrophy), retrotransposon insertion variant GNE (glucosamine [UDP-N-acetyl]-2-epimerase/N-	
acetylmannosamine kinase) (eg, inclusion body myopathy 2 [IBM2], Nonaka myopathy), M712T variant Human Platelet Antigen 1 genotyping (HPA-1), ITGB3	
(integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), HPA-1a/b	
(L33P) Human Platelet Antigen 2 genotyping (HPA-2), GP1BA (glycoprotein Ib [platelet], alpha polypeptide [GPIba]) (eg, neonatal alloimmune	
thrombocytopenia [NAIT], post-transfusion purpura), HPA-2a/b (T145M) Human Platelet Antigen 3 genotyping (HPA-3), ITGA2B (integrin, alpha 2b [platelet	
glycoprotein IIb of IIb/IIIa complex], antigen CD41 [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), HPA-3a/b (I843S)	
Human Platelet Antigen 4 genotyping (HPA-4), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 [GPIIIa]) (eg, neonatal alloimmune	
thrombocytopenia [NAIT], post-transfusion purpura), HPA-4a/b (R143Q) Human Platelet Antigen 5 genotyping (HPA-5), ITGA2 (integrin, alpha 2 [CD49B, alpha	
2 subunit of VLA-2 receptor] [GPIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), HPA-5a/b (K505E) Human Platelet Antigen	
6 genotyping (HPA-6w), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa, antigen CD61] [GPIIIa]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-	
transfusion purpura), HPA-6a/b (R489Q) Human Platelet Antigen 9 genotyping (HPA-9w), ITGA2B (integrin, alpha 2b [platelet glycoprotein IIb of IIb/IIIa	
complex, antigen CD41] [GPIIb]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), HPA-9a/b (V837M) Human Platelet Antigen 15	
genotyping (HPA-15), CD109 (CD109 molecule) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), HPA-15a/b (S682Y) IL28B	
(interleukin 28B [interferon, lambda 3]) (eg, drug response), rs12979860 variant IVD (isovaleryl-CoA dehydrogenase) (eg, isovaleric acidemia), A282V variant	
LCT (lactase-phlorizin hydrolase) (eg, lactose intolerance), 13910 C>T variant NEB (nebulin) (eg, nemaline myopathy 2), exon 55 deletion variant PCDH15	
(protocadherin-related 15) (eg, Usher syndrome type 1F), R245X variant SERPINE1 (serpine peptidase inhibitor clade E, member 1, plasminogen activator	
inhibitor -1, PAI-1) (eg, thrombophilia), 4G variant SHOC2 (soc-2 suppressor of clear homolog) (eg, Noonan-like syndrome with loose anagen hair), S2G variant	
SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse drug reaction), V174A variant SMN1 (survival of motor neuron 1,	
telomeric) (eg, spinal muscular atrophy), exon 7 deletion SRY (sex determining region Y) (eg, 46,XX testicular disorder of sex development, gonadal dysgenesis),	
gene analysis TOR1A (torsin family 1, member A [torsin A]) (eg, early-onset primary dystonia [DYT1]), 907_909delGAG (904_906delGAG) variant	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or	\$ 369.00
detection of a dynamic mutation disorder/triplet repeat) ABCC8 (ATP-binding cassette, sub-family C [CFTR/MRP], member 8) (eg, familial hyperinsulinism),	
common variants (eg, c.3898-9G>A [c.3992-9G>A], F1388del) ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib resistance),	
T315I variant ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (eg, medium chain acyl dehydrogenase deficiency), commons variants (eg,	
K304E, Y42H) ADRB2 (adrenergic beta-2 receptor surface) (eg, drug metabolism), common variants (eg, G16R, Q27E) AFF2 (AF4/FMR2 family, member 2	
[FMR2]) (eg, fragile X mental retardation 2 [FRAXE]), evaluation to detect abnormal (eg, expanded) alleles APOB (apolipoprotein B) (eg, familial	
hypercholesterolemia type B), common variants (eg, R3500Q, R3500W) APOE (apolipoprotein E) (eg, hyperlipoproteinemia type III, cardiovascular disease,	
Alzheimer disease), common variants (eg, *2, *3, *4) AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome	
inactivation), characterization of alleles (eg, expanded size or methylation status) ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to	
detect abnormal (eg, expanded) alleles ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg,	
spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease), evaluation	
to detect abnormal (eg, expanded) alleles ATXN7 (ataxin 7) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8	
opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN10 (ataxin 10) (eg, spinocerebellar	
ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar	
ataxia), evaluation to detect abnormal (eg, expanded) alleles CBFB/MYH11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed	
CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, I278T, G307S) CCND1/IGH (BCL1/IgH,	
t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CFH/ARMS2 (complement factor	
H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger,	
nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht-	
Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug	
metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common	
variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK	
(dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute	
lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or	
inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1	
(t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma),	
translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
analysis, qualitative, and quantitative, if performed EWSR1/FLI1 (t(11;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation analysis,	
qualitative, and quantitative, if performed EWSR1/WT1 (t(11;22)) (eg, desmoplastic small round cell tumor), translocation analysis, qualitative, and	
quantitative, if performed F11 (coagulation factor XI) (eg, coagulation disorder), common variants (eg, E117X [Type II], F283L [Type III], IVS14del14, and	
IVS14+1G>A [Type I]) FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), common variants (eg, 1138G>A, 1138G>C,	
1620C>A, 1620C>G) FIP1L1/PDGFRA (del[4q12]) (eg, imatinib-sensitive chronic eosinophilic leukemia), qualitative, and quantitative, if performed FLG (filaggrin)	
(eg. ichthyosis vulgaris) common variants (eg. 8501X, 2282del/, 82447X, S3247X, 3702delG) EOX01/PAX3 (t(2:13)) (eg. alveolar rhabdomyosarroma)	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or	\$ 2,607.00
detection of a dynamic mutation disorder/triplet repeat) ABCC8 (ATP-binding cassette, sub-family C [CFTR/MRP], member 8) (eg, familial hyperinsulinism),	
common variants (eg, c.3898-9G>A [c.3992-9G>A], F1388del) ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib resistance),	
T315I variant ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (eg, medium chain acyl dehydrogenase deficiency), commons variants (eg,	
K304E, Y42H) ADRB2 (adrenergic beta-2 receptor surface) (eg, drug metabolism), common variants (eg, G16R, Q27E) AFF2 (AF4/FMR2 family, member 2	
[FMR2]) (eg, fragile X mental retardation 2 [FRAXE]), evaluation to detect abnormal (eg, expanded) alleles APOB (apolipoprotein B) (eg, familial	
hypercholesterolemia type B), common variants (eg, R3500Q, R3500W) APOE (apolipoprotein E) (eg, hyperlipoproteinemia type III, cardiovascular disease,	
Alzheimer disease), common variants (eg, *2, *3, *4) AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome	
inactivation), characterization of alleles (eg, expanded size or methylation status) ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to	
detect abnormal (eg, expanded) alleles ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg,	
spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease), evaluation	
to detect abnormal (eg, expanded) alleles ATXN7 (ataxin 7) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8	
opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN10 (ataxin 10) (eg, spinocerebellar	
ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar	
ataxia), evaluation to detect abnormal (eg, expanded) alleles CBFB/MYH11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed	
CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, I278T, G307S) CCND1/IGH (BCL1/IgH,	
t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CFH/ARMS2 (complement factor	
H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger,	
nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht-	
Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug	
metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common	
variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK	
(dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute	
lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or	
inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1	
(t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma),	
translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
analysis, qualitative, and quantitative, if performed EWSR1/FLI1 (t(11;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation analysis,	
qualitative, and quantitative, if performed EWSR1/WT1 (t(11;22)) (eg, desmoplastic small round cell tumor), translocation analysis, qualitative, and	
quantitative, if performed F11 (coagulation factor XI) (eg, coagulation disorder), common variants (eg, E117X [Type II], F283L [Type III], IVS14del14, and	
IVS14+1G>A [Type I]) FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), common variants (eg, 1138G>A, 1138G>C,	
1620C>A, 1620C>G) FIP1L1/PDGFRA (del[4q12]) (eg, imatinib-sensitive chronic eosinophilic leukemia), qualitative, and quantitative, if performed FLG (filaggrin)	
g ichthyosis vulgaris) common variants (eg. 8501X, 2282deld, 82447X, S3247X, 3702delG) EOXO1/PAX3 (t/2·13)) (eg. alveolar rhabdomyosarcoma)	

DESCRIPTION		CHARGE
Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or	\$	7,134.00
detection of a dynamic mutation disorder/triplet repeat) ABCC8 (ATP-binding cassette, sub-family C [CFTR/MRP], member 8) (eg, familial hyperinsulinism),		
common variants (eg, c.3898-9G>A [c.3992-9G>A], F1388del) ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib resistance),		
T315I variant ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (eg, medium chain acyl dehydrogenase deficiency), commons variants (eg,		
K304E, Y42H) ADRB2 (adrenergic beta-2 receptor surface) (eg, drug metabolism), common variants (eg, G16R, Q27E) AFF2 (AF4/FMR2 family, member 2		
[FMR2]) (eg, fragile X mental retardation 2 [FRAXE]), evaluation to detect abnormal (eg, expanded) alleles APOB (apolipoprotein B) (eg, familial		
hypercholesterolemia type B), common variants (eg, R3500Q, R3500W) APOE (apolipoprotein E) (eg, hyperlipoproteinemia type III, cardiovascular disease,		
Alzheimer disease), common variants (eg, *2, *3, *4) AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome		
inactivation), characterization of alleles (eg, expanded size or methylation status) ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to		
detect abnormal (eg, expanded) alleles ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg,		
spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease), evaluation		
to detect abnormal (eg, expanded) alleles ATXN7 (ataxin 7) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8		
opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN10 (ataxin 10) (eg, spinocerebellar		
ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar		
ataxia), evaluation to detect abnormal (eg, expanded) alleles CBFB/MYH11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed		
CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, I278T, G307S) CCND1/IGH (BCL1/IgH,		
t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CFH/ARMS2 (complement factor		
H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger,		
nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht-		
Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug		
metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common		
variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK		
(dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute		
lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or		
inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1		
(t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma),		
translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation		
analysis, qualitative, and quantitative, if performed EWSR1/FLI1 (t(11;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation analysis,		
qualitative, and quantitative, if performed EWSR1/WT1 (t(11;22)) (eg, desmoplastic small round cell tumor), translocation analysis, qualitative, and	l	
quantitative, if performed F11 (coagulation factor XI) (eg, coagulation disorder), common variants (eg, E117X [Type II], F283L [Type III], IVS14del14, and	l	
IVS14+1G>A [Type I]) FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), common variants (eg, 1138G>A, 1138G>C,	l	
1620C>A, 1620C>G) FIP1L1/PDGFRA (del[4q12]) (eg, imatinib-sensitive chronic eosinophilic leukemia), qualitative, and quantitative, if performed FLG (filaggrin)	l	
(eg. ichthyosis yulgaris) common variants (eg. 8501X, 2282del/, 82447X, S3247X, 3702delG) EOXO1/PAX3 (t/2:13)) (eg. alveolar rhabdomyosarcoma)	ĺ	

Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or 4 detection of a dynamic mutation disorder/triplet repeat) ABCC8 (ATP-binding cassette, sub-family C [CTFI/MRP], member 8) (eg, familial hyperinsulinism), common variants (eg, c.3898-9G>A (c.3992-9G>A), F1388del) ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib resistance), T3151 variant ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight thain, MCAD) (eg, medium chain acyl dehydrogenase deficiency), commons variants (eg, K364, Y42H) ADR82 (adrenergic beta-2 receptor surface) (eg, drug metabolism), common variants (eg, G16R, Q2TE) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]), evaluation to detect abnormal (eg, expanded) alleles APOB (apolipoprotein B) (eg, familial hypercholesterolemia type B), common variants (eg, R3500Q, R3500W) APOE (apolipoprotein E) (eg, hyperlipoproteinemia type III, cardiovascular disease, Alzheimer disease), common variants (eg, expanded size or methylation status) ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, volt	HARGE
common variants (eg. c.3898-9G>A [c.3992-9G>A], F1388del) ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib resistance), T3151 variant ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (eg, medium chain acyl dehydrogenase deficiency), commons variants (eg, S304E, Y42H) ADR82 (adrenergic beta-2 receptor surface) (eg, drug metabolism), common variants (eg, G1GR, Q2FE) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]), evaluation to detect abnormal (eg, expanded) alleles APOB (apolipoprotein B) (eg, familial hypercholesterolemia type B), common variants (eg, R3500Q, R3500W) APOE (apolipoprotein E) (eg, hyperlipoproteinemia type III, cardiovascular disease, Alzheimer disease), common variants (eg, *2, *3, *4) AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), characterization of alleles (eg, expanded size or methylation status) ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to detect abnormal (eg, expanded) alleles ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAFNA1M (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAFNA1M (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAFNA1M (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAFNA1M (calcium channel, eg, V2	2,031.00
T315I variant ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (eg, medium chain acyl dehydrogenase deficiency), commons variants (eg, K304E, Y42H) ADR82 (adrenergic beta-2 receptor surface) (eg, drug metabolism), common variants (eg, G16R, Q27E) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]), evaluation to detect abnormal (eg, expanded) alleles APOB (apolipoprotein B) (eg, familial hypercholesterolemia type B), common variants (eg, *2, *3, *4) AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), characterization of alleles (eg, expanded size or methylation status) ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to detect abnormal (eg, expanded) alleles ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN1 (ataxin 7) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8 (ataxin 3) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel,	
K304E, Y42H) ADRB2 (adrenergic beta-2 receptor surface) (eg, drug metabolism), common variants (eg, G16R, Q27E) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]), evaluation to detect abnormal (eg, expanded) alleles APOB (apolipoprotein B) (eg, familial hypercholesterolemia type B), common variants (eg, R3500Q, R3500W) APOE (apolipoprotein E) (eg, hyperlipoproteinemia type III, cardiovascular disease, Alzheimer disease), common variants (eg, *2, *3, *4) AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), characterization of alleles (eg, expanded size or methylation status) ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to detect abnormal (eg, expanded) alleles ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8 (ataxin 3) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN80 (Ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN80 (Ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN80 (Ataxin 10) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CARNA1 (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CBFB/MYH11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, I2787, G3075) CCND1/IGH (BCL1/IgH, t11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, and quantitative, if performed CH/Age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A695 [
(FMR2]) (eg, fragile X mental retardation 2 (FRAXE]), evaluation to detect abnormal (eg, expanded) alleles APOB (apolipoprotein B) (eg, familial hypercholesterolemia type B), common variants (eg, R35000Q, R3500W) APOE (apolipoprotein E) (eg, hyperlipoproteinemia type III, cardiovascular disease, Alzheimer disease), common variants (eg, *2, *3, *4) AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), characterization of alleles (eg, expanded) size or methylation status) ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to detect abnormal (eg, expanded) alleles ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN1 (ataxin 7) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1	
hypercholesterolemia type B), common variants (eg, R3500Q, R3500W) APOE (apolipoprotein E) (eg, hyperlipoproteinemia type III, cardiovascular disease, Alzheimer disease), common variants (eg, *2, *3, *4) AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), characterization of alleles (eg, expanded size or methylation status) ANTI (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to detect abnormal (eg, expanded) alleles ATXN1 (atxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (atxin 2) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (atxin 3) (eg, spinocerebellar ataxia, Mchado-Joseph disease), evaluation to detect abnormal (eg, expanded) alleles ATXN7 (atxin 7) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8 (atxin 3) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAFM/H11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, 12787, G3075) CCND1/GH (BCL1/gH, t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CFH/ARMS2 (complement factor H/age-related maculopathy susceptibility 2) (eg, macular degeneration),	
Alzheimer disease), common variants (eg, *2, *3, *4) AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation), characterization of alleles (eg, expanded size or methylation status) ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8 (ataxin 2) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN80S (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN80S (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN80S (ATXN8 ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN80S (ATXN8 ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN80S (ATXN8 ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CASN10 (ataxin 10) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CASN10 (ataxin 10) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CASN10 (ataxin 10) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CASN10 (ataxin 10) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CASN10 (ataxin 10) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CASN10 (ataxin 10) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CASN10 (CHC1/gH, t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, i	
inactivation), characterization of alleles (eg, expanded size or methylation status) ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to detect abnormal (eg, expanded) alleles ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CHANMS2 (complement factor H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A695 [ARMS2]) CNBP (CCHC-type zinc finger, nuclei	
detect abnormal (eg, expanded) alleles ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia), Machado-Joseph disease), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 7) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN10 (ataxin 10) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN10 (ataxin 10) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CBFB/MYH11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, 1278T, G307S) CCND1/IGH (BCL1/IgH, t11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CH/ARMS2 (complement factor H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, 4202H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger, nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolis	
spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 7) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN10 (ataxin 10) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN10 (ataxin 10) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAENA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAENA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAENA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAENA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAENA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAENA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAENA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAENA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (bg, spinocerebellar ataxia), evaluation to detect abnormal (eg, vantade) alleles C	
to detect abnormal (eg, expanded) alleles ATXN7 (ataxin 7) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN10 (ataxin 10) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CBFB/MYH11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, 1278T, G307S) CCND1/IGH (BCL1/IgH, t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CFH/ARMS2 (complement factor H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, 4402H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger, nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht- Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYB (cytothrome P450, family 3, subfamily A, polypeptide 4) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, if performed DMPK (dystrophia myotonic-a-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed E	
opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN10 (ataxin 10) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CAENA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CBFB/MYH11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, 1278T, G307S) CCND1/IGH (BCL1/IgH, t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CFH/ARMS2 (complement factor H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger, nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or inversion analysis for analysis, qualitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or inversion analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma), translocation analysis, qualitative, and quantitative, if performed	
ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles CBFB/MYH11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, 1278T, G307S) CCND1/IGH (BCL1/IgH, t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CFH/ARMS2 (complement factor H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger, nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht- Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK (dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;22)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and q	
ataxia), evaluation to detect abnormal (eg, expanded) alleles CBFB/MYH11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, I278T, G307S) CCND1/IGH (BCL1/IgH, t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CFH/ARMS2 (complement factor H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger, nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht- Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK (dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;22)) (eg, clear cell sarcoma), translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, 1278T, G307S) CCND1/IGH (BCL1/IgH, t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CFH/ARMS2 (complement factor H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger, nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK (dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;22)) (eg, clear cell sarcoma), translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CFH/ARMS2 (complement factor H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger, nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht- Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK (dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger, nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK (dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht- Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK (dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK (dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(1;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(1;2;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma), translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK (dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma), translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK (dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK (inv(2)) (eg, non-small cell lung cancer), translocation or inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(1;22)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma), translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
(dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma), translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
ymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma), translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1 (t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma), translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
(t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma), translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
analysis, qualitative, and quantitative, if performed EWSR1/FL11 (t(11;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation analysis,	
qualitative, and quantitative, if performed EWSR1/WT1 (t(11;22)) (eg, desmoplastic small round cell tumor), translocation analysis, qualitative, and	
quantitative, if performed F11 (coagulation factor XI) (eg, coagulation disorder), common variants (eg, E117X [Type II], F283L [Type III], IVS14del14, and	
IVS14+1G>A [Type I]) FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), common variants (eg, 1138G>A, 1138G>C,	
1620C>A, 1620C>G) FIP1L1/PDGFRA (del[4q12]) (eg, imatinib-sensitive chronic eosinophilic leukemia), qualitative, and quantitative, if performed FLG (filaggrin)	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or	\$ 12,767.00
detection of a dynamic mutation disorder/triplet repeat) ABCC8 (ATP-binding cassette, sub-family C [CFTR/MRP], member 8) (eg, familial hyperinsulinism),	
common variants (eg, c.3898-9G>A [c.3992-9G>A], F1388del) ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib resistance),	
T315I variant ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (eg, medium chain acyl dehydrogenase deficiency), commons variants (eg,	
K304E, Y42H) ADRB2 (adrenergic beta-2 receptor surface) (eg, drug metabolism), common variants (eg, G16R, Q27E) AFF2 (AF4/FMR2 family, member 2	
[FMR2]) (eg, fragile X mental retardation 2 [FRAXE]), evaluation to detect abnormal (eg, expanded) alleles APOB (apolipoprotein B) (eg, familial	
hypercholesterolemia type B), common variants (eg, R3500Q, R3500W) APOE (apolipoprotein E) (eg, hyperlipoproteinemia type III, cardiovascular disease,	
Alzheimer disease), common variants (eg, *2, *3, *4) AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome	
inactivation), characterization of alleles (eg, expanded size or methylation status) ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to	
detect abnormal (eg, expanded) alleles ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg,	
spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease), evaluation	
to detect abnormal (eg, expanded) alleles ATXN7 (ataxin 7) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8	
opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN10 (ataxin 10) (eg, spinocerebellar	
ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar	
ataxia), evaluation to detect abnormal (eg, expanded) alleles CBFB/MYH11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed	
CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, I278T, G307S) CCND1/IGH (BCL1/IgH,	
t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CFH/ARMS2 (complement factor	
H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger,	
nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht-	
Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug	
metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common	
variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK	
(dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute	
lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or	
inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1	
(t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma),	
translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
analysis, qualitative, and quantitative, if performed EWSR1/FLI1 (t(11;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation analysis,	
qualitative, and quantitative, if performed EWSR1/WT1 (t(11;22)) (eg, desmoplastic small round cell tumor), translocation analysis, qualitative, and	
quantitative, if performed F11 (coagulation factor XI) (eg, coagulation disorder), common variants (eg, E117X [Type II], F283L [Type III], IVS14del14, and	
IVS14+1G>A [Type I]) FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), common variants (eg, 1138G>A, 1138G>C,	
1620C>A, 1620C>G) FIP1L1/PDGFRA (del[4q12]) (eg, imatinib-sensitive chronic eosinophilic leukemia), qualitative, and quantitative, if performed FLG (filaggrin)	
(eg. ichthyosis yulgaris) common variants (eg. B501X, 2282del/, B2/47X, S3247X, 3702delG) EOX01/PAX3 (t/2:13)) (eg. alveolar rhabdomyosarcoma)	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or	\$ 700.00
detection of a dynamic mutation disorder/triplet repeat) ABCC8 (ATP-binding cassette, sub-family C [CFTR/MRP], member 8) (eg, familial hyperinsulinism),	
common variants (eg, c.3898-9G>A [c.3992-9G>A], F1388del) ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib resistance),	
T315I variant ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (eg, medium chain acyl dehydrogenase deficiency), commons variants (eg,	
K304E, Y42H) ADRB2 (adrenergic beta-2 receptor surface) (eg, drug metabolism), common variants (eg, G16R, Q27E) AFF2 (AF4/FMR2 family, member 2	
[FMR2]) (eg, fragile X mental retardation 2 [FRAXE]), evaluation to detect abnormal (eg, expanded) alleles APOB (apolipoprotein B) (eg, familial	
hypercholesterolemia type B), common variants (eg, R3500Q, R3500W) APOE (apolipoprotein E) (eg, hyperlipoproteinemia type III, cardiovascular disease,	
Alzheimer disease), common variants (eg, *2, *3, *4) AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome	
inactivation), characterization of alleles (eg, expanded size or methylation status) ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to	
detect abnormal (eg, expanded) alleles ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg,	
spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease), evaluation	
to detect abnormal (eg, expanded) alleles ATXN7 (ataxin 7) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8	
opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN10 (ataxin 10) (eg, spinocerebellar	
ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar	
ataxia), evaluation to detect abnormal (eg, expanded) alleles CBFB/MYH11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed	
CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, I278T, G307S) CCND1/IGH (BCL1/IgH,	
t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CFH/ARMS2 (complement factor	
H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger,	
nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht-	
Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug	
metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common	
variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK	
(dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute	
lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or	
inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1	
(t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma),	
translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
analysis, qualitative, and quantitative, if performed EWSR1/FLI1 (t(11;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation analysis,	
qualitative, and quantitative, if performed EWSR1/WT1 (t(11;22)) (eg, desmoplastic small round cell tumor), translocation analysis, qualitative, and	
quantitative, if performed F11 (coagulation factor XI) (eg, coagulation disorder), common variants (eg, E117X [Type II], F283L [Type III], IVS14del14, and	
IVS14+1G>A [Type I]) FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), common variants (eg, 1138G>A, 1138G>C,	
1620C>A, 1620C>G) FIP1L1/PDGFRA (del[4q12]) (eg, imatinib-sensitive chronic eosinophilic leukemia), qualitative, and quantitative, if performed FLG (filaggrin)	
(eg. ichthyosis vulgaris) common variants (eg. R501X, 2282deld, R2/4/7X, S32/47X, 3702delG) FOXO1/PAX3 (t(2-13)) (eg. alveolar rhabdomyosarcoma)	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or	\$ 1,531.00
detection of a dynamic mutation disorder/triplet repeat) ABCC8 (ATP-binding cassette, sub-family C [CFTR/MRP], member 8) (eg, familial hyperinsulinism),	
common variants (eg, c.3898-9G>A [c.3992-9G>A], F1388del) ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib resistance),	
T315I variant ACADM (acyl-CoA dehydrogenase, C-4 to C-12 straight chain, MCAD) (eg, medium chain acyl dehydrogenase deficiency), commons variants (eg,	
K304E, Y42H) ADRB2 (adrenergic beta-2 receptor surface) (eg, drug metabolism), common variants (eg, G16R, Q27E) AFF2 (AF4/FMR2 family, member 2	
[FMR2]) (eg, fragile X mental retardation 2 [FRAXE]), evaluation to detect abnormal (eg, expanded) alleles APOB (apolipoprotein B) (eg, familial	
hypercholesterolemia type B), common variants (eg, R3500Q, R3500W) APOE (apolipoprotein E) (eg, hyperlipoproteinemia type III, cardiovascular disease,	
Alzheimer disease), common variants (eg, *2, *3, *4) AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome	
inactivation), characterization of alleles (eg, expanded size or methylation status) ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy), evaluation to	
detect abnormal (eg, expanded) alleles ATXN1 (ataxin 1) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN2 (ataxin 2) (eg,	
spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease), evaluation	
to detect abnormal (eg, expanded) alleles ATXN7 (ataxin 7) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN8OS (ATXN8	
opposite strand [non-protein coding]) (eg, spinocerebellar ataxia), evaluation to detect abnormal (eg, expanded) alleles ATXN10 (ataxin 10) (eg, spinocerebellar	
ataxia), evaluation to detect abnormal (eg, expanded) alleles CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, spinocerebellar	
ataxia), evaluation to detect abnormal (eg, expanded) alleles CBFB/MYH11 (inv(16)) (eg, acute myeloid leukemia), qualitative, and quantitative, if performed	
CBS (cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), common variants (eg, I278T, G307S) CCND1/IGH (BCL1/IgH,	
t(11;14)) (eg, mantle cell lymphoma) translocation analysis, major breakpoint, qualitative, and quantitative, if performed CFH/ARMS2 (complement factor	
H/age-related maculopathy susceptibility 2) (eg, macular degeneration), common variants (eg, Y402H [CFH], A69S [ARMS2]) CNBP (CCHC-type zinc finger,	
nucleic acid binding protein) (eg, myotonic dystrophy type 2), evaluation to detect abnormal (eg, expanded) alleles CSTB (cystatin B [stefin B]) (eg, Unverricht-	
Lundborg disease), evaluation to detect abnormal (eg, expanded) alleles CYP3A4 (cytochrome P450, family 3, subfamily A, polypeptide 4) (eg, drug	
metabolism), common variants (eg, *2, *3, *4, *5, *6) CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) (eg, drug metabolism), common	
variants (eg, *2, *3, *4, *5, *6) DEK/NUP214 (t(6;9)) (eg, acute myeloid leukemia), translocation analysis, qualitative, and quantitative, if performed DMPK	
(dystrophia myotonica-protein kinase) (eg, myotonic dystrophy, type 1), evaluation to detect abnormal (eg, expanded) alleles E2A/PBX1 (t(1;19)) (eg, acute	
lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EML4/ALK (inv(2)) (eg, non-small cell lung cancer), translocation or	
inversion analysis ETV6/NTRK3 (t(12;15)) (eg, congenital/infantile fibrosarcoma), translocation analysis, qualitative, and quantitative, if performed ETV6/RUNX1	
(t(12;21)) (eg, acute lymphocytic leukemia), translocation analysis, qualitative, and quantitative, if performed EWSR1/ATF1 (t(12;22)) (eg, clear cell sarcoma),	
translocation analysis, qualitative, and quantitative, if performed EWSR1/ERG (t(21;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation	
analysis, qualitative, and quantitative, if performed EWSR1/FLI1 (t(11;22)) (eg, Ewing sarcoma/peripheral neuroectodermal tumor), translocation analysis,	
qualitative, and quantitative, if performed EWSR1/WT1 (t(11;22)) (eg, desmoplastic small round cell tumor), translocation analysis, qualitative, and	
quantitative, if performed F11 (coagulation factor XI) (eg, coagulation disorder), common variants (eg, E117X [Type II], F283L [Type III], IVS14del14, and	
IVS14+1G>A [Type I]) FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), common variants (eg, 1138G>A, 1138G>C,	
1620C>A, 1620C>G) FIP1L1/PDGFRA (del[4q12]) (eg, imatinib-sensitive chronic eosinophilic leukemia), qualitative, and quantitative, if performed FLG (filaggrin)	
(eg. ichthyosis yulgaris) common variants (eg. 8501X, 2282del/, 82447X, S3247X, 3702delG) EOXO1/PAX3 (t/2:13)) (eg. alveolar rhabdomyosarcoma)	

DESCRIPTION	c	HARGE
Molecular pathology procedure, Level 2 (eg. 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat) ABCC8 (ATP-binding cassette, sub-family C (CTRT//ARP), member 8) (eg. familia hyperinsulinism), common variants (eg. c.3898-9G-A), F1388del) ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg. acquired imatinib resistance), 1319 variant ACADM (acyl-CAA dehydrogenase, C-4 to C-12 straight chain, MCAD) (eg. medium chain acyl dehydrogenase deficiency), common variants (eg. (acyler, 422H) ADR82 (adrenergic beta-2 receptor surface) (eg. drug metabolism), common variants (eg. G, G16R, Q27E) AFE2 (AF4/FM82 family, member 2 [FMR2]) (eg. fragile X mental retardation 2 [FRAXE]), evaluation to detect abnormal (eg. expanded) alleles APOB (apolipoprotein B) (eg. framilial hypercholesterolemia type B), common variants (eg. R3500Q) APOC (apolipoprotein E) (eg. hyperlipoproteinemia type III, cardiovascular disease, Atheimer disease), common variants (eg. *2, *3, *4) AR (androgen receptor) (eg. spinal and bulbar mucular atrophy, kennedy disease, X chromosome inactivation), characterization of alleles (eg. expanded) alleles ATNN1 (atxix) X1 (eg. spinocerebellar ataxia), evaluation to detect abnormal (eg. expanded) alleles ATNN1 (atxix 1) (eg. spinocerebellar ataxia), evaluation to detect abnormal (eg. expanded) alleles ATNN3 (atxix 3) (eg. spinocerebellar ataxia), evaluation to detect abnormal (eg. expanded) alleles CACNA1A (clacium channel, voltage dependent, P/C type, alpha 1A subunit) (eg. spinocerebellar ataxia), evaluation to detect abnormal (eg. expanded) alleles CACNA1A (clacium channel, voltage dependent, P/C type, alpha 1A subunit) (eg. spinocerebellar ataxia), evaluation to detect abnormal (eg. expanded) alleles CACNA1A (clacium channel, voltage dependent, P/C type, alpha 1A subunit) (eg. spinocerebellar ataxia), evaluation to detect abnormal (eg. expanded) alleles CACNA1A (clacium channel, voltag	\$	322.0
Molecular pathology procedure, Level 3 (eg, >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD]) Chromosome 1p-/19q- (eg, glial tumors), deletion analysis Chromosome 18q- (eg, D18S55, D18S58, D18S61, D18S64, and D18S69) (eg, colon cancer), allelic imbalance assessment (ie, loss of heterozygosity) COL1A1/PDGFB (t(17;22)) (eg, dermatofibrosarcoma protuberans), translocation analysis, multiple breakpoints, qualitative, and quantitative, if performed CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2) (eg, congenital adrenal hyperplasia, 21-hydroxylase deficiency), common variants (eg, IVS2-13G, P30L, I172N, exon 6 mutation cluster [I235N, V236E, M238K], V281L, L307FfsX6, Q318X, R356W, P453S, G110VfsX21, 30-kb deletion variant) ESR1/PGR (receptor 1/progesterone receptor) ratio (eg, breast cancer) IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma), translocation analysis; major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative MEFV (Mediterranean fever) (eg, familial Mediterranean fever), common variants (eg, E148Q, P369S, F479L, M680I, I692del, M694V, M694I, K695R, V726A, A744S, R761H) MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), common variants (eg, W515A, W515L, W515R) TRD@ (T cell antigen receptor, delta) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population Uniparental disomy (UPD) (eg, Russell-Silver syndrome, Prader-Willi/Angelman syndrome), short tandem repeat (STR) analysis	\$	100.0
Molecular pathology procedure, Level 3 (eg, >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD]) Chromosome 1p-/19q- (eg, glial tumors), deletion analysis Chromosome 18q- (eg, D18S55, D18S58, D18S61, D18S64, and D18S69) (eg, colon cancer), allelic imbalance assessment (ie, loss of heterozygosity) COL1A1/PDGFB (t(17;22)) (eg, dermatofibrosarcoma protuberans), translocation analysis, multiple breakpoints, qualitative, and quantitative, if performed CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2) (eg, congenital adrenal hyperplasia, 21-hydroxylase deficiency), common variants (eg, IVS2-13G, P30L, I172N, exon 6 mutation cluster [I235N, V236E, M238K], V281L, L307FfsX6, Q318X, R356W, P453S, G110VfsX21, 30-kb deletion variant) ESR1/PGR (receptor 1/progesterone receptor) ratio (eg, breast cancer) IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma), translocation analysis; major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative MEFV (Mediterranean fever) (eg, familial Mediterranean fever), common variants (eg, E148Q, P369S, F479L, M680I, I692del, M694V, M694I, K695R, V726A, A744S, R761H) MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), common variants (eg, V515A, W515L, W515R) TRD@ (T cell antigen receptor, delta) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population Uniparental disomy (UPD) (eg, Russell-Silver syndrome, Prader-Willi/Angelman syndrome), short tandem repeat (STR) analysis	\$	210.0

DESCRIPTION		CHARGE
Molecular pathology procedure, Level 3 (eg, >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD]) Chromosome 1p-/19q- (eg, glial tumors), deletion analysis Chromosome 18q- (eg, D18555, D18558, D18561, D18564, and D18569) (eg, colon cancer), allelic imbalance assessment (ie, loss of heterozygosity) COL1A1/PDGFB (t(17;22)) (eg, dermatofibrosarcoma protuberans), translocation analysis, multiple breakpoints, qualitative, and quantitative, if performed CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2) (eg, congenital adrenal hyperplasia, 21-hydroxylase deficiency), common variants (eg, IVS2-13G, P30L, 1172N, exon 6 mutation cluster [I235N, V236E, M238K], V281L, L307FfsX6, Q318X, R356W, P453S, G110VfsX21, 30-kb deletion variant) ESR1/PGR (receptor 1/progesterone receptor) ratio (eg, breast cancer) IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma), translocation analysis; major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative MEFV (Mediterranean fever) (eg, familial Mediterranean fever), common variants (eg, E148Q, P369S, F479L, M680I, I692del, M694V, M694I, K695R, V726A, A744S, R761H) MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), common variants (eg, W515A, W515L, W515R) TRD@ (T cell antigen receptor, delta) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population Uniparental disomy (UPD) (eg, Russell-Silver syndrome, Prader-Willi/Angelman syndrome), short tandem repeat (STR) analysis	\$	483.00
Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) ANG (angiogenin, ribonuclease, RNase A family, 5) (eg, amyotrophic lateral sclerosis), full gene sequence ARX (atristless-related homeobox) (eg, X-linked linsens) guosa genitalia, X-linked imental retardation), duplication/deletion analysis CEL (carboxyl ester lipase [bile salt-stimulated lipase]) (eg, maturity-onsel diabetes of the young [MODY]), targeted sequence analysis of exon 11 (eg, c.1785delC, c.1686delT) CTNNB1 (catenin [cadherin-associated protein], beta 1, 88kDa) (eg, desmoid tumors), targeted sequence analysis of exon 11 (eg, c.1785dRV (deleted in acoospermia and sex determining region Y) (eg, male infertility), common deletions (eg, AZFa, AZFb, AZF, AZF), AZF, AZFd) DNMT3A (DNA [cytosine-5-]-methyltransferase 3 alpha) (eg, acute myeloid leukenia), targeted sequence analysis (eg, exon 2) EPCAM (epithelial cell adhesion nolecule) (eg, Lynch syndrome), duplication/deletion analysis F8 (coagulation factor VIII) (eg, hemophilia A), inversion analysis of exon 9 FGFR3 (fibroblast growth factor receptor 3) (eg, isolated cranicsynostosis), targeted sequence analysis (eg, exon 2), ICT targeted sequence analysis of exon 9 FGFR3 (fibroblast growth factor receptor 3) (eg, isolated cranicsynostosis), targeted sequence (enalysis (eg, exon 2), ICT targeted sequence analysis of exon 9 FGFR3 (fibroblast growth factor receptor 3) (eg, Cloton blood group), ERAM (Edu), full gene sequence GNAQ (guanine nucleotide-londing protein G(gl subunit alpha) (eg, uveal melanoma), common variants (eg, R183, Q209) HBB (hemoglobin, beta, beta-globin) (eg, beta thalassemia), duplication/deletion analysis 4 (Equ Ring), SCAA1 (Edu Blood group), GYPA, GYPB, GYPE (MNS blood group), ERAM (Edu), FUND (Edu), RUDA (Edu), SCAA1 (Edu Blood group), GYPA, GYPB, GYPE (MNS blood group), RAT4 (Dombrock blood gro	Ş	118.00

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more	\$ 1,068.00
independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) ANG (angiogenin, ribonuclease, RNase A family, 5) (eg, amyotrophic	
lateral sclerosis), full gene sequence ARX (aristaless-related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation),	
duplication/deletion analysis CEL (carboxyl ester lipase [bile salt-stimulated lipase]) (eg, maturity-onset diabetes of the young [MODY]), targeted sequence	
analysis of exon 11 (eg, c.1785delC, c.1686delT) CTNNB1 (catenin [cadherin-associated protein], beta 1, 88kDa) (eg, desmoid tumors), targeted sequence	
analysis (eg, exon 3) DAZ/SRY (deleted in azoospermia and sex determining region Y) (eg, male infertility), common deletions (eg, AZFa, AZFb, AZFc, AZFd)	
DNMT3A (DNA [cytosine-5-]-methyltransferase 3 alpha) (eg, acute myeloid leukemia), targeted sequence analysis (eg, exon 23) EPCAM (epithelial cell adhesion	
molecule) (eg, Lynch syndrome), duplication/deletion analysis F8 (coagulation factor VIII) (eg, hemophilia A), inversion analysis, intron 1 and intron 22A F12	
(coagulation factor XII [Hageman factor]) (eg, angioedema, hereditary, type III; factor XII deficiency), targeted sequence analysis of exon 9 FGFR3 (fibroblast	
growth factor receptor 3) (eg, isolated craniosynostosis), targeted sequence analysis (eg, exon 7) (For targeted sequence analysis of multiple FGFR3 exons, use	
81404) GJB1 (gap junction protein, beta 1) (eg, Charcot-Marie-Tooth X-linked), full gene sequence GNAQ (guanine nucleotide-binding protein G[q] subunit	
alpha) (eg, uveal melanoma), common variants (eg, R183, Q209) HBB (hemoglobin, beta, beta-globin) (eg, beta thalassemia), duplication/deletion analysis	
Human erythrocyte antigen gene analyses (eg, SLC14A1 [Kidd blood group], BCAM [Lutheran blood group], ICAM4 [Landsteiner-Wiener blood group], SLC4A1	
[Diego blood group], AQP1 [Colton blood group], ERMAP [Scianna blood group], RHCE [Rh blood group, CcEe antigens], KEL [Kell blood group], DARC [Duffy	
blood group], GYPA, GYPB, GYPE [MNS blood group], ART4 [Dombrock blood group]) (eg, sickle-cell disease, thalassemia, hemolytic transfusion reactions,	
hemolytic disease of the fetus or newborn), common variants HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), exon 2	
sequence IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (eg, glioma), common exon 4 variants (eg, R132H, R132C) IDH2 (isocitrate dehydrogenase 2	
[NADP+], mitochondrial) (eg, glioma), common exon 4 variants (eg, R140W, R172M) JAK2 (Janus kinase 2) (eg, myeloproliferative disorder), exon 12 sequence	
and exon 13 sequence, if performed KCNC3 (potassium voltage-gated channel, Shaw-related subfamily, member 3) (eg, spinocerebellar ataxia), targeted	
sequence analysis (eg, exon 2) KCNJ2 (potassium inwardly-rectifying channel, subfamily J, member 2) (eg, Andersen-Tawil syndrome), full gene sequence	
KCNJ11 (potassium inwardly-rectifying channel, subfamily J, member 11) (eg, familial hyperinsulinism), full gene sequence Killer cell immunoglobulin-like	
receptor (KIR) gene family (eg, hematopoietic stem cell transplantation), genotyping of KIR family genes Known familial variant not otherwise specified, for	
gene listed in Tier 1 or Tier 2, or identified during a genomic sequencing procedure, DNA sequence analysis, each variant exon (For a known familial variant	
that is considered a common variant, use specific common variant Tier 1 or Tier 2 code) MC4R (melanocortin 4 receptor) (eg, obesity), full gene sequence MICA	
(MHC class I polypeptide-related sequence A) (eg, solid organ transplantation), common variants (eg, *001, *002) MPL (myeloproliferative leukemia virus	
oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), exon 10 sequence MT-RNR1 (mitochondrially encoded 12S RNA) (eg,	
nonsyndromic hearing loss), full gene sequence MT-TS1 (mitochondrially encoded tRNA serine 1) (eg, nonsyndromic hearing loss), full gene sequence NDP	
(Norrie disease [pseudoglioma]) (eg, Norrie disease), duplication/deletion analysis NHLRC1 (NHL repeat containing 1) (eg, progressive myoclonus epilepsy), full	
gene sequence PHOX2B (paired-like homeobox 2b) (eg, congenital central hypoventilation syndrome), duplication/deletion analysis PLN (phospholamban) (eg,	
dilated cardiomyopathy, hypertrophic cardiomyopathy), full gene sequence RHD (Rh blood group, D antigen) (eg, hemolytic disease of the fetus and newborn,	
Rh maternal/fetal compatibility), deletion analysis (eg, exons 4, 5, and 7, pseudogene) RHD (Rh blood group, D antigen) (eg, hemolytic disease of the fetus and	
newborn, Rh maternal/fetal compatibility), deletion analysis (eg, exons 4, 5, and 7, pseudogene), performed on cell-free fetal DNA in maternal blood (For	
human enthrocyte gene analysis of RHD, use a senarate unit of 81403) SH2D1A (SH2 domain containing 1A) (eg. X-linked lymphoproliferative syndrome)	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more	\$ 2,070.00
independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) ANG (angiogenin, ribonuclease, RNase A family, 5) (eg, amyotrophic	
lateral sclerosis), full gene sequence ARX (aristaless-related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation),	
duplication/deletion analysis CEL (carboxyl ester lipase [bile salt-stimulated lipase]) (eg, maturity-onset diabetes of the young [MODY]), targeted sequence	
analysis of exon 11 (eg, c.1785delC, c.1686delT) CTNNB1 (catenin [cadherin-associated protein], beta 1, 88kDa) (eg, desmoid tumors), targeted sequence	
analysis (eg, exon 3) DAZ/SRY (deleted in azoospermia and sex determining region Y) (eg, male infertility), common deletions (eg, AZFa, AZFb, AZFc, AZFd)	
DNMT3A (DNA [cytosine-5-]-methyltransferase 3 alpha) (eg, acute myeloid leukemia), targeted sequence analysis (eg, exon 23) EPCAM (epithelial cell adhesion	
molecule) (eg, Lynch syndrome), duplication/deletion analysis F8 (coagulation factor VIII) (eg, hemophilia A), inversion analysis, intron 1 and intron 22A F12	
(coagulation factor XII [Hageman factor]) (eg, angioedema, hereditary, type III; factor XII deficiency), targeted sequence analysis of exon 9 FGFR3 (fibroblast	
growth factor receptor 3) (eg, isolated craniosynostosis), targeted sequence analysis (eg, exon 7) (For targeted sequence analysis of multiple FGFR3 exons, use	
81404) GJB1 (gap junction protein, beta 1) (eg, Charcot-Marie-Tooth X-linked), full gene sequence GNAQ (guanine nucleotide-binding protein G[q] subunit	
alpha) (eg, uveal melanoma), common variants (eg, R183, Q209) HBB (hemoglobin, beta, beta-globin) (eg, beta thalassemia), duplication/deletion analysis	
Human erythrocyte antigen gene analyses (eg, SLC14A1 [Kidd blood group], BCAM [Lutheran blood group], ICAM4 [Landsteiner-Wiener blood group], SLC4A1	
[Diego blood group], AQP1 [Colton blood group], ERMAP [Scianna blood group], RHCE [Rh blood group, CcEe antigens], KEL [Kell blood group], DARC [Duffy	
blood group], GYPA, GYPB, GYPE [MNS blood group], ART4 [Dombrock blood group]) (eg, sickle-cell disease, thalassemia, hemolytic transfusion reactions,	
hemolytic disease of the fetus or newborn), common variants HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), exon 2	
sequence IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (eg, glioma), common exon 4 variants (eg, R132H, R132C) IDH2 (isocitrate dehydrogenase 2	
[NADP+], mitochondrial) (eg, glioma), common exon 4 variants (eg, R140W, R172M) JAK2 (Janus kinase 2) (eg, myeloproliferative disorder), exon 12 sequence	
and exon 13 sequence, if performed KCNC3 (potassium voltage-gated channel, Shaw-related subfamily, member 3) (eg, spinocerebellar ataxia), targeted	
sequence analysis (eg, exon 2) KCNJ2 (potassium inwardly-rectifying channel, subfamily J, member 2) (eg, Andersen-Tawil syndrome), full gene sequence	
KCNJ11 (potassium inwardly-rectifying channel, subfamily J, member 11) (eg, familial hyperinsulinism), full gene sequence Killer cell immunoglobulin-like	
receptor (KIR) gene family (eg, hematopoietic stem cell transplantation), genotyping of KIR family genes Known familial variant not otherwise specified, for	
gene listed in Tier 1 or Tier 2, or identified during a genomic sequencing procedure, DNA sequence analysis, each variant exon (For a known familial variant	
that is considered a common variant, use specific common variant Tier 1 or Tier 2 code) MC4R (melanocortin 4 receptor) (eg, obesity), full gene sequence MICA	
(MHC class I polypeptide-related sequence A) (eg, solid organ transplantation), common variants (eg, *001, *002) MPL (myeloproliferative leukemia virus	
oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), exon 10 sequence MT-RNR1 (mitochondrially encoded 12S RNA) (eg,	
nonsyndromic hearing loss), full gene sequence MT-TS1 (mitochondrially encoded tRNA serine 1) (eg, nonsyndromic hearing loss), full gene sequence NDP	
(Norrie disease [pseudoglioma]) (eg, Norrie disease), duplication/deletion analysis NHLRC1 (NHL repeat containing 1) (eg, progressive myoclonus epilepsy), full	
gene sequence PHOX2B (paired-like homeobox 2b) (eg, congenital central hypoventilation syndrome), duplication/deletion analysis PLN (phospholamban) (eg,	
dilated cardiomyopathy, hypertrophic cardiomyopathy), full gene sequence RHD (Rh blood group, D antigen) (eg, hemolytic disease of the fetus and newborn,	
Rh maternal/fetal compatibility), deletion analysis (eg, exons 4, 5, and 7, pseudogene) RHD (Rh blood group, D antigen) (eg, hemolytic disease of the fetus and	
newborn, Rh maternal/fetal compatibility), deletion analysis (eg, exons 4, 5, and 7, pseudogene), performed on cell-free fetal DNA in maternal blood (For	
human erythrocyte gene analysis of RHD use a senarate unit of \$1403 SH2D1A (SH2 domain containing 1A) (eg. X-linked lymphonroliferative syndrome)	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more	\$ 322.00
independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) ANG (angiogenin, ribonuclease, RNase A family, 5) (eg, amyotrophic	
lateral sclerosis), full gene sequence ARX (aristaless-related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation),	
duplication/deletion analysis CEL (carboxyl ester lipase [bile salt-stimulated lipase]) (eg, maturity-onset diabetes of the young [MODY]), targeted sequence	
analysis of exon 11 (eg, c.1785delC, c.1686delT) CTNNB1 (catenin [cadherin-associated protein], beta 1, 88kDa) (eg, desmoid tumors), targeted sequence	
analysis (eg, exon 3) DAZ/SRY (deleted in azoospermia and sex determining region Y) (eg, male infertility), common deletions (eg, AZFa, AZFb, AZFc, AZFd)	
DNMT3A (DNA [cytosine-5-]-methyltransferase 3 alpha) (eg, acute myeloid leukemia), targeted sequence analysis (eg, exon 23) EPCAM (epithelial cell adhesion	
molecule) (eg, Lynch syndrome), duplication/deletion analysis F8 (coagulation factor VIII) (eg, hemophilia A), inversion analysis, intron 1 and intron 22A F12	
(coagulation factor XII [Hageman factor]) (eg, angioedema, hereditary, type III; factor XII deficiency), targeted sequence analysis of exon 9 FGFR3 (fibroblast	
growth factor receptor 3) (eg, isolated craniosynostosis), targeted sequence analysis (eg, exon 7) (For targeted sequence analysis of multiple FGFR3 exons, use	
81404) GJB1 (gap junction protein, beta 1) (eg, Charcot-Marie-Tooth X-linked), full gene sequence GNAQ (guanine nucleotide-binding protein G[q] subunit	
alpha) (eg, uveal melanoma), common variants (eg, R183, Q209) HBB (hemoglobin, beta, beta-globin) (eg, beta thalassemia), duplication/deletion analysis	
Human erythrocyte antigen gene analyses (eg, SLC14A1 [Kidd blood group], BCAM [Lutheran blood group], ICAM4 [Landsteiner-Wiener blood group], SLC4A1	
[Diego blood group], AQP1 [Colton blood group], ERMAP [Scianna blood group], RHCE [Rh blood group, CcEe antigens], KEL [Kell blood group], DARC [Duffy	
blood group], GYPA, GYPB, GYPE [MNS blood group], ART4 [Dombrock blood group]) (eg, sickle-cell disease, thalassemia, hemolytic transfusion reactions,	
hemolytic disease of the fetus or newborn), common variants HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), exon 2	
sequence IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (eg, glioma), common exon 4 variants (eg, R132H, R132C) IDH2 (isocitrate dehydrogenase 2	
[NADP+], mitochondrial) (eg, glioma), common exon 4 variants (eg, R140W, R172M) JAK2 (Janus kinase 2) (eg, myeloproliferative disorder), exon 12 sequence	
and exon 13 sequence, if performed KCNC3 (potassium voltage-gated channel, Shaw-related subfamily, member 3) (eg, spinocerebellar ataxia), targeted	
sequence analysis (eg, exon 2) KCNJ2 (potassium inwardly-rectifying channel, subfamily J, member 2) (eg, Andersen-Tawil syndrome), full gene sequence	
KCNJ11 (potassium inwardly-rectifying channel, subfamily J, member 11) (eg, familial hyperinsulinism), full gene sequence Killer cell immunoglobulin-like	
receptor (KIR) gene family (eg, hematopoietic stem cell transplantation), genotyping of KIR family genes Known familial variant not otherwise specified, for	
gene listed in Tier 1 or Tier 2, or identified during a genomic sequencing procedure, DNA sequence analysis, each variant exon (For a known familial variant	
that is considered a common variant, use specific common variant Tier 1 or Tier 2 code) MC4R (melanocortin 4 receptor) (eg, obesity), full gene sequence MICA	
(MHC class I polypeptide-related sequence A) (eg, solid organ transplantation), common variants (eg, *001, *002) MPL (myeloproliferative leukemia virus	
oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), exon 10 sequence MT-RNR1 (mitochondrially encoded 12S RNA) (eg,	
nonsyndromic hearing loss), full gene sequence MT-TS1 (mitochondrially encoded tRNA serine 1) (eg, nonsyndromic hearing loss), full gene sequence NDP	
(Norrie disease [pseudoglioma]) (eg, Norrie disease), duplication/deletion analysis NHLRC1 (NHL repeat containing 1) (eg, progressive myoclonus epilepsy), full	
gene sequence PHOX2B (paired-like homeobox 2b) (eg, congenital central hypoventilation syndrome), duplication/deletion analysis PLN (phospholamban) (eg,	
dilated cardiomyopathy, hypertrophic cardiomyopathy), full gene sequence RHD (Rh blood group, D antigen) (eg, hemolytic disease of the fetus and newborn,	
Rh maternal/fetal compatibility), deletion analysis (eg, exons 4, 5, and 7, pseudogene) RHD (Rh blood group, D antigen) (eg, hemolytic disease of the fetus and	
newborn, Rh maternal/fetal compatibility), deletion analysis (eg, exons 4, 5, and 7, pseudogene), performed on cell-free fetal DNA in maternal blood (For	
human enthrocide gene analysis of RHD, use a senarate unit of 81403) SH2D1A (SH2 domain containing 1A) (eg. X-linked lymphoproliferative syndrome)	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more	\$ 322.00
independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) ANG (angiogenin, ribonuclease, RNase A family, 5) (eg, amyotrophic	
lateral sclerosis), full gene sequence ARX (aristaless-related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation),	
duplication/deletion analysis CEL (carboxyl ester lipase [bile salt-stimulated lipase]) (eg, maturity-onset diabetes of the young [MODY]), targeted sequence	
analysis of exon 11 (eg, c.1785delC, c.1686delT) CTNNB1 (catenin [cadherin-associated protein], beta 1, 88kDa) (eg, desmoid tumors), targeted sequence	
analysis (eg, exon 3) DAZ/SRY (deleted in azoospermia and sex determining region Y) (eg, male infertility), common deletions (eg, AZFa, AZFb, AZFc, AZFd)	
DNMT3A (DNA [cytosine-5-]-methyltransferase 3 alpha) (eg, acute myeloid leukemia), targeted sequence analysis (eg, exon 23) EPCAM (epithelial cell adhesion	
molecule) (eg, Lynch syndrome), duplication/deletion analysis F8 (coagulation factor VIII) (eg, hemophilia A), inversion analysis, intron 1 and intron 22A F12	
(coagulation factor XII [Hageman factor]) (eg, angioedema, hereditary, type III; factor XII deficiency), targeted sequence analysis of exon 9 FGFR3 (fibroblast	
growth factor receptor 3) (eg, isolated craniosynostosis), targeted sequence analysis (eg, exon 7) (For targeted sequence analysis of multiple FGFR3 exons, use	
81404) GJB1 (gap junction protein, beta 1) (eg, Charcot-Marie-Tooth X-linked), full gene sequence GNAQ (guanine nucleotide-binding protein G[q] subunit	
alpha) (eg, uveal melanoma), common variants (eg, R183, Q209) HBB (hemoglobin, beta, beta-globin) (eg, beta thalassemia), duplication/deletion analysis	
Human erythrocyte antigen gene analyses (eg, SLC14A1 [Kidd blood group], BCAM [Lutheran blood group], ICAM4 [Landsteiner-Wiener blood group], SLC4A1	
[Diego blood group], AQP1 [Colton blood group], ERMAP [Scianna blood group], RHCE [Rh blood group, CcEe antigens], KEL [Kell blood group], DARC [Duffy	
blood group], GYPA, GYPB, GYPE [MNS blood group], ART4 [Dombrock blood group]) (eg, sickle-cell disease, thalassemia, hemolytic transfusion reactions,	
hemolytic disease of the fetus or newborn), common variants HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), exon 2	
sequence IDH1 (isocitrate dehydrogenase 1 [NADP+], soluble) (eg, glioma), common exon 4 variants (eg, R132H, R132C) IDH2 (isocitrate dehydrogenase 2	
[NADP+], mitochondrial) (eg, glioma), common exon 4 variants (eg, R140W, R172M) JAK2 (Janus kinase 2) (eg, myeloproliferative disorder), exon 12 sequence	
and exon 13 sequence, if performed KCNC3 (potassium voltage-gated channel, Shaw-related subfamily, member 3) (eg, spinocerebellar ataxia), targeted	
sequence analysis (eg, exon 2) KCNJ2 (potassium inwardly-rectifying channel, subfamily J, member 2) (eg, Andersen-Tawil syndrome), full gene sequence	
KCNJ11 (potassium inwardly-rectifying channel, subfamily J, member 11) (eg, familial hyperinsulinism), full gene sequence Killer cell immunoglobulin-like	
receptor (KIR) gene family (eg, hematopoietic stem cell transplantation), genotyping of KIR family genes Known familial variant not otherwise specified, for	
gene listed in Tier 1 or Tier 2, or identified during a genomic sequencing procedure, DNA sequence analysis, each variant exon (For a known familial variant	
that is considered a common variant, use specific common variant Tier 1 or Tier 2 code) MC4R (melanocortin 4 receptor) (eg, obesity), full gene sequence MICA	
(MHC class I polypeptide-related sequence A) (eg, solid organ transplantation), common variants (eg, *001, *002) MPL (myeloproliferative leukemia virus	
oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), exon 10 sequence MT-RNR1 (mitochondrially encoded 12S RNA) (eg,	
nonsyndromic hearing loss), full gene sequence MT-TS1 (mitochondrially encoded tRNA serine 1) (eg, nonsyndromic hearing loss), full gene sequence NDP	
(Norrie disease [pseudoglioma]) (eg, Norrie disease), duplication/deletion analysis NHLRC1 (NHL repeat containing 1) (eg, progressive myoclonus epilepsy), full	
gene sequence PHOX2B (paired-like homeobox 2b) (eg, congenital central hypoventilation syndrome), duplication/deletion analysis PLN (phospholamban) (eg,	
dilated cardiomyopathy, hypertrophic cardiomyopathy), full gene sequence RHD (Rh blood group, D antigen) (eg, hemolytic disease of the fetus and newborn,	
Rh maternal/fetal compatibility), deletion analysis (eg, exons 4, 5, and 7, pseudogene) RHD (Rh blood group, D antigen) (eg, hemolytic disease of the fetus and	
newborn, Rh maternal/fetal compatibility), deletion analysis (eg, exons 4, 5, and 7, pseudogene), performed on cell-free fetal DNA in maternal blood (For	
human enthrocyte gene analysis of RHD, use a separate unit of 81403) SH2D14 (SH2 domain containing 14) (eg. X-linked lymphoproliferative syndrome)	

DESCRIPTION	 CHARGE
Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons,	\$ 74.00
or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis) ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short	
chain acyl-CoA dehydrogenase deficiency), targeted sequence analysis (eg, exons 5 and 6) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental	
retardation 2 [FRAXE]), characterization of alleles (eg, expanded size and methylation status) AQP2 (aquaporin 2 [collecting duct]) (eg, nephrogenic diabetes	
insipidus), full gene sequence ARX (aristaless related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation), full gene	
sequence AVPR2 (arginine vasopressin receptor 2) (eg, nephrogenic diabetes insipidus), full gene sequence BBS10 (Bardet-Biedl syndrome 10) (eg, Bardet-Biedl	
syndrome), full gene sequence BTD (biotinidase) (eg, biotinidase deficiency), full gene sequence C10orf2 (chromosome 10 open reading frame 2) (eg,	
mitochondrial DNA depletion syndrome), full gene sequence CAV3 (caveolin 3) (eg, CAV3-related distal myopathy, limb-girdle muscular dystrophy type 1C), full	
gene sequence CD40LG (CD40 ligand) (eg, X-linked hyper IgM syndrome), full gene sequence CDKN2A (cyclin-dependent kinase inhibitor 2A) (eg, CDKN2A-	
related cutaneous malignant melanoma, familial atypical mole-malignant melanoma syndrome), full gene sequence CLRN1 (clarin 1) (eg, Usher syndrome, type	
3), full gene sequence COX6B1 (cytochrome c oxidase subunit VIb polypeptide 1) (eg, mitochondrial respiratory chain complex IV deficiency), full gene	
sequence CPT2 (carnitine palmitoyltransferase 2) (eg, carnitine palmitoyltransferase II deficiency), full gene sequence CRX (cone-rod homeobox) (eg, cone-rod	
dystrophy 2, Leber congenital amaurosis), full gene sequence CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), full gene sequence CYP1B1	
(cytochrome P450, family 1, subfamily B, polypeptide 1) (eg, primary congenital glaucoma), full gene sequence DMPK (dystrophia myotonica-protein kinase)	
(eg, myotonic dystrophy type 1), characterization of abnormal (eg, expanded) alleles EGR2 (early growth response 2) (eg, Charcot-Marie-Tooth), full gene	
sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), duplication/deletion analysis EPM2A (epilepsy, progressive myoclonus type 2A, Lafora	
disease [laforin]) (eg, progressive myoclonus epilepsy), full gene sequence FGF23 (fibroblast growth factor 23) (eg, hypophosphatemic rickets), full gene	
sequence FGFR2 (fibroblast growth factor receptor 2) (eg, craniosynostosis, Apert syndrome, Crouzon syndrome), targeted sequence analysis (eg, exons 8, 10)	
FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), targeted sequence analysis (eg, exons 8, 11, 12, 13) FHL1 (four and a half	
LIM domains 1) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence FKRP (fukutin related protein) (eg, congenital muscular dystrophy type 1C	
[MDC1C], limb-girdle muscular dystrophy [LGMD] type 2I), full gene sequence FOXG1 (forkhead box G1) (eg, Rett syndrome), full gene sequence FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), evaluation to detect abnormal (eg, deleted) alleles FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), characterization of haplotype(s) (ie, chromosome 4A and 4B	
haplotypes) FXN (frataxin) (eg, Friedreich ataxia), full gene sequence GH1 (growth hormone 1) (eg, growth hormone deficiency), full gene sequence GP1BB	
(glycoprotein lb [platelet], beta polypeptide) (eg, Bernard-Soulier syndrome type B), full gene sequence HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg,	
alpha thalassemia), duplication/deletion analysis (For common deletion variants of alpha globin 1 and alpha globin 2 genes, use 81257) HBB (hemoglobin, beta,	
Beta-Globin) (eg, thalassemia), full gene sequence HNF1B (HNF1 homeobox B) (eg, maturity-onset diabetes of the young [MODY]), duplication/deletion	
analysis HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), full gene sequence HSD3B2 (hydroxy-delta-5-steroid	
dehydrogenase, 3 beta- and steroid delta-isomerase 2) (eg, 3-beta-hydroxysteroid dehydrogenase type II deficiency), full gene sequence HSD11B2	
(hydroxysteroid [11-beta] dehydrogenase 2) (eg, mineralocorticoid excess syndrome), full gene sequence HSPB1 (heat shock 27kDa protein 1) (eg, Charcot-	
Marie-Tooth disease), full gene sequence INS (insulin) (eg, diabetes mellitus), full gene sequence KCNJ1 (potassium inwardly-rectifying channel, subfamily J,	
member 1) (eg, Bartter syndrome), full gene sequence KCNJ10 (potassium inwardly-rectifying channel, subfamily J, member 10) (eg, SeSAME syndrome, EAST	
syndrome sensorineural bearing loss) full gene sequence LITAE (liponolysaccharide-induced TNE factor) (eg. Charcot-Marie-Tooth) full gene sequence MEEV	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons,	\$ 3,376.00
or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis) ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short	
chain acyl-CoA dehydrogenase deficiency), targeted sequence analysis (eg, exons 5 and 6) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental	
retardation 2 [FRAXE]), characterization of alleles (eg, expanded size and methylation status) AQP2 (aquaporin 2 [collecting duct]) (eg, nephrogenic diabetes	
insipidus), full gene sequence ARX (aristaless related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation), full gene	
sequence AVPR2 (arginine vasopressin receptor 2) (eg, nephrogenic diabetes insipidus), full gene sequence BBS10 (Bardet-Biedl syndrome 10) (eg, Bardet-Biedl	
syndrome), full gene sequence BTD (biotinidase) (eg, biotinidase deficiency), full gene sequence C10orf2 (chromosome 10 open reading frame 2) (eg,	
mitochondrial DNA depletion syndrome), full gene sequence CAV3 (caveolin 3) (eg, CAV3-related distal myopathy, limb-girdle muscular dystrophy type 1C), full	
gene sequence CD40LG (CD40 ligand) (eg, X-linked hyper IgM syndrome), full gene sequence CDKN2A (cyclin-dependent kinase inhibitor 2A) (eg, CDKN2A-	
related cutaneous malignant melanoma, familial atypical mole-malignant melanoma syndrome), full gene sequence CLRN1 (clarin 1) (eg, Usher syndrome, type	
3), full gene sequence COX6B1 (cytochrome c oxidase subunit VIb polypeptide 1) (eg, mitochondrial respiratory chain complex IV deficiency), full gene	
sequence CPT2 (carnitine palmitoyltransferase 2) (eg, carnitine palmitoyltransferase II deficiency), full gene sequence CRX (cone-rod homeobox) (eg, cone-rod	
dystrophy 2, Leber congenital amaurosis), full gene sequence CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), full gene sequence CYP1B1	
(cytochrome P450, family 1, subfamily B, polypeptide 1) (eg, primary congenital glaucoma), full gene sequence DMPK (dystrophia myotonica-protein kinase)	
(eg, myotonic dystrophy type 1), characterization of abnormal (eg, expanded) alleles EGR2 (early growth response 2) (eg, Charcot-Marie-Tooth), full gene	
sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), duplication/deletion analysis EPM2A (epilepsy, progressive myoclonus type 2A, Lafora	
disease [laforin]) (eg, progressive myoclonus epilepsy), full gene sequence FGF23 (fibroblast growth factor 23) (eg, hypophosphatemic rickets), full gene	
sequence FGFR2 (fibroblast growth factor receptor 2) (eg, craniosynostosis, Apert syndrome, Crouzon syndrome), targeted sequence analysis (eg, exons 8, 10)	
FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), targeted sequence analysis (eg, exons 8, 11, 12, 13) FHL1 (four and a half	
LIM domains 1) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence FKRP (fukutin related protein) (eg, congenital muscular dystrophy type 1C	
[MDC1C], limb-girdle muscular dystrophy [LGMD] type 21), full gene sequence FOXG1 (forkhead box G1) (eg, Rett syndrome), full gene sequence FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), evaluation to detect abnormal (eg, deleted) alleles FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), characterization of haplotype(s) (ie, chromosome 4A and 4B	
haplotypes) FXN (frataxin) (eg, Friedreich ataxia), full gene sequence GH1 (growth hormone 1) (eg, growth hormone deficiency), full gene sequence GP1BB	
(glycoprotein lb [platelet], beta polypeptide) (eg, Bernard-Soulier syndrome type B), full gene sequence HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg,	
alpha thalassemia), duplication/deletion analysis (For common deletion variants of alpha globin 1 and alpha globin 2 genes, use 81257) HBB (hemoglobin, beta,	
Beta-Globin) (eg, thalassemia), full gene sequence HNF1B (HNF1 homeobox B) (eg, maturity-onset diabetes of the young [MODY]), duplication/deletion	
analysis HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), full gene sequence HSD3B2 (hydroxy-delta-5-steroid	
dehydrogenase, 3 beta- and steroid delta-isomerase 2) (eg, 3-beta-hydroxysteroid dehydrogenase type II deficiency), full gene sequence HSD11B2	
(hydroxysteroid [11-beta] dehydrogenase 2) (eg, mineralocorticoid excess syndrome), full gene sequence HSPB1 (heat shock 27kDa protein 1) (eg, Charcot-	
Marie-Tooth disease), full gene sequence INS (insulin) (eg, diabetes mellitus), full gene sequence KCNJ1 (potassium inwardly-rectifying channel, subfamily J,	
member 1) (eg, Bartter syndrome), full gene sequence KCNJ10 (potassium inwardly-rectifying channel, subfamily J, member 10) (eg, SeSAME syndrome, EAST	
syndrome sensorineural bearing loss) full gene sequence LITAE (liponolysaccharide-induced TNE factor) (eg. Charcot-Marie-Tooth) full gene sequence MEEV	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons,	\$ 2,339.00
or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis) ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short	
chain acyl-CoA dehydrogenase deficiency), targeted sequence analysis (eg, exons 5 and 6) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental	
retardation 2 [FRAXE]), characterization of alleles (eg, expanded size and methylation status) AQP2 (aquaporin 2 [collecting duct]) (eg, nephrogenic diabetes	
insipidus), full gene sequence ARX (aristaless related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation), full gene	
sequence AVPR2 (arginine vasopressin receptor 2) (eg, nephrogenic diabetes insipidus), full gene sequence BBS10 (Bardet-Biedl syndrome 10) (eg, Bardet-Biedl	
syndrome), full gene sequence BTD (biotinidase) (eg, biotinidase deficiency), full gene sequence C10orf2 (chromosome 10 open reading frame 2) (eg,	
mitochondrial DNA depletion syndrome), full gene sequence CAV3 (caveolin 3) (eg, CAV3-related distal myopathy, limb-girdle muscular dystrophy type 1C), full	
gene sequence CD40LG (CD40 ligand) (eg, X-linked hyper IgM syndrome), full gene sequence CDKN2A (cyclin-dependent kinase inhibitor 2A) (eg, CDKN2A-	
related cutaneous malignant melanoma, familial atypical mole-malignant melanoma syndrome), full gene sequence CLRN1 (clarin 1) (eg, Usher syndrome, type	
3), full gene sequence COX6B1 (cytochrome c oxidase subunit VIb polypeptide 1) (eg, mitochondrial respiratory chain complex IV deficiency), full gene	
sequence CPT2 (carnitine palmitoyltransferase 2) (eg, carnitine palmitoyltransferase II deficiency), full gene sequence CRX (cone-rod homeobox) (eg, cone-rod	
dystrophy 2, Leber congenital amaurosis), full gene sequence CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), full gene sequence CYP1B1	
(cytochrome P450, family 1, subfamily B, polypeptide 1) (eg, primary congenital glaucoma), full gene sequence DMPK (dystrophia myotonica-protein kinase)	
(eg, myotonic dystrophy type 1), characterization of abnormal (eg, expanded) alleles EGR2 (early growth response 2) (eg, Charcot-Marie-Tooth), full gene	
sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), duplication/deletion analysis EPM2A (epilepsy, progressive myoclonus type 2A, Lafora	
disease [laforin]) (eg, progressive myoclonus epilepsy), full gene sequence FGF23 (fibroblast growth factor 23) (eg, hypophosphatemic rickets), full gene	
sequence FGFR2 (fibroblast growth factor receptor 2) (eg, craniosynostosis, Apert syndrome, Crouzon syndrome), targeted sequence analysis (eg, exons 8, 10)	
FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), targeted sequence analysis (eg, exons 8, 11, 12, 13) FHL1 (four and a half	
LIM domains 1) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence FKRP (fukutin related protein) (eg, congenital muscular dystrophy type 1C	
[MDC1C], limb-girdle muscular dystrophy [LGMD] type 2I), full gene sequence FOXG1 (forkhead box G1) (eg, Rett syndrome), full gene sequence FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), evaluation to detect abnormal (eg, deleted) alleles FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), characterization of haplotype(s) (ie, chromosome 4A and 4B	
haplotypes) FXN (frataxin) (eg, Friedreich ataxia), full gene sequence GH1 (growth hormone 1) (eg, growth hormone deficiency), full gene sequence GP1BB	
(glycoprotein lb [platelet], beta polypeptide) (eg, Bernard-Soulier syndrome type B), full gene sequence HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg,	
alpha thalassemia), duplication/deletion analysis (For common deletion variants of alpha globin 1 and alpha globin 2 genes, use 81257) HBB (hemoglobin, beta,	
Beta-Globin) (eg, thalassemia), full gene sequence HNF1B (HNF1 homeobox B) (eg, maturity-onset diabetes of the young [MODY]), duplication/deletion	
analysis HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), full gene sequence HSD3B2 (hydroxy-delta-5-steroid	
dehydrogenase, 3 beta- and steroid delta-isomerase 2) (eg, 3-beta-hydroxysteroid dehydrogenase type II deficiency), full gene sequence HSD11B2	
(hydroxysteroid [11-beta] dehydrogenase 2) (eg, mineralocorticoid excess syndrome), full gene sequence HSPB1 (heat shock 27kDa protein 1) (eg, Charcot-	
Marie-Tooth disease), full gene sequence INS (insulin) (eg, diabetes mellitus), full gene sequence KCNJ1 (potassium inwardly-rectifying channel, subfamily J,	
member 1) (eg, Bartter syndrome), full gene sequence KCNJ10 (potassium inwardly-rectifying channel, subfamily J, member 10) (eg, SeSAME syndrome, EAST	
syndrome sensorineural bearing loss) full gene sequence LITAE (linonolysaccharide-induced TNE factor) (eg. Charcot-Marie-Tooth) full gene sequence MEEV	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons,	\$ 7,134.00
or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis) ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short	
chain acyl-CoA dehydrogenase deficiency), targeted sequence analysis (eg, exons 5 and 6) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental	
retardation 2 [FRAXE]), characterization of alleles (eg, expanded size and methylation status) AQP2 (aquaporin 2 [collecting duct]) (eg, nephrogenic diabetes	
insipidus), full gene sequence ARX (aristaless related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation), full gene	
sequence AVPR2 (arginine vasopressin receptor 2) (eg, nephrogenic diabetes insipidus), full gene sequence BBS10 (Bardet-Biedl syndrome 10) (eg, Bardet-Biedl	
syndrome), full gene sequence BTD (biotinidase) (eg, biotinidase deficiency), full gene sequence C10orf2 (chromosome 10 open reading frame 2) (eg,	
mitochondrial DNA depletion syndrome), full gene sequence CAV3 (caveolin 3) (eg, CAV3-related distal myopathy, limb-girdle muscular dystrophy type 1C), full	
gene sequence CD40LG (CD40 ligand) (eg, X-linked hyper IgM syndrome), full gene sequence CDKN2A (cyclin-dependent kinase inhibitor 2A) (eg, CDKN2A-	
related cutaneous malignant melanoma, familial atypical mole-malignant melanoma syndrome), full gene sequence CLRN1 (clarin 1) (eg, Usher syndrome, type	
3), full gene sequence COX6B1 (cytochrome c oxidase subunit VIb polypeptide 1) (eg, mitochondrial respiratory chain complex IV deficiency), full gene	
sequence CPT2 (carnitine palmitoyltransferase 2) (eg, carnitine palmitoyltransferase II deficiency), full gene sequence CRX (cone-rod homeobox) (eg, cone-rod	
dystrophy 2, Leber congenital amaurosis), full gene sequence CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), full gene sequence CYP1B1	
(cytochrome P450, family 1, subfamily B, polypeptide 1) (eg, primary congenital glaucoma), full gene sequence DMPK (dystrophia myotonica-protein kinase)	
(eg, myotonic dystrophy type 1), characterization of abnormal (eg, expanded) alleles EGR2 (early growth response 2) (eg, Charcot-Marie-Tooth), full gene	
sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), duplication/deletion analysis EPM2A (epilepsy, progressive myoclonus type 2A, Lafora	
disease [laforin]) (eg, progressive myoclonus epilepsy), full gene sequence FGF23 (fibroblast growth factor 23) (eg, hypophosphatemic rickets), full gene	
sequence FGFR2 (fibroblast growth factor receptor 2) (eg, craniosynostosis, Apert syndrome, Crouzon syndrome), targeted sequence analysis (eg, exons 8, 10)	
FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), targeted sequence analysis (eg, exons 8, 11, 12, 13) FHL1 (four and a half	
LIM domains 1) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence FKRP (fukutin related protein) (eg, congenital muscular dystrophy type 1C	
[MDC1C], limb-girdle muscular dystrophy [LGMD] type 2I), full gene sequence FOXG1 (forkhead box G1) (eg, Rett syndrome), full gene sequence FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), evaluation to detect abnormal (eg, deleted) alleles FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), characterization of haplotype(s) (ie, chromosome 4A and 4B	
haplotypes) FXN (frataxin) (eg, Friedreich ataxia), full gene sequence GH1 (growth hormone 1) (eg, growth hormone deficiency), full gene sequence GP1BB	
(glycoprotein Ib [platelet], beta polypeptide) (eg, Bernard-Soulier syndrome type B), full gene sequence HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg,	
alpha thalassemia), duplication/deletion analysis (For common deletion variants of alpha globin 1 and alpha globin 2 genes, use 81257) HBB (hemoglobin, beta,	
Beta-Globin) (eg, thalassemia), full gene sequence HNF1B (HNF1 homeobox B) (eg, maturity-onset diabetes of the young [MODY]), duplication/deletion	
analysis HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), full gene sequence HSD3B2 (hydroxy-delta-5-steroid	
dehydrogenase, 3 beta- and steroid delta-isomerase 2) (eg, 3-beta-hydroxysteroid dehydrogenase type II deficiency), full gene sequence HSD11B2	
(hydroxysteroid [11-beta] dehydrogenase 2) (eg, mineralocorticoid excess syndrome), full gene sequence HSPB1 (heat shock 27kDa protein 1) (eg, Charcot-	
Marie-Tooth disease), full gene sequence INS (insulin) (eg, diabetes mellitus), full gene sequence KCNJ1 (potassium inwardly-rectifying channel, subfamily J,	
member 1) (eg, Bartter syndrome), full gene sequence KCNJ10 (potassium inwardly-rectifying channel, subfamily J, member 10) (eg, SeSAME syndrome, EAST	
syndrome sensorineural bearing loss) full gene sequence LITAE (linonolysaccharide-induced TNE factor) (eg. Charcot-Marie-Tooth) full gene sequence MEEV	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons,	\$ 565.00
or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis) ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short	
chain acyl-CoA dehydrogenase deficiency), targeted sequence analysis (eg, exons 5 and 6) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental	
retardation 2 [FRAXE]), characterization of alleles (eg, expanded size and methylation status) AQP2 (aquaporin 2 [collecting duct]) (eg, nephrogenic diabetes	
insipidus), full gene sequence ARX (aristaless related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation), full gene	
sequence AVPR2 (arginine vasopressin receptor 2) (eg, nephrogenic diabetes insipidus), full gene sequence BBS10 (Bardet-Biedl syndrome 10) (eg, Bardet-Biedl	
syndrome), full gene sequence BTD (biotinidase) (eg, biotinidase deficiency), full gene sequence C10orf2 (chromosome 10 open reading frame 2) (eg,	
mitochondrial DNA depletion syndrome), full gene sequence CAV3 (caveolin 3) (eg, CAV3-related distal myopathy, limb-girdle muscular dystrophy type 1C), full	
gene sequence CD40LG (CD40 ligand) (eg, X-linked hyper IgM syndrome), full gene sequence CDKN2A (cyclin-dependent kinase inhibitor 2A) (eg, CDKN2A-	
related cutaneous malignant melanoma, familial atypical mole-malignant melanoma syndrome), full gene sequence CLRN1 (clarin 1) (eg, Usher syndrome, type	
3), full gene sequence COX6B1 (cytochrome c oxidase subunit VIb polypeptide 1) (eg, mitochondrial respiratory chain complex IV deficiency), full gene	
sequence CPT2 (carnitine palmitoyltransferase 2) (eg, carnitine palmitoyltransferase II deficiency), full gene sequence CRX (cone-rod homeobox) (eg, cone-rod	
dystrophy 2, Leber congenital amaurosis), full gene sequence CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), full gene sequence CYP1B1	
(cytochrome P450, family 1, subfamily B, polypeptide 1) (eg, primary congenital glaucoma), full gene sequence DMPK (dystrophia myotonica-protein kinase)	
(eg, myotonic dystrophy type 1), characterization of abnormal (eg, expanded) alleles EGR2 (early growth response 2) (eg, Charcot-Marie-Tooth), full gene	
sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), duplication/deletion analysis EPM2A (epilepsy, progressive myoclonus type 2A, Lafora	
disease [laforin]) (eg, progressive myoclonus epilepsy), full gene sequence FGF23 (fibroblast growth factor 23) (eg, hypophosphatemic rickets), full gene	
sequence FGFR2 (fibroblast growth factor receptor 2) (eg, craniosynostosis, Apert syndrome, Crouzon syndrome), targeted sequence analysis (eg, exons 8, 10)	
FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), targeted sequence analysis (eg, exons 8, 11, 12, 13) FHL1 (four and a half	
LIM domains 1) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence FKRP (fukutin related protein) (eg, congenital muscular dystrophy type 1C	
[MDC1C], limb-girdle muscular dystrophy [LGMD] type 2I), full gene sequence FOXG1 (forkhead box G1) (eg, Rett syndrome), full gene sequence FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), evaluation to detect abnormal (eg, deleted) alleles FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), characterization of haplotype(s) (ie, chromosome 4A and 4B	
haplotypes) FXN (frataxin) (eg, Friedreich ataxia), full gene sequence GH1 (growth hormone 1) (eg, growth hormone deficiency), full gene sequence GP1BB	
(glycoprotein lb [platelet], beta polypeptide) (eg, Bernard-Soulier syndrome type B), full gene sequence HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg,	
alpha thalassemia), duplication/deletion analysis (For common deletion variants of alpha globin 1 and alpha globin 2 genes, use 81257) HBB (hemoglobin, beta,	
Beta-Globin) (eg, thalassemia), full gene sequence HNF1B (HNF1 homeobox B) (eg, maturity-onset diabetes of the young [MODY]), duplication/deletion	
analysis HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), full gene sequence HSD3B2 (hydroxy-delta-5-steroid	
dehydrogenase, 3 beta- and steroid delta-isomerase 2) (eg, 3-beta-hydroxysteroid dehydrogenase type II deficiency), full gene sequence HSD11B2	
(hydroxysteroid [11-beta] dehydrogenase 2) (eg, mineralocorticoid excess syndrome), full gene sequence HSPB1 (heat shock 27kDa protein 1) (eg, Charcot-	
Marie-Tooth disease), full gene sequence INS (insulin) (eg, diabetes mellitus), full gene sequence KCNJ1 (potassium inwardly-rectifying channel, subfamily J,	
member 1) (eg, Bartter syndrome), full gene sequence KCNJ10 (potassium inwardly-rectifying channel, subfamily J, member 10) (eg, SeSAME syndrome, EAST	
syndrome sensorineural hearing loss) full gene sequence LITAE (lipopolysarcharide-induced TNE factor) (eg. Charcot-Marie-Tooth) full gene sequence MEEV	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons,	\$ 2,074.00
or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis) ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short	
chain acyl-CoA dehydrogenase deficiency), targeted sequence analysis (eg, exons 5 and 6) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental	
retardation 2 [FRAXE]), characterization of alleles (eg, expanded size and methylation status) AQP2 (aquaporin 2 [collecting duct]) (eg, nephrogenic diabetes	
insipidus), full gene sequence ARX (aristaless related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation), full gene	
sequence AVPR2 (arginine vasopressin receptor 2) (eg, nephrogenic diabetes insipidus), full gene sequence BBS10 (Bardet-Biedl syndrome 10) (eg, Bardet-Biedl	
syndrome), full gene sequence BTD (biotinidase) (eg, biotinidase deficiency), full gene sequence C10orf2 (chromosome 10 open reading frame 2) (eg,	
mitochondrial DNA depletion syndrome), full gene sequence CAV3 (caveolin 3) (eg, CAV3-related distal myopathy, limb-girdle muscular dystrophy type 1C), full	
gene sequence CD40LG (CD40 ligand) (eg, X-linked hyper IgM syndrome), full gene sequence CDKN2A (cyclin-dependent kinase inhibitor 2A) (eg, CDKN2A-	
related cutaneous malignant melanoma, familial atypical mole-malignant melanoma syndrome), full gene sequence CLRN1 (clarin 1) (eg, Usher syndrome, type	
3), full gene sequence COX6B1 (cytochrome c oxidase subunit VIb polypeptide 1) (eg, mitochondrial respiratory chain complex IV deficiency), full gene	
sequence CPT2 (carnitine palmitoyltransferase 2) (eg, carnitine palmitoyltransferase II deficiency), full gene sequence CRX (cone-rod homeobox) (eg, cone-rod	
dystrophy 2, Leber congenital amaurosis), full gene sequence CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), full gene sequence CYP1B1	
(cytochrome P450, family 1, subfamily B, polypeptide 1) (eg, primary congenital glaucoma), full gene sequence DMPK (dystrophia myotonica-protein kinase)	
(eg, myotonic dystrophy type 1), characterization of abnormal (eg, expanded) alleles EGR2 (early growth response 2) (eg, Charcot-Marie-Tooth), full gene	
sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), duplication/deletion analysis EPM2A (epilepsy, progressive myoclonus type 2A, Lafora	
disease [laforin]) (eg, progressive myoclonus epilepsy), full gene sequence FGF23 (fibroblast growth factor 23) (eg, hypophosphatemic rickets), full gene	
sequence FGFR2 (fibroblast growth factor receptor 2) (eg, craniosynostosis, Apert syndrome, Crouzon syndrome), targeted sequence analysis (eg, exons 8, 10)	
FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), targeted sequence analysis (eg, exons 8, 11, 12, 13) FHL1 (four and a half	
LIM domains 1) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence FKRP (fukutin related protein) (eg, congenital muscular dystrophy type 1C	
[MDC1C], limb-girdle muscular dystrophy [LGMD] type 21), full gene sequence FOXG1 (forkhead box G1) (eg, Rett syndrome), full gene sequence FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), evaluation to detect abnormal (eg, deleted) alleles FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), characterization of haplotype(s) (ie, chromosome 4A and 4B	
haplotypes) FXN (frataxin) (eg, Friedreich ataxia), full gene sequence GH1 (growth hormone 1) (eg, growth hormone deficiency), full gene sequence GP1BB	
(glycoprotein Ib [platelet], beta polypeptide) (eg, Bernard-Soulier syndrome type B), full gene sequence HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg,	
alpha thalassemia), duplication/deletion analysis (For common deletion variants of alpha globin 1 and alpha globin 2 genes, use 81257) HBB (hemoglobin, beta,	
Beta-Globin) (eg, thalassemia), full gene sequence HNF1B (HNF1 homeobox B) (eg, maturity-onset diabetes of the young [MODY]), duplication/deletion	
analysis HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), full gene sequence HSD3B2 (hydroxy-delta-5-steroid	
dehydrogenase, 3 beta- and steroid delta-isomerase 2) (eg, 3-beta-hydroxysteroid dehydrogenase type II deficiency), full gene sequence HSD11B2	
(hydroxysteroid [11-beta] dehydrogenase 2) (eg, mineralocorticoid excess syndrome), full gene sequence HSPB1 (heat shock 27kDa protein 1) (eg, Charcot-	
Marie-Tooth disease), full gene sequence INS (insulin) (eg, diabetes mellitus), full gene sequence KCNJ1 (potassium inwardly-rectifying channel, subfamily J,	
member 1) (eg, Bartter syndrome), full gene sequence KCNJ10 (potassium inwardly-rectifying channel, subfamily J, member 10) (eg, SeSAME syndrome, EAST	
syndrome sensorineural bearing loss) full gene sequence LITAE (linonolysarcharide-induced TNE factor) (eg. Charcot-Marie-Tooth) full gene sequence MEEV	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons,	\$ 322.00
or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis) ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short	
chain acyl-CoA dehydrogenase deficiency), targeted sequence analysis (eg, exons 5 and 6) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental	
retardation 2 [FRAXE]), characterization of alleles (eg, expanded size and methylation status) AQP2 (aquaporin 2 [collecting duct]) (eg, nephrogenic diabetes	
insipidus), full gene sequence ARX (aristaless related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation), full gene	
sequence AVPR2 (arginine vasopressin receptor 2) (eg, nephrogenic diabetes insipidus), full gene sequence BBS10 (Bardet-Biedl syndrome 10) (eg, Bardet-Biedl	
syndrome), full gene sequence BTD (biotinidase) (eg, biotinidase deficiency), full gene sequence C10orf2 (chromosome 10 open reading frame 2) (eg,	
mitochondrial DNA depletion syndrome), full gene sequence CAV3 (caveolin 3) (eg, CAV3-related distal myopathy, limb-girdle muscular dystrophy type 1C), full	
gene sequence CD40LG (CD40 ligand) (eg, X-linked hyper IgM syndrome), full gene sequence CDKN2A (cyclin-dependent kinase inhibitor 2A) (eg, CDKN2A-	
related cutaneous malignant melanoma, familial atypical mole-malignant melanoma syndrome), full gene sequence CLRN1 (clarin 1) (eg, Usher syndrome, type	
3), full gene sequence COX6B1 (cytochrome c oxidase subunit VIb polypeptide 1) (eg, mitochondrial respiratory chain complex IV deficiency), full gene	
sequence CPT2 (carnitine palmitoyltransferase 2) (eg, carnitine palmitoyltransferase II deficiency), full gene sequence CRX (cone-rod homeobox) (eg, cone-rod	
dystrophy 2, Leber congenital amaurosis), full gene sequence CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), full gene sequence CYP1B1	
(cytochrome P450, family 1, subfamily B, polypeptide 1) (eg, primary congenital glaucoma), full gene sequence DMPK (dystrophia myotonica-protein kinase)	
(eg, myotonic dystrophy type 1), characterization of abnormal (eg, expanded) alleles EGR2 (early growth response 2) (eg, Charcot-Marie-Tooth), full gene	
sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), duplication/deletion analysis EPM2A (epilepsy, progressive myoclonus type 2A, Lafora	
disease [laforin]) (eg, progressive myoclonus epilepsy), full gene sequence FGF23 (fibroblast growth factor 23) (eg, hypophosphatemic rickets), full gene	
sequence FGFR2 (fibroblast growth factor receptor 2) (eg, craniosynostosis, Apert syndrome, Crouzon syndrome), targeted sequence analysis (eg, exons 8, 10)	
FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), targeted sequence analysis (eg, exons 8, 11, 12, 13) FHL1 (four and a half	
LIM domains 1) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence FKRP (fukutin related protein) (eg, congenital muscular dystrophy type 1C	
[MDC1C], limb-girdle muscular dystrophy [LGMD] type 2I), full gene sequence FOXG1 (forkhead box G1) (eg, Rett syndrome), full gene sequence FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), evaluation to detect abnormal (eg, deleted) alleles FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), characterization of haplotype(s) (ie, chromosome 4A and 4B	
haplotypes) FXN (frataxin) (eg, Friedreich ataxia), full gene sequence GH1 (growth hormone 1) (eg, growth hormone deficiency), full gene sequence GP1BB	
(glycoprotein lb [platelet], beta polypeptide) (eg, Bernard-Soulier syndrome type B), full gene sequence HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg,	
alpha thalassemia), duplication/deletion analysis (For common deletion variants of alpha globin 1 and alpha globin 2 genes, use 81257) HBB (hemoglobin, beta,	
Beta-Globin) (eg, thalassemia), full gene sequence HNF1B (HNF1 homeobox B) (eg, maturity-onset diabetes of the young [MODY]), duplication/deletion	
analysis HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), full gene sequence HSD3B2 (hydroxy-delta-5-steroid	
dehydrogenase, 3 beta- and steroid delta-isomerase 2) (eg, 3-beta-hydroxysteroid dehydrogenase type II deficiency), full gene sequence HSD11B2	
(hydroxysteroid [11-beta] dehydrogenase 2) (eg, mineralocorticoid excess syndrome), full gene sequence HSPB1 (heat shock 27kDa protein 1) (eg, Charcot-	
Marie-Tooth disease), full gene sequence INS (insulin) (eg, diabetes mellitus), full gene sequence KCNJ1 (potassium inwardly-rectifying channel, subfamily J,	
member 1) (eg, Bartter syndrome), full gene sequence KCNJ10 (potassium inwardly-rectifying channel, subfamily J, member 10) (eg, SeSAME syndrome, EAST	
syndrome sensorineural hearing loss) full gene sequence LITAE (linonolysaccharide-induced TNE factor) (eg. Charcot-Marie-Tooth) full gene sequence MEEV	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons,	\$ 322.00
or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis) ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short	
chain acyl-CoA dehydrogenase deficiency), targeted sequence analysis (eg, exons 5 and 6) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental	
retardation 2 [FRAXE]), characterization of alleles (eg, expanded size and methylation status) AQP2 (aquaporin 2 [collecting duct]) (eg, nephrogenic diabetes	
insipidus), full gene sequence ARX (aristaless related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation), full gene	
sequence AVPR2 (arginine vasopressin receptor 2) (eg, nephrogenic diabetes insipidus), full gene sequence BBS10 (Bardet-Biedl syndrome 10) (eg, Bardet-Biedl	
syndrome), full gene sequence BTD (biotinidase) (eg, biotinidase deficiency), full gene sequence C10orf2 (chromosome 10 open reading frame 2) (eg,	
mitochondrial DNA depletion syndrome), full gene sequence CAV3 (caveolin 3) (eg, CAV3-related distal myopathy, limb-girdle muscular dystrophy type 1C), full	
gene sequence CD40LG (CD40 ligand) (eg, X-linked hyper IgM syndrome), full gene sequence CDKN2A (cyclin-dependent kinase inhibitor 2A) (eg, CDKN2A-	
related cutaneous malignant melanoma, familial atypical mole-malignant melanoma syndrome), full gene sequence CLRN1 (clarin 1) (eg, Usher syndrome, type	
3), full gene sequence COX6B1 (cytochrome c oxidase subunit VIb polypeptide 1) (eg, mitochondrial respiratory chain complex IV deficiency), full gene	
sequence CPT2 (carnitine palmitoyltransferase 2) (eg, carnitine palmitoyltransferase II deficiency), full gene sequence CRX (cone-rod homeobox) (eg, cone-rod	
dystrophy 2, Leber congenital amaurosis), full gene sequence CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), full gene sequence CYP1B1	
(cytochrome P450, family 1, subfamily B, polypeptide 1) (eg, primary congenital glaucoma), full gene sequence DMPK (dystrophia myotonica-protein kinase)	
(eg, myotonic dystrophy type 1), characterization of abnormal (eg, expanded) alleles EGR2 (early growth response 2) (eg, Charcot-Marie-Tooth), full gene	
sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), duplication/deletion analysis EPM2A (epilepsy, progressive myoclonus type 2A, Lafora	
disease [laforin]) (eg, progressive myoclonus epilepsy), full gene sequence FGF23 (fibroblast growth factor 23) (eg, hypophosphatemic rickets), full gene	
sequence FGFR2 (fibroblast growth factor receptor 2) (eg, craniosynostosis, Apert syndrome, Crouzon syndrome), targeted sequence analysis (eg, exons 8, 10)	
FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), targeted sequence analysis (eg, exons 8, 11, 12, 13) FHL1 (four and a half	
LIM domains 1) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence FKRP (fukutin related protein) (eg, congenital muscular dystrophy type 1C	
[MDC1C], limb-girdle muscular dystrophy [LGMD] type 2I), full gene sequence FOXG1 (forkhead box G1) (eg, Rett syndrome), full gene sequence FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), evaluation to detect abnormal (eg, deleted) alleles FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), characterization of haplotype(s) (ie, chromosome 4A and 4B	
haplotypes) FXN (frataxin) (eg, Friedreich ataxia), full gene sequence GH1 (growth hormone 1) (eg, growth hormone deficiency), full gene sequence GP1BB	
(glycoprotein lb [platelet], beta polypeptide) (eg, Bernard-Soulier syndrome type B), full gene sequence HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg,	
alpha thalassemia), duplication/deletion analysis (For common deletion variants of alpha globin 1 and alpha globin 2 genes, use 81257) HBB (hemoglobin, beta,	
Beta-Globin) (eg, thalassemia), full gene sequence HNF1B (HNF1 homeobox B) (eg, maturity-onset diabetes of the young [MODY]), duplication/deletion	
analysis HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), full gene sequence HSD3B2 (hydroxy-delta-5-steroid	
dehydrogenase, 3 beta- and steroid delta-isomerase 2) (eg, 3-beta-hydroxysteroid dehydrogenase type II deficiency), full gene sequence HSD11B2	
(hydroxysteroid [11-beta] dehydrogenase 2) (eg, mineralocorticoid excess syndrome), full gene sequence HSPB1 (heat shock 27kDa protein 1) (eg, Charcot-	
Marie-Tooth disease), full gene sequence INS (insulin) (eg, diabetes mellitus), full gene sequence KCNJ1 (potassium inwardly-rectifying channel, subfamily J,	
member 1) (eg, Bartter syndrome), full gene sequence KCNJ10 (potassium inwardly-rectifying channel, subfamily J, member 10) (eg, SeSAME syndrome, EAST	
syndrome sensorineural bearing loss) full gene sequence LITAE (linonolysarcharide-induced TNE factor) (eg. Charcot-Marie-Tooth) full gene sequence MEEV	

DESCRIPTION	 CHARGE
Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons,	\$ 40.00
or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis) ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short	
chain acyl-CoA dehydrogenase deficiency), targeted sequence analysis (eg, exons 5 and 6) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental	
retardation 2 [FRAXE]), characterization of alleles (eg, expanded size and methylation status) AQP2 (aquaporin 2 [collecting duct]) (eg, nephrogenic diabetes	
insipidus), full gene sequence ARX (aristaless related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation), full gene	
sequence AVPR2 (arginine vasopressin receptor 2) (eg, nephrogenic diabetes insipidus), full gene sequence BBS10 (Bardet-Biedl syndrome 10) (eg, Bardet-Biedl	
syndrome), full gene sequence BTD (biotinidase) (eg, biotinidase deficiency), full gene sequence C10orf2 (chromosome 10 open reading frame 2) (eg,	
mitochondrial DNA depletion syndrome), full gene sequence CAV3 (caveolin 3) (eg, CAV3-related distal myopathy, limb-girdle muscular dystrophy type 1C), full	
gene sequence CD40LG (CD40 ligand) (eg, X-linked hyper IgM syndrome), full gene sequence CDKN2A (cyclin-dependent kinase inhibitor 2A) (eg, CDKN2A-	
related cutaneous malignant melanoma, familial atypical mole-malignant melanoma syndrome), full gene sequence CLRN1 (clarin 1) (eg, Usher syndrome, type	
3), full gene sequence COX6B1 (cytochrome c oxidase subunit VIb polypeptide 1) (eg, mitochondrial respiratory chain complex IV deficiency), full gene	
sequence CPT2 (carnitine palmitoyltransferase 2) (eg, carnitine palmitoyltransferase II deficiency), full gene sequence CRX (cone-rod homeobox) (eg, cone-rod	
dystrophy 2, Leber congenital amaurosis), full gene sequence CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), full gene sequence CYP1B1	
(cytochrome P450, family 1, subfamily B, polypeptide 1) (eg, primary congenital glaucoma), full gene sequence DMPK (dystrophia myotonica-protein kinase)	
(eg, myotonic dystrophy type 1), characterization of abnormal (eg, expanded) alleles EGR2 (early growth response 2) (eg, Charcot-Marie-Tooth), full gene	
sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), duplication/deletion analysis EPM2A (epilepsy, progressive myoclonus type 2A, Lafora	
disease [laforin]) (eg, progressive myoclonus epilepsy), full gene sequence FGF23 (fibroblast growth factor 23) (eg, hypophosphatemic rickets), full gene	
sequence FGFR2 (fibroblast growth factor receptor 2) (eg, craniosynostosis, Apert syndrome, Crouzon syndrome), targeted sequence analysis (eg, exons 8, 10)	
FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), targeted sequence analysis (eg, exons 8, 11, 12, 13) FHL1 (four and a half	
LIM domains 1) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence FKRP (fukutin related protein) (eg, congenital muscular dystrophy type 1C	
[MDC1C], limb-girdle muscular dystrophy [LGMD] type 2I), full gene sequence FOXG1 (forkhead box G1) (eg, Rett syndrome), full gene sequence FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), evaluation to detect abnormal (eg, deleted) alleles FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), characterization of haplotype(s) (ie, chromosome 4A and 4B	
haplotypes) FXN (frataxin) (eg, Friedreich ataxia), full gene sequence GH1 (growth hormone 1) (eg, growth hormone deficiency), full gene sequence GP1BB	
(glycoprotein lb [platelet], beta polypeptide) (eg, Bernard-Soulier syndrome type B), full gene sequence HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg,	
alpha thalassemia), duplication/deletion analysis (For common deletion variants of alpha globin 1 and alpha globin 2 genes, use 81257) HBB (hemoglobin, beta,	
Beta-Globin) (eg, thalassemia), full gene sequence HNF1B (HNF1 homeobox B) (eg, maturity-onset diabetes of the young [MODY]), duplication/deletion	
analysis HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), full gene sequence HSD3B2 (hydroxy-delta-5-steroid	
dehydrogenase, 3 beta- and steroid delta-isomerase 2) (eg, 3-beta-hydroxysteroid dehydrogenase type II deficiency), full gene sequence HSD11B2	
(hydroxysteroid [11-beta] dehydrogenase 2) (eg, mineralocorticoid excess syndrome), full gene sequence HSPB1 (heat shock 27kDa protein 1) (eg, Charcot-	
Marie-Tooth disease), full gene sequence INS (insulin) (eg, diabetes mellitus), full gene sequence KCNJ1 (potassium inwardly-rectifying channel, subfamily J,	
member 1) (eg, Bartter syndrome), full gene sequence KCNJ10 (potassium inwardly-rectifying channel, subfamily J, member 10) (eg, SeSAME syndrome, EAST	
syndrome sensorineural bearing loss) full gene sequence LITAE (liponolysaccharide-induced TNE factor) (eg. Charcot-Marie-Tooth) full gene sequence MEEV	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons,	\$ 39.00
or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis) ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short	
chain acyl-CoA dehydrogenase deficiency), targeted sequence analysis (eg, exons 5 and 6) AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental	
retardation 2 [FRAXE]), characterization of alleles (eg, expanded size and methylation status) AQP2 (aquaporin 2 [collecting duct]) (eg, nephrogenic diabetes	
insipidus), full gene sequence ARX (aristaless related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked mental retardation), full gene	
sequence AVPR2 (arginine vasopressin receptor 2) (eg, nephrogenic diabetes insipidus), full gene sequence BBS10 (Bardet-Biedl syndrome 10) (eg, Bardet-Biedl	
syndrome), full gene sequence BTD (biotinidase) (eg, biotinidase deficiency), full gene sequence C10orf2 (chromosome 10 open reading frame 2) (eg,	
mitochondrial DNA depletion syndrome), full gene sequence CAV3 (caveolin 3) (eg, CAV3-related distal myopathy, limb-girdle muscular dystrophy type 1C), full	
gene sequence CD40LG (CD40 ligand) (eg, X-linked hyper IgM syndrome), full gene sequence CDKN2A (cyclin-dependent kinase inhibitor 2A) (eg, CDKN2A-	
related cutaneous malignant melanoma, familial atypical mole-malignant melanoma syndrome), full gene sequence CLRN1 (clarin 1) (eg, Usher syndrome, type	
3), full gene sequence COX6B1 (cytochrome c oxidase subunit VIb polypeptide 1) (eg, mitochondrial respiratory chain complex IV deficiency), full gene	
sequence CPT2 (carnitine palmitoyltransferase 2) (eg, carnitine palmitoyltransferase II deficiency), full gene sequence CRX (cone-rod homeobox) (eg, cone-rod	
dystrophy 2, Leber congenital amaurosis), full gene sequence CSTB (cystatin B [stefin B]) (eg, Unverricht-Lundborg disease), full gene sequence CYP1B1	
(cytochrome P450, family 1, subfamily B, polypeptide 1) (eg, primary congenital glaucoma), full gene sequence DMPK (dystrophia myotonica-protein kinase)	
(eg, myotonic dystrophy type 1), characterization of abnormal (eg, expanded) alleles EGR2 (early growth response 2) (eg, Charcot-Marie-Tooth), full gene	
sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), duplication/deletion analysis EPM2A (epilepsy, progressive myoclonus type 2A, Lafora	
disease [laforin]) (eg, progressive myoclonus epilepsy), full gene sequence FGF23 (fibroblast growth factor 23) (eg, hypophosphatemic rickets), full gene	
sequence FGFR2 (fibroblast growth factor receptor 2) (eg, craniosynostosis, Apert syndrome, Crouzon syndrome), targeted sequence analysis (eg, exons 8, 10)	
FGFR3 (fibroblast growth factor receptor 3) (eg, achondroplasia, hypochondroplasia), targeted sequence analysis (eg, exons 8, 11, 12, 13) FHL1 (four and a half	
LIM domains 1) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence FKRP (fukutin related protein) (eg, congenital muscular dystrophy type 1C	
[MDC1C], limb-girdle muscular dystrophy [LGMD] type 2I), full gene sequence FOXG1 (forkhead box G1) (eg, Rett syndrome), full gene sequence FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), evaluation to detect abnormal (eg, deleted) alleles FSHMD1A	
(facioscapulohumeral muscular dystrophy 1A) (eg, facioscapulohumeral muscular dystrophy), characterization of haplotype(s) (ie, chromosome 4A and 4B	
haplotypes) FXN (frataxin) (eg, Friedreich ataxia), full gene sequence GH1 (growth hormone 1) (eg, growth hormone deficiency), full gene sequence GP1BB	
(glycoprotein lb [platelet], beta polypeptide) (eg, Bernard-Soulier syndrome type B), full gene sequence HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg,	
alpha thalassemia), duplication/deletion analysis (For common deletion variants of alpha globin 1 and alpha globin 2 genes, use 81257) HBB (hemoglobin, beta,	
Beta-Globin) (eg, thalassemia), full gene sequence HNF1B (HNF1 homeobox B) (eg, maturity-onset diabetes of the young [MODY]), duplication/deletion	
analysis HRAS (v-Ha-ras Harvey rat sarcoma viral oncogene homolog) (eg, Costello syndrome), full gene sequence HSD3B2 (hydroxy-delta-5-steroid	
dehydrogenase, 3 beta- and steroid delta-isomerase 2) (eg, 3-beta-hydroxysteroid dehydrogenase type II deficiency), full gene sequence HSD11B2	
(hydroxysteroid [11-beta] dehydrogenase 2) (eg, mineralocorticoid excess syndrome), full gene sequence HSPB1 (heat shock 27kDa protein 1) (eg, Charcot-	
Marie-Tooth disease), full gene sequence INS (insulin) (eg, diabetes mellitus), full gene sequence KCNJ1 (potassium inwardly-rectifying channel, subfamily J,	
member 1) (eg, Bartter syndrome), full gene sequence KCNJ10 (potassium inwardly-rectifying channel, subfamily J, member 10) (eg, SeSAME syndrome, EAST	
syndrome, sensorineural hearing loss) full gene sequence LITAE (linonolysaccharide-induced TNE factor) (eg. Charcot-Marie-Tooth) full gene sequence MEEV	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 38.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 38.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg	

DESCRIPTION		CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$	38.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	1	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha		
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial		
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	1	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)		
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,		
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	1	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis		
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	1	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4		
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,		
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	1	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV		
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence		
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family		
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	1	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for		
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-		
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not		
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type		
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene		
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	1	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-		
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	1	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic		
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	1	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann		
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	1	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	1	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	1	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	1	
(ganglioside_induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg	L	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 93.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease) full gene sequence GEAP (glial fibrillary acidic protein) (eg	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 1,053.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease) full gene sequence GEAP (glial fibrillary acidic protein) (eg	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 7,134.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg.	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 3,187.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease) full gene sequence GEAP (glial fibrillary acidic protein) (eg	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 3,710.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg.	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 2,074.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg	

DESCRIPTION	CHARGE	
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 32	2.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene		
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha		
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial		
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,		
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)		
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,		
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence		
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis		
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,		
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4		
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,		
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain		
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV		
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence		
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family		
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted		
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for		
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-		
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not		
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type		
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene		
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK		
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-		
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing		
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic		
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),		
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann		
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene		
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])		
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy		
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1		
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg		

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 38.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 38.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease) full gene sequence GEAP (glial fibrillary acidic protein) (eg	

DESCRIPTION		CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$	38.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	1	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha		
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial		
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	1	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)		
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,		
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	1	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis		
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	1	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4		
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,		
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	1	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV		
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence		
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family		
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	1	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for		
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-		
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not		
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type		
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene		
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	1	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-		
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	1	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic		
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	1	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann		
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	1	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	1	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	1	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	1	
(ganglioside_induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg	L	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 38.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease) full gene sequence GEAP (glial fibrillary acidic protein) (eg	

DESCRIPTION		CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$	40.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene		
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha		
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial		
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	1	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)		
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,		
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence		
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis		
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	1	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4		
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,		
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	1	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV		
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence		
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family		
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	1	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for		
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	1	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not		
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	1	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene		
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	1	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-		
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing		
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic		
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),		
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann		
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	1	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	1	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	1	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	1	
(ganglioside_induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg	<u> </u>	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 40.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease), full gene sequence GEAP (glial fibrillary acidic protein) (eg	

DESCRIPTION		CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$	40.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene		
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha		
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial		
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	1	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)		
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,		
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence		
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis		
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	1	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4		
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,		
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	1	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV		
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence		
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family		
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	1	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for		
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	1	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not		
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	1	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene		
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	1	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-		
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing		
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic		
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),		
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann		
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	1	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	1	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	1	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	1	
(ganglioside_induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg	<u> </u>	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 40.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg.	

DESCRIPTION		CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$	40.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene		
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha		
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial		
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	1	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)		
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,		
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence		
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis		
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	1	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4		
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,		
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	1	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV		
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence		
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family		
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	1	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for		
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	1	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not		
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	1	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene		
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	1	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-		
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing		
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic		
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),		
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann		
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	1	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	1	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	1	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	1	
(ganglioside_induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg	<u> </u>	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 40.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease), full gene sequence GEAP (glial fibrillary acidic protein) (eg	

DESCRIPTION		CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$	40.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene		
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha		
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial		
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	1	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)		
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,		
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence		
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis		
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	1	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4		
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,		
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	1	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV		
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence		
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family		
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	1	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for		
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	1	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not		
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	1	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene		
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	1	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-		
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing		
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic		
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),		
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann		
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	1	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	1	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	1	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	1	
(ganglioside_induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg	<u> </u>	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$ 40.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha	
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial	
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)	
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,	
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis	
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4	
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,	
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV	
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence	
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family	
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for	
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not	
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene	
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-	
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing	
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic	
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann	
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	
(ganglioside-induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg	

DESCRIPTION		CHARGE
Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25	\$	39.00
exons, regionally targeted cytogenomic array analysis) ABCD1 (ATP-binding cassette, sub-family D [ALD], member 1) (eg, adrenoleukodystrophy), full gene	1	
sequence ACADS (acyl-CoA dehydrogenase, C-2 to C-3 short chain) (eg, short chain acyl-CoA dehydrogenase deficiency), full gene sequence ACTA2 (actin, alpha		
2, smooth muscle, aorta) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence ACTC1 (actin, alpha, cardiac muscle 1) (eg, familial		
hypertrophic cardiomyopathy), full gene sequence ANKRD1 (ankyrin repeat domain 1) (eg, dilated cardiomyopathy), full gene sequence APTX (aprataxin) (eg,	1	
ataxia with oculomotor apraxia 1), full gene sequence AR (androgen receptor) (eg, androgen insensitivity syndrome), full gene sequence ARSA (arylsulfatase A)		
(eg, arylsulfatase A deficiency), full gene sequence BCKDHA (branched chain keto acid dehydrogenase E1, alpha polypeptide) (eg, maple syrup urine disease,		
type 1A), full gene sequence BCS1L (BCS1-like [S. cerevisiae]) (eg, Leigh syndrome, mitochondrial complex III deficiency, GRACILE syndrome), full gene sequence	1	
BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), duplication/deletion analysis		
CASQ2 (calsequestrin 2 [cardiac muscle]) (eg, catecholaminergic polymorphic ventricular tachycardia), full gene sequence CASR (calcium-sensing receptor) (eg,	1	
hypocalcemia), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), duplication/deletion analysis CHRNA4		
(cholinergic receptor, nicotinic, alpha 4) (eg, nocturnal frontal lobe epilepsy), full gene sequence CHRNB2 (cholinergic receptor, nicotinic, beta 2 [neuronal]) (eg,		
nocturnal frontal lobe epilepsy), full gene sequence COX10 (COX10 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain	1	
complex IV deficiency), full gene sequence COX15 (COX15 homolog, cytochrome c oxidase assembly protein) (eg, mitochondrial respiratory chain complex IV		
deficiency), full gene sequence CYP11B1 (cytochrome P450, family 11, subfamily B, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence		
CYP17A1 (cytochrome P450, family 17, subfamily A, polypeptide 1) (eg, congenital adrenal hyperplasia), full gene sequence CYP21A2 (cytochrome P450, family		
21, subfamily A, polypeptide2) (eg, steroid 21-hydroxylase isoform, congenital adrenal hyperplasia), full gene sequence Cytogenomic constitutional targeted	1	
microarray analysis of chromosome 22q13 by interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for		
chromosomal abnormalities (When performing genome-wide cytogenomic constitutional microarray analysis, see 81228, 81229) (Do not report analyte-	1	
specific molecular pathology procedures separately when the specific analytes are included as part of the microarray analysis of chromosome 22q13) (Do not		
report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple syrup urine disease, type	1	
2), duplication/deletion analysis DCX (doublecortin) (eg, X-linked lissencephaly), full gene sequence DES (desmin) (eg, myofibrillar myopathy), full gene		
sequence DFNB59 (deafness, autosomal recessive 59) (eg, autosomal recessive nonsyndromic hearing impairment), full gene sequence DGUOK	1	
(deoxyguanosine kinase) (eg, hepatocerebral mitochondrial DNA depletion syndrome), full gene sequence DHCR7 (7-dehydrocholesterol reductase) (eg, Smith-		
Lemli-Opitz syndrome), full gene sequence EIF2B2 (eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa) (eg, leukoencephalopathy with vanishing		
white matter), full gene sequence EMD (emerin) (eg, Emery-Dreifuss muscular dystrophy), full gene sequence ENG (endoglin) (eg, hereditary hemorrhagic		
telangiectasia, type 1), duplication/deletion analysis EYA1 (eyes absent homolog 1 [Drosophila]) (eg, branchio-oto-renal [BOR] spectrum disorders),	1	
duplication/deletion analysis F9 (coagulation factor IX) (eg, hemophilia B), full gene sequence FGFR1 (fibroblast growth factor receptor 1) (eg, Kallmann		
syndrome 2), full gene sequence FH (fumarate hydratase) (eg, fumarate hydratase deficiency, hereditary leiomyomatosis with renal cell cancer), full gene	1	
sequence FKTN (fukutin) (eg, limb-girdle muscular dystrophy [LGMD] type 2M or 2L), full gene sequence FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli])	1	
(eg, X-linked mental retardation 9), duplication/deletion analysis GABRG2 (gamma-aminobutyric acid [GABA] A receptor, gamma 2) (eg, generalized epilepsy	1	
with febrile seizures), full gene sequence GCH1 (GTP cyclohydrolase 1) (eg, autosomal dominant dopa-responsive dystonia), full gene sequence GDAP1	1	
(ganglioside_induced differentiation-associated protein 1) (eg. Charcot-Marie-Tooth disease). full gene sequence GEAP (glial fibrillary acidic protein) (eg	L	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination (vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination (vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination (vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination (vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination/vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination (vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination/vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 41.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination (vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 7,134.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination/vanishing white matter) full gene seguence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 5,169.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hynomyelination/vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 4,228.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination/vanishing white matter) full gene sequence ENG (endodin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 4,609.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination (vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 7,598.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination/vanishing white matter) full gene seguence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 3,187.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hynomyelination (vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagis telangiestasia, tyne 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 3,187.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination/vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 3,189.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination (vanishing white matter) full gene seguence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 3,710.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hynomyelination/vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 2,074.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hynomyelination/vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, tyne 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hynomyelination (vanishing white matter) full gene seguence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, tyne 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination (vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hynomyelination (vanishing white matter) full gene seguence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, tyne 1) full gene	

DESCRIPTION		CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$	38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	1	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	1	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	1	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	1	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	1	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	1	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	1	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	1	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	1	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	1	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	1	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	1	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	ł	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	1	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	ł	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	ł	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	1	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	ł	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	ł	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	1	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	1	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	1	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	1	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	1	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	1	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	1	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	1	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	1	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	1	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	l	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	1	
nervous system hypomyelination (vanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	Ĺ	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hynomyelination (vanishing white matter) full gene seguence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, tyne 1) full gene	

DESCRIPTION		CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$	38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase		
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2		
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene		
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-		
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate		
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+		
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson		
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl		
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene		
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine		
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full		
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton		
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)		
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS		
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin		
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full		
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,		
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2		
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine		
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence		
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of		
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do		
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis		
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple		
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence		
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular		
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence		
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	l	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	l	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	l	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	l	
nervous system hypomyelination (vanishing white matter) full gene sequence FNG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene		

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 38.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hynomyelination (vanishing white matter) full gene seguence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, tyne 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 40.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination Avanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 40.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination (vanishing white matter) full gene seguence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50	\$ 40.00
exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase	
deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2	
[S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene	
sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-	
girdle muscular dystrophy), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate	
synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+	
transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson	
disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl	
syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene	
sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine	
kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full	
gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Berardinelli-Seip congenital lipodystrophy), full gene sequence BTK (Bruton	
agammaglobulinemia tyrosine kinase) (eg, X-linked agammaglobulinemia), full gene sequence CACNB2 (calcium channel, voltage-dependent, beta 2 subunit)	
(eg, Brugada syndrome), full gene sequence CAPN3 (calpain 3) (eg, limb-girdle muscular dystrophy [LGMD] type 2A, calpainopathy), full gene sequence CBS	
(cystathionine-beta-synthase) (eg, homocystinuria, cystathionine beta-synthase deficiency), full gene sequence CDH1 (cadherin 1, type 1, E-cadherin	
[epithelial]) (eg, hereditary diffuse gastric cancer), full gene sequence CDKL5 (cyclin-dependent kinase-like 5) (eg, early infantile epileptic encephalopathy), full	
gene sequence CLCN1 (chloride channel 1, skeletal muscle) (eg, myotonia congenita), full gene sequence CLCNKB (chloride channel, voltage-sensitive Kb) (eg,	
Bartter syndrome 3 and 4b), full gene sequence CNTNAP2 (contactin-associated protein-like 2) (eg, Pitt-Hopkins-like syndrome 1), full gene sequence COL6A2	
(collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), duplication/deletion analysis CPT1A (carnitine palmitoyltransferase 1A [liver]) (eg, carnitine	
palmitoyltransferase 1A [CPT1A] deficiency), full gene sequence CRB1 (crumbs homolog 1 [Drosophila]) (eg, Leber congenital amaurosis), full gene sequence	
CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), duplication/deletion analysis Cytogenomic microarray analysis, neoplasia (eg, interrogation of	
copy number, and loss-of-heterozygosity via single nucleotide polymorphism [SNP]-based comparative genomic hybridization [CGH] microarray analysis) (Do	
not report analyte-specific molecular pathology procedures separately when the specific analytes are included as part of the cytogenomic microarray analysis	
for neoplasia) (Do not report 88271 when performing cytogenomic microarray analysis) DBT (dihydrolipoamide branched chain transacylase E2) (eg, maple	
syrup urine disease, type 2), full gene sequence DLAT (dihydrolipoamide S-acetyltransferase) (eg, pyruvate dehydrogenase E2 deficiency), full gene sequence	
DLD (dihydrolipoamide dehydrogenase) (eg, maple syrup urine disease, type III), full gene sequence DSC2 (desmocollin) (eg, arrhythmogenic right ventricular	
dysplasia/cardiomyopathy 11), full gene sequence DSG2 (desmoglein 2) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 10), full gene sequence	
DSP (desmoplakin) (eg, arrhythmogenic right ventricular dysplasia/cardiomyopathy 8), full gene sequence EFHC1 (EF-hand domain [C-terminal] containing 1)	
(eg, juvenile myoclonic epilepsy), full gene sequence EIF2B3 (eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa) (eg, leukoencephalopathy	
with vanishing white matter), full gene sequence EIF2B4 (eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa) (eg, leukoencephalopathy with	
vanishing white matter), full gene sequence EIF2B5 (eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa) (eg, childhood ataxia with central	
nervous system hypomyelination Avanishing white matter) full gene sequence ENG (endoglin) (eg. hereditary hemorrhagic telangiectasia, type 1) full gene	

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 7 (eg. analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg. very long chain acyl-coenzyme A dehydrogenase deficiency). full gene sequence ACTN4 (actinin, alpha 4) (eg. focal segmental glomerulosclerosis). full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 (E. crevisiae) (eg., spinoterebellar atxai), full gene sequence ARE (autoimmune regulator) (eg., autoimmune polyendocrinopathy syndrome type 1), full gene sequence ADS (anottamin 5) (eg., limb-girdle muscular dystrophy), full gene sequence ATL (attastin GTPase 1) (eg., spatic parabellar), atxai, ling ene sequence ATLA2 (ATPSase, Na*/K+ transporting, alpha 2 polypeptide) (eg., familial hemiplegic migraine), full gene sequence ATLA2 (ATPSase, Na*/K+ transporting, alpha 2 polypeptide) (eg., familial hemiplegic migraine), full gene sequence ATLA2 (ATPSase, Na*/K+ transporting, alpha 2 polypeptide) (eg., familial hemiplegic migraine), full gene sequence BASE (Bardet-Biel Syndrome 2) (eg., Bardet-Biel Syndrome), full gene sequence BKS1 (Bardet-Biel Syndrome 1) (eg., Bardet-Biel Syndrome), full gene sequence BKS2 (Bardet-Biel Syndrome 2) (eg., Bardet-Biel Syndrome), full gene sequence BKS2 (Bardet-Biel Syndrome), full gene sequence BKS2 (Bardet-Biel Syndrome), full gene sequence BKS2 (Bardet-Biel Syndrome), full gene sequence CBK2 (Syndrome) (eg., Nonan syndrome), full gene sequence CBK2 (Syndrome) (eg., Nonan syndrome), full gene sequence CANS2 (calciam channel, voltage-dependent, beta 2 subunit) (eg. Brandiell-Seip congenital lipodystrophy), full gene sequence CBK2 (Syndrome), full gene sequence CCMS2 (calciam channel, voltage-dependent, beta 2 subunit) (eg., Brandiell-Seip congenital lipodystrophy), full gene sequence CBK2 (Syndrome), full gene sequence CCMS2 (calciam channel, voltage-dependent, beta 2 subunit) (eg., Bardet-Biel (eg., herdication), full gene seq	\$ 39.00
Molecular pathology procedure, Level 8 (eg, analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform) ABCC8 (ATP-binding cassette, sub-family C [CTR/MRP], member 8) (eg, familial hyperinsulinism), full gene sequence AGL (anylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase) (eg, glycogen storage disease type III), full gene sequence AHI (Abelson helper integration site 1) (eg, Joubert syndrome), full gene sequence ASPM (asp [abnormal spindle] homolog, microcephaly associated [Drosophila]) (eg, primary microcephaly), full gene sequence COLAA1 (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, familial hemiplegic migraine), full gene sequence CDLA5 (collagen, type V), alpha 5) (eg, Alport syndrome), duplication/deletion analysis COL6A1 (collagen, type V, alpha 4) (eg, Alport syndrome), full gene sequence COLA54 (collagen, type V, alpha 3) (eg, collagen type VI-related disorders), full gene sequence COL6A2 (collagen, type V, alpha 2) (eg, collagen type VI-related disorders), full gene sequence CAGA3 (collagen, type V, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CAGA3 (collagen, type V, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CAGA3 (collagen, type V, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CAGA3 (collagen, type V, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CAGA3 (collagen, type VI, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CAGA3 (collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), full gene sequence CAGA3 (collagen, type VI, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CAGA3 (collagen, type VI, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CAGA4 (collagen, type VI, alpha 2) (eg, CAGA3 (collagen, type VI, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CAGA4 (\$ 3,710.00

DESCRIPTION	CI	HARGE
Molecular pathology procedure, Level 8 (eg, analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform) ABCC8 (ATP-binding cassette, sub-family C [CFTR/MRP], member 8) (eg, familial hyperinsulinism), full gene sequence ALII (Abelson helper integration site 1) (eg, Joubert syndrome), full gene sequence ASPM (asp [abnormal spindle] homolog, microcephaly associated [Drosophila]) (eg, primary microcephaly), full gene sequence CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, familial hemiplegic migraine), full gene sequence CHD7 (chromodomain helicase DNA binding protein 7) (eg, CHARGE syndrome), full gene sequence COL4A4 (collagen, type IV, alpha 4) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence COL4A4 (collagen, type VI, alpha 4) (eg, Callagen type VI-related disorders), full gene sequence CACBA2 (collagen, type VI, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CACBA2 (collagen, type VI, alpha 3) (eg, collagen type VI-related disorders), full gene sequence LAGA1 (loge, Lagy (eg, Alagy Syndrome), full gene sequence CAMA1 (eg, Alagy Syndrome), full gene sequence CAMA2 (collagen, type VI, alpha 3) (eg, collagen type VI-related disorders), full gene sequence LAGA1 (eg, Alagy Syndrome), full gene sequence CAMA2 (collagen, type VI, alpha 3) (eg, collagen type VI-related disorders), full gene sequence LAGA1 (collagen, type VI, alpha 3) (eg, Callagen type VI-related disorders), full gene sequence CAMA2 (collagen, type VI, alpha 5) (eg, Alpha) (eg, Rubinstein-Taybi syndrome), full gene sequence CAMA44 (collagen, type VI, alpha 5) (eg, Callagen type VI-related disorders), full gene sequence LAGA1 (collagen, type VI, alpha 5) (eg, Callagen type VI-related disorders), full gene sequence CAMA44 (collagen, type VI-related disorders), full gene sequence CAMA44 (collagen) (eg, Alpha) (eg, Rubinitial	\$	3,710.00
Molecular pathology procedure, Level 8 (eg, analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform) ABCC8 (ATP-binding cassette, sub-family C [CFTR/MRP], member 8) (eg, familial hyperinsulinism), full gene sequence AGL (amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase) (eg, glocgen storage disease type III), full gene sequence AH11 (Abelson helper integration site 1) (eg, Joubert syndrome), full gene sequence ASPM (asp Jahormal spindle) homolog, microcephaly asociated [Drosophila]) (eg, primary microcephaly), full gene sequence CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, familial hemiplegic migraine), full gene sequence CDLAA5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence COLAA4 (collagen, type IV, alpha 4) (eg, Alport syndrome), full gene sequence CACIAA1 (collagen, type IV, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CREBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), full gene sequence F8 (coagulation factor VIII) (eg, hemophilia A), full gene sequence CREBBP (CREB binding protein), full gene sequence CACIAA4 (Locagulation factor VIII) (eg, hemophilia A), full gene sequence CALAA015 (KIAA0196) (eg, sastic paraplegia), full gene sequence CALAA0 (12 cell adhesion molecule) (eg, MASA syndrome, X-linked hydrocephaly), full gene sequence CALAA015 (KIAA0196) (eg, sastic paraplegia), full gene sequence CAMD7 (myosin, heavy chain 6, cardiac cardiomyopathy), full gene sequence CMTA7 (myosin, heavy chain 7, cardiac muscle, alpha) (eg, familial hypertrophic cardiac) muscle, alpha) (eg, familial hypertrophic Cardiac) (eg, familial gene sequence MTA7 (myosin, he	Ş	38.00

DESCRIPTION	CHARGE	
Molecular pathology procedure, Level 8 (eg, analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform) ABCC8 (ATP-binding cassette, sub-family C [CTFR/MRP], member 8) (eg, familial hyperinsulinism), full gene sequence AGL (amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase) (eg, glycogen storage disease type III), full gene sequence AHI (Abelson helper integration site 1) (eg, Joubert syndrome), full gene sequence CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, familial hemiplegic migraine), full gene sequence COLAA1 (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, familial hemiplegic migraine), full gene sequence COLA45 (collagen, type IV, alpha 3) (eg, collagen type VI-related disorders), full gene sequence COL6A2 (collagen, type VI, alpha 2) (eg, collagen type VI-related disorders), full gene sequence COL6A2 (collagen, type VI, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CAGI (algon, type VI, alpha 2) (eg, collagen type VI-related disorders), full gene sequence CAGI (collagen, type VI, alpha 3) (eg, collagen type VI-related disorders), full gene sequence KIAA0196 (KIAA0196) (eg, apasitic paraplegia), full gene sequence LOAM (L1 cell adhesion molecule) (eg, XLinked mental retardation), full gene sequence KIAA0196 (KIAA0196) (eg, sastic paraplegia), full gene sequence LICAM (L1 cell adhesion molecule) (eg, MASA syndrome, X.inked hydrocephalv), full gene sequence AMB2 (laminin, beta 2 [laminin 5]) (eg, Fierson syndrome), full gene sequence MYPG (myosin heavy chain 6, cardiac muscle, alpha) (eg, familial hypertrophic cardiomyopathy), full gene sequence MYPA (myosin, heavy chain 6, cardiac muscle, alpha) (eg, familial dised cardiomyopathy), full gene sequence MYPA (myosin, heavy chain 6, cardiac muscle, alpha) (eg, potic atrophy), full gene sequence MYPA (myosin, heavy chain 6, cardiac muscle, alpha) (eg, familial hypertroph	\$ 3	38.00
Molecular pathology procedure, Level 8 (eg. analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform) ABCC8 (ATP-binding cassette, sub-family C [CFTR/MRP], member 8) (eg, familial hyperinsulinism), full gene sequence AGL (amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase) (eg, glocogen storage disease type III), full gene sequence AH1 (Abelson helper integration site 1) (eg, Joubert syndrome), full gene sequence CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (eg, familial hemiplegic migraine), full gene sequence CDLAA1 (collagen, type IV, alpha 4) (eg, Alport syndrome), full gene sequence COLAA5 (collagen, type IV, alpha 5) (eg, Alport syndrome), duplication/deletion analysis COL6A1 (collagen, type IV, alpha 4) (eg, Clagen type VI-related disorders), full gene sequence COLAA3 (collagen, type V, alpha 3) (eg, collagen type VI-related disorders), full gene sequence COLGA2 (collagen, type V, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CACBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), full gene sequence COLGA2 (collagen, type V, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CACBBP (CREB binding protein) (eg, Rubinstein-Taybi syndrome), full gene sequence COLGA2 (collagen, type VI, alpha 3) (eg, Cleg, X-linked mental retartation), full gene sequence LAAG1 (gaged 1) (eg, Alagille syndrome), full gene sequence KDMBCC (lys, alpha 4) (eg, familial hypertrophic cardiomyopathy), full gene sequence CMCMA (La cardiomyopathy), full gene sequence MDMC (lagen, type VI, alpha 4) (eg, Alpha 4) (eg, Alagille syndrome), full gene sequence MDMCC (lys, Alpha 4) (eg, Alpha 5) (eg, Xal	\$ 4	40.00

DESCRIPTION	CHARGE
Molecular pathology procedure, Level 8 (eg. analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform) ABCC8 (ATP-binding cassette, sub-family C [CFTR/MRP], member 8) (eg. familial hyperinsulinism), full gene sequence AGL (amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase) (eg. glycogen storage disease type III), full gene sequence AM11 (Abelson helper integration site 1) (eg. Joubert syndrome), full gene sequence ASPM (asp [abnormal spindle] homolog, microcephaly associated [Drosophila]) (eg, primary microcephaly), full gene sequence COL4A1 (calcium channel, voltage-dependent, P/Q type, alpha 1 subunit) (eg, familial hemiplegic migraine), full gene sequence CHD7 (chromodomain helicase DNA binding protein 7) (eg, CHARGE syndrome), full gene sequence COL4A3 (collagen, type IV, alpha 4) (eg, Alport syndrome), full gene sequence COL4A3 (collagen, type VI, alpha 4) (eg, COL3gen, type VI, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CACA3 (collagen, type VI, alpha 3) (eg, collagen type VI-related disorders), full gene sequence CACA3 (collagen, type VI, alpha 3) (eg, collagen type VI-related disorders), full gene sequence KARDE9 (CREB binding protein) (eg, Rubinstein-Taybi syndrome), full gene sequence F8 (coagulation factor VIII) (eg, hemophilia A), full gene sequence KAA0156 (KIAA0156) (eg, sastic paraplegia), full gene sequence CADMK (1) cell adhesion molecule) (eg, XMAS syndrome, X-linked hydrocephaly), full gene sequence LAMM2 (laminin, beta 2 [laminin 5)) (eg, Fierson syndrome), full gene sequence MYBC3 (myosin binding protein C, cardiac (Ug, familial hypertrophic cardiomyopathy), full gene sequence MYD7A (myosin, heavy chain 7, cardiac muscle, beta) (eg, familial hypertrophic cardiomyopathy), full gene sequence PCD115 (protocadherin-related 15) (eg, Usher syndrome, type 1), full gene sequence OPA1 (optic avalve disease), full gene sequence PCD115 (protocadherin-related 15	\$ 39.
Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A3 (collagen, type I), full gene sequence COL4A3 (collagen, type I), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy) (eg, limb-girdle muscular dystrophy), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, catecholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence VPS13B (vacuolar protein sortin	\$ 38.
Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type 1, alpha 1) (eg, osteogenesis imperfecta, type 1), full gene sequence COL4A3 (collagen, type 1), full gene sequence COL4A1 (collagen, type 1, alpha 2) (eg, osteogenesis imperfecta, type 1), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy) 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence EBN1 (fibrillin 1) (eg, Congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular d	\$ 38.

		CHARGE
Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy) 2B [autosomal recessive]) (eg, imb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence FBN1 (fibrillin 1) (eg, congenital muscular dystrophy), full gene sequence LRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal receptor 2 [cardiac]) (eg, catecholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplaia), full gene sequence GYR2 (ryanodine receptor 2 [cardiac]) (eg, catecholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplaia), full gene sequence or targeted sequence nalysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome 2A [autosomal recessive,	\$	38.00
Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CD142 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A3 (collagen, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence CD14A5 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy) 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, catecholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VVF13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VVF13B (vacuol	\$	38.00
Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis	\$	12,469.00
Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) (List separately in	\$ \$	12,469.00 6,235.00
addition to code for primary procedure)		0,233.00
Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) (List separately in addition to code for primary procedure)	\$	6,235.00
	\$	381.00
Unlisted molecular pathology procedure	\$	523.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$	4,606.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$	38.00
Unlisted molecular pathology procedure	\$	38.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	~	38.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$	38.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$	50:00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure Unlisted molecular pathology procedure Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$	367.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$ \$	367.00 1,928.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$ \$ \$	367.00 1,928.00 1,928.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$ \$ \$ \$	367.00 1,928.00 1,928.00 1,928.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$ \$ \$ \$ \$	367.00 1,928.00 1,928.00 1,928.00 1,928.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$ \$ \$ \$ \$	367.00 1,928.00 1,928.00 1,928.00 1,928.00 1,928.00 1,625.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$ \$ \$ \$ \$ \$	367.00 1,928.00 1,928.00 1,928.00 1,928.00 1,625.00 2,398.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	367.00 1,928.00 1,928.00 1,928.00 1,928.00 1,625.00 2,398.00 2,607.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	367.00 1,928.00 1,928.00 1,928.00 1,928.00 1,625.00 2,398.00 2,607.00 1,218.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	367.00 1,928.00 1,928.00 1,928.00 1,928.00 1,625.00 2,398.00 2,607.00 1,218.00 1,344.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	367.00 1,928.00 1,928.00 1,928.00 1,928.00 2,398.00 2,607.00 1,218.00 1,344.00 1,129.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	367.00 1,928.00 1,928.00 1,928.00 1,625.00 2,398.00 2,607.00 1,218.00 1,344.00 1,129.00 3,680.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	367.00 1,928.00 1,928.00 1,928.00 1,625.00 2,398.00 2,607.00 1,218.00 1,344.00 1,129.00 3,680.00 2,339.00
Unlisted molecular pathology procedure	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	367.00 1,928.00 1,928.00 1,928.00 1,625.00 2,398.00 2,607.00 1,218.00 1,344.00 1,129.00 3,680.00 2,339.00 2,031.00
Unlisted molecular pathology procedure Unlisted molecular pathology procedure	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	367.00 1,928.00 1,928.00 1,928.00 1,625.00 2,398.00 2,607.00 1,218.00 1,344.00 1,129.00 3,680.00 2,339.00

DESCRIPTION		CHARGE
Unlisted molecular pathology procedure	\$	3,680.00
Unlisted molecular pathology procedure	\$	1,928.00
Unlisted molecular pathology procedure	\$	1,928.00
Unlisted molecular pathology procedure	\$	1,928.00
Unlisted molecular pathology procedure	\$	1,625.00
Unlisted molecular pathology procedure	\$	2,916.00
Unlisted molecular pathology procedure	\$	12,343.00
Unlisted molecular pathology procedure	\$	13,180.00
Unlisted molecular pathology procedure	\$	7,134.00
Unlisted molecular pathology procedure	\$	273.00
Unlisted molecular pathology procedure	\$	35.00
Unlisted molecular pathology procedure	\$	21.00
Unlisted molecular pathology procedure	\$	1,898.00
Unlisted molecular pathology procedure	\$	3,666.00
Unlisted molecular pathology procedure	\$	3,666.00
Unlisted molecular pathology procedure	\$	3,666.00
Unlisted molecular pathology procedure	\$	3,666.00
Unlisted molecular pathology procedure	\$	3,666.00
Unlisted molecular pathology procedure	\$	322.00
Unlisted molecular pathology procedure	\$	322.00
Unlisted molecular pathology procedure	\$	322.00
Unlisted molecular pathology procedure	\$	322.00
Unlisted molecular pathology procedure	\$	322.00
Unlisted molecular pathology procedure	\$	38.00
Unlisted molecular pathology procedure	\$	40.00
Unlisted molecular pathology procedure	\$	40.00
Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as	\$	16,951.00
recurrence score		
Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 genes (50 content and 8 housekeeping), utilizing formalin-fixed paraffin-embedded	\$	11,048.00
tissue, algorithm reported as a recurrence risk score	Ċ	16 207 00
Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastasis	\$	16,207.00
Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded	\$	13,317.00
tissue, algorithm reported as a recurrence score	Ļ	13,317.00
Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4	\$	1,926.00
and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result	ļ	1,520.00
Unlisted multianalyte assay with algorithmic analysis	\$	1,214.00
Unlisted multianalyte assay with algorithmic analysis	\$	8,798.00
Ketone body(s) (eg, acetone, acetoacetic acid, beta-hydroxybutyrate); quantitative	\$	249.00
Acylcarnitines; qualitative, each specimen	\$	63.00
Acylcarnitines; quantitative, each specimen	\$	1,151.00
Adrenocorticotropic hormone (ACTH)	\$	376.00
Albumin; serum, plasma or whole blood	\$	23.00
Albumin; serum, plasma or whole blood	\$	24.00
Albumin; serum, plasma or whole blood	\$	17.00
Albumin; urine or other source, quantitative, each specimen	\$	23.00
Albumin; urine or other source, quantitative, each specimen	\$	8.00
Albumin; urine or other source, quantitative, each specimen	\$	17.00
Albumin; urine, microalbumin, quantitative	\$	68.00
Albumin; urine, microalbumin, quantitative	\$	68.00
Aldolase	\$	115.00
Aldosterone	\$	103.00
Aldosterone	\$	104.00
Aldosterone	\$	104.00
Aldosterone	\$	245.00
Aldosterone	\$	245.00
Aldosterone	\$	245.00
Alpha-1-antitrypsin; total	\$	178.00
Alpha-1-antitrypsin; total	\$	458.00
Alpha-1-antitrypsin; total	\$	73.00
Alpha-fetoprotein (AFP); serum	\$	100.00
Alpha-fetoprotein (AFP); serum	\$	100.00
Alpha-fetoprotein (AFP); serum	\$	45.00

DESCRIPTION	CHARGE
Alpha-fetoprotein (AFP); amniotic fluid	\$ 56.00
Alpha-fetoprotein (AFP); amniotic fluid	\$ 66.00
Alpha-fetoprotein (AFP); amniotic fluid	\$ 96.00
Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio)	\$ 251.00
Aluminum	\$ 75.00
Amino acids; single, quantitative, each specimen	\$ 163.00
Amino acids; single, quantitative, each specimen	\$ 198.00
Amino acids; single, quantitative, each specimen	\$ 142.00
Aminolevulinic acid, delta (ALA); Aminolevulinic acid (protein) level	\$ 29.00
Amino acids, 6 or more amino acids, quantitative, each specimen	\$ 1,360.00
Ammonia	\$ 154.00
Ammonia	\$ 15.00
Amniotic fluid scan (spectrophotometric)	\$ 29.00
Amylase	\$ 68.00
Amylase	\$ 68.00
Amylase	\$ 69.00
Amylase	\$ 69.00
	\$ 28.00
Amylase	
Amylase Amylase	\$ 28.00 \$ 97.00
Amylase	
Androstenedione	\$ 90.00
Androstenedione	\$ 236.00
Androstenedione	\$ 83.00
Androstenedione	\$ 350.00
Angiotensin I - converting enzyme (ACE)	\$ 40.00
Angiotensin I - converting enzyme (ACE)	\$ 39.00
Apolipoprotein, each	\$ 25.00
Apolipoprotein, each	\$ 25.00
Apolipoprotein, each	\$ 149.00
Apolipoprotein, each	\$ 290.00
Arsenic	\$ 90.00
Arsenic	\$ 89.00
Arsenic	\$ 54.00
Arsenic	\$ 75.00
Ascorbic acid (Vitamin C), blood	\$ 38.00
Beta-2 microglobulin	\$ 222.00
Beta-2 microglobulin	\$ 170.00
Beta-2 microglobulin	\$ 92.00
Bile acids; total	\$ 520.00
Bilirubin; total	\$ 23.00
Bilirubin; total	\$ 23.00
Bilirubin; total	\$ 101.00
Bilirubin; direct	\$ 23.00
Biotinidase, each specimen	\$ 357.00
Biotinidase, each specimen	\$ 53.00
Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm	\$ 41.00
screening (ie, patient was provided 3 cards or single triple card for consecutive collection)	φ
Blood, occult, by peroxidase activity (eg, guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm	\$ 41.00
screening (ie, patient was provided 3 cards or single triple card for consecutive collection)	,
Blood, occult, by peroxidase activity (eg, guaiac), qualitative; other sources	\$ 7.00
Blood, occult, by peroxidase activity (eg, gualac), qualitative; other sources	\$ 19.00
Blood, occult, by peroxidase activity (eg, gualac), qualitative, feces, 1-3 simultaneous determinations, performed for other than colorectal neoplasm screening	\$ 47.00
Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations	\$ 94.00
Cadmium Vitamia D. 25 hydrowy includes fraction(s) if performed	\$ 68.00
Vitamin D; 25 hydroxy, includes fraction(s), if performed	\$ 256.00
Vitamin D; 25 hydroxy, includes fraction(s), if performed	\$ 136.00
Vitamin D; 25 hydroxy, includes fraction(s), if performed	\$ 52.00
Calcitonin	\$ 288.00
Calcitonin	\$ 152.00
Calcium; total	\$ 23.00
Calcium; total	\$ 23.00
Calcium; total	\$ 23.00

DESCRIPTION	CHARGE
Calcium; ionized	\$ 135.00
Calcium; urine quantitative, timed specimen	\$ 74.00
Calcium; urine quantitative, timed specimen	\$ 39.00
Calcium; urine quantitative, timed specimen	\$ 51.00
Calculus; infrared spectroscopy	\$ 141.00
Carbon dioxide (bicarbonate)	\$ 23.00
Carbon dioxide (bicarbonate)	\$ 23.00
Carbon dioxide (bicarbonate)	\$ 23.00
Carboxyhemoglobin; quantitative	\$ 92.00
Carcinoembryonic antigen (CEA)	\$ 175.00
Carnitine (total and free), quantitative, each specimen	\$ 348.00
Carnitine (total and free), quantitative, each specimen	\$ 583.00
Carnitine (total and free), quantitative, each specimen	\$ 1,052.00
Carnitine (total and free), quantitative, each specimen	\$ 1,052.00
Carotene Coto de la misera functionata d	\$ 52.00
Catecholamines; fractionated	\$ 322.00
Catecholamines; fractionated Catecholamines; fractionated	 322.00
Catecholamines; fractionated	\$ 104.00 142.00
Catecholamines, fractionated	\$ 142.00
Ceruloplasmin	\$ 133.00
Ceruloplasmin	\$ 28.00
Chemiluminescent assay	\$ 270.00
Chemiluminescent assay	\$ 241.00
Chemiluminescent assay	\$ 802.00
Chloramphenicol	\$ 65.00
Chloride; blood	\$ 23.00
Chloride; urine	\$ 25.00
Chloride; urine	\$ 45.00
Chloride; other source	\$ 47.00
Chloride; other source	\$ 47.00
Chloride; other source	\$ 47.00
Chlorinated hydrocarbons, screen	\$ 264.00
Cholesterol, serum or whole blood, total	\$ 34.00
Cholesterol, serum or whole blood, total	\$ 34.00
Cholesterol, serum or whole blood, total	\$ 15.00
Cholinesterase; serum	\$ 62.00
Cholinesterase; serum	\$ 29.00
Cholinesterase; RBC	\$ 40.00
Chromium	\$ 76.00
Citrate	\$ 27.00
Citrate	\$ 141.00
Citrate	\$ 100.00
Collagen cross links, any method	\$ 156.00
Collagen cross links, any method	\$ 70.00
Copper	\$ 27.00
Copper Corticol: free	\$ 29.00
Cortisol; free	\$ 56.00
Cortisol; free Cortisol; total	\$ 119.00 175.00
Cortisol; total	\$ 90.00
Cortisol; total	\$ 123.00
Cortisol; total	\$ 123.00
	132.00
Cortisol; total	\$

DESCRIPTION		CHARGE
Cortisol; total	\$	97.00
Cortisol; total	\$	97.00
Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen	\$	159.00
Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen	\$	363.00
Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen	\$	387.00
Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen	\$	306.00
Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen	\$	353.00
Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen	\$	185.00
Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen	\$	94.00
Creatine kinase (CK), (CPK); total	\$	71.00
Creatine kinase (CK), (CPK); total	\$	8.00
Creatine kinase (CK), (CPK); isoenzymes	\$	31.00
Creatine kinase (CK), (CPK); MB fraction only	\$	94.00
Creatinine; blood	\$	23.00
Creatinine; blood	\$	23.00
Creatinine; blood	\$	23.00
Creatinine; other source	\$	31.00
Creatinine; other source	\$	31.00
Creatinine; other source	\$	53.00
Creatinine; other source	\$	18.00
Creatinine; other source	\$	57.00
Creatinine; other source	\$	32.00
Creatinine; other source	\$	59.00
Creatinine; other source	\$	21.00
Creatinine; other source	\$	18.00
Creatinine; other source	\$	84.00
Creatinine; other source	\$ c	32.00
Creatinine; other source Creatinine: other source	\$ \$	23.00 8.00
Creatinine; other source	\$	20.00
Creatinine; other source	\$	29.00
Creatinine; other source	\$	29.00
Creatinine; other source	\$	30.00
Creatinine; other source	\$	29.00
Creatinine; other source	\$	29.00
Creatinine; other source	\$	29.00
Creatinine; other source	\$	29.00
Creatinine; clearance	\$	94.00
Cryoglobulin, qualitative or semi-quantitative (eg, cryocrit)	\$	53.00
Cyanide	\$	74.00
Cyanocobalamin (Vitamin B-12)	\$	172.00
Dehydroepiandrosterone (DHEA)	\$	61.00
Dehydroepiandrosterone (DHEA)	\$	90.00
Dehydroepiandrosterone (DHEA)	\$	191.00
Dehydroepiandrosterone (DHEA)	\$	203.00
Dehydroepiandrosterone (DHEA)	\$	303.00
Dehydroepiandrosterone-sulfate (DHEA-S)	\$	42.00
Desoxycorticosterone, 11-	\$	465.00
Desoxycorticosterone, 11-	\$	90.00
Desoxycorticosterone, 11-	\$	371.00
Deoxycortisol, 11-	\$	141.00
Deoxycortisol, 11-	\$	90.00
Deoxycortisol, 11-	\$	150.00
Deoxycortisol, 11-	\$	219.00
Dibucaine number	\$	39.00
Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed	\$	69.00

DESCRIPTION		CHARGE
Elastase, pancreatic (EL-1), fecal, qualitative or semi-quantitative	\$	898.00
Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen	\$	500.00
Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen	\$	383.00
Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen	\$	353.00
Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen	\$	162.00
Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen	\$	162.00
Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen	\$	162.00
Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen	\$	162.00
Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen	\$	1,575.00
Electrophoretic technique, not elsewhere specified	\$	26.00
Electrophoretic technique, not elsewhere specified	\$	255.00
Erythropoietin	\$	221.00
Erythropoietin	\$	103.00
Estradiol	\$	167.00
Estradiol	\$	270.00
Estradiol	\$	271.00
Estrogens; total	\$	69.00
Estriol	\$	144.00
Estriol	\$	65.00
Estrone	\$	110.00
Ethylene glycol	\$	53.00
Ethylene glycol	\$	53.00
Ethylene glycol	\$	53.00
Fat or lipids, feces; qualitative	\$	95.00
Fat or lipids, feces; qualitative	\$	95.00
Fat or lipids, feces; qualitative	\$	97.00
Fat or lipids, feces; quantitative	\$	119.00
Fatty acids, nonesterified	\$	66.00
Very long chain fatty acids	\$ ¢	886.00
Ferritin Fetal fibronectin, cervicovaginal secretions, semi-quantitative	\$ \$	140.00 388.00
Folic acid; serum	\$	202.00
Folic acid; RBC	\$	173.00
Folic acid; RBC	\$	25.00
Galactose-1-phosphate uridyl transferase; quantitative	\$	711.00
Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each	\$	56.00
Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each	\$	56.00
Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each	\$	56.00
Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each	\$	44.00
Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each	\$	44.00
Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each	\$	29.00
Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each	\$	29.00
Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each	\$	84.00
Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each	\$	301.00
Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each	\$	301.00
Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each	\$	94.00
Gammaglobulin (immunoglobulin); IgE	\$	179.00
Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, IgG1, 2, 3, or 4), each	\$	19.00
Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, IgG1, 2, 3, or 4), each	\$	19.00
Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, IgG1, 2, 3, or 4), each	\$	19.00
Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, IgG1, 2, 3, or 4), each	\$	19.00
Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, IgG1, 2, 3, or 4), each	\$	71.00
Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, IgG1, 2, 3, or 4), each	\$	71.00
Gases, blood, pH only	\$	51.00
Gases, blood, pH only	\$	51.00
Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including calculated O2 saturation)	\$	116.00
Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including calculated O2 saturation)	\$	116.00
Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including calculated O2 saturation)	\$	294.00
Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including calculated O2 saturation)	\$	294.00
Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including calculated O2 saturation)	\$	294.00
Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including calculated O2 saturation)	\$	116.00
Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including calculated O2 saturation); with O2 saturation, by direct measurement, except pulse	\$	299.00
oximetry		

DESCRIPTION		CHARGE
Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including calculated O2 saturation); with O2 saturation, by direct measurement, except pulse oximetry	\$	299.00
Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including calculated O2 saturation); with O2 saturation, by direct measurement, except pulse oximetry	\$	299.00
Gases, blood, any combination of pH, pCO2, pO2, CO2, HCO3 (including calculated O2 saturation); with O2 saturation, by direct measurement, except pulse oximetry	\$	299.00
Gases, blood, O2 saturation only, by direct measurement, except pulse oximetry	\$	52.00
Gastrin	\$	200.00
Gastrin	\$	100.00
Glucagon	\$	251.00
Glucose, body fluid, other than blood	\$	111.00
Glucose, body fluid, other than blood	\$	112.00
Glucose, body fluid, other than blood	\$	112.00
Glucose, body fluid, other than blood	\$	111.00
Glucose; quantitative, blood (except reagent strip)	\$	23.00
Glucose; quantitative, blood (except reagent strip)	\$	23.00
Glucose; quantitative, blood (except reagent strip)	\$ \$	23.00 23.00
Glucose; quantitative, blood (except reagent strip) Glucose; quantitative, blood (except reagent strip)	\$	23.00
Glucose; quantitative, blood (except reagent strip)	\$	23.00
Glucose; quantitative, blood (except reagent strip)	\$	23.00
Glucose; quantitative, blood (except reagent strip)	\$	23.00
Glucose; quantitative, blood (except reagent strip)	\$	23.00
Glucose; quantitative, blood (except reagent strip)	\$	23.00
Glucose; post glucose dose (includes glucose)	\$	104.00
Glucose; post glucose dose (includes glucose)	\$	104.00
Glucose; tolerance test (GTT), 3 specimens (includes glucose)	\$	197.00
Glucose; tolerance test (GTT), 3 specimens (includes glucose)	\$	197.00
Glucose; tolerance test (GTT), 3 specimens (includes glucose)	\$	197.00
Glucose; tolerance test, each additional beyond 3 specimens (List separately in addition to code for primary procedure)	\$	29.00
Glucose; tolerance test, each additional beyond 3 specimens (List separately in addition to code for primary procedure)	\$	29.00
Glucose; tolerance test, each additional beyond 3 specimens (List separately in addition to code for primary procedure)	\$	29.00
Glucose; tolerance test, each additional beyond 3 specimens (List separately in addition to code for primary procedure)	\$	29.00
Glucose; tolerance test, each additional beyond 3 specimens (List separately in addition to code for primary procedure)	\$	29.00
Glucose; tolerance test, each additional beyond 3 specimens (List separately in addition to code for primary procedure)	\$	29.00
Glucose; tolerance test, each additional beyond 3 specimens (List separately in addition to code for primary procedure)	\$	29.00
Glucose-6-phosphate dehydrogenase (G6PD); quantitative	\$	24.00
Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use	\$	20.00
Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use	\$	42.00
Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use	\$	20.00
Glutamyltransferase, gamma (GGT)	\$	79.00 134.00
Glutamyltransferase, gamma (GGT)	\$	
Glycated protein Gonadotropin; follicle stimulating hormone (FSH)	\$ \$	26.00 162.00
Gonadotropin; luteinizing hormone (LH)	\$	162.00
Growth hormone, human (HGH) (somatotropin)	\$	154.00
Haptoglobin; quantitative	\$	157.00
Haptoglobin; quantitative	\$	235.00
Heavy metal (eg, arsenic, barium, beryllium, bismuth, antimony, mercury); quantitative, each, not elsewhere specified	\$	156.00
Heavy metal (eg, arsenic, barium, beryllium, bismuth, antimony, mercury); quantitative, each, not elsewhere specified	\$	124.00
Heavy metal (eg, arsenic, barium, beryllium, bismuth, antimony, mercury); quantitative, each, not elsewhere specified	\$	125.00
Hemoglobin fractionation and quantitation; chromatography (eg, A2, S, C, and/or F)	\$	71.00
Hemoglobin fractionation and quantitation; chromatography (eg, A2, S, C, and/or F)	\$	38.00
Hemoglobin fractionation and quantitation; chromatography (eg, A2, S, C, and/or F)	\$	200.00
Hemoglobin fractionation and quantitation; chromatography (eg, A2, S, C, and/or F)	\$	38.00
Hemoglobin; F (fetal), qualitative	\$	172.00
Hemoglobin; F (fetal), qualitative	\$	38.00
Hemoglobin; glycosylated (A1C)	\$	100.00
Hemoglobin; glycosylated (A1C)	\$	100.00
Hemoglobin; glycosylated (A1C)	\$	646.00
Hemoglobin; methemoglobin, quantitative	\$	28.00
Hemoglobin; plasma	\$	46.00
Hemoglobin; urine	\$	47.00

DESCRIPTION	CHARGE
Histamine	\$ 370.00
Histamine	\$ 177.00
Homocysteine	\$ 162.00
Homocysteine	\$ 283.00
Homovanillic acid (HVA)	\$ 70.00
Homovanillic acid (HVA)	\$ 70.00
Homovanillic acid (HVA)	\$ 63.00
Homovanillic acid (HVA)	\$ 63.00
Hydroxycorticosteroids, 17- (17-OHCS)	\$ 39.00
Hydroxyindolacetic acid, 5-(HIAA)	\$ 37.00
Hydroxyindolacetic acid, 5-(HIAA)	\$ 32.00
Hydroxyprogesterone, 17-d	\$ 229.00
Hydroxyprogesterone, 17-d	\$ 90.00
Hydroxyprogesterone, 17-d	\$ 204.00
Hydroxyprogesterone, 17-d	\$ 218.00
Hydroxyprogesterone, 17-d	\$ 72.00
Hydroxyprogesterone, 17-d	\$ 327.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 123.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 123.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 69.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 237.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 873.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 681.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 1,170.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 602.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 144.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 144.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 144.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 144.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 144.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 876.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 876.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 1,170.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 39.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 602.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 1,694.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 76.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 72.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 72.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method	\$ 91.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 565.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 74.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 346.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 238.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 792.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 690.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 1,100.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 825.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 2,942.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 113.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 1,083.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 824.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 1,755.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 1,586.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	 1,509.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 210.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 210.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 1,441.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 1,048.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 1,048.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 1,048.00 287.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$

DESCRIPTION	CHARGE
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 287.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 287.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 287.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 1,016.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 117.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 82.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 82.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 82.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 82.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 82.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 80.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 80.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 80.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 80.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 80.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 80.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 80.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 80.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 80.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 80.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 1,044.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 185.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 307.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 249.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 249.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 248.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 248.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)	\$ 248.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 76.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 76.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 75.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 75.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 75.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 75.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 75.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 205.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 390.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 502.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 91.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 502.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 626.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 626.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 626.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 626.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 626.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 626.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 626.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 626.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 626.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 375.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 269.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 269.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 269.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 269.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 269.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 800.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 726.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 726.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 933.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 933.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 933.00
ummunoassay for analysis other than intectious agent antinedy or intectious agent antigen; quantitative, not otherwise specified	\$ 933.00

DESCRIPTION	CHARGE
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 367.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 189.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 483.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 269.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 269.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 269.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 285.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 626.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 626.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 618.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 933.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 133.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 378.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 462.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 462.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 1,587.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 1,008.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 1,148.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 1,163.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 1,241.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 1,433.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 1,068.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 1,068.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 1,068.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 1,016.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 1,016.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 556.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 410.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 378.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 378.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 436.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 1,118.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 377.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 216.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 66.00
Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified	\$ 831.00
Insulin; total	\$ 72.00
Insulin; free	\$ 196.00
Iron	\$ 75.00
Iron	\$ 5.00
Iron	\$ 251.00
Iron binding capacity	\$ 83.00
Ketosteroids, 17- (17-KS); total	\$ 100.00
Ketosteroids, 17- (17-KS); total	\$ 46.00
Lactate (lactic acid)	\$ 111.00
Lactate dehydrogenase (LD), (LDH)	\$ 53.00
Lactate dehydrogenase (LD), (LDH)	\$ 53.00
Lactate dehydrogenase (LD), (LDH)	\$ 14.00
Lactate dehydrogenase (LD), (LDH); isoenzymes, separation and quantitation	\$ 27.00
Lactoferrin, fecal; qualitative	\$ 117.00
Lead	\$ 149.00
Lead	\$ 150.00
Lead	\$ 46.00
Lead	\$ 37.00
Lead	\$ 32.00
Lead	\$ 48.00
Lead	\$ 29.00
Fetal lung maturity assessment; lecithin sphingomyelin (L/S) ratio	\$ 275.00
Fetal lung maturity assessment; lecithin sphingomyelin (L/S) ratio	\$ 111.00

DESCRIPTION		CHARGE
Fetal lung maturity assessment; lamellar body density	\$	114.00
Lipase	\$	74.00
Lipase	\$	75.00
Lipase	\$	97.00
Lipoprotein (a)	\$	74.00
Lipoprotein (a)	\$	182.00
Lipoprotein-associated phospholipase A2 (Lp-PLA2)	\$	203.00
Lipoprotein, blood; quantitation of lipoprotein particle number(s) (eg, by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed	\$	286.00
Lipoprotein, blood; quantitation of lipoprotein particle number(s) (eg, by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed	\$	186.00
Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol)	\$	80.00
Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol)	\$	10.00
Lipoprotein, direct measurement; LDL cholesterol	\$	57.00
Luteinizing releasing factor (LRH)	\$	1,050.00
Magnesium	\$	53.00
Magnesium	\$	16.00
Magnesium	\$	62.00
Magnesium	\$	45.00
Magnesium	\$	26.00
Magnesium	\$	38.00
Magnesium	\$	67.00
Manganese	\$	183.00
Mass spectrometry and tandem mass spectrometry (eg, MS, MS/MS, MALDI, MS-TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen	\$	264.00
Mass spectrometry and tandem mass spectrometry (eg, MS, MS/MS, MALDI, MS-TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen	\$	34.00
Mercury, quantitative	\$	90.00
Mercury, quantitative	\$	56.00
Mercury, quantitative	\$	56.00
Mercury, quantitative	\$	45.00
Mercury, quantitative	\$	66.00
Metanephrines	\$	297.00
Metanephrines	\$	297.00
Metanephrines	\$	398.00
Metanephrines	\$	95.00
Metanephrines	\$	95.00
Mucopolysaccharides, acid, quantitative	\$	47.00
Myelin basic protein, cerebrospinal fluid	\$	54.00
Myelin basic protein, cerebrospinal fluid	\$	56.00
Myoglobin	\$	177.00
Myoglobin	\$	122.00
Natriuretic peptide	\$	203.00
Natriuretic peptide	\$	200.00
Natriuretic peptide	\$	200.00
Natriuretic peptide	\$	200.00
Nephelometry, each analyte not elsewhere specified	\$	321.00
Nephelometry, each analyte not elsewhere specified	\$	321.00
Nephelometry, each analyte not elsewhere specified	\$	26.00
Nephelometry, each analyte not elsewhere specified	\$	26.00
Nephelometry, each analyte not elsewhere specified	\$	45.00
Nephelometry, each analyte not elsewhere specified	\$	45.00
Nephelometry, each analyte not elsewhere specified	\$	383.00
Nephelometry, each analyte not elsewhere specified	\$	258.00
Nucleotidase 5'-	\$	40.00
Oligoclonal immune (oligoclonal bands)	\$	61.00
Oligoclonal immune (oligoclonal bands)	\$	68.00
Organic acids; total, quantitative, each specimen	\$	1,151.00
Organic acid, single, quantitative	\$	528.00
Organic acid, single, quantitative	\$	377.00
Organic acid, single, quantitative	\$	104.00
Osmolality; blood	\$ ¢	96.00
Osmolality; urine	\$	87.00

DESCRIPTION	CHARGE
Osteocalcin (bone g1a protein)	\$ 392.00
Oxalate	\$ 91.00
Oxalate	\$ 65.00
Oxalate	\$ 54.00
Parathormone (parathyroid hormone)	\$ 350.00
Parathormone (parathyroid hormone)	\$ 354.00
Parathormone (parathyroid hormone)	\$ 354.00
pH; body fluid, not otherwise specified	\$ 18.00
pH; body fluid, not otherwise specified	\$ 18.00
pH; body fluid, not otherwise specified	\$ 17.00
pH; body fluid, not otherwise specified	\$ 17.00
pH; body fluid, not otherwise specified	\$ 21.00
pH; body fluid, not otherwise specified	\$ 18.00
pH; body fluid, not otherwise specified	\$ 46.00
Phencyclidine (PCP) drug level	\$ 82.00
Phencyclidine (PCP) drug level	\$ 264.00
Phencyclidine (PCP) drug level	\$ 791.00
Phencyclidine (PCP) drug level	\$ 58.00
Calprotectin, fecal	\$ 495.00
Phenylalanine (PKU), blood	\$ 273.00
Phosphatase, acid; prostatic	\$ 31.00
Phosphatase, alkaline	\$ 23.00
Phosphatase, alkaline	\$ 10.00
Phosphatase, alkaline	\$ 17.00
Phosphatase, alkaline	\$ 259.00
Phosphatase, alkaline; heat stable (total not included)	\$ 10.00
Phosphatase, alkaline; isoenzymes	\$ 60.00
Phosphatase, alkaline; isoenzymes	\$ 46.00
Phosphatase, alkaline; isoenzymes	\$ 262.00
Phosphorus inorganic (phosphate)	\$ 23.00
Phosphorus inorganic (phosphate)	\$ 23.00
Phosphorus inorganic (phosphate)	\$ 57.00
Phosphorus inorganic (phosphate); urine	\$ 51.00
Phosphorus inorganic (phosphate); urine	\$ 29.00
Phosphorus inorganic (phosphate); urine	\$ 32.00
Phosphorus inorganic (phosphate); urine	\$ 31.00
Porphobilinogen, urine; quantitative	\$ 26.00
Porphobilinogen, urine; quantitative	\$ 23.00
Evaluation of cervicovaginal fluid for specific amniotic fluid protein(s) (eg, placental alpha microglobulin-1 [PAMG-1], placental protein 12 [PP12], alpha-	\$ 382.00
fetoprotein), qualitative, each specimen	
Porphyrins, urine; quantitation and fractionation	\$ 208.00
Porphyrins, urine; quantitation and fractionation	\$ 59.00
Potassium; serum, plasma or whole blood	\$ 23.00
Potassium; serum, plasma or whole blood	\$ 23.00
Potassium; serum, plasma or whole blood	\$ 23.00
Potassium; serum, plasma or whole blood	\$ 23.00
Potassium; serum, plasma or whole blood	\$ 23.00
Potassium; serum, plasma or whole blood	\$ 23.00
Potassium; urine	\$ 23.00
Potassium; urine	\$ 23.00
Potassium; urine	\$ 28.00
Potassium; urine	\$ 15.00
Prealbumin	\$ 98.00
Pregnenolone	\$ 390.00
17 Oh Pregnenolone	\$ 447.00
17 Oh Pregnenolone	\$ 90.00
17 Oh Pregnenolone	\$ 273.00
Progesterone	\$ 228.00
Progesterone	\$ 90.00
Progesterone	\$ 249.00
Procalcitonin (PCT)	\$ 159.00
Procalcitonin (PCT)	\$ 159.00
Prolactin	\$ 226.00

DESCRIPTION		CHARGE
Prostate specific antigen (PSA); total	\$	149.00
Prostate specific antigen (PSA); total	\$	149.00
Prostate specific antigen (PSA); free	\$	249.00
Protein, total, except by refractometry; serum, plasma or whole blood	\$	23.00
Protein, total, except by refractometry; urine	\$	58.00
Protein, total, except by refractometry; urine	\$	58.00
Protein, total, except by refractometry; other source (eg, synovial fluid, cerebrospinal fluid)	\$	103.00
Protein, total, except by refractometry; other source (eg, synovial fluid, cerebrospinal fluid)	\$	103.00
Protein, total, except by refractometry; other source (eg, synovial fluid, cerebrospinal fluid)	\$	26.00
Protein, total, except by refractometry; other source (eg, synovial fluid, cerebrospinal fluid)	\$	49.00
Pregnancy-associated plasma protein-A (PAPP-A)	\$	89.00
Pregnancy-associated plasma protein-A (PAPP-A)	\$	173.00
Protein; electrophoretic fractionation and quantitation, serum	\$	96.00
Protein; electrophoretic fractionation and quantitation, other fluids with concentration (eg, urine, CSF)	\$	197.00
Protein; electrophoretic fractionation and quantitation, other fluids with concentration (eg, urine, CSF)	\$	120.00
Protein; Western Blot, with interpretation and report, blood or other body fluid	\$	552.00
Protein; Western Blot, with interpretation and report, blood or other body fluid	\$	1,024.00
Protein; Western Blot, with interpretation and report, blood or other body fluid	\$	605.00
Protein; Western Blot, with interpretation and report, blood or other body fluid	\$	1,820.00
Protein; Western Blot, with interpretation and report, blood or other body fluid	\$	927.00
Protein; Western Blot, with interpretation and report, blood or other body fluid	\$	392.00
Protein; Western Blot, with interpretation and report, blood or other body fluid	\$	164.00
Protein; Western Blot, with interpretation and report, blood or other body fluid	\$	93.00
Protein; Western Blot, with interpretation and report, blood or other body fluid	\$	1,413.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	1,083.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	1,083.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	1,083.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$ \$	1,083.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	1	1,083.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$ \$	1,083.00 1,755.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	1,755.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	975.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	975.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	975.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	975.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	975.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	1,404.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	1,404.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	1,404.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	1,404.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	1,404.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	1,404.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	860.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	387.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	824.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	828.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	973.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	98.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	629.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	629.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	629.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	629.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	629.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	630.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	98.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	98.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	98.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	98.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	98.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	98.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$	98.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	Ś	98.00

DESCRIPTION	CHARGE
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$ 98.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$ 98.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$ 98.00
Protein; Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each	\$ 98.00
Protoporphyrin, RBC; quantitative	\$ 27.00
Protoporphyrin, RBC; quantitative	\$ 49.00
Protoporphyrin, RBC; quantitative	\$ 87.00
Proinsulin	\$ 317.00
Pyridoxal phosphate (Vitamin B-6)	\$ 62.00
Pyruvate	\$ 36.00
Pyruvate kinase	\$ 282.00
Receptor assay; non-endocrine (specify receptor)	\$ 1,039.00
Renin	\$ 72.00
Renin	\$ 70.00
Renin Renin	\$ 272.00 272.00
Renin	\$ 272.00
Riboflavin (Vitamin B-2)	\$ 81.00
Selenium	\$ 241.00
Serotonin	\$ 147.00
Sex hormone binding globulin (SHBG)	\$ 186.00
Sex hormone binding globulin (SHBG)	\$ 62.00
Sodium; serum, plasma or whole blood	\$ 23.00
Sodium; serum, plasma or whole blood	\$ 23.00
Sodium; serum, plasma or whole blood	\$ 23.00
Sodium; serum, plasma or whole blood	\$ 23.00
Sodium; urine	\$ 23.00
Sodium; urine	\$ 23.00
Sodium; urine	\$ 30.00
Sodium; urine	\$ 24.00
Sodium; other source	\$ 29.00
Somatomedin	\$ 294.00
Somatomedin	\$ 73.00
Somatomedin	\$ 112.00
Spectrophotometry, analyte not elsewhere specified	\$ 41.00
Spectrophotometry, analyte not elsewhere specified	\$ 111.00
Spectrophotometry, analyte not elsewhere specified	\$ 488.00
Spectrophotometry, analyte not elsewhere specified	\$ 97.00
Specific gravity (except urine)	\$ 16.00
Sugars (mono-, di-, and oligosaccharides); single qualitative, each specimen	\$ 49.00
Sugars (mono-, di-, and oligosaccharides); single qualitative, each specimen	\$ 32.00
Sugars (mono-, di-, and oligosaccharides); single quantitative, each specimen	\$ 933.00
Sulfate, urine	\$ 26.00
Testosterone; free	\$ 402.00
Testosterone; free Testosterone; total	\$ 37.00 341.00
Testosterone; total	\$ 90.00
Testosterone; total	\$ 194.00
Testosterone; total	\$ 207.00
Testosterone; total	\$ 40.00
Testosterone; total	\$ 310.00
Testosterone; total	\$ 41.00
Thiamine (Vitamin B-1)	\$ 72.00
Thiamine (Vitamin B-1)	\$ 67.00
Thiocyanate	\$ 114.00
Thyroglobulin	\$ 95.00
Thyroxine; total	\$ 83.00
Thyroxine; free	\$ 259.00
Thyroxine; free	\$ 71.00
Thyroxine binding globulin (TBG)	\$ 34.00

DESCRIPTION		CHARGE
Thyroid stimulating hormone (TSH)	\$	182.00
Thyroid stimulating hormone (TSH)	\$	182.00
Thyroid stimulating hormone (TSH)	\$	203.00
Thyroid stimulating immune globulins (TSI)	\$	506.00
Tocopherol alpha (Vitamin E)	\$	174.00
Transferase; aspartate amino (AST) (SGOT)	\$	23.00
Transferase; alanine amino (ALT) (SGPT)	\$	23.00
Transferase; alanine amino (ALT) (SGPT)	\$	23.00
Transferase; alanine amino (ALT) (SGPT)	\$	
Transferrin	\$	
Triglycerides	\$	34.00
Triglycerides	\$	34.00
Triglycerides	\$	15.00
Thyroid hormone (T3 or T4) uptake or thyroid hormone binding ratio (THBR)	\$	17.00
Triiodothyronine T3; total (TT-3)	\$	
Triiodothyronine T3; total (TT-3)	\$	
Triiodothyronine T3; free	\$	
Triiodothyronine T3; free	\$ \$	
Triiodothyronine T3; reverse Troponin, quantitative	\$	
Troponin, quantitative	\$	
Troponin, quantitative	\$	
Troponin, quantitative	\$	
Trypsin; duodenal fluid	\$	102.00
Urea nitrogen; quantitative	\$	23.00
Urea nitrogen; quantitative	\$	23.00
Urea nitrogen; quantitative	\$	23.00
Urea nitrogen; quantitative	\$	23.00
Urea nitrogen; quantitative	\$	23.00
Urea nitrogen, urine	\$	53.00
Urea nitrogen, urine	\$	23.00
Uric acid; blood	\$	49.00
Uric acid; other source	\$	58.00
Uric acid; other source	\$	59.00
Uric acid; other source	\$	59.00
Uric acid; other source	\$	25.00
Uric acid; other source	\$	19.00
Vanillylmandelic acid (VMA), urine	\$	
Vanillylmandelic acid (VMA), urine	\$	
Vanillylmandelic acid (VMA), urine	\$	84.00
Vanillylmandelic acid (VMA), urine	\$	84.00
Vasoactive intestinal peptide (VIP)	\$	
Vasopressin (antidiuretic hormone, ADH)	\$	
Vitamin A	\$	
Vitamin K	\$	
Volatiles (eg, acetic anhydride, diethylether)	\$	
Volatiles (eg, acetic anhydride, diethylether) Volatiles (eg, acetic anhydride, diethylether)	\$	
Volatiles (eg, acetic anhydride, diethylether)	\$	168.00 82.00
Xylose absorption test, blood and/or urine	\$	63.00
Xylose absorption test, blood and/or urine Xylose absorption test, blood and/or urine	\$	59.00
Zinc	\$	34.00
Zinc	\$	
Zinc	\$	49.00
C-peptide	\$	
Gonadotropin, chorionic (hCG); quantitative	\$	
Gonadotropin, chorionic (hCG); quantitative	\$	
Gonadotropin, chorionic (hCG); quantitative	\$	
Gonadotropin, chorionic (hCG); quantitative	\$	39.00
Gonadotropin, chorionic (hCG); qualitative	\$	
Unlisted chemistry procedure	\$	97.00
Blood count; blood smear, microscopic examination with manual differential WBC count	\$	68.00
Blood count; blood smear, microscopic examination with manual differential WBC count	\$	69.00

DESCRIPTION	CHARGE
Blood count; blood smear, microscopic examination without manual differential WBC count	\$ 29.00
Blood count; blood smear, microscopic examination without manual differential WBC count	\$ 29.00
Blood count; manual differential WBC count, buffy coat	\$ 23.00
Blood count; manual differential WBC count, buffy coat	\$ 23.00
Blood count; spun microhematocrit	\$ 15.00
Blood count; hematocrit (Hct)	\$ 32.00
Blood count; hemoglobin (Hgb)	\$ 30.00
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count	\$ 62.00
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count	\$ 63.00
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count)	\$ 62.00
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count)	\$ 62.00
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count)	\$ 63.00
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count)	\$ 63.00
Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count)	\$ 63.00
Blood count; red blood cell (RBC), automated	\$ 40.00
Blood count; red blood cell (RBC), automated	\$ 40.00
Blood count; reticulocyte, manual	\$ 26.00
Blood count; reticulocyte, manual	\$ 177.00
Blood count; reticulocyte, automated	\$ 53.00
Blood count; reticulocytes, automated, including 1 or more cellular parameters (eg, reticulocyte hemoglobin content [CHr], immature reticulocyte fraction	\$ 34.00
[IRF], reticulocyte volume [MRV], RNA content), direct measurement	
Blood count; leukocyte (WBC), automated	\$ 40.00
Blood count; leukocyte (WBC), automated	\$ 39.00
Blood count; leukocyte (WBC), automated	\$ 40.00
Blood count; platelet, automated	\$ 46.00
Reticulated platelet assay	\$ 159.00
Bone marrow, smear interpretation	\$ 284.00
Clotting; factor II, prothrombin, specific	\$ 57.00
Clotting; factor V (AcG or proaccelerin), labile factor	\$ 104.00
Clotting; factor VII (proconvertin, stable factor)	\$ 105.00
Clotting; factor VIII (AHG), 1-stage	\$ 249.00
Clotting; factor VIII (AHG), 1-stage	\$ 349.00
Clotting; factor VIII, VW factor, ristocetin cofactor	\$ 136.00
Clotting; factor VIII, VW factor, ristocetin cofactor	\$ 349.00
Clotting; factor VIII, VW factor antigen	\$ 136.00
Clotting; factor VIII, VW factor antigen	\$ 649.00
Clotting; factor VIII, VW factor antigen	\$ 349.00
Clotting; factor VIII, von Willebrand factor, multimetric analysis	\$ 278.00
Clotting; factor VIII, von Willebrand factor, multimetric analysis	\$ 349.00
Clotting; factor IX (PTC or Christmas)	\$ 287.00
Clotting; factor X (Stuart-Prower)	\$ 280.00
Clotting; factor XI (PTA)	\$ 280.00
Clotting; factor XII (Hageman)	\$ 183.00
Clotting; factor XIII (fibrin stabilizing), screen solubility	\$ 49.00
Clotting inhibitors or anticoagulants; antithrombin III, activity	\$ 111.00
Clotting inhibitors or anticoagulants; protein C, antigen	\$ 120.00
Clotting inhibitors or anticoagulants; protein C, activity	\$ 133.00
Clotting inhibitors or anticoagulants; protein S, total	\$ 74.00
Clotting inhibitors or anticoagulants; protein S, free	\$ 92.00
Clotting inhibitors or anticoagulants; protein S, free	\$ 92.00
Activated Protein C (APC) resistance assay	\$ 92.00
Factor inhibitor test	\$ 34.00
Factor inhibitor test	\$ 648.00
Factor inhibitor test	\$ 118.00
Coagulation time; activated	\$ 31.00

DESCRIPTION		CHARGE
Coagulation time; activated	\$	31.00
Coagulation time; activated	\$	31.00
Coagulation time; activated	\$	31.00
Fibrin(ogen) degradation (split) products (FDP) (FSP); agglutination slide, semiquantitative	\$	75.00
Fibrin(ogen) degradation (split) products (FDP) (FSP); paracoagulation	\$	52.00
Fibrin degradation products, D-dimer; quantitative	\$	75.00
Fibrinogen; activity	\$	
Fibrinogen; activity	\$	
Fibrinogen; activity	\$	149.00
Fibrinogen; antigen	\$	
Coagulation and fibrinolysis, functional activity, not otherwise specified (eg, ADAMTS-13), each analyte	\$	491.00
Coagulation and fibrinolysis, functional activity, not otherwise specified (eg, ADAMTS-13), each analyte	\$	
Fibrinolytic factors and inhibitors; alpha-2 antiplasmin	\$	308.00
Fibrinolytic factors and inhibitors; plasminogen activator	\$	764.00
Fibrinolytic factors and inhibitors; plasminogen activator	\$	771.00
Fibrinolytic factors and inhibitors; plasminogen activator	\$	297.00
Fibrinolytic factors and inhibitors; plasminogen, except antigenic assay	\$	257.00
Heinz bodies; direct	\$	40.00
Hemoglobin or RBCs, fetal, for fetomaternal hemorrhage; differential lysis (Kleihauer-Betke)	\$	
Hemoglobin or RBCs, fetal, for fetomaternal hemorrhage; differential lysis (Kleihauer-Betke)	\$	38.00
Hemoglobin or RBCs, fetal, for fetomaternal hemorrhage; rosette	\$	41.00
Hemolysin, acid	\$	53.00
Heparin assay	\$	315.00
Heparin neutralization	\$	71.00
Iron stain, peripheral blood	\$	40.00
Leukocyte alkaline phosphatase with count	\$	95.00
Muramidase	\$	66.00
Muramidase	\$	66.00
Osmotic fragility, RBC; incubated	\$	26.00
Platelet, aggregation (in vitro), each agent	\$	
Platelet, aggregation (in vitro), each agent	\$	
Platelet, aggregation (in vitro), each agent	\$	
Platelet, aggregation (in vitro), each agent	\$	
Platelet, aggregation (in vitro), each agent	\$	
Platelet, aggregation (in vitro), each agent	\$	
Platelet, aggregation (in vitro), each agent	\$	
Platelet, aggregation (in vitro), each agent	\$ \$	
Platelet, aggregation (in vitro), each agent Platelet, aggregation (in vitro), each agent	\$	
Platelet, aggregation (in vitro), each agent Platelet, aggregation (in vitro), each agent	\$	
Phospholipid neutralization; platelet	\$	
Phospholipid neutralization; platelet	\$	
Prothrombin time	\$	46.00
Prothrombin time	\$	47.00
Prothrombin time	\$	47.00
Prothrombin time	\$	
Prothrombin time	\$	47.00
Prothrombin time	\$	46.00
Prothrombin time; substitution, plasma fractions, each	\$	24.00
Russell viper venom time (includes venom); diluted	\$	57.00
Reptilase test	\$	44.00
Sedimentation rate, erythrocyte; non-automated	\$	47.00
Sedimentation rate, erythrocyte; non-automated	\$	47.00
Sedimentation rate, erythrocyte; non-automated	\$	47.00
Sedimentation rate, erythrocyte; automated	\$	35.00
Sickling of RBC, reduction	\$	124.00
Sickling of RBC, reduction	\$	123.00
Thrombin time; plasma	\$	
Thrombin time; plasma	\$	
Thrombin time; plasma	\$	72.00
Thromboplastin time, partial (PTT); plasma or whole blood	\$	69.00
Thromboplastin time, partial (PTT); plasma or whole blood	\$	69.00
Thromboplastin time, partial (PTT); plasma or whole blood	\$	69.00

DESCRIPTION	C	HARGE
Thromboplastin time, partial (PTT); plasma or whole blood	\$	69.00
Thromboplastin time, partial (PTT); substitution, plasma fractions, each	\$	39.00
Thromboplastin time, partial (PTT); substitution, plasma fractions, each	\$	39.00
Viscosity	\$	142.00
Allergen specific IgG quantitative or semiquantitative, each allergen	\$	65.00
Allergen specific IgG quantitative or semiquantitative, each allergen	\$	65.00
Allergen specific IgG quantitative or semiquantitative, each allergen	\$	65.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ \$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00 31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative of semiquantitative, each allergen Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative of semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ \$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00 31.00
Allergen specific IGE; quantitative of semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative of semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative of semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative of semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative of semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	31.00

DESCRIPTION	CHARGE
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31. ¢ 21.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31. \$ 31.
Allergen specific IGE; quantitative of semiquantitative, each allergen	\$ 31. \$ 31.
Allergen specific IGE; quantitative of semiquantitative, each allergen	\$ 31. \$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE: quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 31.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 42.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 51.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 80.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 29.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 42.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 84.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 42.
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.

DESCRIPTION	CHARGE
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 29.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 80.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 42.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 29.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 84.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 84.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 29.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$

DESCRIPTION	CHARGE
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 80.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 130.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 42.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 42.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 130.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 130.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 130.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 130.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 130.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 84.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 84.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 51.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 51.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 84.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 51.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 51.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 84.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 163.00 \$ 163.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 163.00 \$ 163.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	
Allergen specific IGE; quantitative or semiquantitative, each allergen Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 119.00 \$ 163.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 163.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 163.00
Allergen specific IGE; quantitative of semiquantitative, each allergen	\$ 163.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 163.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 163.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 80.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 51.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 51.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 51.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 51.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 80.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 51.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 51.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 84.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 79.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 79.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 125.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 79.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 79.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 125.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 125.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 79.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 125.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 125.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 79.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 125.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$ 44.00

DESCRIPTION		CHARGE
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	79.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	125.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	48.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	125.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	125.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	44.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	76.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	48.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	153.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	25.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	25.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	130.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	80.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	436.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	10.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	19.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	19.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	26.00
Allergen specific IGE; quantitative or semiquantitative, each allergen	\$	19.00
Allergen specific IGE; quantitative or semiquantitative, recombinant or purified component, each	\$	26.00
Allergen specific IGE; quantitative or semiquantitative, recombinant or purified component, each	\$	26.00
Allergen specific IGE; quantitative or semiquantitative, recombinant or purified component, each	\$	26.00
Allergen specific IGE; quantitative or semiquantitative, recombinant or purified component, each	\$	26.00
Allergen specific IGE; quantitative or semiquantitative, recombinant or purified component, each	\$	26.00
Antibody identification; leukocyte antibodies	\$	2,005.00
Antibody identification; leukocyte antibodies	\$	1,615.00
Antibody identification; leukocyte antibodies	\$	1,827.00
Antibody identification; leukocyte antibodies	\$	590.00
Antibody identification; leukocyte antibodies	\$	122.00
Antibody identification; leukocyte antibodies	\$	501.00
Antibody identification; platelet antibodies	\$	142.00
Antibody identification; platelet antibodies	\$	2,381.00
Antibody identification; platelet antibodies	\$	680.00
Antibody identification; platelet antibodies	\$	161.00
Antibody identification; platelet antibodies	\$	161.00
Antibody identification; platelet antibodies	\$	161.00
Antibody identification; platelet antibodies	\$	161.00
Antibody identification; platelet antibodies	\$	561.00
Antibody identification; platelet antibodies	\$	306.00
Antibody identification; platelet antibodies	\$	131.00
Antibody identification; platelet antibodies	\$	131.00
Antibody identification; platelet antibodies	\$	131.00
Antibody identification; platelet antibodies	\$	131.00
Antibody identification; platelet antibodies	\$	130.00
Antibody identification test for platelet antibodies	\$	176.00
Antinuclear antibodies (ANA)	\$	135.00
Antinuclear antibodies (ANA); titer	\$	74.00
Antistreptolysin 0; titer	\$	105.00
Antistreptolysin 0; titer	\$	41.00
Blood bank physician services; investigation of transfusion reaction including suspicion of transmissible disease, interpretation and written report	\$	222.00
C-reactive protein	\$	100.00
C-reactive protein; high sensitivity (hsCRP)	\$	100.00
Beta 2 Glycoprotein I antibody, each	\$	313.00
Beta 2 Glycoprotein I antibody, each	\$	313.00
Beta 2 Glycoprotein I antibody, each	\$	313.00
Beta 2 Glycoprotein I antibody, each	\$	153.00
Beta 2 Glycoprotein I antibody, each	\$	153.00
Beta 2 Glycoprotein I antibody, each	\$	153.00
Cardiolipin (phospholipid) antibody, each Ig class	\$	384.00
Cardiolipin (phospholipid) antibody, each Ig class	Ś	384.00

DESCRIPTION		CHARGE
Cardiolipin (phospholipid) antibody, each Ig class	\$	384.00
Cardiolipin (phospholipid) antibody, each Ig class	\$	153.00
Cardiolipin (phospholipid) antibody, each Ig class	\$	153.00
Cardiolipin (phospholipid) antibody, each Ig class	\$	153.00
Anti-phosphatidylserine (phospholipid) antibody	\$	96.00
Anti-phosphatidylserine (phospholipid) antibody	\$	96.00
Anti-phosphatidylserine (phospholipid) antibody	\$	96.00
Anti-phosphatidylserine (phospholipid) antibody	\$	49.00
Anti-phosphatidylserine (phospholipid) antibody	\$	49.00
Anti-phosphatidylserine (phospholipid) antibody	\$	49.00
Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood)	\$	933.00
Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood)	\$	1,178.00
Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood)	\$	1,178.00
Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood)	\$	1,402.00
Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood); physician interpretation and report, when required	\$	1,178.00
Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood); physician interpretation and report, when required	\$	1,178.00
Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood); physician interpretation and report,	\$	1,402.00
when required Cold agglutinin; titer	\$	18.00
Complement; antigen, each component	\$	140.00
Complement; antigen, each component	\$	140.00
Complement; antigen, each component	\$	42.00
Complement; antigen, each component	\$	39.00
Complement; antigen, each component	\$	131.00
Complement; functional activity, each component	\$	86.00
Complement; functional activity, each component	\$	550.00
Complement; total hemolytic (CH50)	\$	44.00
Cyclic citrullinated peptide (CCP), antibody	\$	76.00
Deoxyribonuclease, antibody	\$	45.00
Deoxyribonucleic acid (DNA) antibody; native or double stranded	\$	155.00
Deoxyribonucleic acid (DNA) antibody; single stranded	\$	79.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	269.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	269.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	269.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	269.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	269.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	269.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	217.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	57.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	66.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	122.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	122.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	122.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	122.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	122.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, JO1), each antibody	\$	122.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	122.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	122.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$	122.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	\$ \$	122.00
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody	1	240.00 240.00
	\$ \$	
Extractable nuclear antigen, antibody to, any method (eg, nRNP, SS-A, SS-B, Sm, RNP, Sc170, J01), each antibody Fluorescent noninfectious agent antibody; screen, each antibody	\$	105.00 71.00
Fluorescent noninfectious agent antibody; screen, each antibody Fluorescent noninfectious agent antibody; screen, each antibody	\$	71.00
Fluorescent noninfectious agent antibody, screen, each antibody Fluorescent noninfectious agent antibody; screen, each antibody	\$	53.00
Fluorescent noninfectious agent antibody, screen, each antibody	\$	579.00
Fluorescent noninfectious agent antibody, screen, each antibody	\$	159.00
Fluorescent noninfectious agent antibody, screen, each antibody	\$	431.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	749.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,299.00

DESCRIPTION		CHARGE
Fluorescent noninfectious agent antibody; screen, each antibody	\$	281.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	514.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	292.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	930.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	930.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	930.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,299.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,299.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,732.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,458.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,458.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,458.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	71.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	71.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	71.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,155.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,181.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	926.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	113.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	222.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	222.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	222.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	222.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	222.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	222.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	222.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	222.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	222.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	222.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,890.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,403.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,404.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,404.00
Fluorescent noninfectious agent antibody; screen, each antibody	· · · · · · · · · · · · · · · · · · ·	1,404.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	1,950.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	71.00
Fluorescent noninfectious agent antibody; screen, each antibody Fluorescent noninfectious agent antibody; screen, each antibody	\$	71.00 71.00
Fluorescent noninfectious agent antibody, screen, each antibody	\$	71.00
Fluorescent noninfectious agent antibody, screen, each antibody	\$	71.00
Fluorescent noninfectious agent antibody, screen, each antibody	\$	71.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	71.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	71.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	71.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	71.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	71.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	Ş	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	\$	72.00
Fluorescent noninfectious agent antibody; screen, each antibody	Ś	72.00

DESCRIPTION	CHARGE
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 93.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 93.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 57.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 57.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 83.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 198.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 198.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 198.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 198.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 198.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 198.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 198.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 198.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 198.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 73.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 52.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 57.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 3,035.00
Fluorescent noninfectious agent antibody; titer, each antibody	\$ 3,035.00
Growth hormone, human (HGH), antibody	\$ 313.00
Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29)	\$ 178.00
Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29) Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29)	\$ 178.00 59.00
Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29)	\$ 51.00
Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29) Immunoassay for tumor antigen, quantitative; CA 19-9	\$ 49.00 178.00
	 243.00
Immunoassay for tumor antigen, quantitative; CA 125 Human epididymis protein 4 (HE4)	\$
	 594.00
Heterophile antibodies; screening	\$ 88.00
Immunoassay for tumor antigen, other antigen, quantitative (eg, CA 50, 72-4, 549), each	\$ 423.00
Immunoassay for tumor antigen, other antigen, quantitative (eg, CA 50, 72-4, 549), each	\$ 381.00
Immunoassay for tumor antigen, other antigen, quantitative (eg, CA 50, 72-4, 549), each	\$ 381.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$ 162.00

DESCRIPTION		CHARGE
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	161.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	139.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	61.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	68.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	68.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	68.00 68.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	68.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	68.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	57.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	57.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	57.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	57.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	57.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	57.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	57.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	57.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	57.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	57.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	57.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	57.00
Immunoassay for infectious agent antibody, quantitative, not otherwise specified	\$	67.00
Immunodiffusion; not elsewhere specified	\$	30.00
Immunodiffusion; not elsewhere specified	\$	258.00
Immunodiffusion; gel diffusion, qualitative (Ouchterlony), each antigen or antibody	\$	59.00
Immunodiffusion; gel diffusion, qualitative (Ouchterlony), each antigen or antibody	\$	44.00
Immunodiffusion; gel diffusion, qualitative (Ouchterlony), each antigen or antibody	\$	45.00
Immune complex assay	\$	115.00
Immune complex assay	\$	80.00
Immunofixation electrophoresis; serum	\$	
Immunofixation electrophoresis; other fluids with concentration (eg, urine, CSF)	\$	
Immunofixation electrophoresis; other fluids with concentration (eg, urine, CSF)	\$	
Inhibin A	\$	
Inhibin A	\$	37.00
Insulin antibodies	\$	35.00
Intrinsic factor antibodies	\$	
Islet cell antibody	\$	75.00
Islet cell antibody	\$	91.00
Islet cell antibody	\$	
Islet cell antibody	\$	906.00
Islet cell antibody Islet cell antibody	\$	
Islet cell antibody	\$	
Islet cell antibody	\$	
Islet cell antibody	\$	
Leukocyte histamine release test (LHR)	\$	
Cellular function assay involving stimulation (eg, mitogen or antigen) and detection of biomarker (eg, ATP)	\$	
Lymphocyte transformation, mitogen (phytomitogen) or antigen induced blastogenesis	\$	
Lymphocyte transformation, mitogen (phytomitogen) or antigen induced blastogenesis	\$	
	Ý	

DESCRIPTION		CHARGE
Lymphocyte transformation, mitogen (phytomitogen) or antigen induced blastogenesis	\$	461.00
Lymphocyte transformation, mitogen (phytomitogen) or antigen induced blastogenesis	\$	461.00
Lymphocyte transformation, mitogen (phytomitogen) or antigen induced blastogenesis	\$	461.00
Lymphocyte transformation, mitogen (phytomitogen) or antigen induced blastogenesis	\$	461.00
Lymphocyte transformation, mitogen (phytomitogen) or antigen induced blastogenesis	\$	461.00
Lymphocyte transformation, mitogen (phytomitogen) or antigen induced blastogenesis	\$	461.00
B cells, total count	\$	223.00
Natural killer (NK) cells, total count	\$	
T cells; total count	\$	223.00
T cells; total count	\$	223.00
T cells; total count	\$	130.00
T cells; absolute CD4 and CD8 count, including ratio	\$	
Stem cells (ie, CD34), total count	\$	
Microsomal antibodies (eg, thyroid or liver-kidney), each	\$	
Microsomal antibodies (eg, thyroid or liver-kidney), each	\$	
Microsomal antibodies (eg, thyroid or liver-kidney), each	\$	
Neutralization test, viral	\$	1,371.00
Neutralization test, viral	\$	213.00
Neutralization test, viral Neutralization test, viral	· ·	213.00
Particle agglutination; screen, each antibody	\$	141.00 59.00
Particle agglutination, screen, each antibody	\$	202.00
Particle agglutination, screen, each antibody	\$	34.00
Particle agglutination, screen, each antibody	\$	34.00
Particle agglutination; screen, each antibody	\$	34.00
Particle agglutination; screen, each antibody	\$	34.00
Particle agglutination; screen, each antibody	\$	34.00
Particle agglutination; screen, each antibody	\$	21.00
Particle agglutination; screen, each antibody	\$	10.00
Particle agglutination; titer, each antibody	\$	63.00
Rheumatoid factor; quantitative	\$	170.00
Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon	\$	200.00
Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART)	\$	28.00
Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART)	\$	17.00
Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART)	\$	69.00
Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART)	\$	17.00
Syphilis test, non-treponemal antibody; quantitative	\$	59.00
Antibody; adenovirus	\$	59.00
Antibody; Aspergillus	\$	75.00
Antibody; Aspergillus	\$	75.00
Antibody; Aspergillus	\$	37.00
Antibody; Aspergillus	\$	162.00
Antibody; Aspergillus	\$	44.00
Antibody; Aspergillus	\$	44.00
Antibody; Aspergillus	\$	44.00
Antibody; bacterium, not elsewhere specified	\$	44.00
Antibody; bacterium, not elsewhere specified	\$	44.00
Antibody; bacterium, not elsewhere specified	\$	71.00
Antibody; bacterium, not elsewhere specified	\$	71.00
Antibody; bacterium, not elsewhere specified Antibody; bacterium, not elsewhere specified	\$	71.00
Antibody; bacterium, not elsewhere specified Antibody; bacterium, not elsewhere specified	\$	71.00 66.00
Antibody; bacterium, not elsewhere specified Antibody; bacterium, not elsewhere specified	\$	66.00
Antibody; bacterium, not elsewhere specified Antibody; bacterium, not elsewhere specified	\$	66.00
Antibody; bacterium, not elsewhere specified Antibody; bacterium, not elsewhere specified	\$	66.00
Antibody; bacterium, not elsewhere specified Antibody; bacterium, not elsewhere specified	\$	71.00
Antibody; bacterium, not elsewhere specified Antibody; bacterium, not elsewhere specified	\$	71.00
Antibody; bacterium, not elsewhere specified Antibody; bacterium, not elsewhere specified	\$	71.00
Antibody; bacterium, not elsewhere specified	\$	71.00
Antibody; bacterium, not elsewhere specified	\$	71.00
Antibody; bacterium, not elsewhere specified	\$	71.00
Antibody; bacterium, not elsewhere specified	\$	71.00
Antibody; bacterium, not elsewhere specified	Ś	71.00

DESCRIPTION	CHARGE
Antibody; bacterium, not elsewhere specified	\$ 71.00
Antibody; bacterium, not elsewhere specified	\$ 71.00
Antibody; bacterium, not elsewhere specified	\$ 71.00
Antibody; bacterium, not elsewhere specified	\$ 71.00
Antibody; bacterium, not elsewhere specified	\$ 71.00
Antibody; bacterium, not elsewhere specified	\$ 71.00
Antibody; bacterium, not elsewhere specified	\$ 71.00
Antibody; bacterium, not elsewhere specified	\$ 71.00
Antibody; bacterium, not elsewhere specified	\$ 71.00
Antibody; bacterium, not elsewhere specified	\$ 71.00
Antibody; bacterium, not elsewhere specified	\$ 66.00
Antibody; bacterium, not elsewhere specified	\$ 66.00
Antibody; bacterium, not elsewhere specified	\$ 66.00
Antibody; bacterium, not elsewhere specified	\$ 66.00
Antibody; bacterium, not elsewhere specified	\$ 66.00
Antibody; bacterium, not elsewhere specified	\$ 66.00
Antibody; bacterium, not elsewhere specified	\$ 66.00
Antibody; bacterium, not elsewhere specified	\$ 66.00
Antibody; bacterium, not elsewhere specified	\$ 66.00 66.00
Antibody; bacterium, not elsewhere specified	\$ 66.00
Antibody; bacterium, not elsewhere specified Antibody; bacterium, not elsewhere specified	\$ 66.00
Antibody; Bacterian, not elsewhere specified Antibody; Bartonella	\$ 35.00
Antibody; Bartonella	\$ 35.00
Antibody; Bartonella	\$ 35.00
Antibody; Bartonella	\$ 35.00
Antibody; Bartonella	\$ 89.00
Antibody; Blastomyces	\$ 27.00
Antibody; Blastomyces	\$ 25.00
Antibody; Blastomyces	\$ 25.00
Antibody; Blastomyces	\$ 152.00
Antibody; Bordetella	\$ 118.00
Antibody; Bordetella	\$ 118.00
Antibody; Bordetella	\$ 118.00
Antibody; Bordetella	\$
Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot)	\$
Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot)	\$
Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot)	\$ 1,023.00
Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot)	\$ 1,023.00
Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot)	\$ 39.00
Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot)	\$ 39.00
Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot)	\$
Antibody; Borrelia burgdorferi (Lyme disease) confirmatory test (eg, Western Blot or immunoblot)	\$
Antibody; Borrelia burgdorferi (Lyme disease)	\$
Antibody; Borrelia burgdorferi (Lyme disease)	\$
Antibody; Borrelia burgdorferi (Lyme disease)	\$
Antibody; Borrelia burgdorferi (Lyme disease)	\$
Antibody; Borrelia burgdorferi (Lyme disease) Antibody; Campylobacter	\$ 47.00 529.00
Antibody, Campyloacter Antibody; Chlamydia	\$
Antibody, Chlamydia Antibody; Chlamydia	\$
Antibody, Chlamydia Antibody; Chlamydia	\$
Antibody, Chlamydia Antibody; Chlamydia	\$ 50.00
Antibody; Chlamydia Antibody; Chlamydia	\$
Antibody; Chlamydia Antibody; Chlamydia	\$
Antibody; Chlamydia	\$
Antibody; Chlamydia	\$
Antibody; Chlamydia	\$
Antibody; Chlamydia	\$
Antibody; Chlamydia	\$

DESCRIPTION	CHARGE
Antibody; Chlamydia	\$ 5 269.00
Antibody; Chlamydia	\$ 5 150.00
Antibody; Chlamydia	\$ 28.00
Antibody; Chlamydia	\$ 28.00
Antibody; Chlamydia, IgM	\$
Antibody; Coccidioides	\$
Antibody; Coccidioides	\$
Antibody; Coxiella burnetii (Q fever)	\$
Antibody; Coxiella burnetii (Q fever)	\$
Antibody; Coxiella burnetii (Q fever)	\$
Antibody; Coxiella burnetii (Q fever) Antibody: Coxiella burnetii (Q fever)	\$
Antibody; Coxiella burnetii (Q fever) Antibody; Coxiella burnetii (Q fever)	\$
Antibody; Coxiella burnetii (Q fever) Antibody; Coxiella burnetii (Q fever)	\$
Antibody; Coxiella burnetii (Q fever)	\$
Antibody; Coxiella burnetii (Q fever)	\$
Antibody; Coxiella burnetii (Q fever)	\$
Antibody; Coxiella burnetii (Q fever)	\$
Antibody; Coxiella burnetii (Q fever)	\$
Antibody; cytomegalovirus (CMV)	\$
Antibody; cytomegalovirus (CMV), IgM	\$
Antibody; Diphtheria	\$
Analysis for antibody to La crosse (California) virus (encephalitis causing virus)	\$
Analysis for antibody to La crosse (California) virus (encephalitis causing virus)	\$ 250.00
Analysis for antibody to Eastern equine virus (viral encephalitis)	\$ 5 250.00
Analysis for antibody to Eastern equine virus (viral encephalitis)	\$ 250.00
Analysis for antibody to St. Louis virus (viral encephalitis)	\$ 250.00
Analysis for antibody to St. Louis virus (viral encephalitis)	\$ 250.00
Analysis for antibody to Western equine virus (viral encephalitis)	\$ 5 250.00
Analysis for antibody to Western equine virus (viral encephalitis)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg. coxsackie, echo, polio)	\$
Antibody; enterovirus (eg. coxsackie, echo, polio)	\$
Antibody; enterovirus (eg. coxsackie, echo, polio) Antibody: enterovirus (eg. coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio) Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio) Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio) Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio) Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio) Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; enterovirus (eg, coxsackie, echo, polio) Antibody; enterovirus (eg, coxsackie, echo, polio)	\$
Antibody; Enterovirus (eg. coxsackie, ecrio, polio) Antibody; Epstein-Barr (EB) virus, early antigen (EA)	\$
Antibody; Epstein-Barr (EB) virus, early antigen (EA) Antibody; Epstein-Barr (EB) virus, early antigen (EA)	\$

DESCRIPTION	CHARGE
Antibody; Epstein-Barr (EB) virus, nuclear antigen (EBNA)	\$ 203.00
Antibody; Epstein-Barr (EB) virus, viral capsid (VCA)	\$ 134.00
Antibody; Epstein-Barr (EB) virus, viral capsid (VCA)	\$ 134.00
Antibody; Ehrlichia	\$ 192.00
Antibody; Ehrlichia	\$ 192.00
Antibody; fungus, not elsewhere specified	\$ 44.00
Antibody; fungus, not elsewhere specified	\$ 44.00
Antibody; fungus, not elsewhere specified	\$ 175.00
Antibody; fungus, not elsewhere specified	\$ 175.00
Antibody; Giardia lamblia	\$
Antibody; Giardia lamblia	\$ 125.00
Antibody; Giardia lamblia	\$ 125.00
Antibody; Giardia lamblia	\$ 163.00
Antibody; Helicobacter pylori	\$ 88.00
Antibody; Helicobacter pylori Antibody: Helicobacter pylori	\$ 65.00
Antibody; Helicobacter pylori	\$ 65.00 65.00
Antibody; Helicobacter pylori Antibody; Helicobacter pylori	\$ 31.00
Antibody; Helicobacter pylori Antibody; Helicobacter pylori	\$ 31.00
Antibody; helminth, not elsewhere specified	\$ 199.00
Antibody; helminth, not elsewhere specified	\$ 311.00
Antibody; helminth, not elsewhere specified	\$
Antibody; helminth, not elsewhere specified	\$ 291.00
Antibody; helminth, not elsewhere specified	\$ 243.00
Antibody; Haemophilus influenza	\$ 134.00
Antibody; HTLV-I	\$ 139.00
Antibody; HTLV-I	\$ 34.00
Antibody; HTLV-II	\$ 176.00
Antibody; HTLV-II	\$ 42.00
Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)	\$ 261.00
Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)	\$ 79.00
Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)	\$ 287.00
Antibody; herpes simplex, non-specific type test	\$ 87.00
Antibody; herpes simplex, type 1	\$ 79.00
Antibody; herpes simplex, type 1	\$ 79.00
Antibody; herpes simplex, type 2	\$ 115.00
Antibody; herpes simplex, type 2	\$ 115.00
Antibody; herpes simplex, type 2	\$ 30.00
Antibody; histoplasma	\$ 30.00
Antibody; histoplasma	\$ 20.00
Antibody; histoplasma	\$ 152.00
Antibody; HIV-1	\$
Antibody; HIV-1	\$ 101.00
Antibody; HIV-2	\$
Antibody; HIV-2	\$ 118.00
Antibody; HIV-2 Antibody; HIV-1 and HIV-2, single result	\$ 119.00 134.00
Antibody; HIV-1 and HIV-2, single result Antibody; HIV-1 and HIV-2, single result	\$
Antibody; HIV-1 and HIV-2, single result Antibody; HIV-1 and HIV-2, single result	\$ 134.00
Antibody; HIV-1 and HIV-2, single result Antibody; HIV-1 and HIV-2, single result	\$ 134.00
Antibody; HIV-1 and HIV-2, single result	\$ 26.00
Antibody; HIV-1 and HIV-2, single result	\$ 54.00
Hepatitis B core antibody (HBcAb); total	\$ 135.00
Hepatitis B core antibody (HBcAb); total	\$ 41.00
Hepatitis B core antibody (HBcAb); total	\$ 23.00
Hepatitis B core antibody (HBcAb); total	\$ 48.00
Hepatitis B core antibody (HBcAb); IgM antibody	\$ 78.00
Hepatitis B core antibody (HBcAb); IgM antibody	\$ 40.00
Hepatitis B surface antibody (HBsAb)	\$ 130.00
Hepatitis B surface antibody (HBsAb)	\$ 32.00
Hepatitis B surface antibody (HBsAb)	\$ 36.00
Hepatitis Be antibody (HBeAb)	\$ 100.00
Hepatitis Be antibody (HBeAb)	\$ 39.00

DESCRIPTION		CHARGE
Hepatitis Be antibody (HBeAb)	\$	32.00
Hepatitis A antibody (HAAb)	\$	115.00
Hepatitis A antibody (HAAb)	\$	41.00
Hepatitis A antibody (HAAb), IgM antibody	\$	100.00
Hepatitis A antibody (HAAb), IgM antibody	\$	38.00
Antibody; influenza virus	\$	47.00
Antibody; influenza virus	\$	47.00
Antibody; Legionella	\$	46.00
Antibody; Legionella	\$	23.00
Antibody; Legionella	\$	
Antibody; Legionella	\$	23.00
Antibody; Legionella Antibody; Legionella	\$	80.00 80.00
Antibody; Legionena Antibody; Leptospira	\$	51.00
Antibody; numps	\$	
Antibody; mumps	\$	
Antibody; mumps	\$	
Antibody; mycoplasma	\$	42.00
Antibody; mycoplasma	\$	51.00
Antibody; Nocardia	\$	45.00
Antibody; parvovirus	\$	39.00
Antibody; parvovirus	\$	39.00
Antibody; protozoa, not elsewhere specified	\$	59.00
Antibody; protozoa, not elsewhere specified	\$	49.00
Antibody; Rickettsia	\$	30.00
Antibody; Rickettsia	\$	30.00
Antibody; Rickettsia	\$	47.00
Antibody; Rickettsia	\$	56.00
Antibody; Rickettsia	\$	56.00
Antibody; Rickettsia	\$	66.00
Antibody; Rickettsia	\$	66.00
Antibody; rubella	\$	
Antibody; rubella	\$	
Antibody; rubella	\$	
Antibody; rubella Antibody; rubeola	\$	
Antibody; rubeola	\$	
Antibody; tetanus	\$	76.00
Antibody; Toxoplasma	\$	
Antibody; Toxoplasma, IgM	\$	
Antibody; Treponema pallidum	\$	
Antibody; Treponema pallidum	\$	34.00
Antibody; Treponema pallidum	\$	32.00
Antibody; Trichinella	\$	196.00
Antibody; varicella-zoster	\$	
Antibody; varicella-zoster	\$	
Antibody; varicella-zoster	\$	52.00
Antibody; varicella-zoster	\$	75.00
Antibody; varicella-zoster	\$	75.00
Antibody; virus, not elsewhere specified	\$	
Antibody; virus, not elsewhere specified	\$	
Antibody; virus, not elsewhere specified	\$	50.00
Antibody; virus, not elsewhere specified	\$	1,402.00
Antibody; virus, not elsewhere specified	\$	70.00
Antibody; Zika virus, IgM	\$	
Thyroglobulin antibody	\$	
Thyroglobulin antibody	\$	
Hepatitis C antibody	\$	
Hepatitis C antibody	\$	
Hepatitis C antibody	\$	100.00

DESCRIPTION	CHARGE
Hepatitis C antibody	\$ 95
Hepatitis C antibody	\$ 47
Hepatitis C antibody	\$ 28
Hepatitis C antibody	\$ 57
Hepatitis C antibody; confirmatory test (eg, immunoblot)	\$ 267
Lymphocytotoxicity assay, visual crossmatch; with titration	\$ 1,218
Lymphocytotoxicity assay, visual crossmatch; with titration	\$ 1,218
Lymphocytotoxicity assay, visual crossmatch; with titration	\$ 3,309
Lymphocytotoxicity assay, visual crossmatch; with titration	\$ 3,309.
Lymphocytotoxicity assay, visual crossmatch; with titration	\$ 964
Lymphocytotoxicity assay, visual crossmatch; with titration	\$ 546
Lymphocytotoxicity assay, visual crossmatch; with titration	\$ 546
Lymphocytotoxicity assay, visual crossmatch; with titration	\$ 546
Lymphocytotoxicity assay, visual crossmatch; with titration	\$ 546
Lymphocytotoxicity assay, visual crossmatch; with titration	\$ 546
Serum screening for cytotoxic percent reactive antibody (PRA); standard method	\$ 853
Serum screening for cytotoxic percent reactive antibody (PRA); standard method	\$ 853
HLA typing; A, B, or C (eg, A10, B7, B27), single antigen	\$ 205 \$ 202
HLA typing; A, B, or C (eg, A10, B7, B27), single antigen	\$ 203.
HLA typing; A, B, or C (eg, A10, B7, B27), single antigen	\$ 488. \$ 75
HLA typing; A, B, or C (eg, A10, B7, B27), single antigen HLA typing; A, B, or C, multiple antigens	\$ 75 \$ 348
HLA typing; DR/DQ, single antigen Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (eg, using flow cytometry); first serum sample or dilution	\$ 885. \$ 5,720
Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (eg, using flow cytometry); first serum sample or dilution Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (eg, using flow cytometry); first serum sample or dilution	\$ 5,720 \$ 1,142
Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (eg, using flow cytometry); first serum sample or dilution Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (eg, using flow cytometry); first serum sample or dilution	\$ 1,142
Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (eg, using flow cytometry); first serum sample or dilution	\$ 1,149
Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (eg, using flow cytometry); first serum sample or dilution	\$ 1,467
Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (eg, using flow cytometry); each additional serum sample or sample dilution (List separately in	\$ 477
addition to primary procedure)	φ
Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (eg, using flow cytometry); each additional serum sample or sample dilution (List separately in	\$ 477
addition to primary procedure)	
Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (eg, using flow cytometry); each additional serum sample or sample dilution (List separately in	\$ 477.
addition to primary procedure)	
Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (eg, using flow cytometry); each additional serum sample or sample dilution (List separately in	\$ 477.
addition to primary procedure)	
Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (eg, using flow cytometry); each additional serum sample or sample dilution (List separately in	\$ 427
addition to primary procedure)	
Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (eg, using flow cytometry); each additional serum sample or sample dilution (List separately in	\$ 216
addition to primary procedure)	
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, flow cytometry); qualitative assessment of the presence or	\$ 1,990
absence of antibody(ies) to HLA Class I and Class II HLA antigens	
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); antibody identification by qualitative	\$ 494
panel using complete HLA phenotypes, HLA Class I	
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); antibody identification by qualitative	\$ 423
panel using complete HLA phenotypes, HLA Class II	4
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); high definition qualitative panel for	\$ 2,342.
identification of antibody specificities (eg, individual antigen per bead methodology), HLA Class I	<u> </u>
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); high definition qualitative panel for	\$ 982
identification of antibody specificities (eg, individual antigen per bead methodology), HLA Class I	ć C 001
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); high definition qualitative panel for identification of antibody specificities (eg, individual antigen per bead methodology), HLA Class I	\$ 6,881
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); high definition qualitative panel for	\$ 2,930
identification of antibody specificities (eg, individual antigen per bead methodology), HLA Class I	\$ 2,930
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); high definition qualitative panel for	\$ 1,889
identification of antibody specificities (eg, individual antigen per bead methodology), HLA Class II	, т,689
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); high definition qualitative panel for	\$ 870
identification of antibody specificities (eg, individual antigen per bead methodology), HLA Class II	- 370
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); high definition qualitative panel for	\$ 6,881
identification of antibody specificities (eg, individual antigen per bead methodology), HLA Class II	. 0,001
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); semi-quantitative panel (eg, titer), HLA	\$ 2,047
Class I	,
	4
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); semi-quantitative panel (eg, titer), HLA	\$ 2,047

DESCRIPTION		CHARGE
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); semi-quantitative panel (eg, titer), HLA	\$	1,850.00
Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); semi-quantitative panel (eg, titer), HLA Class II	\$	1,850.00
Unlisted immunology procedure	\$	251.00
Unlisted immunology procedure	\$	39.00
Antibody screen, RBC, each serum technique	\$	54.00
Antibody screen, RBC, each serum technique	\$	54.00
Antibody screen, RBC, each serum technique	\$	10.00
Antibody elution (RBC), each elution	\$	113.00
Antibody elution (RBC), each elution	\$	114.00
Antibody identification, RBC antibodies, each panel for each serum technique	\$	129.00
Antibody identification, RBC antibodies, each panel for each serum technique	\$	129.00
Antihuman globulin test (Coombs test); direct, each antiserum	\$	39.00
Antihuman globulin test (Coombs test); direct, each antiserum	\$	39.00
Antihuman globulin test (Coombs test); direct, each antiserum	\$	39.00
Antihuman globulin test (Coombs test); indirect, each antibody titer	\$	110.00
Antihuman globulin test (Coombs test); indirect, each antibody titer Antihuman globulin test (Coombs test); indirect, each antibody titer	\$ \$	111.00 111.00
Antihuman globulin test (Coombs test); indirect, each antibody titer	\$	111.00
Antihuman globulin test (Coombs test); indirect, each antibody titer	\$	111.00
Autologous blood or component, collection processing and storage; predeposited	\$	248.00
Blood typing, serologic; ABO	\$	31.00
Blood typing, serologic; ABO	\$	13.00
Blood typing, serologic; Rh (D)	\$	26.00
Blood typing, serologic; Rh (D)	\$	13.00
Blood typing, serologic; antigen testing of donor blood using reagent serum, each antigen test	\$	124.00
Blood typing, serologic; antigen testing of donor blood using reagent serum, each antigen test	\$	124.00
Blood typing, serologic; antigen testing of donor blood using reagent serum, each antigen test	\$	124.00
Blood typing, serologic; antigen testing of donor blood using reagent serum, each antigen test	\$	125.00
Blood typing, serologic; antigen testing of donor blood using reagent serum, each antigen test	\$	125.00
Blood typing, serologic; antigen testing of donor blood using reagent serum, each antigen test	\$	125.00
Blood typing, serologic; antigen testing of donor blood using reagent serum, each antigen test	\$	125.00
Blood typing, serologic; antigen testing of donor blood using reagent serum, each antigen test Blood typing, serologic; antigen testing of donor blood using reagent serum, each antigen test	\$ \$	125.00 125.00
Blood typing, serologic; antigen testing of donor blood using reagent serum, each antigen test	\$	125.00
Blood typing, serologic; RBC antigens, other than ABO or Rh (D), each	\$	49.00
Blood typing, serologic; RBC antigens, other than ABO or Rh (D), each	\$	80.00
Blood typing, serologic; RBC antigens, other than ABO or Rh (D), each	\$	49.00
Blood typing, serologic; Rh phenotyping, complete	\$	83.00
Compatibility test each unit; immediate spin technique	\$	70.00
Compatibility test each unit; antiglobulin technique	\$	80.00
Compatibility test each unit; electronic	\$	129.00
Fresh frozen plasma, thawing, each unit	\$	87.00
Fresh frozen plasma, thawing, each unit	\$	87.00
Frozen blood, each unit; thawing	\$	248.00
Frozen blood, each unit; thawing	\$	248.00
Hemolysins and agglutinins; auto, screen, each	\$	38.00
Irradiation of blood product, each unit	\$	65.00
Irradiation of blood product, each unit Volume reduction of blood or blood product (eg, red blood cells or platelets), each unit	\$ \$	66.00 131.00
Pooling of platelets or other blood products	\$	87.00
Pretreatment of serum for use in RBC antibody identification; by differential red cell absorption using patient RBCs or RBCs of known phenotype, each	\$	101.00
absorption	Ý	101.00
Pretreatment of serum for use in RBC antibody identification; by differential red cell absorption using patient RBCs or RBCs of known phenotype, each absorption	\$	101.00
Splitting of blood or blood products, each unit	\$	248.00
Unlisted transfusion medicine procedure	\$	167.00
Unlisted transfusion medicine procedure	\$	167.00
Concentration (any type), for infectious agents	\$	61.00
Concentration (any type), for infectious agents	\$	61.00
Concentration (any type), for infectious agents	\$	70.00
Concentration (any type), for infectious agents	\$	110.00

DESCRIPTION	CHARGE
Culture, bacterial; blood, aerobic, with isolation and presumptive identification of isolates (includes anaerobic culture, if appropriate)	\$ 103.00
Culture, bacterial; stool, aerobic, with isolation and preliminary examination (eg, KIA, LIA), Salmonella and Shigella species	\$ 155.00
Culture, bacterial; stool, aerobic, additional pathogens, isolation and presumptive identification of isolates, each plate	\$ 87.00
Culture, bacterial; stool, aerobic, additional pathogens, isolation and presumptive identification of isolates, each plate	\$ 87.00
Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates	\$ 79.00
Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates	\$ 79.00
Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates	\$ 79.00
Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates	\$ 79.00
Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates	\$ 79.00
Culture, bacterial; quantitative, aerobic with isolation and presumptive identification of isolates, any source except urine, blood or stool	\$ 153.00
Culture, bacterial; quantitative, aerobic with isolation and presumptive identification of isolates, any source except urine, blood or stool	\$ 83.00
Culture, bacterial; any source, except blood, anaerobic with isolation and presumptive identification of isolates	\$ 256.00
Culture, bacterial; any source, except blood, anaerobic with isolation and presumptive identification of isolates	\$ 259.00
Culture, bacterial; anaerobic isolate, additional methods required for definitive identification, each isolate	\$ 58.00
Culture, bacterial; anaerobic isolate, additional methods required for definitive identification, each isolate	\$ 58.00
Culture, bacterial; anaerobic isolate, additional methods required for definitive identification, each isolate Culture, bacterial; anaerobic isolate, additional methods required for definitive identification, each isolate	\$ 59.00 59.00
Culture, bacterial; anaerobic isolate, additional methods required for definitive identification, each isolate	\$ 58.00
Culture, bacterial; anaerobic isolate, additional methods required for definitive identification, each isolate	\$ 58.00
Culture, bacterial; anaerobic isolate, additional methods required for definitive identification, each isolate	\$ 58.00
Culture, bacterial, anaerobic isolate, additional methods required for definitive identification, each isolate	\$ 59.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 58.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 58.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 58.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 59.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 59.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 59.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 58.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 39.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 59.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 59.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 59.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 59.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 59.00
Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate	\$ 59.00
Culture, presumptive, pathogenic organisms, screening only	\$ 87.00
Culture, presumptive, pathogenic organisms, screening only	\$ 69.00
Culture, presumptive, pathogenic organisms, screening only	\$ 46.00
Culture, presumptive, pathogenic organisms, screening only	\$ 46.00
Culture, presumptive, pathogenic organisms, screening only	\$ 89.00
Culture, presumptive, pathogenic organisms, screening only	\$ 47.00
Culture, presumptive, pathogenic organisms, screening only	\$ 145.00
Culture, presumptive, pathogenic organisms, screening only	\$ 258.00
Culture, presumptive, pathogenic organisms, screening only	\$ 135.00
Culture, presumptive, pathogenic organisms, screening only	\$ 535.00
Culture, bacterial; quantitative colony count, urine	\$ 98.00
Culture, bacterial; with isolation and presumptive identification of each isolate, urine	\$ 51.00
Culture, bacterial; with isolation and presumptive identification of each isolate, urine	\$ 51.00
Culture, bacterial; with isolation and presumptive identification of each isolate, urine Culture, bacterial; with isolation and presumptive identification of each isolate, urine	\$ 51.00
Culture, bacterial; with isolation and presumptive identification of each isolate, unne	\$ 51.00 51.00
Culture, bacterial; with isolation and presumptive identification of each isolate, unine	\$ 51.00
Culture, bacterial; with isolation and presumptive identification of each isolate, urine	\$ 51.00
Culture, bacterial; with isolation and presumptive identification of each isolate, unine	\$ 51.00
Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; skin, hair, or nail	\$ 53.00
Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; skin, hair, or nail	\$ 53.00
Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; other source (except blood)	\$ 123.00
Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; other source (except blood)	\$ 123.00
Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; blood	\$ 83.00
Culture, fungi (mold or yeast) isolation, with presumptive identification of isolates; blood	\$ 53.00
Culture, fungi, definitive identification, each organism; yeast	\$ 94.00
Culture, fungi, definitive identification, each organism; yeast	\$ 95.00
Culture, fungi, definitive identification, each organism; yeast	\$ 95.00

DESCRIPTION	c	HARGE
Culture, fungi, definitive identification, each organism; yeast	\$	94.00
Culture, fungi, definitive identification, each organism; yeast	\$	94.00
Culture, fungi, definitive identification, each organism; yeast	\$	95.00
Culture, fungi, definitive identification, each organism; yeast	\$	95.00
Culture, fungi, definitive identification, each organism; mold	\$	63.00
Culture, fungi, definitive identification, each organism; mold	\$	63.00
Culture, fungi, definitive identification, each organism; mold	\$	63.00
Culture, mycoplasma, any source	\$	18.00
Culture, mycoplasma, any source	\$	338.00
Culture, mycoplasma, any source	\$	97.00
Culture, mycoplasma, any source	\$	66.00
Culture, chlamydia, any source Culture, tubercle or other acid-fast bacilli (eg, TB, AFB, mycobacteria) any source, with isolation and presumptive identification of isolates	\$	51.00 96.00
Culture, tubercle of other acid-fast bacilli (eg, TB, AFB, mycobacteria) any source, with isolation and presumptive identification of isolates	\$	66.00
Culture, typing; immunofluorescent method, each antiserum	\$	9.00
Culture, typing, immunofluorescent method, each antiserum	\$	28.00
Culture, typing, immunofluorescent method, each antiserum	\$	28.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum Culture, typing; immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00 31.00
Culture, typing, immunologic method, other than immunofluorescence (eg, agglutination grouping), per antiserum	\$	31.00
Culture, typing, identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed	\$	119.00
Culture, typing, identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed	\$	119.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed	\$	119.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	48.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00 49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing, identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing, identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	48.00
Culture, typing, identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing, identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00

DESCRIPTION	C	HARGE
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed	\$	49.00
Macroscopic examination; arthropod	\$	59.00
Macroscopic examination; arthropod	\$	122.00
Macroscopic examination; parasite	\$	44.00
Pinworm exam (eg, cellophane tape prep)	\$	68.00
Ova and parasites, direct smears, concentration and identification Ova and parasites, direct smears, concentration and identification	\$	53.00
	\$	39.00 28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip) Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip) Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip) Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	1	28.00
סטטכבירוטווירא אנטובא, מונוווונוטטומו מצבווג, מצמו טווטנוטו ווופנווטט, אפו מצפווג (פג, מונוטוטנוג צומטופוו גוווט)	\$	28.00

DESCRIPTION		CHARGE
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; agar dilution method, per agent (eg, antibiotic gradient strip)	\$	28.00
Susceptibility studies, antimicrobial agent; disk method, per plate (12 or fewer agents)	\$	41.00
Susceptibility studies, antimicrobial agent; disk method, per plate (12 or fewer agents)	\$	141.00
Susceptibility studies, antimicrobial agent; disk method, per plate (12 or fewer agents)	\$	42.00
Susceptibility studies, antimicrobial agent; disk method, per plate (12 of fewer agents)	\$	42.00
Susceptibility studies, antimicrobial agent; enzyme detection (eg, beta lactamase), per enzyme	\$	28.00
Susceptibility studies, antimicrobial agent; microdilution or agar dilution (minimum inhibitory concentration [MIC] or breakpoint), each multi-antimicrobial, per	\$	229.00
plate		
Susceptibility studies, antimicrobial agent; microdilution or agar dilution (minimum inhibitory concentration [MIC] or breakpoint), each multi-antimicrobial, per plate	\$	226.00
Susceptibility studies, antimicrobial agent; microdilution or agar dilution (minimum inhibitory concentration [MIC] or breakpoint), each multi-antimicrobial, per plate	\$	229.00
Susceptibility studies, antimicrobial agent; microdilution or agar dilution (minimum inhibitory concentration [MIC] or breakpoint), each multi-antimicrobial, per plate	\$	229.00
Susceptibility studies, antimicrobial agent; microdilution or agar dilution (minimum inhibitory concentration [MIC] or breakpoint), each multi-antimicrobial, per plate	\$	226.00
Susceptibility studies, antimicrobial agent; microdilution or agar dilution (minimum inhibitory concentration [MIC] or breakpoint), each multi-antimicrobial, per plate	\$	226.00
Susceptibility studies, antimicrobial agent; microdilution or agar dilution (minimum inhibitory concentration [MIC] or breakpoint), each multi-antimicrobial, per plate	\$	229.00
Smear, primary source with interpretation; Gram or Giemsa stain for bacteria, fungi, or cell types	\$	60.00
Smear, primary source with interpretation; Gram or Giemsa stain for bacteria, fungi, or cell types	\$	59.00
Smear, primary source with interpretation; Gram or Giemsa stain for bacteria, fungi, or cell types	\$	59.00
Smear, primary source with interpretation; Gram or Giemsa stain for bacteria, fungi, or cell types	\$	60.00
Smear, primary source with interpretation; fluorescent and/or acid fast stain for bacteria, fungi, prasites, viruses or cell types	\$	69.00
Smear, primary source with interpretation; fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types Smear, primary source with interpretation; fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types	\$	69.00
Smear, primary source with interpretation; fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types Smear, primary source with interpretation; fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types	\$	80.00
	1	70.00
Smear, primary source with interpretation; fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types	\$	
Smear, primary source with interpretation; fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types	\$	70.00
Smear, primary source with interpretation; special stain for inclusion bodies or parasites (eg, malaria, coccidia, microsporidia, trypanosomes, herpes viruses)	\$	80.00
Smear, primary source with interpretation; special stain for inclusion bodies or parasites (eg, malaria, coccidia, microsporidia, trypanosomes, herpes viruses)	\$	80.00
Smear, primary source with interpretation; special stain for inclusion bodies or parasites (eg, malaria, coccidia, microsporidia, trypanosomes, herpes viruses)	\$	265.00
Smear, primary source with interpretation; special stain for inclusion bodies or parasites (eg, malaria, coccidia, microsporidia, trypanosomes, herpes viruses)	\$	110.00
Smear, primary source with interpretation; complex special stain (eg, trichrome, iron hemotoxylin) for ova and parasites	\$	134.00
Smear, primary source with interpretation; complex special stain (eg, trichrome, iron hemotoxylin) for ova and parasites	\$	76.00
Smear, primary source with interpretation; wet mount for infectious agents (eg, saline, India ink, KOH preps)	\$	88.00
Smear, primary source with interpretation; wet mount for infectious agents (eg, saline, India ink, KOH preps)	\$	88.00
Smear, primary source with interpretation; wet mount for infectious agents (eg, saline, India ink, KOH preps)	\$	88.00
Smear, primary source with interpretation; wet mount for infectious agents (eg, saline, India ink, KOH preps)	\$	88.00
Tissue examination by KOH slide of samples from skin, hair, or nails for fungi or ectoparasite ova or mites (eg, scabies)	1	135.00
	\$	
Virus isolation; tissue culture inoculation, observation, and presumptive identification by cytopathic effect	\$ c	157.00
Virus isolation; tissue culture inoculation, observation, and presumptive identification by cytopathic effect Virus isolation; tissue culture, additional studies or definitive identification (eg, hemabsorption, neutralization, immunofluorescence stain), each isolate	\$ \$	51.00 122.00
Virus isolation; tissue culture, additional studies or definitive identification (eg, hemabsorption, neutralization, immunofluorescence stain), each isolate	\$	122.00
Virus isolation; tissue culture, additional studies or definitive identification (eg, hemabsorption, neutralization, immunofluorescence stain), each isolate	\$	122.00
Virus isolation; tissue culture, additional studies or definitive identification (eg, hemabsorption, neutralization, immunofluorescence stain), each isolate	\$	122.00
Virus isolation; tissue culture, additional studies or definitive identification (eg, hemabsorption, neutralization, immunofluorescence stain), each isolate	\$	51.00

DESCRIPTION	(CHARGE
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	118.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	116.00
Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with immunofluorescence stain, each virus	\$	264.00
Virus isolation; including identification by non-immunologic method, other than by cytopathic effect (eg, virus specific enzymatic activity)	\$	200.00
Infectious agent antigen detection by immunofluorescent technique; adenovirus	\$	67.00
Infectious agent antigen detection by immunofluorescent technique; influenza B virus	\$	67.00
Infectious agent antigen detection by immunofluorescent technique; influenza A virus	\$	67.00
Infectious agent antigen detection by immunofluorescent technique; Parainfluenza virus, each type	\$	67.00
Infectious agent antigen detection by immunofluorescent technique; Parainfluenza virus, each type	\$	67.00
Infectious agent antigen detection by immunofluorescent technique; Parainfluenza virus, each type	\$	67.00
Infectious agent antigen detection by immunofluorescent technique; Parainfluenza virus, each type	\$	67.00
Infectious agent antigen detection by immunofluorescent technique; respiratory syncytial virus	\$	67.00
Infectious agent antigen detection by immunofluorescent technique, polyvalent for multiple organisms, each polyvalent antiserum	\$	67.00
Infectious agent antigen detection by immunofluorescent technique, polyvalent for multiple organisms, each polyvalent antiserum	\$	67.00
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	389.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; Aspergillus	1	
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	402.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; Aspergillus		
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	136.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; Clostridium difficile toxin(s)	Lċ	02.00
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	83.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; cryptosporidium		02.00
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; cryptosporidium	\$	83.00
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	79.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; giardia	Ş	79.00
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	79.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; giardia	Ļ	79.00
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	353.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; Helicobacter pylori, stool	Ş	555.00
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	78.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg)	Ļ	78.00
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	78.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg)	ļ	70.00
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	34.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg)	Ŷ	51.00
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	25.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg)	Ŷ	20100
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	41.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg)	Ŷ	12100
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	95.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg) neutralization		
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	95.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg) neutralization		
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	105.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis Be antigen (HBeAg)		
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	39.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis Be antigen (HBeAg)		
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$	32.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis Be antigen (HBeAg)	1	

DESCRIPTION	CHARGE
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$ 136.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single	
result	
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$ 285.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; HIV-1	
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$ 101.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; respiratory syncytial virus	
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$ 67.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; respiratory syncytial virus	
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$ 66.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; rotavirus	
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$ 66.00
immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; rotavirus	
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$ 164.00
immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; multiple-step method, not otherwise specified, each organism	
Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],	\$ 521.00
immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; multiple-step method, not otherwise specified, each organism	
Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella quintana, amplified probe technique	\$ 878.00
Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, amplified probe technique	\$ 667.00
Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, amplified probe technique	\$ 853.00
Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, amplified probe technique	\$ 853.00
Infectious agent detection by nucleic acid (DNA or RNA); Borrelia burgdorferi, amplified probe technique	\$ 532.00
Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique	\$ 199.00
Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, amplified probe technique	\$ 208.00
Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, amplified probe technique	\$ 208.00
Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, amplified probe technique	\$ 489.00
Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, direct probe technique	\$ 29.00
Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique	\$ 268.00
Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique	\$ 97.00
Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique	\$ 82.00
Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique	\$ 49.00
Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique	\$ 201.00
Infectious agent detection by nucleic acid (DNA or RNA); Clostridium difficile, toxin gene(s), amplified probe technique	\$ 365.00
Infectious agent detection by nucleic acid (DNA or RNA); Clostridium difficile, toxin gene(s), amplified probe technique	\$ 369.00
Infectious agent detection by nucleic acid (DNA or RNA); Clostridium difficile, toxin gene(s), amplified probe technique	\$ 369.00
Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, quantification	\$ 321.00
Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, quantification	\$ 353.00
Infectious agent detection by nucleic acid (DNA or RNA); enterovirus, amplified probe technique, includes reverse transcription when performed	\$ 208.00
Infectious agent detection by nucleic acid (DNA or RNA); enterovirus, amplified probe technique, includes reverse transcription when performed	\$ 574.00
Infectious agent detection by nucleic acid (DNA or RNA); vancomycin resistance (eg, enterococcus species van A, van B), amplified probe technique	\$ 208.00
Infectious agent detection by nucleic acid (DNA or RNA); Gardnerella vaginalis, direct probe technique	\$ 199.00
Infectious agent detection by nucleic acid (DNA or RNA); hepatitis B virus, amplified probe technique	\$ 602.00
Infectious agent detection by nucleic acid (DNA or RNA); hepatitis B virus, quantification	\$ 521.00
Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed	\$ 538.00
Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed	\$ 538.00
Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed	\$ 512.00
Infectious agent detection by nucleic acid (DNA or RNA); Herpes simplex virus, amplified probe technique	\$ 262.00
Infectious agent detection by nucleic acid (DNA or RNA); Herpes simplex virus, amplified probe technique	\$ 262.00
Infectious agent detection by nucleic acid (DNA or RNA); Herpes simplex virus, amplified probe technique	\$ 836.00
Infectious agent detection by nucleic acid (DNA or RNA); Herpes simplex virus, amplified probe technique	\$ 262.00
Infectious agent detection by nucleic acid (DNA or RNA); Herpes simplex virus, amplified probe technique	\$ 262.00
Infectious agent detection by nucleic acid (DNA or RNA); Herpes simplex virus, quantification	\$ 194.00
Infectious agent detection by nucleic acid (DNA or RNA); Herpes virus-6, quantification	\$ 1,002.00
Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed	\$ 538.00
Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed	\$ 430.00
Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, amplified probe technique	\$ 745.00
Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, amplified probe technique	\$ 619.00
Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria tuberculosis, amplified probe technique	\$ 208.00
Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria tuberculosis, amplified probe technique	\$ 998.00
Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria tuberculosis, amplified probe technique	\$ 492.00
Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria tuberculosis, amplified probe technique	\$ 619.00
Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria avium-intracellulare, amplified probe technique	\$ 492.00
Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, amplified probe technique	\$ 208.00

DESCRIPTION		CHARGE
Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, amplified probe technique	\$	208.00
Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique	\$	268.00
Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique	\$	66.00
Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique	\$	82.00
Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique	\$	50.00
Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique	\$	201.00
Detection test for human papillomavirus (hpv)	\$	208.00
Detection test for human papillomavirus (hpv)	\$	140.00
Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed	\$	212.00
Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets	\$	770.00
Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets	\$	759.00
Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets	\$	2,469.00
Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets	\$	2,469.00
Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, amplified probe technique	\$	204.00
Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, methicillin resistant, amplified probe technique	\$	212.00
Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, methicillin resistant, amplified probe technique	\$	208.00
Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, methicillin resistant, amplified probe technique	\$	516.00
Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, direct probe technique	\$	120.00
Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group A, amplified probe technique	\$	208.00
Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group B, amplified probe technique	\$	208.00
Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, direct probe technique	\$	199.00
Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique	\$	198.00
Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique	\$	365.00
Infectious agent detection by nucleic acid (DNA or RNA); Zika virus, amplified probe technique	\$	348.00
Infectious agent detection by nucleic acid (DNA or RNA); Zika virus, amplified probe technique	\$	348.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	\$	531.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	\$	524.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	\$	524.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	\$	524.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	\$	208.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	\$	208.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	\$	446.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	\$	986.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	\$	414.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	\$	414.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	\$	1,057.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	\$	953.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism	\$	1,184.00
Infectious agent detection by nucleic acid (DNA of RNA), not otherwise specified; amplified probe technique, each organism	\$	
		137.00 940.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$	
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$ c	492.00
	\$	543.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$ ¢	529.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$	440.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$ c	529.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$	440.00
nfectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$ c	522.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$	529.00
nfectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$	482.00
nfectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$	570.0
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$	522.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$	522.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$	812.00
Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	\$	1,209.00
Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; direct probe(s) technique	\$	57.00

DESCRIPTION		CHARGE
Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique	\$	746.00
Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique	\$	423.00
Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique	\$	522.00
Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique	\$	1,096.00
Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique	\$	689.00
Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique	\$	689.00
Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique	\$	1,566.00
Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique	\$	1,566.00
Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique	\$	689.00
Infectious agent detection by nucleic acid (DNA or RNA), multiple organisms; amplified probe(s) technique	\$	275.00
Infectious agent antigen detection by immunoassay with direct optical observation; respiratory syncytial virus	\$	67.00
Infectious agent antigen detection by immunoassay with direct optical observation; respiratory syncytial virus	\$	203.00
Infectious agent antigen detection by immunoassay with direct optical observation; Streptococcus, group A	\$	67.00
Infectious agent antigen detection by immunoassay with direct optical observation; Streptococcus, group A	\$	66.00
Infectious agent antigen detection by immunoassay with direct optical observation; not otherwise specified	\$	45.00
Infectious agent antigen detection by immunoassay with direct optical observation; not otherwise specified	\$	45.00
Infectious agent antigen detection by immunoassay with direct optical observation; not otherwise specified	\$	87.00
Infectious agent antigen detection by immunoassay with direct optical observation; not otherwise specified	\$	82.00
Infectious agent antigen detection by immunoassay with direct optical observation; not otherwise specified	\$	82.00
Infectious agent antigen detection by immunoassay with direct optical observation; not otherwise specified	\$	96.00
Infectious agent drug susceptibility analysis	\$	658.00
Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions	\$	1,234.00
Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions	\$	1,298.00
Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus	\$	1,525.00
Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus	\$ \$	502.00 2,189.00
Analysis test for HIV-1 virus	\$	649.00
Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus	\$	1,056.00
Unlisted microbiology procedure	\$	53.00
Unlisted microbiology procedure	\$	45.00
Unlisted microbiology procedure	\$	93.00
Unlisted microbiology procedure	\$	79.00
Unlisted microbiology procedure	\$	116.00
Unlisted microbiology procedure	\$	82.00
Cytopathology, fluids, washings or brushings, except cervical or vaginal; smears with interpretation	\$	164.00
Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique)	\$	161.00
Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique)	\$	161.00
Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique)	\$	163.00
Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal	\$	412.00
Cytopathology, in situ hybridization (eg, FISH), urinary tract specimen with morphometric analysis, 3-5 molecular probes, each specimen; manual	\$	1,327.00
Cytopathology, in situ hybridization (eg, FISH), urinary tract specimen with morphometric analysis, 3-5 molecular probes, each specimen; manual	\$	1,118.00
Cytopathology, in situ hybridization (eg, FISH), urinary tract specimen with morphometric analysis, 3-5 molecular probes, each specimen; using computer-	\$	738.00
assisted technology Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician	l ć	118.00
supervision	\$	118.00
Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician	\$	117.00
supervision		
Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician	\$	117.00
supervision		
Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician	\$	117.00
supervision		
Pap test (Pap smear)	\$	82.00
Cytopathology, slides, cervical or vaginal, definitive hormonal evaluation (eg, maturation index, karyopyknotic index, estrogenic index) (List separately in	\$	38.00
addition to code[s] for other technical and interpretation services)	1 .	
Cytopathology, smears, any other source; screening and interpretation	\$	125.00
Cytopathology, smears, any other source; preparation, screening and interpretation	\$	82.00
Cytopathology, smears, any other source; preparation, screening and interpretation	\$	82.00
Cytopathology, smears, any other source; extended study involving over 5 slides and/or multiple stains	\$	157.00
Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision	\$	59.00
Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision	\$ c	59.00
Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site	\$	61.00
Cytopathology, evaluation of fine needle aspirate; interpretation and report	\$	161.00

DESCRIPTION	CHARGE
Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision	\$ 157.00
Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision	\$ 159.00
Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, each separate additional evaluation episode, same site (List separately in addition to code for primary procedure)	\$ 40.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker	\$ 149.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker	\$ 149.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker	\$ 122.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker	\$ 141.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker	\$ 183.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker	\$ 157.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker	\$ 3,042.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker	\$ 646.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker	\$ 149.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$ 115.00

DESCRIPTION	C	HARGE
low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.0
narker)	\$	115.0
narker)	Ş	115.0
low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$	115.0
low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.0
narker) Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.00
narker) Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.00
narker) Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.00
narker) Tow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.00
narker) Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.00
narker) -low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.00
narker)		
-low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first narker)	\$	115.00
low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first narker)	\$	115.00
-low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first narker)	\$	115.00
-low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$	115.00
low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.00
narker) Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	76.00
narker) How cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	76.00
narker) How cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	76.00
narker) low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	76.00
narker) low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	76.00
narker) Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	183.00
narker) Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	157.00
narker) low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	157.00
narker)		
low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first narker)	\$	157.00
-low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first narker)	\$	157.0
-low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first narker)	\$	157.00
low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$	157.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first narker)	\$	157.0
low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	157.0
narker) Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	3,042.0
narker) Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	3,042.0
narker) -low cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	3,042.0
narker)		

DESCRIPTION		CHARGE
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	3,042.00
marker)		2 0 4 2 0 0
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$	3,042.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	306.00
marker)		
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.00
marker)		
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)	\$	115.00
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.00
marker)	Ť	
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.00
marker)		
Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.00
marker) Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first	\$	115.00
marker)	ç	115.00
Flow cytometry, interpretation; 2 to 8 markers	\$	194.00
Flow cytometry, interpretation; 2 to 8 markers	\$	183.00
Flow cytometry, interpretation; 2 to 8 markers	\$	194.00
Flow cytometry, interpretation; 9 to 15 markers	\$	157.00
Tissue culture for non-neoplastic disorders; lymphocyte	\$	509.00
Tissue culture for non-neoplastic disorders; lymphocyte	\$	972.00
Tissue culture for non-neoplastic disorders; lymphocyte	\$	569.00
Tissue culture for non-neoplastic disorders; lymphocyte	\$	663.00
Tissue culture for non-neoplastic disorders; lymphocyte	\$	622.00
Tissue culture for non-neoplastic disorders; lymphocyte	\$	570.00
Tissue culture for non-neoplastic disorders; lymphocyte	\$	517.00
Tissue culture for non-neoplastic disorders; skin or other solid tissue biopsy	\$	700.00
Tissue culture for non-neoplastic disorders; skin or other solid tissue biopsy	\$	287.00
Tissue culture for non-neoplastic disorders; amniotic fluid or chorionic villus cells Tissue culture for non-neoplastic disorders; amniotic fluid or chorionic villus cells	\$	538.00
Tissue culture for non-neoplastic disorders; amniotic fluid or chorionic villus cells Tissue culture for non-neoplastic disorders; amniotic fluid or chorionic villus cells	\$ \$	471.00 721.00
Tissue culture for non-neoplastic disorders; amniotic fluid or chorionic villus cells	\$	550.00
Tissue culture for non-neoplastic disorders; anniotic fluid or chorionic villus cells	\$	880.00
Tissue culture for neoplastic disorders; bone marrow, blood cells	\$	537.00
Tissue culture for neoplastic disorders; bone marrow, blood cells	\$	595.00
Tissue culture for neoplastic disorders; bone marrow, blood cells	\$	436.00
Tissue culture for neoplastic disorders; bone marrow, blood cells	\$	1,336.00
Tissue culture for neoplastic disorders; bone marrow, blood cells	\$	1,343.00
Tissue culture for neoplastic disorders; bone marrow, blood cells	\$	554.00
Tissue culture for neoplastic disorders; bone marrow, blood cells	\$	705.00
Tissue culture for neoplastic disorders; solid tumor	\$	595.00
Tissue culture for neoplastic disorders; solid tumor	\$	999.00
Chromosome analysis for breakage syndromes; score 100 cells, clastogen stress (eg, diepoxybutane, mitomycin C, ionizing radiation, UV radiation)	\$	825.00
Chromosome analysis; count 15-20 cells, 2 karyotypes, with banding	\$	976.00
Chromosome analysis; count 15-20 cells, 2 karyotypes, with banding	\$	620.00
Chromosome analysis; count 15-20 cells, 2 karyotypes, with banding	\$	292.00
Chromosome analysis; count 15-20 cells, 2 karyotypes, with banding	\$	570.00
Chromosome analysis; count 45 cells for mosaicism, 2 karyotypes, with banding	\$	788.00
Chromosome analysis; analyze 20-25 cells	\$	503.00
Chromosome analysis; analyze 20-25 cells	\$	531.00
Chromosome analysis; analyze 20-25 cells	\$	503.00
Chromosome analysis; analyze 20-25 cells	\$ ¢	432.00
Chromosome analysis; analyze 20-25 cells Chromosome analysis ampiotic fluid or chorionic villus, count 15 colls, 1 kanyotype, with handing	\$	581.00
Chromosome analysis, amniotic fluid or chorionic villus, count 15 cells, 1 karyotype, with banding Chromosome analysis, in situ for amniotic fluid cells, count cells from 6-12 colonies, 1 karyotype, with banding	\$	885.00 609.00
Chromosome analysis, in situ for aminotic fluid cells, count cells from 6-12 colonies, 1 karyotype, with banding Chromosome analysis, in situ for aminotic fluid cells, count cells from 6-12 colonies, 1 karyotype, with banding	\$	534.00
Chromosome analysis, in situ for ammotic fluid cells, count cells from 6-12 colonies, 1 karyotype, with banding	\$	465.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$	163.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$	241.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$	175.00

DESCRIPTION	CHARGE
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 175.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 175.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	
Molecular cytogenetics; DNA probe, each (eg, FISH) Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH) Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 96.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 96.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 96.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 96.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 96.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 96.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 96.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 176.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 176.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 176.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 167.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 167.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 95.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 95.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 95.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 95.00
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$
Molecular cytogenetics; DNA probe, each (eg, FISH)	\$ 346.00

 Mencular optignantic, DNA proke ach (p., PSH) Metodal an optignatic, DNA proke ach (p., PSH) Metodal and optignatic, DNA pro	DESCRIPTION		CHARGE
 Metaclar orgogenetic, DNA proke, ach (kg. PSH) Metaclar orgogenetic, DNA proke, ach (kg. PSH) Metaclar orgogenetic, DNA proke, ach (kg. PSH) Station (kg. PSH)	Molecular cytogenetics; DNA probe, each (eg, FISH)		346.00
Molecular otypemetics; DNA probe, each (pr. PSH)9 46.0Molecular otypemetics; DNA probe, each (pr. PSH)5 15.0Molecular otypemetics; DNA probe, each (pr. PSH)5 12.0Molecular otypemetics; DNA probe, each (pr. PSH)5 12.0Molec	Molecular cytogenetics; DNA probe, each (eg, FISH)	\$	346.00
 Mencalar opgenetics: DNA probe ach (e., PSN) S1550 Melcolar opgenetics: DNA probe ach (e., PSN) S1550 Melcolar opgenetics: DNA probe ach (e., PSN) S1500 <	Molecular cytogenetics; DNA probe, each (eg, FISH)	\$	346.00
Modeular (ryopanetics; UM apobe. ach (eg. FIsH) \$ 257.0 <	Molecular cytogenetics; DNA probe, each (eg, FISH)	\$	346.00
Modecular orgometric, DNA puble, edit, Og, FBH) \$ 25.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 15.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 17.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 188.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 188.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 188.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 188.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 28.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 200.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 200.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 200.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 200.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 200.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 200.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 200.0 Modecular orgometric, DNA puble, edit, Og, FBH) \$ 200.0 Modecular o	Molecular cytogenetics; DNA probe, each (eg, FISH)		155.00
Modeclar (ryogenetics, DMA probe, edv. (eg., FBH) \$ 177.0	Molecular cytogenetics; DNA probe, each (eg, FISH)		155.00
Miceolar orgometics, DMA pobe, end (e.g., FIsh) \$ 177.0 \$ 187.0 <			267.00
Meteolar gragenetics (DA probe, exc) (eg. FBH)\$15.0Meteolar gragenetics (DA probe, exc) (eg. FBH)\$15.0Meteolar gragenetics (DA probe, exc) (eg. FBH)\$15.0Meteolar gragenetics (DA probe, exc) (eg. FBH)\$25.0Meteolar gragenetics (DA probe, exc) (eg. FBH)\$25.0Meteolar gragenetics (DA probe, exc) (eg. FBH)\$2000Meteolar gragenetics (DA probe, exc) (eg. FBH)\$2000Meteolar gragenetics (DA probe, exc) (eg. FBH)\$2000Meteolar gragenetics (DA probe, exc) (eg. FBH)\$3Meteolar gragenetics (DA probe, exc) (eg. FBH)\$3 <td></td> <td></td> <td>185.00</td>			185.00
Molecular cytogenetics DNA probe, each (eg. 158)\$188.0Molecular cytogenetics DNA probe, each (eg. 158)\$222.0Molecular cytogenetics DNA probe, each (eg. 158)\$220.0Molecular cytogenetics DNA probe, each (eg. 158)\$230.0Molecular cytogenetics DNA probe, each (eg. 158)\$240.0Molecular cytogenetics DNA probe, each (eg. 158)\$240.0Molecular cytogenetics DNA probe, each (eg. 158)\$140.0Molecular cytogenetics DNA probe, each (eg. 158) </td <td></td> <td>1</td> <td>177.00</td>		1	177.00
Meterslar organetics DMA probe, excl (eg. 158)\$15220Meterslar organetics DMA probe, excl (eg. 158)\$2220Meterslar organetics DMA probe, excl (eg. 158)\$2200Meterslar organetics DMA probe, excl (eg. 158)\$2000Meterslar organetics DMA pro			177.00
Möcelar (ryogenetics, DNA probe, each (eg., 158)\$222.0Möcelar (ryogenetics, DNA probe, each (eg., 158)\$200.0Möcelar (ryogenetics, DNA probe, each (eg., 158) </td <td></td> <td>1</td> <td>188.00</td>		1	188.00
Meckelar cytogenetics: DNA probe, exch (exg, FSH)\$ 125.0Meckelar cytogenetics: DNA probe, exch (exg, FSH)\$ 220.0Meckelar cytogenetics: DNA probe, exch (exg, FSH)\$ 130.0Meckelar cytogenetics: DNA probe, exch (exg, FSH)\$ 130.0Meckelar cytogenetics: DNA probe, exch (exg, FSH)\$ 130.0Meckelar cytogenetics: DNA probe, exch (exg, FSH)\$ 125.0Meckelar cytogenetics: DNA probe, exch (exg, FSH)\$ 126.0Meckelar cytogenetics: DNA probe, exch (exg, FSH)\$ 126.0Meckelar cytogenetics: DNA probe, exch (exg, FSH)\$ 146.0Meckelar cytogenetics: DNA probe, exch			188.00
Midecular cycogenetics; DNA probe, exch (eg., FISH)\$ 222.0Midecular cycogenetics; DNA probe, exch (eg., FISH)\$ 200.0Midecular cycogenetics; DNA probe, exch (eg., FISH)\$ 131.0Midecular cycogenetics; DNA probe, exch (eg., FISH)\$ 132.0Midecular cycogenetics; DNA probe, exch (eg., FISH)\$ 125.0Midecular cycogenetics; DNA probe, exch (eg., FISH)\$ 125.0Midecular cycogenetics; DNA probe, exch (eg., FISH)\$ 146.0Midecular cycogenetics; DNA probe, exch (eg., FISH)\$ 146.0 <td></td> <td></td> <td>222.00</td>			222.00
Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 220.0Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 320.0Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 280.0Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 280.0Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 280.0Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 191.0Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 195.0Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 195.0Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 195.0Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 2120.0Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 2120.0Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 146.0Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 224.0Milecular cytogenetics; DNA probe, each (eg., FBH)\$ 226.0Milecular cy	Molecular cytogenetics; DNA probe, each (eg, FISH)		185.00
Medeclary tytogenetics; DNA probe, each (e.g., FISH)S2000.Medeclary tytogenetics; DNA probe, each (e.g., FISH)S313.0Medeclary tytogenetics; DNA probe, each (e.g., FISH)S328.0Medeclary tytogenetics; DNA probe, each (e.g., FISH)S318.0Medeclary tytogenetics; DNA probe, each (e.g., FISH)S319.0Medeclary tytogenetics; DNA probe, each (e.g., FISH)S328.0Medeclary tytogenetics; DNA probe, each (e.g., FISH)S329.0Medeclary tytogenetics; DNA probe, each (e.g., FISH)S320.0Medeclary tytogenetics; DNA probe, each (e.g., FISH)S320.0Medeclary tytogenetics; DNA probe, each (e.g., FISH)S340.0Medeclary tytogenetics; DNA probe, each (e.g., FISH) <td>Molecular cytogenetics; DNA probe, each (eg, FISH)</td> <td></td> <td>267.00</td>	Molecular cytogenetics; DNA probe, each (eg, FISH)		267.00
Molecular cytogenetics DNA probe, each (e.g. FISH)\$2000Molecular cytogenetics DNA probe, each (e.g. FISH)\$312.0Molecular cytogenetics DNA probe, each (e.g. FISH)\$228.0Molecular cytogenetics DNA probe, each (e.g. FISH)\$313.0Molecular cytogenetics DNA probe, each (e.g. FISH)\$319.0Molecular cytogenetics DNA probe, each (e.g. FISH)\$319.0Molecular cytogenetics DNA probe, each (e.g. FISH)\$319.0Molecular cytogenetics DNA probe, each (e.g. FISH)\$310.0Molecular cytogenetics DNA probe, each (e.g. FISH)\$314.0Molecular cytogenetics DNA probe, each (e.g. FISH)\$314.0Molecul			212.00
Meecular cytogenetics; DNA probe, each (e.g., FISH)\$ 131.0Melecular cytogenetics; DNA probe, each (e.g., FISH)\$ 132.0Melecular cytogenetics; DNA probe, each (e.g., FISH)\$ 135.0Melecular cytogenetics; DNA probe, each (e.g., FISH)\$ 135.0Melecular cytogenetics; DNA probe, each (e.g., FISH)\$ 135.0Melecular cytogenetics; DNA probe, each (e.g., FISH)\$ 125.0Melecular cytogenetics; DNA probe, each (e.g., FISH)\$ 125.0Melecular cytogenetics; DNA probe, each (e.g., FISH)\$ 146.0Melecular cytogenetics; DNA probe, each (e.g., FISH)<			200.00
Meckular cytogenetics; DNA probe, each (e.g., FSH)\$323.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$333.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$353.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$223.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$223.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$223.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$243.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$146.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$224.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$224.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$23.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$23.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$23.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$3.00Molecular cytogenetics; DNA probe, each (e.g., FSH)\$<			200.00
Melecular cytogenetics; DNA probe, each (eg., FISH) \$ 238.0 318.0 Melecular cytogenetics; DNA probe, each (eg., FISH) \$ 139.0 319.0 Melecular cytogenetics; DNA probe, each (eg., FISH) \$ 219.0			131.00
Molecular optogenetics; DNA probe, each (eg., FISH) \$ 195.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 2150.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 2150.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 2150.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 1450.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 1450.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 1450.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 1450.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 1450.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 1450.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 1450.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 2240.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 2240.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 2250.0 Molecular optogenetics; DNA probe, each (eg., FISH) \$ 2250.0 Molecular optogenetics; DNA probe, each (eg., FISH)			131.00
Melecular cytogenetics: DNA probe, each (eg., FISH) \$ 195.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 2150.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 224.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 224.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 224.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 224.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 224.0 Molecular cytogenetics: DNA probe, each (eg., FISH) \$ 235.0			228.00
Melecular cytogenetics: DNA probe each (eg. FISH) \$ 195.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 219.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 146.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 224.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 224.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 224.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 224.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 224.0 Molecular cytogenetics: DNA probe, each (eg. FISH) \$ 224.0 Molecula			183.00
Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 2210.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 1460.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 1460.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 1460.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 1460.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 1460.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 1460.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 1460.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 1460.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 1460.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 2240.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 2240.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 2240.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 2240.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 2250.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 2250.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 310.0 Molecular cytogenetics; DNA probe, each (eg., FISH) \$ 330.0			195.00
Molecular cytogenetics; DNA probe, each (eg. FISH)S104000Molecular cytogenetics; DNA probe, each (eg. FISH)S146.0Molecular cytogenetics; DNA probe, each (eg. FISH)S224.0Molecular cytogenetics; DNA probe, each (eg. FISH)S224.0Molecular cytogenetics; DNA probe, each (eg. FISH)S224.0Molecular cytogenetics; DNA probe, each (eg. FISH)S225.00Molecular cytogenetics; DNA probe, each (eg. FISH)S311.0Molecular cytogenetics; DNA probe, each (eg. FISH)S313.0Molecular cytogenetics; DNA probe, each (eg. FISH)S313.0Molecular cytogenetics; DNA probe, each (eg. FISH)S310.0Molecular cytogenetics; Chromosomal in situ hybridization, analyze 10-30 cells (eg. for micro			195.00
Molecular cytogenetics; DNA probe, each (eg, FISH)S146.0Molecular cytogenetics; DNA probe, each (eg, FISH)S224.0Molecular cytogenetics; DNA probe, each (eg, FISH)S225.00Molecular cytogenetics; DNA probe, each (eg, FISH)S225.00Molecular cytogenetics; DNA probe, each (eg, FISH)S318.0Molecular cytogenetics; DNA probe, each (eg, FISH)S318.0Mole			219.00
Molecular cytogenetics; DNA probe, each (eg. FISH)\$146.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$311.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$313.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$313.0Mole			219.00
Molecular cytogenetics; DNA probe, each (eg., FISH)\$146.0Molecular cytogenetics; DNA probe, each (eg., FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg., FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg., FISH)\$214.0Molecular cytogenetics; DNA probe, each (eg., FISH)\$215.0Molecular cytogenetics; DNA probe, each (eg., FISH)\$318.10Molecular cytogenetics; DNA probe, each (eg., FISH)\$31		1	146.00
Molecular cytogenetics; DNA probe, each (eg., FISH)\$146.0Molecular cytogenetics; DNA probe, each (eg., FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg., FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg., FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg., FISH)\$216.0Molecular cytogenetics; DNA probe, each (eg., FISH)\$216.0Molecular cytogenetics; DNA probe, each (eg., FISH)\$216.0Molecular cytogenetics; DNA probe, each (eg., FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg., FISH)\$218.0Molecular cytogenetics; DNA probe, each (eg., FISH)\$311.0Molecular cytogenetics; Chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$318.0Molecular cytogenetics; Chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$350.0Molecular cytogenetics; interphase in situ hybridization, analyze			146.00
Molecular cytogenetics; DNA probe, each (eg. FISH)\$146.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$214.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$214.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$97.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$97.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$215.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$215.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$318.0Molecular cytogenetics; Chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$318.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$336.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$336.0Molecular cytogenetics; interphase in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$3		1	146.00
Molecular cytogenetics: DNA probe, each (eg. FISH)\$146.0Molecular cytogenetics: DNA probe, each (eg. FISH)\$146.0Molecular cytogenetics: DNA probe, each (eg. FISH)\$146.0Molecular cytogenetics: DNA probe, each (eg. FISH)\$224.0Molecular cytogenetics: DNA probe, each (eg. FISH)\$210.0Molecular cytogenetics: DNA probe, each (eg. FISH)\$210.0Molecular cytogenetics: DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics: DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics: DNA probe, each (eg. FISH)\$213.0Molecular cytogenetics: DNA probe, each (eg. FISH)\$214.0Molecular cytogenetics: DNA probe, each (eg. FISH)\$311.0Molecular cytogenetics: thromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$390.0Molecular cytogenetics: chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$390.0Molecular cytogenetics: thromosomal in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics: interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics: interphase in situ hybridization, analyze 25-99 cells\$265.0			146.00
Molecular cytogenetics; DNA probe, each (eg, FISH)\$146.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$146.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$214.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$90.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$90.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg, FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg, FISH)\$225.00Molecular cytogenetics; ChA probe, each (eg, FISH)\$318.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$318.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$396.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 2		1	
Molecular cytogenetics; DNA probe, each (eg. FISH)\$146.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$214.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$105.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$214.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$215.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$215.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$311.0Molecular cytogenetics; chromosonal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$311.0Molecular cytogenetics; chromosonal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$338.0Molecular cytogenetics; chromosonal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$338.0Molecular cytogenetics; chromosonal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$338.0Molecular cytogenetics; chromosonal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$336.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells<			
Molecular cytogenetics; DNA probe, each (eg. FISH)\$146.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$214.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$214.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$105.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$97.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$181.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$181.0Molecular cytogenetics; Chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$311.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$390.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$390.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$210.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells <td></td> <td>1</td> <td></td>		1	
Molecular cytogenetics; DNA probe, each (eg, FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$214.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$214.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$214.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg, FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg, FISH)\$311.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$311.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$311.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$311.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 25.99 cells\$398.0Molecular cytogenetics; interphase in situ hybridization, analyze 25.99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25.99 cells\$206.0Molecular cytogenetics; interphase in situ hybridization, analyze 25.99 cells\$206.0Molecular cytogenetics; interphase in situ hybridiz			
Molecular cytogenetics; DNA probe, each (eg. FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$210.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$105.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$311.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$311.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg. for microdeletions)\$390.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$210.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$210.0 <t< td=""><td></td><td>1</td><td></td></t<>		1	
Molecular cytogenetics; DNA probe, each (eg, FISH)\$224.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$105.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$105.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg, FISH)\$181.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$181.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$398.0Molecular cytogenetics; Charonsomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$396.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$210.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$210.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$210.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$275.0Molecular cytogenetics; interphase in situ hybridization, analyze			
Molecular cytogenetics; DNA probe, each (eg, FISH)\$214.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$105.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$97.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg, FISH)\$181.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$311.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$311.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$390.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$202.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$202.0Molecular cytogenetics; interphase in situ hybridization, analyze		1	
Molecular cytogenetics; DNA probe, each (eg. FISH)\$105.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg. FISH)\$181.0Molecular cytogenetics; DNA probe, each (eg. FISH)\$311.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 25-99 cells\$225.00Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$225.00Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$210.00Molecular cytogenetics; interphase in situ hybridization, analyze 10-300 cells\$210.00Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$210.00Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$210.00Molecular cytogenetics; inte			
Molecular cytogenetics; DNA probe, each (eg, FISH)\$97.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$225.00Molecular cytogenetics; DNA probe, each (eg, FISH)\$181.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$311.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$311.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; interphase in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$120.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$210.0Molecular cytogenetics; interphase in situ hybridization, analyze 10-300 cells\$795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 ce		1	
Molecular cytogenetics; DNA probe, each (eg, FISH)\$ 225.00Molecular cytogenetics; DNA probe, each (eg, FISH)\$ 225.00Molecular cytogenetics; DNA probe, each (eg, FISH)\$ 181.0Molecular cytogenetics; DNA probe, each (eg, FISH)\$ 311.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 381.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 390.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 396.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 200.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 075.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 075.0Mole			
Molecular cytogenetics; DNA probe, each (eg, FISH)\$225.00Molecular cytogenetics; ONA probe, each (eg, FISH)\$181.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$311.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; interphase in situ hybridization, analyze 20-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$200.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$200.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytoge			
Molecular cytogenetics; DNA probe, each (eg, FISH)\$181.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$331.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$390.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$200.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$200.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0 </td <td></td> <td></td> <td></td>			
Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 311.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 485.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 398.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0<		1	
Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 465.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 398.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$			
Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$465.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$398.0Molecular cytogenetics; interphase in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$390.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$200.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$200.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$200.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytog		1	
Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 398.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 336.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 390.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 705.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, a			
Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 336.0Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 390.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 120.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 120.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 120.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 120.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cel		1	
Molecular cytogenetics; chromosomal in situ hybridization, analyze 10-30 cells (eg, for microdeletions)\$ 390.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 120.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 120.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0 <td></td> <td></td> <td></td>			
Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$120.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$120.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$120.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$585.0 <td></td> <td>1</td> <td></td>		1	
Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$120.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$120.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$120.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$585.0<			
Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$265.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$120.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$120.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$120.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$507.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$507.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$507.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$553.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$553.			
Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 120.0Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 120.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 553.0			
Molecular cytogenetics; interphase in situ hybridization, analyze 25-99 cells\$ 120.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 553.0		1	
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 553.0			
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$553.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$553.0		1	
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 795.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 553.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 553.0			
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 553.0		1	
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 607.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$ 553.0			
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$585.0Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells\$\$553.0		1	
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells \$ 553.0			
		1	
	Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$ \$	553.00

DESCRIPTION		CHARGE
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	314.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	314.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	314.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	314.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	980.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	569.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	429.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	560.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	557.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	1,109.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	1,109.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	1,109.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	892.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	619.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	563.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	601.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	744.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	622.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	892.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	704.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	638.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	432.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	767.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	609.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	711.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	711.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	520.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	520.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	520.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	520.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	792.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	792.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	792.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	712.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	314.00
Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells	\$	734.00
Chromosome analysis; additional karyotypes, each study	\$	93.00
Chromosome analysis; additional karyotypes, each study	\$	101.00
Chromosome analysis; additional karyotypes, each study	\$	101.00
Chromosome analysis; additional karyotypes, each study	\$	100.00
Chromosome analysis; additional karyotypes, each study	\$	130.00
Chromosome analysis; additional karyotypes, each study	\$	87.00
Chromosome analysis; additional high resolution study	\$	146.00
Cytogenetics and molecular cytogenetics	\$	74.00
Cytogenetics and molecular cytogenetics	\$	281.00
Cytogenetics and molecular cytogenetics	\$	407.00
Level I - Surgical pathology, gross examination only	\$	58.00
Level II - Surgical pathology, gross and microscopic examination Appendix, incidental Fallopian tube, sterilization Fingers/toes, amputation, traumatic Foreskin,	\$	147.00
newborn Hernia sac, any location Hydrocele sac Nerve Skin, plastic repair Sympathetic ganglion Testis, castration Vaginal mucosa, incidental Vas deferens,		
sterilization	1	
Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than	\$	235.00
incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologic fracture Bursa/synovial cyst Carpal tunnel tissue		
Cartilage, shavings Cholesteatoma Colon, colostomy stoma Conjunctiva - biopsy/pterygium Cornea Diverticulum - esophagus/small intestine Dupuytren's		
contracture tissue Femoral head, other than fracture Fissure/fistula Foreskin, other than newborn Gallbladder Ganglion cyst Hematoma Hemorrhoids Hydatid		
of Morgagni Intervertebral disc Joint, loose body Meniscus Mucocele, salivary Neuroma - Morton's/traumatic Pilonidal cyst/sinus Polyps, inflammatory - nasal/sinusoidal Skin - cyst/tag/debridement Soft tissue, debridement Soft tissue, lipoma Spermatocele Tendon/tendon sheath Testicular appendage Thrombu	_	
	2	
or embolus Tonsil and/or adenoids Varicocele Vas deferens, other than sterilization Vein, varicosity		

DESCRIPTION		CHARGE
Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgical margins Breast, reduction mammoplasty Bronchus, biopsy Cell block, any source Cervix, biopsy Colon, biopsy Duodenum, biopsy Endocervix, curettings/biopsy Endometrium, curettings/biopsy Esophagus, biopsy Extremity, amputation, traumatic Fallopian tube, biopsy Fallopian tube, ectopic pregnancy Femoral head, fracture Fingers/toes, amputation, non-traumatic Gingiva/oral mucosa, biopsy Heart valve Joint, resection Kidney, biopsy Larynx, biopsy Leiomyoma(s), uterine myomectomy - without uterus Lip, biopsy/wedge resection Lung, transbronchial biopsy Lymph node, biopsy Muscle, biopsy Nasal mucosa, biopsy Nasopharynx/oropharynx, biopsy Nerve, biopsy Odontogenic/dental cyst Omentum, biopsy Ovary with or without tube, non-neoplastic Ovary, biopsy/wedge resection Parathyroid gland Peritoneum, biopsy Pituitary tumor Placenta, other than third trimester Pleura/pericardium - biopsy/tissue Polyp, cervical/endometrial Polyp, colorectal Polyp, stomach/small intestine Prostate, needle biopsy Prostate, TUR Salivary gland, biopsy Sinus, paranasal biopsy Sinu, other than cyst/tag/debridement/plastic repair Small intestine, biopsy Soft tissue, other than tumor/mass/lipoma/debridement Spleen Stomach, biopsy Synovium Testis, other than tumor/biopsy/castration Thyroglossal duct/brachial cleft cyst Tongue, biopsy Tonsil, biopsy Trachea, biopsy Ureter, biopsy Urethra, biopsy Urinary bladder, biopsy Uterus, with or without tubes and ovaries, for prolapse Vagina, biopsy Vulva/labia, biopsy	\$	248.00
Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgical margins Breast, reduction mammoplasty Bronchus, biopsy Cell block, any source Cervix, biopsy Colon, biopsy Duodenum, biopsy Endocervix, curettings/biopsy Endometrium, curettings/biopsy Esophagus, biopsy Extremity, amputation, traumatic Fallopian tube, biopsy Fallopian tube, ectopic pregnancy Femoral head, fracture Fingers/toes, amputation, non-traumatic Gingiva/oral mucosa, biopsy Heart valve Joint, resection Kidney, biopsy Larynx, biopsy Leiomyoma(s), uterine myomectomy - without uterus Lip, biopsy/wedge resection Lung, transbronchial biopsy Lymph node, biopsy Muscle, biopsy Nasal mucosa, biopsy Nasopharynx/oropharynx, biopsy Nerve, biopsy Odontogenic/dental cyst Omentum, biopsy Ovary with or without tube, non-neoplastic Ovary, biopsy/wedge resection Parathyroid gland Peritoneum, biopsy Pituitary tumor Placenta, other than third trimester Pleura/pericardium - biopsy/tissue Polyp, cervical/endometrial Polyp, colorectal Polyp, stomach/small intestine Prostate, needle biopsy Prostate, TUR Salivary gland, biopsy Sinus, paranasal biopsy Skin, other than cyst/tag/debridement/plastic repair Small intestine, biopsy Soft tissue, other than tumor/mass/lipoma/debridement Spleen Stomach, biopsy Synovium Testis, other than tumor/biopsy/castration Thyroglossal duct/brachial cleft cyst Tongue, biopsy Tonsil, biopsy Trachea, biopsy Ureter, biopsy Urethra, biopsy Urinary bladder, biopsy Uterus, with or without tubes and ovaries, for prolapse Vagina, biopsy Vulva/labia, biopsy	\$	251.00
Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgical margins Breast, reduction mammoplasty Bronchus, biopsy Cell block, any source Cervix, biopsy Colon, biopsy Duodenum, biopsy Endocervix, curettings/biopsy Endometrium, curettings/biopsy Esophagus, biopsy Extremity, amputation, traumatic Fallopian tube, biopsy Fallopian tube, ectopic pregnancy Femoral head, fracture Fingers/toes, amputation, non-traumatic Gingiva/oral mucosa, biopsy Heart valve Joint, resection Kidney, biopsy Larynx, biopsy Leiomyoma(s), uterine myomectomy - without uterus Lip, biopsy/wedge resection Lung, transbronchial biopsy Lymph node, biopsy Muscle, biopsy Nasal mucosa, biopsy Nasopharynx/oropharynx, biopsy Nerve, biopsy Odontogenic/dental cyst Omentum, biopsy Ovary with or without tube, non-neoplastic Ovary, biopsy/wedge resection Parathyroid gland Peritoneum, biopsy Pituitary tumor Placenta, other than third trimester Pleura/pericardium - biopsy/tissue Polyp, cervical/endometrial Polyp, colorectal Polyp, stomach/small intestine, biopsy Soft tissue, other than tumor/mass/lipoma/debridement Spleen Stomach, biopsy Synovium Testis, other than tumor/biopsy/castration Thyroglossal duct/brachial cleft cyst Tongue, biopsy Tonsil, biopsy Trachea, biopsy Ureter, biopsy Urethra, biopsy Urinary bladder, biopsy Uterus, with or without tubes and ovaries, for prolapse Vagina, biopsy Vulva/labia, biopsy	\$	248.00
Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of surgical margins Breast, mastectomy - partial/simple Cervix, conization Colon, segmental resection, other than for tumor Extremity, amputation, non-traumatic Eye, enucleation Kidney, partial/total nephrectomy Larynx, partial/total resection Liver, biopsy - needle/wedge Liver, partial resection Lung, wedge biopsy Lymph nodes, regional resection Mediastinum, mass Myocardium, biopsy Odontogenic tumor Ovary with or without tube, neoplastic Pancreas, biopsy Placenta, third trimester Prostate, except radical resection Salivary gland Sentinel lymph node Small intestine, resection, other than for tumor Soft tissue mass (except lipoma) - biopsy/simple excision Stomach - subtotal/total resection, other than for tumor Testis, biopsy Thymus, tumor Thyroid, total/lobe Ureter, resection Urinary bladder, TUR Uterus, with or without tubes and ovaries, other than neoplastic/prolapse	\$	380.00
Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of surgical margins Breast, mastectomy - partial/simple Cervix, conization Colon, segmental resection, other than for tumor Extremity, amputation, non-traumatic Eye, enucleation Kidney, partial/total nephrectomy Larynx, partial/total resection Liver, biopsy - needle/wedge Liver, partial resection Lung, wedge biopsy Lymph nodes, regional resection Mediastinum, mass Myocardium, biopsy Odontogenic tumor Ovary with or without tube, neoplastic Pancreas, biopsy Placenta, third trimester Prostate, except radical resection Salivary gland Sentinel lymph node Small intestine, resection, other than for tumor Soft tissue mass (except lipoma) - biopsy/simple excision Stomach - subtotal/total resection, other than for tumor Testis, biopsy Thymus, tumor Thyroid, total/lobe Ureter, resection Urinary bladder, TUR Uterus, with or without tubes and ovaries, other than neoplastic/prolapse	\$	385.00
Level VI - Surgical pathology, gross and microscopic examination Bone resection Breast, mastectomy - with regional lymph nodes Colon, segmental resection for tumor Colon, total resection Esophagus, partial/total resection Extremity, disarticulation Fetus, with dissection Larynx, partial/total resection - with regional lymph nodes Lung - total/lobe/segment resection Pancreas, total/subtotal resection Prostate, radical resection Small intestine, resection for tumor Soft tissue tumor, extensive resection Stomach - subtotal/total resection for tumor Testis, tumor Tongue/tonsil -resection for tumor Urinary bladder, partial/total resection Uterus, with or without tubes and ovaries, neoplastic Vulva, total/subtotal resection	\$	380.00
Decalcification procedure (List separately in addition to code for surgical pathology examination)	\$	249.00
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver) Special stain including interpretation and report; Group II all other (eg, icon, trichromo), except stain for microorganisms, stains for enzyme constituents, or	\$ ¢	226.00
Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry	\$	94.00

DESCRIPTION		CHARGE
Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or	\$	94.00
immunocytochemistry and immunohistochemistry		207.00
Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry	\$	307.00
Special stain including interpretation and report; histochemical stain on frozen tissue block (List separately in addition to code for primary procedure)	\$	131.00
Special stain including interpretation and report; Group III, for enzyme constituents	\$	73.00
Special stain including interpretation and report; Group III, for enzyme constituents	\$	73.00
Consultation and report on referred slides prepared elsewhere	\$	903.00
Consultation and report on referred material requiring preparation of slides	\$	581.00
Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen	\$	157.00
Pathology consultation during surgery; each additional tissue block with frozen section(s) (List separately in addition to code for primary procedure)	\$	117.00
Pathology consultation during surgery; cytologic examination (eg, touch prep, squash prep), initial site	\$	62.00
Pathology consultation during surgery; cytologic examination (eg, touch prep, squash prep), each additional site (List separately in addition to code for primary procedure)	\$	63.00
Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary	\$	246.00
procedure)		
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure	\$	226.00
Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure	\$	447.00
Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure	\$	246.00
Immunofluorescence, per specimen; initial single antibody stain procedure	\$ ¢	439.00
Immunofluorescence, per specimen; initial single antibody stain procedure Immunofluorescence, per specimen; initial single antibody stain procedure	\$ \$	141.00 588.00
	1	588.00
Immunofluorescence, per specimen; initial single antibody stain procedure Electron microscopy, diagnostic	\$ \$	1,539.00
Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)	\$	445.00
Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)	\$	141.00
Morphometric analysis; tumor (eg, DNA ploidy)	\$	654.00
Morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per	\$	170.00
specimen, each single antibody stain procedure; manual Morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure; using computer-assisted technology	\$	279.00
Morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure; using computer-assisted technology	\$	1,178.00
Morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per	\$	622.00
specimen, each single antibody stain procedure; using computer-assisted technology In situ hybridization (eg, FISH), per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)	\$	275.00
In situ hybridization (eg, FISH), per specimen; initial single probe stain procedure	\$	398.00
In situ hybridization (eg, FISH), per specimen; each multiplex probe stain procedure	Ś	434.00
Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), using computer-assisted technology, per specimen; initial single probe stain procedure	\$	40.00
Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; initial single probe stain procedure	\$	275.00
Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; initial single probe stain procedure	\$	279.00
Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; initial single probe stain procedure	\$	279.00
Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; initial single probe stain procedure	\$	279.00
Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; initial single probe stain procedure	\$	1,151.00
Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; initial single probe stain procedure	\$	536.00
Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; initial single probe stain procedure Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; each additional single probe stain procedure (List	\$ \$	536.00 791.00
separately in addition to code for primary procedure) Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; each additional single probe stain procedure (List	\$	791.00
separately in addition to code for primary procedure) Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; each additional single probe stain procedure (List	\$	791.00
separately in addition to code for primary procedure)		
Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), using computer-assisted technology, per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)	\$	791.00
Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), using computer-assisted technology, per specimen; each multiplex probe stain procedure	\$	781.00
Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; each multiplex probe stain procedure	\$	781.00
Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; each multiplex processian procedure	\$	781.00
Morphometric analysis, in situ hybridization (quantitative or semi-quantitative), manual, per specimen; each multiplex probe stain procedure	\$	791.00
Unlisted surgical pathology procedure		OPEN

DESCRIPTION		CHARGE
Bilirubin, total, transcutaneous	\$	29.0
Cell count, miscellaneous body fluids (eg, cerebrospinal fluid, joint fluid), except blood	\$	69.0
Cell count, miscellaneous body fluids (eg, cerebrospinal fluid, joint fluid), except blood	\$	41.00
Cell count, miscellaneous body fluids (eg, cerebrospinal fluid, joint fluid), except blood; with differential count	\$	134.0
Cell count, miscellaneous body fluids (eg, cerebrospinal fluid, joint fluid), except blood; with differential count	\$	31.0
Leukocyte assessment, fecal, qualitative or semiquantitative	\$	118.0
Crystal identification by light microscopy with or without polarizing lens analysis, tissue or any body fluid (except urine)	\$	44.0
Crystal identification by light microscopy with or without polarizing lens analysis, tissue or any body fluid (except urine)	\$	59.0
Nasal smear for eosinophils	\$	45.0
Nasal smear for eosinophils	\$	45.0
Sweat collection by iontophoresis	\$	144.00
Sweat collection by iontophoresis	, \$	144.0
Semen analysis; sperm presence and motility of sperm, if performed	\$	146.0
Botulism immune globulin, human, for intravenous use	Ŷ	OPEN
Rabies immune globulin (RIg), human, for intramuscular and/or subcutaneous use		OPEN
Rabies immune globulin (Rig), human, for intramuscular and/or subcutaneous use		OPEN
		OPEN
Rabies immune globulin, heat-treated (RIg-HT), human, for intramuscular and/or subcutaneous use		
Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each		OPEN
Varicella-zoster immune globulin, human, for intramuscular use	ć	OPEN 180.0
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)	\$	180.0
mmunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)	\$	132.00
mmunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)	\$	132.0
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)	\$	132.0
mmunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)	\$	180.0
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)	\$	132.00
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)	\$	132.0
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)	\$	132.0
Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB), 2 dose schedule, for intramuscular use		OPEN
Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB), 3 dose schedule, for intramuscular use		OPEN
Hepatitis A vaccine (HepA), adult dosage, for intramuscular use	\$	182.00
Hepatitis A vaccine (HepA), adult dosage, for intramuscular use	Ŷ	OPEN
Hepatitis A vaccine (HepA), adult dosage, for intramuscular use		OPEN
Hepatitis A vaccine (HepA), adult dosage, for intranuscular use		OPEN
Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use		
		OPEN
Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use	ć	OPEN TO O
Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use	\$	70.00
Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use		OPEN
Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use	\$	62.00
Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use		OPEN
Human Papillomavirus vaccine, types 6, 11, 16, 18, quadrivalent (4vHPV), 3 dose schedule, for intramuscular use		OPEN
influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use		OPEN
Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use		OPEN
Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use	\$	35.0
influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use		OPEN
Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use		OPEN
nfluenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$	35.0
nfluenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$	35.0
nfluenza virus vaccine, trivalent (ccllV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$	35.0
nfluenza virus vaccine, trivalent (ccllV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use		OPEN
nfluenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$	35.0
nfluenza virus vaccine, trivalent (ccllV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$ \$	35.0
	\$	35.0
Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$	35.0

DESCRIPTION	CHARGE
Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use	\$ 50.00
Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use	\$ 50.00
Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use	\$ 50.00
Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use	\$ 50.00
Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use	\$ 50.00
Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use	\$ 50.00
Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use	\$ 50.00
Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use	\$ 237.08
Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use	OPEN
Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	\$ 35.00
Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	\$ 35.00
Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	\$ 35.00
Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	OPEN
Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	\$ 35.00
Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	\$ 35.00
Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	\$ 35.00
Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	\$ 35.00
Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use	\$ 50.00
Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use	\$ 50.00
Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use	\$ 50.00
Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular	\$ 50.00
use Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular	\$ 50.00
use Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular	\$ 50.00
use Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular	\$ 50.00
use Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular	\$ 50.00
use	
Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use	\$ 50.00
Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$ 35.00
Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$ 35.00
Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$ 35.00
Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$ 35.00
Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	OPEN
Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$ 35.00
Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$ 35.00
Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$ 35.00
Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	\$ 35.00
Rabies vaccine, for intramuscular use	OPEN
Rabies vaccine, for intramuscular use	OPEN
Rabies vaccine, for intramuscular use	OPEN
Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	OPEN
Influenza virus vaccine, guadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use	\$ 50.00
Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for	\$ 50.00
intramuscular use Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for	\$ 50.00
intramuscular use	

DESCRIPTION		CHARGE
Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for	\$	50.00
intramuscular use		
Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use		OPEN
Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use	\$	50.00
Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use	\$	50.00
Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for	\$	50.00
intramuscular use Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use	\$ \$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use		OPEN
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	\$	35.00
Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use		OPEN
Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	\$	35.00
Typhoid vaccine, Vi capsular polysaccharide (ViCPs), for intramuscular use		OPEN
Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular		OPEN
use		
Vaccine for diphtheria, tetanus, and acellular pertussis (whooping cough) injection into muscle, child younger than 7 years	\$	81.00
Vaccine for diphtheria, tetanus, and acellular pertussis (whooping cough) injection into muscle, child younger than 7 years	\$	81.00
Vaccine for diphtheria, tetanus, and acellular pertussis (whooping cough) injection into muscle, child younger than 7 years		OPEN
Vaccine for diphtheria, tetanus, and acellular pertussis (whooping cough) injection into muscle, child younger than 7 years		OPEN
Vaccine for diphtheria, tetanus, and acellular pertussis (whooping cough) injection into muscle, child younger than 7 years	ć	OPEN 120.00
Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use	\$	139.00 OPEN
Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use	\$	
Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use	Ş	190.00 OPEN
Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use		OPEN
Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use	\$	77.00
Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use	Ļ	OPEN
Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use		OPEN
Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use		OPEN
Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use	\$	88.00
Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use	\$	101.00
Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use	Ŧ	OPEN
Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use		OPEN
Varicella virus vaccine (VAR), live, for subcutaneous use		OPEN
Varicella virus vaccine (VAR), live, for subcutaneous use		OPEN
Yellow fever vaccine, live, for subcutaneous use		OPEN
Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use		OPEN
Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use		OPEN
Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for		OPEN
subcutaneous or intramuscular use		OPEN
subcutaneous or intramuscular use Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for		l. I
subcutaneous or intramuscular use	\$	253.00

DESCRIPTION	CHARGE
Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MCV4 or MenACWY), for intramuscular use	OPEN
Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MCV4 or MenACWY), for intramuscular use	OPEN
Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MCV4 or MenACWY), for intramuscular use	\$ 312.0
Zoster (shingles) vaccine (HZV), live, for subcutaneous injection	OPEN
Zoster (shingles) vaccine (HZV), live, for subcutaneous injection	OPEN
Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use	OPEN
Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use	OPEN
Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use	\$ 167.0
Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use	OPEN
Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use	OPEN
Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use	OPEN
Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use	OPEN
Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use	\$ 153.0
Unlisted vaccine/toxoid	\$ 139.0
Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use	\$ 375.0
Unlisted dialysis procedure, inpatient or outpatient	\$ 1,001.0
Esophageal motility (manometric study of the esophagus and/or gastroesophageal junction) study with interpretation and report; with stimulation or perfusion (eg, stimulant, acid or alkali perfusion) (List separately in addition to code for primary procedure)	\$ 1,144.0
Esophagus, gastroesophageal reflux test; with nasal catheter pH electrode(s) placement, recording, analysis and interpretation	\$ 1,329.0
Esophagus, gastroesophageal reflux test; with mucosal attached telemetry pH electrode placement, recording, analysis and interpretation	\$ 1,329.0
Colon motility (manometric) study, minimum 6 hours continuous recording (including provocation tests, eg, meal, intracolonic balloon distension, pharmacologic agents, if performed), with interpretation and report	\$ 1,722.0
Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters	\$ 319.0
plotted and static determination within the central 30Ű, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual	
field analyzer full threshold programs 30-2, 24-2, or 30/60-2)	ć 170.0
Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual	\$ 173.0
Evaluation of speech sound production (eg, articulation, phonological process, apraxia, dysarthria)	\$ 383.0 \$ 702.0
Evaluation of speech sound production (eg, articulation, phonological process, apraxia, dysarthria); with evaluation of language comprehension and expression (eg, receptive and expressive language)	\$ 793.0
Treatment of swallowing dysfunction and/or oral function for feeding	\$ 173.0
Auditory evoked potentials for evoked response audiometry and/or testing of the central nervous system; comprehensive	\$ 892.0
Evaluation of oral and pharyngeal swallowing function	\$ 338.0
Motion fluoroscopic evaluation of swallowing function by cine or video recording	\$ 338.0
Cardiopulmonary resuscitation (eg, in cardiac arrest)	\$ 857.0
Temporary transcutaneous pacing	\$ 611.0
Cardioversion, elective, electrical conversion of arrhythmia; external	\$ 1,669.0
Cardioversion, elective, electrical conversion of arrhythmia; external	\$ 1,814.0
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	\$ 139.0
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report	\$ 437.0
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report	\$ 437.0
External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; recording (includes connection, recording, and	\$ 361.0
disconnection)	\$ 625.0
External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; scanning analysis with report Transthoracic echocardiography for congenital cardiac anomalies; complete	\$ 625.0 \$ 1,486.0
Transthoracic echocardiography for congenital cardiac anomalies; follow-up or limited study	\$ 1,480.0
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler	\$ 1,801.0
echocardiography, and with color flow Doppler echocardiography Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, without spectral or color	\$ 1,486.0
Doppler echocardiography Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study	\$ 516.0
Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report	\$ 1,263.0
Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); placement of transesophageal probe only	\$ 2,875.0
Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); image acquisition, interpretation and report only	\$ 2,875.0
Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete	\$ 194.0
Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)	\$ 194.0
	\$ 194.0

DESCRIPTION	CHARGE
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous	\$ 2,450.00
electrocardiographic monitoring, with supervision by a physician or other qualified health care professional	
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular	\$ 2,450.00
stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous	
electrocardiographic monitoring, with supervision by a physician or other qualified health care professional	
Insertion and placement of flow directed catheter (eg, Swan-Ganz) for monitoring purposes	\$ 3,551.00
Evaluation of cardiovascular function with tilt table evaluation, with continuous ECG monitoring and intermittent blood pressure monitoring, with or without	\$ 1,418.00
pharmacological intervention	
Peripheral arterial disease (PAD) rehabilitation, per session	\$ 424.00
Physician or other qualified health care professional services for outpatient cardiac rehabilitation; without continuous ECG monitoring (per session)	\$ 424.00
Physician or other qualified health care professional services for outpatient cardiac rehabilitation; without continuous ECG monitoring (per session)	\$ 5.00
Physician or other qualified health care professional services for outpatient cardiac rehabilitation; without continuous ECG monitoring (per session)	\$ 30.00
Physician or other qualified health care professional services for outpatient cardiac rehabilitation; with continuous ECG monitoring (per session)	\$ 424.00
Unlisted cardiovascular service or procedure	\$ 89.00
Duplex scan of extracranial arteries; complete bilateral study	\$ 926.00
Duplex scan of extracranial arteries; complete bilateral study	\$ 785.00
Duplex scan of extracranial arteries; complete bilateral study	\$ 926.00
Duplex scan of extracranial arteries; complete bilateral study	\$ 926.00
Duplex scan of extracranial arteries; complete bilateral study	\$ 926.00
Duplex scan of extracranial arteries; complete bilateral study	\$ 926.00
Duplex scan of extracranial arteries; unilateral or limited study	\$ 876.00
Transcranial Doppler study of the intracranial arteries; complete study	\$ 785.00
Transcranial Doppler study of the intracranial arteries; complete study	\$ 785.00
Transcranial Doppler study of the intracranial arteries; limited study	\$ 554.00
Transcranial Doppler study of the intracranial arteries; limited study	\$ 744.00
Transcranial Doppler study of the intracranial arteries; vasoreactivity study	\$ 554.00
Transcranial Doppler study of the intracranial arteries; emboli detection without intravenous microbubble injection	\$ 554.00
Transcranial Doppler study of the intracranial arteries; emboli detection with intravenous microbubble injection	\$ 554.00
Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording and analysis at 1-2 levels, or ankle/brachial indices at distal posterior	\$ 1,310.00
tibial and anterior tibial/dorsalis pedis arteries plus volume plethysmography at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries with, transcutaneous oxygen tension measurement at 1-2 levels)	
Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial	\$ 556.00
and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording and analysis at 1-2 levels, or ankle/brachial indices at distal posterior	
tibial and anterior tibial/dorsalis pedis arteries plus volume plethysmography at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior	
tibial/dorsalis pedis arteries with, transcutaneous oxygen tension measurement at 1-2 levels)	
Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial	\$ 546.00
and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording and analysis at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus volume plethysmography at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior	
tibial/dorsalis pedis arteries with, transcutaneous oxygen tension measurement at 1-2 levels)	
Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial	\$ 574.00
and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording and analysis at 1-2 levels, or ankle/brachial indices at distal posterior	
tibial and anterior tibial/dorsalis pedis arteries plus volume plethysmography at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries with, transcutaneous oxygen tension measurement at 1-2 levels)	
Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial	\$ 1,310.00
and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording and analysis at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus volume plethysmography at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries with, transcutaneous oxygen tension measurement at 1-2 levels)	
Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording and analysis at 1-2 levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus volume plethysmography at 1-2 levels, or ankle/brachial indices at distal posterior tibial/dorsalis pedis arteries with, transcutaneous oxygen tension measurement at 1-2 levels)	\$ 574.00

DESCRIPTION	CHARGE
Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure measurements with bidirectional Doppler waveform recording and analysis, at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental volume plethysmography at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental transcutaneous oxygen tension measurements at 3 or more levels), or single level study with provocative functional maneuvers (eg, measurements with postural provocative tests, or measurements with reactive hyperemia)	
Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at 4 distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure measurements with bidirectional Doppler waveform recording and analysis, at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental volume plethysmography at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental transcutaneous oxygen tension measurements at 3 or more levels), or single level study with provocative functional maneuvers (eg, measurements with postural provocative tests, or measurements with reactive hyperemia)	595.00
Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure measurements with bidirectional Doppler waveform recording and analysis, at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental volume plethysmography at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental transcutaneous oxygen tension measurements at 3 or more levels), or single level study with provocative functional maneuvers (eg, measurements with postural provocative tests, or measurements with reactive hyperemia)	556.00
Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure measurements with bidirectional Doppler waveform recording and analysis, at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental volume plethysmography at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental transcutaneous oxygen tension measurements at 3 or more levels), or single level study with provocative functional maneuvers (eg, measurements with postural provocative tests, or measurements with reactive hyperemia)	595.00
Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure measurements with bidirectional Doppler waveform recording and analysis, at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental volume plethysmography at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental transcutaneous oxygen tension measurements at 3 or more levels), or single level study with provocative functional maneuvers (eg, measurements with postural provocative tests, or measurements with reactive hyperemia)	595.00
Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure measurements with bidirectional Doppler waveform recording and analysis, at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental volume plethysmography at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental transcutaneous oxygen tension measurements at 3 or more levels), or single level study with provocative functional maneuvers (eg, measurements with postural provocative tests, or measurements with reactive hyperemia)	574.00
Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at 4 distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure measurements with bidirectional Doppler waveform recording and analysis, at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental volume plethysmography at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental transcutaneous oxygen tension measurements at 3 or more levels), or single level study with provocative functional maneuvers (eg, measurements with postural provocative tests, or measurements with reactive hyperemia)	595.00
Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure measurements with bidirectional Doppler waveform recording and analysis, at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental volume plethysmography at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental transcutaneous oxygen tension measurements at 3 or more levels), or single level study with provocative functional maneuvers (eg, measurements with postural provocative tests, or measurements with reactive hyperemia)	574.00
Noninvasive physiologic studies of lower extremity arteries, at rest and following treadmill stress testing, (ie, bidirectional Doppler waveform or volume plethysmography recording and analysis at rest with ankle/brachial indices immediately after and at timed intervals following performance of a standardized protocol on a motorized treadmill plus recording of time of onset of claudication or other symptoms, maximal walking time, and time to recovery) complete bilateral study	546.00
Noninvasive physiologic studies of lower extremity arteries, at rest and following treadmill stress testing, (ie, bidirectional Doppler waveform or volume plethysmography recording and analysis at rest with ankle/brachial indices immediately after and at timed intervals following performance of a standardized protocol on a motorized treadmill plus recording of time of onset of claudication or other symptoms, maximal walking time, and time to recovery) complete bilateral study	574.00
Noninvasive physiologic studies of lower extremity arteries, at rest and following treadmill stress testing, (ie, bidirectional Doppler waveform or volume plethysmography recording and analysis at rest with ankle/brachial indices immediately after and at timed intervals following performance of a standardized protocol on a motorized treadmill plus recording of time of onset of claudication or other symptoms, maximal walking time, and time to recovery) complete bilateral study	574.00
Duplex scan of lower extremity arteries or arterial bypass grafts; complete bilateral study \$	
Duplex scan of lower extremity arteries or arterial bypass grafts; complete bilateral study \$	
Duplex scan of lower extremity arteries or arterial bypass grafts; complete bilateral study\$Duplex scan of lower extremity arteries or arterial bypass grafts; complete bilateral study\$	1,602.00 1,602.00

DESCRIPTION	CHARGE
Duplex scan of lower extremity arteries or arterial bypass grafts; complete bilateral study	\$ 1,598.00
Duplex scan of lower extremity arteries or arterial bypass grafts; complete bilateral study	\$ 1,598.00
Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study	\$ 781.00
Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study	\$ 744.00
Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study	\$ 744.00
Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study	\$ 781.00
Duplex scan of lower extremity arteries or arterial bypass grafts; unilateral or limited study	\$ 781.00
Duplex scan of upper extremity arteries or arterial bypass grafts; complete bilateral study	\$ 1,525.00
Duplex scan of upper extremity arteries or arterial bypass grafts; complete bilateral study	\$ 785.00
Duplex scan of upper extremity arteries or arterial bypass grafts; unilateral or limited study	\$ 744.00
Duplex scan of upper extremity arteries or arterial bypass grafts; unilateral or limited study	\$ 781.00
Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study	\$ 785.00
Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study	\$ 785.00
Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study	\$ 755.00
Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study	\$ 785.00
Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study	\$ 785.00
Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study	\$ 785.00
Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study	\$ 781.00
Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study	\$ 554.00
Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study	\$ 554.00
Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study	\$ 781.00
Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study	\$ 781.00
Duplex scan of extremity veins including responses to compression and other maneuvers; unilateral or limited study	\$ 781.00
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study	\$ 1,602.00
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study	\$ 1,525.00
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study	\$ 1,602.00
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study	\$ 1,602.00
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study	\$ 1,602.00
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; complete study	\$ 1,602.00 \$ 781.00
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study	
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study	\$ 785.00 \$ 781.00
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitorieal organs; limited study	\$ 781.00
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitorieal organs; limited study	\$ 781.00
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitorieal organs; limited study	\$ 781.00
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitorical organs; limited study	\$ 781.00
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitorical organs; limited study	\$ 781.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; complete study	\$ 1,525.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; complete study	\$ 1,525.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; complete study	\$ 1,602.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; complete study	\$ 1,525,00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; complete study	\$ 744.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; complete study	\$ 1,525.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; complete study	\$ 744.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; complete study	\$ 785.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; unilateral or limited study	\$ 781.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; unilateral or limited study	\$ 744.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; unilateral or limited study	\$ 781.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; unilateral or limited study	\$ 781.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; unilateral or limited study	\$ 781.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; unilateral or limited study	\$ 781.00
Duplex scan of aorta, inferior vena cava, iliac vasculature, or bypass grafts; unilateral or limited study	\$ 781.00
Duplex scan of arterial inflow and venous outflow of penile vessels; complete study	\$ 785.00
Duplex scan of arterial inflow and venous outflow of penile vessels; complete study	\$ 785.00
Duplex scan of hemodialysis access (including arterial inflow, body of access and venous outflow)	\$ 881.00
Ventilation assist and management, initiation of pressure or volume preset ventilators for assisted or controlled breathing; hospital inpatient/observation, initial day	\$ 1,435.00
Ventilation assist and management, initiation of pressure or volume preset ventilators for assisted or controlled breathing; hospital inpatient/observation, each subsequent day	\$ 1,435.00
Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation	\$ 366.00
Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation	\$ 366.00

DESCRIPTION		CHARGE
Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration	\$	557.00
Bronchospasm provocation evaluation, multiple spirometric determinations as in 94010, with administered agents (eg, antigen[s], cold air, methacholine)	\$	533.00
Vital capacity, total (separate procedure)	\$	32.00
Maximum breathing capacity, maximal voluntary ventilation	\$	249.00
Respiratory flow volume loop	\$	100.00
Exercise test for bronchospasm, including pre- and post-spirometry, electrocardiographic recording(s), and pulse oximetry	\$	342.00
Exercise test for bronchospasm, including pre- and post-spirometry, electrocardiographic recording(s), and pulse oximetry	\$	342.00
Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed	\$ \$	216.00 216.00
Cardiopulmonary exercise testing, including measurements of minute ventilation, CO2 production, O2 uptake, and electrocardiographic recordings	\$	1,217.00
Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum	\$	322.00
induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (IPPB) device	Ŧ	
Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (IPPB) device	\$	322.00
Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum	\$	237.00
induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (IPPB) device Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum	\$	322.00
induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (IPPB) device	,	322.00
Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum	\$	173.00
induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (IPPB) device		
Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum	\$	322.00
induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (IPPB) device		
Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (IPPB) device	\$	322.00
Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum	\$	322.00
induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (IPPB) device		
Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum	\$	322.00
induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (IPPB) device		
Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum	\$	322.00
induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing (IPPB) device		
Continuous inhalation treatment with aerosol medication for acute airway obstruction; first hour	\$	348.00
Continuous inhalation treatment with aerosol medication for acute airway obstruction; first hour	\$	366.00
Continuous inhalation treatment with aerosol medication for acute airway obstruction; each additional hour (List separately in addition to code for primary procedure)	\$	348.00
Continuous inhalation treatment with aerosol medication for acute airway obstruction; each additional hour (List separately in addition to code for primary	\$	366.00
procedure)		
Continuous positive airway pressure ventilation (CPAP), initiation and management	\$	344.00
Continuous positive airway pressure ventilation (CPAP), initiation and management	\$	344.00
Continuous positive airway pressure ventilation (CPAP), initiation and management	\$	1,143.00
Continuous positive airway pressure ventilation (CPAP), initiation and management	\$	818.00
Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device	\$	404.00
Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device	\$	322.00
Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation	\$ \$	322.00 322.00
Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation	\$	322.00
Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation	\$	322.00
Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; subsequent	\$	162.00
Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; subsequent	\$	162.00
Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; subsequent	\$	162.00
Mechanical chest wall oscillation to facilitate lung function, per session	\$	237.00
Oxygen uptake, expired gas analysis; including CO2 output, percentage oxygen extracted	\$	556.00
Plethysmography for determination of lung volumes and, when performed, airway resistance	\$	394.00
Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes	\$	366.00
Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)	\$	249.00
Noninvasive ear or pulse oximetry for oxygen saturation; by continuous overnight monitoring (separate procedure)	\$	762.00
Noninvasive ear or pulse oximetry for oxygen saturation; by continuous overnight monitoring (separate procedure) Carbon dioxide, expired assidetermination by infrared apply or	\$	538.00
Carbon dioxide, expired gas determination by infrared analyzer Circadian respiratory pattern recording (pediatric pneumogram), 12-24 hour continuous recording, infant	\$ \$	1,001.00 1,962.00
Unisted pulmonary service or procedure	\$ \$	237.00
Unlisted pulmonary service or procedure	\$	237.00
Unlisted pulmonary service or procedure	\$	225.00
Unlisted pulmonary service or procedure	\$	225.00
	1 7	

DESCRIPTION	(CHARGE
Unlisted pulmonary service or procedure	\$	168.00
Allergy testing, any combination of percutaneous (scratch, puncture, prick) and intracutaneous (intradermal), sequential and incremental, with drugs or biologicals, immediate type reaction, including test interpretation and report, specify number of tests	\$	120.00
Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; patient-provided equipment, sensor placement, hook-up, calibration of monitor, patient training, and printout of recording	\$	355.00
Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; patient-provided equipment, sensor placement, hook-up, calibration of monitor, patient training, and printout of recording	\$	370.00
Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist	\$	3,338.00
Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi-level ventilation, attended by a technologist	\$	3,580.00
Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (eg, by airflow or peripheral arterial tone), and sleep time	\$	747.00
Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis (eg, by airflow or peripheral arterial tone)	\$	747.00
Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording)	\$	260.00
Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation of physiological measurements of sleep during multiple trials to assess sleepiness	\$	3,544.00
Sleep study, unattended, simultaneous recording of, heart rate, oxygen saturation, respiratory airflow, and respiratory effort (eg, thoracoabdominal movement)	\$	510.00
Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist	\$	1,808.00
Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist	\$	3,544.00
Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist	\$	3,544.00
Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist	\$	3,580.00
Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist	\$	3,580.00
Electroencephalogram (EEG) extended monitoring; 41-60 minutes	\$	1,234.00
Electroencephalogram (EEG) extended monitoring; greater than 1 hour	\$	1,234.00
Electroencephalogram (EEG); including recording awake and drowsy	\$	747.00
Electroencephalogram (EEG); including recording awake and asleep	\$	747.00
Electroencephalogram (EEG); recording in coma or sleep only	\$	747.00
Electroencephalogram (EEG); cerebral death evaluation only	\$	892.00
Electrocorticogram at surgery (separate procedure)	\$	747.00
Muscle testing, manual (separate procedure) with report; extremity (excluding hand) or trunk	\$	79.00
Muscle testing, manual (separate procedure) with report; extremity (excluding hand) or trunk Muscle testing, manual (separate procedure) with report; extremity (excluding hand) or trunk	\$ \$	79.00 79.00
Muscle testing, manual (separate procedure) with report; hand, with or without comparison with normal side	\$ \$	79.00
Muscle testing, manual (separate procedure) with report; hand, with or without comparison with normal side	\$	79.00
Muscle testing, manual (separate procedure) with report; total evaluation of body, excluding hands	\$	100.00
Muscle testing, manual (separate procedure) with report; total evaluation of body, excluding hands	\$	100.00
Muscle testing, manual (separate procedure) with report; total evaluation of body, including hands	Ś	145.00
Muscle testing, manual (separate procedure) with report; total evaluation of body, including hands	\$	145.00
Range of motion measurements and report (separate procedure); each extremity (excluding hand) or each trunk section (spine)	\$	79.00
Range of motion measurements and report (separate procedure); each extremity (excluding hand) or each trunk section (spine)	\$	79.00
Range of motion measurements and report (separate procedure); hand, with or without comparison with normal side	\$	70.00
Range of motion measurements and report (separate procedure); hand, with or without comparison with normal side	\$	70.00
Needle electromyography; 1 extremity with or without related paraspinal areas	\$	690.00
Needle electromyography; 2 extremities with or without related paraspinal areas	\$	713.00
Needle electromyography; 3 extremities with or without related paraspinal areas	\$	749.00
Needle electromyography; 4 extremities with or without related paraspinal areas	\$	777.00
Needle electromyography; larynx	\$	207.00
Needle electromyography; hemidiaphragm	\$	207.00
Needle electromyography; cranial nerve supplied muscle(s), unilateral	\$	527.00
Needle electromyography; cranial nerve supplied muscles, bilateral	\$	321.00
Needle electromyography; thoracic paraspinal muscles (excluding T1 or T12)	\$	207.00
Needle electromyography; limited study of muscles in 1 extremity or non-limb (axial) muscles (unilateral or bilateral), other than thoracic paraspinal, cranial nerve supplied muscles, or sphincters	\$	261.00
Needle electromyography using single fiber electrode, with quantitative measurement of jitter, blocking and/or fiber density, any/all sites of each muscle studied	\$	527.00
Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; limited (List separately in addition to code for primary procedure)	\$	892.00
Needle electromyography, each extremity, with related paraspinal areas, when performed, done with nerve conduction, amplitude and latency/velocity study; complete, five or more muscles studied, innervated by three or more nerves or four or more spinal levels (List separately in addition to code for primary	\$	892.00
procedure)		

Needle electromyography, non-extremity (tranial nerve supplied or axial) muscle(s) done with nerve conduction, amplitude and latency/velocity study (List \$ Separately in addition to code for primary procedure) \$ Verve conduction studies; 3: 4 studies \$ Verve conduction studies; 5: 4 studies \$ Verve conduction studies; 7: 8 studies \$ Verve conduction studies; 7: 12 studies \$ Verve conduction studies; 13 or more studies \$ Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper \$ Short-latency somatosensory evoked potential study, transcranial motor stimulation); upper limbs \$ Central motor evoked potential (Vertranscranial motor stimulation); upper limbs \$ Short-latency somatosensory evoked potential study, transcranial motor stimulation, paried stimuli), each nerve, any 1 method \$ Short-latency somatosensory evoked potential study, transcranial motor stimulation, paried stimuli), each nerve, any 1 method \$ Sometrains oucli (bink) reflex, by electrodiagnostic testing \$ <th>892.00</th>	892.00
Nerve conduction studies; 1-2 studies\$Verve conduction studies; 5-4 studies\$Verve conduction studies; 5-5 studies\$Verve conduction studies; 7-8 studies\$Verve conduction studies; 5-5 studies\$Verve conduction studies; 1-12 studies\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower\$Short-latency somatosensory evoked potential study (transcranial motor stimulation); upper limbs\$Central motor evoked potential study (transcranial motor stimulation); lower limbs\$Short-latency somatosensory evoked potential study (transcranial motor stimulation); lower limbs\$Short-latency somatosensory evoked potential study (transcranial motor stimulation); lower limbs\$Short-latency somatosensory evoked potential study (transcranial motor stimulation); lower limbs\$Short-latency somatosensory evoked potential study (transcranial motor stimulation); upper and lower limbs\$Short-latency somatosensory evoked potential study (transcranial motor stimulation); in upper and lower limbs\$Continuous intraoperative neurophysiology monitoring in the operating room, one on emonitoring requiring personal attendance, each 15 minutes (List eparately in addition to code for primary procedure)\$Vonitoring for lo	892.00 892.00 892.00 892.00 892.00 527.00 527.00 527.00 392.00 207.00 892.00 892.00 892.00
Nerve conduction studies; 3-4 studies\$Verve conduction studies; 3-6 studies\$Verve conduction studies; 5-6 studies\$Verve conduction studies; 5-0 studies\$Verve conduction studies; 5-0 studies\$Verve conduction studies; 11-12 studies\$Serve conduction studies; 11-12 studies\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower\$Short-latency somatosensory evoked potential study (transcranial motor stimulation); upper limbs\$Schral notor evoked potential study (transcranial motor stimulation); lower limbs\$Server conduction studies; 12 studies\$Server and coll (blink) reflex, by electrodiagnostic testing\$Visual evoked potential study (transcranial motor stimulation); lower limbs\$Server-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper\$Server-latency somatosensory evoked potential study, transcranial motor stimulation); lower limbs\$Server-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper\$Server-latency somatosensory evoked potential study, stimulation); in upper and lower limbs\$Server-latency somatosensory evoked potential study, stimulation); in upper and lower limbs\$Continuous intraoperative neurophysiology monitoring in the operating room, one on emonitoring peripheral nerves or skin sites, recording from the central n	892.00 892.00 892.00 892.00 892.00 527.00 527.00 527.00 392.00 207.00 892.00 892.00 892.00
Nerve conduction studies; 5-6 studies\$Verve conduction studies; 7-8 studies\$Verve conduction studies; 7-8 studies\$Nerve conduction studies; 10 studies\$Verve conduction studies; 11-12 studies\$Verve conduction studies; 11 or more studies\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower\$Short-latency somatosensory evoked potential study (transcranial motor stimulation); upper limbs\$Central motor evoked potential study (transcranial motor stimulation); lower limbs\$Susal evoked potential (VEP) testing central nervous system, checkerboard or flash\$Veucomuscular junction testing (repetitive stimulation, paired stimuli); in upper and lower limbs\$Sont-latency somatosensory evoked potential study (transcranial motor stimulation); in upper and lower limbs\$Sont-latency somatosensory evoked potential study (transcranial motor stimulation); in upper and lower limbs\$Sont-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower\$Sont-latency somatosensory evoked potential study, stimulation, apare and lower limbs\$Sont-latency somatosensory evoked potential study, stimulation, apare and lower limbs\$Sont-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites	892.00 892.00 892.00 892.00 527.00 527.00 527.00 392.00 207.00 892.00 892.00 1,380.00
Nerve conduction studies; 7-8 studies\$Verve conduction studies; 9-10 studies\$Verve conduction studies; 9-11 2 studies\$Nerve conduction studies; 11-2 studies\$Nerve conduction studies; 11-2 studies\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower\$Short-latency somatosensory evoked potential study (transcranial motor stimulation); upper limbs\$Central motor evoked potential study (transcranial motor stimulation); lower limbs\$Solucied (link) reflex, by electrodiagnostic testing\$Orbicularis oculi (link) reflex, by electrodiagnostic testing\$Solucied soculi (link) reflex, by electrodiagnostic testing\$Soluci and soculi (link) reflex, by electrodiagnostic testing\$Soluci aris oculi (link) reflex, by electrodiagnostic testing\$Soluci aris oculi (link) reflex, by electrodiagnostic testing\$Soluci aris oculi (link) reflex, by electrodiagnostic testing (repetitive stimulation); in upper and lower limbs\$Soluci aris oculi (link) reflex, by electrodiagnostic testing (repetitive stimulation); in upper and lower limbs\$Soluci aris oculi (link) reflex, by electrodiagnostic testing (repetitive stimulation); in upper and lower limbs\$Soluci aris oculi (link) reflex, be electrodiagnostic testing (room, one on one monitoring requiring personal attendance, each 15 minutes (listi epa	892.00 892.00 892.00 892.00 527.00 527.00 392.00 207.00 892.00 892.00 1,380.00
Nerve conduction studies; 9-10 studies \$ Verve conduction studies; 11-12 studies \$ Verve conduction studies; 10 or more studies \$ Sevre conduction studies; 10 or more studies \$ Schort-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower \$ Schort-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower \$ Schort-latency somatosensory evoked potential study (transcranial motor stimulation); upper limbs \$ Central motor evoked potential study (transcranial motor stimulation); upper limbs \$ Visual evoked potential (VEP) testing central nervous system, checkerboard or flash \$ Ververomuscular junction testing (repetitive stimulation, paired stimuli), each nerve, any 1 method \$ Schort-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper and lower limbs \$ Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby) or for monitoring of more than one case while in the operating room, per hour (List separately in addition to code for primary procedure) \$ Continuous intraoperative neurophysiology monitoring, from outside the operating room (892.00 892.00 892.00 527.00 527.00 527.00 392.00 207.00 892.00 892.00 1,380.00
Nerve conduction studies; 11-12 studies\$Verve conduction studies; 13 or more studies\$Verve conduction studies; 13 or more studies\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower\$Short-latency somatosensory evoked potential study (transcranial motor stimulation); lower limbs\$Central motor evoked potential study (transcranial motor stimulation); lower limbs\$Susal evoked potential (VEP) testing central nervous system; checkerboard or flash\$System source (VEP) testing central nervous system; in upper\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper\$System source (VEP) testing central nervous system; in upper\$\$System source (VEP) testing central nervos system; in upper and lower limbs\$Source (VEP) testing source (VEP) testing central nervos or skin sites, recording from the central nervous system; in upper\$Source (VEP) testing central motor stimulation); in upper and lower limbs\$Source (VEP) testing central nervos system; provedure\$Source (VEP) testing central nervos system; provedure\$Source (VEP) testing central nervos system; provedure\$Source (VEP) testing central seture focus by cable or primary procedure\$Source (VEP) testing central se	892.00 892.00 527.00 892.00 207.00 392.00 207.00 892.00 892.00 1,380.00
Nerve conduction studies; 13 or more studies\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower\$Short-latency somatosensory evoked potential study, stimulation); upper limbs\$Central motor evoked potential study (transcranial motor stimulation); lower limbs\$Surve conduction evoked potential study (transcranial motor stimulation); lower limbs\$Visual evoked potential (VEP) testing central nervous system, checkerboard or flash\$Sorth-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper\$Sorth-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper\$Sorth-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper\$Sorth-latency somatosensory evoked potential study (transcranial motor stimulation); in upper and lower limbs\$Continuous intraoperative neurophysiology monitoring in the operating room, one on memotiring requiring personal attendance, each 15 minutes (List\$Sorthardoperative neurophysiology monitoring, from outside the operating room (remote or nearby) or for monitoring of more than one case while in the operating room, nervoer or enarby) or for monitoring of more than one case while in the operating norm, one on me channel E	892.00 892.00 527.00 207.00 392.00 207.00 892.00 892.00 1,380.00
Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper \$ Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower \$ Short-latency somatosensory evoked potential study (transcranial motor stimulation); upper limbs \$ Scentral motor evoked potential study (transcranial motor stimulation); upper limbs \$ Svala evoked potential (VEP) testing central nervous system, checkerboard or flash \$ Visual evoked potential study (transcranial motor stimulation); in per and lower limbs \$ Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper \$ Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper \$ Sont-latency intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List sparately in addition to code for primary procedure) \$ Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby) or for monitoring of more than one case while in the operating room (remote or nearby) or for monitoring of more than one case while in the operating room, per hour (List separately in addition to code for primary procedure) \$ <td>892.00 527.00 207.00 527.00 392.00 207.00 892.00 1,380.00</td>	892.00 527.00 207.00 527.00 392.00 207.00 892.00 1,380.00
imbs Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower imbs S Central motor evoked potential study (transcranial motor stimulation); upper limbs S Central motor evoked potential study (transcranial motor stimulation); upper limbs S Objecularis oculi (blink) reflex, by electrodiagnostic testing S Veuromuscular junction testing (repetitive stimulation, paired stimuli), each nerve, any 1 method S Schort-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper and lower limbs S Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs S Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs S Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List separately in addition to code for primary procedure) S Monitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical localization), each 24 hours S Ventoring for localization of cerebral seizure focus by cable or radio, 16 or more channel EEG, electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical lo	527.00 892.00 207.00 527.00 392.00 207.00 892.00 1,380.00
imbsSCentral motor evoked potential study (transcranial motor stimulation); upper limbs\$Central motor evoked potential (VEP) testing central nervous system, checkerboard or flash\$Solvicularis oculi (blink) reflex, by electrodiagnostic testing\$Neuromuscular junction testing (repetitive stimulation, paired stimuli), each nerve, any 1 method\$Sohort-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper\$Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs\$Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs\$Continuous intraoperative neurophysiology monitoring, in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List separately in addition to code for primary procedure)\$Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby) or for monitoring of more than one case while in the operating room, per hour (List separately in addition to code for primary procedure)\$Monitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical localization), each 24 hours\$Pharmacological or physical activation requiring physician or other qualified health care professional attendance during EEG recording of activation phase (eg, for epileptic spike analysis)\$Cherchercephalogram (EEG) during nonintracranial surgery (eg, carctid surgery)\$\$Cherchercephalogram (E	892.00 207.00 392.00 207.00 892.00 892.00 1,380.00
Central motor evoked potential study (transcranial motor stimulation); lower limbs\$Visual evoked potential (VEP) testing central nervous system, checkerboard or flash\$Visual evoked potential (VEP) testing central nervous system, checkerboard or flash\$Veuromuscular junction testing (repetitive stimulation, paired stimuli), each nerve, any 1 method\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper and lower limbs\$Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs\$Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List separately in addition to code for primary procedure)\$Vonitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video tecording and interpretation (eg, for presurgical localization), each 24 hours\$Wonitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel EEG, electroencephalographic (EEG) and video tecording and interpretation (eg, for presurgical localization), each 24 hours\$Wonitoring for localization of cerebral seizure focus by computerized portable 16 or more channel EEG, electroencephalographic (EEG) recording and nterpretation, each 24 hours, unattended\$Pharmacological or physical activation requiring physical or other qualified health care professional attendance during EEG recording of activation phase (eg, pipital analysis of electroencephalogram (EEG) (eg, for epileptic spike analysis)\$Wata ac	207.00 527.00 392.00 207.00 892.00 892.00 1,380.00
Visual evoked potential (VEP) testing central nervous system, checkerboard or flash\$Orbicularis oculi (blink) reflex, by electrodiagnostic testing\$Neuromuscular junction testing (repetitive stimulation, paired stimuli), each nerve, any 1 method\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper and lower limbs\$Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs\$Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby) or for monitoring of more than one case while in the operating room, per hour (List separately in addition to code for primary procedure)\$Monitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical localization), each 24 hours\$Monitoring for localization of cerebral seizure focus by computerized portable 16 or more channel EEG, electroencephalographic (EEG) recording and nterpretation, each 24 hours, unattended\$Pharmacological or physical activation requiring physician or other qualified health care professional attendance during EEG recording of activation phase (eg, pipela analysis of electroencephalogram (EEG) (eg, for cepileptic spike analysis)\$Wada activation test for hemispheric function, including electroencephalographic (EEG) monitoring physical activation test)\$Digital analysis of electroencephalo	527.00 392.00 207.00 892.00 892.00 1,380.00
Drbicularis oculi (blink) reflex, by electrodiagnostic testing\$Neuromuscular junction testing (repetitive stimulation, paired stimuli), each nerve, any 1 method\$Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper\$Sand lower limbs\$Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs\$Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List\$Scontinuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby) or for monitoring of more than one case while in the operating room, per hour (List separately in addition to code for primary procedure)\$Wonitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical localization), each 24 hours\$Wonitoring for localization of cerebral seizure focus by computerized portable 16 or more channel EEG, electroencephalographic (EEG) recording and therpretation, each 24 hours, unattended\$Pharmacological or physical activation requiring physician or other qualified health care professional attendance during EEG recording of activation phase (eg, thiopental activation test)\$Digital analysis of electroencephalogram (EEG) (eg, for epileptic spike analysis)\$Wada activation test for hemispheric function, including electroencephalographic (EEG) monitoring\$Sucial analysis of electroencephalogram (EEG) (eg, for epileptic spike ana	392.00 207.00 892.00 892.00 1,380.00
Neuromuscular junction testing (repetitive stimulation, paired stimuli), each nerve, any 1 method \$ Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper and lower limbs \$ Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs \$ Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List separately in addition to code for primary procedure) \$ Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby) or for monitoring of more than one case while in the operating room, per hour (List separately in addition to code for primary procedure) \$ Wonitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical localization), each 24 hours \$ Vonitoring for localization of cerebral seizure focus by computerized portable 16 or more channel EEG, electroencephalographic (EEG) recording and therpretation, each 24 hours, unattended \$ Pharmacological or physical activation requiring physician or other qualified health care professional attendance during EEG recording of activation phase (eg, friopental activation test) \$ Digital analysis of electroencephalogram (EEG) (eg, for epileptic spike analysis) \$ Wada activation test	207.00 892.00 892.00 1,380.00
Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper and lower limbs \$ Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs \$ Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List separately in addition to code for primary procedure) \$ Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby) or for monitoring of more than one case while in the operating room, per hour (List separately in addition to code for primary procedure) \$ Monitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical localization), each 24 hours \$ Monitoring for localization of cerebral seizure focus by computerized portable 16 or more channel EEG, electroencephalographic (EEG) recording and nterpretation, each 24 hours, unattended \$ *harmacological or physical activation requiring physician or other qualified health care professional attendance during EEG recording of activation phase (eg, for preileptic spike analysis) \$ Wada activation test for hemispheric function, including electroencephalographic (EEG) monitoring \$ Wada activation test in the operating selectroencephalographic (EEG) monitoring \$ Purectional cortical and subcortical mapping by	892.00 892.00 1,380.00
and lower limbs \$ Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs \$ Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List separately in addition to code for primary procedure) \$ Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby) or for monitoring of more than one case while in the operating room, per hour (List separately in addition to code for primary procedure) \$ Monitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video \$ recording and interpretation (eg, for presurgical localization), each 24 hours \$ Monitoring for localization of cerebral seizure focus by computerized portable 16 or more channel EEG, electroencephalographic (EEG) recording and nterpretation, each 24 hours, unattended \$ Pharmacological or physical activation requiring physician or other qualified health care professional attendance during EEG recording of activation phase (eg, ricipatal activation test) \$ Digital analysis of electroencephalogram (EEG) during nonintracranial surgery (eg, carotid surgery) \$ Digital analysis of electroencephalogram (EEG) (eg, for epileptic spike analysis) \$ Wada activation test for hemispheric function, including electroencephalographic (EEG) monitoring \$ Punction	892.00 1,380.00
Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List separately in addition to code for primary procedure)\$Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby) or for monitoring of more than one case while in the operating room, per hour (List separately in addition to code for primary procedure)\$Monitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video recording and interpretation (eg, for presurgical localization), each 24 hours\$Monitoring for localization of cerebral seizure focus by computerized portable 16 or more channel EEG, electroencephalographic (EEG) recording and nterpretation, each 24 hours, unattended\$Pharmacological or physical activation requiring physician or other qualified health care professional attendance during EEG recording of activation phase (eg, thiopental activation test)\$Electroencephalogram (EEG) during nonintracranial surgery (eg, carotid surgery)\$Digital analysis of electroencephalogram (EEG) (eg, for epileptic spike analysis)\$Wada activation test for hemispheric function, including electroencephalographic (EEG) monitoring\$Functional cortical and subcortical mapping by stimulation and/or recording of electrodes on brain surface, or of depth electrodes, to provoke seizures or dentify vital brain structures; initial hour of attendance by a physician or other qualified health care professional\$	1,380.00
separately in addition to code for primary procedure) Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby) or for monitoring of more than one case while in the operating room, per hour (List separately in addition to code for primary procedure) Monitoring for localization of cerebral seizure focus by cable or radio, 16 or more channel telemetry, combined electroencephalographic (EEG) and video cercording and interpretation (eg, for presurgical localization), each 24 hours Monitoring for localization of cerebral seizure focus by computerized portable 16 or more channel EEG, electroencephalographic (EEG) recording and nterpretation, each 24 hours, unattended Pharmacological or physical activation requiring physician or other qualified health care professional attendance during EEG recording of activation phase (eg, thiopental activation test) Electroencephalogram (EEG) during nonintracranial surgery (eg, carotid surgery) Sectional cortical and subcortical mapping by stimulation and/or recording of electrodes on brain surface, or of depth electrodes, to provoke seizures or dentify vital brain structures; initial hour of attendance by a physician or other qualified health care professional 	
the operating room, per hour (List separately in addition to code for primary procedure) Image: Content of the image: Content of t	1,380.00
recording and interpretation (eg, for presurgical localization), each 24 hours Monitoring for localization of cerebral seizure focus by computerized portable 16 or more channel EEG, electroencephalographic (EEG) recording and seizure focus by computerized portable 16 or more channel EEG, electroencephalographic (EEG) recording and seizure focus by computerized portable 16 or more channel EEG, electroencephalographic (EEG) recording and seizure focus by computerized portable 16 or more channel EEG, electroencephalographic (EEG) recording and seizure focus by computerized portable 16 or more channel EEG, electroencephalographic (EEG) recording of activation phase (eg, choice the formation test) Electroencephalogram (EEG) during nonintracranial surgery (eg, carotid surgery) Electroencephalogram (EEG) (eg, for epileptic spike analysis) Seizuration test for hemispheric function, including electroencephalographic (EEG) monitoring Seizuration cortical and subcortical mapping by stimulation and/or recording of electrodes on brain surface, or of depth electrodes, to provoke seizures or dentify vital brain structures; initial hour of attendance by a physician or other qualified health care professional	
nterpretation, each 24 hours, unattended Pharmacological or physical activation requiring physician or other qualified health care professional attendance during EEG recording of activation phase (eg, frieder ender e	3,544.00
chiopental activation test) \$ Electroencephalogram (EEG) during nonintracranial surgery (eg, carotid surgery) \$ Digital analysis of electroencephalogram (EEG) (eg, for epileptic spike analysis) \$ Wada activation test for hemispheric function, including electroencephalographic (EEG) monitoring \$ Functional cortical and subcortical mapping by stimulation and/or recording of electrodes on brain surface, or of depth electrodes, to provoke seizures or \$ dentify vital brain structures; initial hour of attendance by a physician or other qualified health care professional \$	2,793.00
Electroencephalogram (EEG) during nonintracranial surgery (eg, carotid surgery)\$Digital analysis of electroencephalogram (EEG) (eg, for epileptic spike analysis)\$Wada activation test for hemispheric function, including electroencephalographic (EEG) monitoring\$Functional cortical and subcortical mapping by stimulation and/or recording of electrodes on brain surface, or of depth electrodes, to provoke seizures or\$dentify vital brain structures; initial hour of attendance by a physician or other qualified health care professional\$	527.00
Wada activation test for hemispheric function, including electroencephalographic (EEG) monitoring\$Functional cortical and subcortical mapping by stimulation and/or recording of electrodes on brain surface, or of depth electrodes, to provoke seizures or dentify vital brain structures; initial hour of attendance by a physician or other qualified health care professional\$	747.00
Functional cortical and subcortical mapping by stimulation and/or recording of electrodes on brain surface, or of depth electrodes, to provoke seizures or dentify vital brain structures; initial hour of attendance by a physician or other qualified health care professional \$	747.00
dentify vital brain structures; initial hour of attendance by a physician or other qualified health care professional	3,544.00
unctional cortical and subcortical mapping by stimulation and/or recording of electrodes on brain surface, or of depth electrodes, to provoke seizures or \$	892.00
dentify vital brain structures; each additional hour of attendance by a physician or other qualified health care professional (List separately in addition to code for primary procedure)	892.00
Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); simple or complex brain, spinal cord, or peripheral (ie, cranial nerve, peripheral nerve, sacral nerve, neuromuscular) neurostimulator pulse generator/transmitter, without reprogramming	207.00
Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, \$ electrode selectability, output modulation, cycling, impedance and patient compliance measurements); simple spinal cord, or peripheral (ie, peripheral nerve, sacral nerve, neuromuscular) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming	477.00
Canalith repositioning procedure(s) (eg, Epley maneuver, Semont maneuver), per day \$	183.00
Canalith repositioning procedure(s) (eg, Epley maneuver, Semont maneuver), per day \$	174.00
Medical genetics and genetic counseling services, each 30 minutes face-to-face with patient/family \$	110.00
ntravenous infusion, hydration; initial, 31 minutes to 1 hour \$	443.00
ntravenous infusion, hydration; initial, 31 minutes to 1 hour \$	443.00
ntravenous infusion, hydration; initial, 31 minutes to 1 hour \$	443.00
ntravenous infusion, hydration; initial, 31 minutes to 1 hour \$	443.00
ntravenous infusion, hydration; initial, 31 minutes to 1 hour \$	363.00
ntravenous infusion, hydration; initial, 31 minutes to 1 hour \$	443.00
ntravenous infusion, hydration; initial, 31 minutes to 1 hour \$	443.00
ntravenous infusion, hydration; initial, 31 minutes to 1 hour \$	457.00
ntravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure) \$	
ntravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure) \$	
ntravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure) \$	444.00
ntravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure) \$	444.00 444.00 444.00
ntravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure) \$ ntravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure) \$	444.00

DESCRIPTION	C	HARGE
Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)	\$	444.00
Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)	\$	457.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour	\$	375.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour	\$	444.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour	\$	708.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour	\$	708.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour	\$	708.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour	\$	708.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour	\$	708.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour	\$	722.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)	\$	443.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)	\$	443.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)	\$	443.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)	\$	443.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)	\$	443.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)	\$	443.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)	\$	443.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)	\$	457.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)	\$	180.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)	\$	180.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)	\$	180.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)	\$	180.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)	\$	180.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)	\$	180.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)	\$	180.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)	\$	194.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)	\$	423.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)	\$	423.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)	\$	423.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)	\$	423.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)	\$	423.00
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary	\$	423.00
procedure) Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)	\$	423.00
procedure) Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)	\$	437.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	\$	180.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	\$	180.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	\$	180.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	\$	180.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	\$	180.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	\$	180.00

DESCRIPTION	CHARGE
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	\$ 180.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	\$ 194.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	\$ 180.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug	\$ 436.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug	\$ 436.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug	\$ 436.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug	\$ 436.00
	\$ 436.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug	\$ 436.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug	\$ 436.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug	\$ 448.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)	\$ 180.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List	\$ 180.00
separately in addition to code for primary procedure) Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List	\$ 180.00
separately in addition to code for primary procedure)	ý 100.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)	\$ 180.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)	\$ 180.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List	\$ 180.00
separately in addition to code for primary procedure)	ć 190.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)	\$ 180.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)	\$ 194.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)	\$ 180.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug	\$ 180.00
provided in a facility (List separately in addition to code for primary procedure) Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug	\$ 180.00
provided in a facility (List separately in addition to code for primary procedure) Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug	\$ 180.00
provided in a facility (List separately in addition to code for primary procedure)	
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)	\$ 180.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)	\$ 83.00
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug	\$ 83.00
provided in a facility (List separately in addition to code for primary procedure) Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug	\$ 96.00
provided in a facility (List separately in addition to code for primary procedure)	
	\$ 56.00
Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic	\$ 448.00
Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic	\$ 448.00
Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic	\$ 194.00
Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic	\$ 194.00
Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic	\$ 194.00
Chemotherapy administration; intravenous, push technique, single or initial substance/drug	\$ 722.00
Chemotherapy administration; intravenous, push technique, single or initial substance/drug	\$ 722.00
Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)	\$ 194.00
Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)	\$ 194.00
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	\$ 1,244.00
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	\$ 1,244.00
Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)	\$ 194.00
Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)	\$ 194.00
Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump	\$ 1,100.00
	\$ 194.00

DESCRIPTION		CHARGE
Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in	\$	194.00
addition to code for primary procedure)		
Refilling and maintenance of implantable pump or reservoir for drug delivery, systemic (eg, intravenous, intra-arterial)	\$	680.00
Irrigation of implanted venous access device for drug delivery systems	\$	333.00
Irrigation of implanted venous access device for drug delivery systems	\$	333.00
Irrigation of implanted venous access device for drug delivery systems	\$	333.00
Irrigation of implanted venous access device for drug delivery systems	\$	333.00
Irrigation of implanted venous access device for drug delivery systems	\$	347.00
Application of a modality to 1 or more areas; vasopneumatic devices	\$	180.00
Application of a modality to 1 or more areas; paraffin bath	\$ \$	95.00 95.00
Application of a modality to 1 or more areas; paraffin bath Application of a modality to 1 or more areas; electrical stimulation (manual), each 15 minutes	\$	168.00
Application of a modality to 1 or more areas; electrical stimulation (manual), each 15 minutes Application of a modality to 1 or more areas; electrical stimulation (manual), each 15 minutes	\$	168.00
Application of a modality to 1 of more areas; iontophoresis, each 15 minutes	\$	157.00
Application of a modality to 1 or more areas; ultrasound, each 15 minutes	\$	157.00
Application of a modality to 1 or more areas; ultrasound, each 15 minutes	\$	157.00
Unlisted modality (specify type and time if constant attendance)	\$	52.00
Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility	\$	89.00
Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility	\$	89.00
Therapeutic procedure, 1 or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or	\$	89.00
proprioception for sitting and/or standing activities		
Therapeutic procedure, 1 or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or	\$	89.00
proprioception for sitting and/or standing activities		
Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)	\$	89.00
Therapeutic procedure, 1 or more areas, each 15 minutes; massage, including effleurage, petrissage and/or tapotement (stroking, compression, percussion)	\$	89.00
Therapeutic procedure, 1 or more areas, each 15 minutes; massage, including effleurage, petrissage and/or tapotement (stroking, compression, percussion)	\$	89.00
Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem solving, and/or pragmatic	\$	189.00
functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing and sequencing		
tasks), direct (one-on-one) patient contact		
Unlisted therapeutic procedure (specify)	\$	72.00
Manual therapy techniques (eg, mobilization/ manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes	\$	95.00
Manual therapy techniques (eg, mobilization/ manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes	\$	95.00
Therapeutic procedure(s), group (2 or more individuals)	\$ ¢	73.00
Therapeutic procedure(s), group (2 or more individuals) Physical therapy evaluation: low complexity, requiring these components: A history with no personal factors and/or comorbidities that impact the plan of care;	\$ \$	118.00 168.00
An examination of body system(s) using standardized tests and measures addressing 1-2 elements from any of the following: body structures and functions, activity limitations, and/or participation restrictions; A clinical presentation with stable and/or uncomplicated characteristics; and Clinical decision making of low complexity using standardized patient assessment instrument and/or measurable assessment of functional outcome. Typically, 20 minutes are spent face-to-face with the patient and/or family.	ç	108.00
Physical therapy evaluation: moderate complexity, requiring these components: A history of present problem with 1-2 personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures in addressing a total of 3 or more elements from any of the following: body structures and functions, activity limitations, and/or participation restrictions; An evolving clinical presentation with changing characteristics; and Clinical decision making of moderate complexity using standardized patient assessment instrument and/or measurable assessment of functional outcome. Typically, 30 minutes are spent face-to-face with the patient and/or family.	\$	224.00
Physical therapy evaluation: high complexity, requiring these components: A history of present problem with 3 or more personal factors and/or comorbidities that impact the plan of care; An examination of body systems using standardized tests and measures addressing a total of 4 or more elements from any of the following: body structures and functions, activity limitations, and/or participation restrictions; A clinical presentation with unstable and unpredictable characteristics; and Clinical decision making of high complexity using standardized patient assessment instrument and/or measurable assessment of functional outcome. Typically, 45 minutes are spent face-to-face with the patient and/or family.	\$	281.00
Re-evaluation of physical therapy established plan of care, requiring these components: An examination including a review of history and use of standardized tests and measures is required; and Revised plan of care using a standardized patient assessment instrument and/or measurable assessment of functional outcome Typically, 20 minutes are spent face-to-face with the patient and/or family.	\$	116.00
Occupational therapy evaluation, low complexity, requiring these components: An occupational profile and medical and therapy history, which includes a brief history including review of medical and/or therapy records relating to the presenting problem; An assessment(s) that identifies 1-3 performance deficits (ie, relating to physical, cognitive, or psychosocial skills) that result in activity limitations and/or participation restrictions; and Clinical decision making of low complexity, which includes an analysis of the occupational profile, analysis of data from problem-focused assessment(s), and consideration of a limited number of treatment options. Patient presents with no comorbidities that affect occupational performance. Modification of tasks or assistance (eg, physical or verbal) with assessment(s) is not necessary to enable completion of evaluation component. Typically, 30 minutes are spent face-to-face with the patient and/or family.	\$	168.00

DESCRIPTION	С	HARGE
Occupational therapy evaluation, moderate complexity, requiring these components: An occupational profile and medical and therapy history, which includes an expanded review of medical and/or therapy records and additional review of physical, cognitive, or psychosocial history related to current functional performance; An assessment(s) that identifies 3-5 performance deficits (ie, relating to physical, cognitive, or psychosocial skills) that result in activity limitations and/or participation restrictions; and Clinical decision making of moderate analytic complexity, which includes an analysis of the occupational profile, analysis of data from detailed assessment(s), and consideration of several treatment options. Patient may present with comorbidities that affect occupational performance. Minimal to moderate modification of tasks or assistance (eg, physical or verbal) with assessment(s) is necessary to enable patient to complete evaluation component. Typically, 45 minutes are spent face-to-face with the patient and/or family.	\$	224.00
Occupational therapy evaluation, high complexity, requiring these components: An occupational profile and medical and therapy history, which includes review of medical and/or therapy records and extensive additional review of physical, cognitive, or psychosocial history related to current functional performance; An assessment(s) that identifies 5 or more performance deficits (ie, relating to physical, cognitive, or psychosocial skills) that result in activity limitations and/or participation restrictions; and Clinical decision making of high analytic complexity, which includes an analysis of the patient profile, analysis of data from comprehensive assessment(s), and consideration of multiple treatment options. Patient presents with comorbidities that affect occupational performance. Significant modification of tasks or assistance (eg, physical or verbal) with assessment(s) is necessary to enable patient to complete evaluation component. Typically, 60 minutes are spent face-to-face with the patient and/or family.	\$	281.00
Re-evaluation of occupational therapy established plan of care, requiring these components: An assessment of changes in patient functional or medical status with revised plan of care; An update to the initial occupational profile to reflect changes in condition or environment that affect future interventions and/or goals; and A revised plan of care. A formal reevaluation is performed when there is a documented change in functional status or a significant change to the plan of care is required. Typically, 30 minutes are spent face-to-face with the patient and/or family.	\$	116.00
	\$	89.00
	\$ \$	89.00 89.00
	\$	89.00
Wheelchair management (eg, assessment, fitting, training), each 15 minutes	\$	89.00
Debridement (eg, high pressure waterjet with/without suction, sharp selective debridement with scissors, scalpel and forceps), open wound, (eg, fibrin, devitalized epidermis and/or dermis, exudate, debris, biofilm), including topical application(s), wound assessment, use of a whirlpool, when performed and instruction(s) for ongoing care, per session, total wound(s) surface area; first 20 sq cm or less	\$	605.00
Debridement (eg, high pressure waterjet with/without suction, sharp selective debridement with scissors, scalpel and forceps), open wound, (eg, fibrin, devitalized epidermis and/or dermis, exudate, debris, biofilm), including topical application(s), wound assessment, use of a whirlpool, when performed and instruction(s) for ongoing care, per session, total wound(s) surface area; first 20 sq cm or less	\$	605.00
Debridement (eg, high pressure waterjet with/without suction, sharp selective debridement with scissors, scalpel and forceps), open wound, (eg, fibrin, devitalized epidermis and/or dermis, exudate, debris, biofilm), including topical application(s), wound assessment, use of a whirlpool, when performed and instruction(s) for ongoing care, per session, total wound(s) surface area; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)	\$	605.00
Debridement (eg, high pressure waterjet with/without suction, sharp selective debridement with scissors, scalpel and forceps), open wound, (eg, fibrin, devitalized epidermis and/or dermis, exudate, debris, biofilm), including topical application(s), wound assessment, use of a whirlpool, when performed and instruction(s) for ongoing care, per session, total wound(s) surface area; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)	\$	344.00
Removal of devitalized tissue from wound(s), non-selective debridement, without anesthesia (eg, wet-to-moist dressings, enzymatic, abrasion, larval therapy), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session	\$	345.00
Negative pressure wound therapy (eg, vacuum assisted drainage collection), utilizing durable medical equipment (DME), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area less than or equal to 50 square centimeters	\$	345.00
Negative pressure wound therapy (eg, vacuum assisted drainage collection), utilizing durable medical equipment (DME), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area greater than 50 square centimeters	\$	607.00
Negative pressure wound therapy, (eg, vacuum assisted drainage collection), utilizing disposable, non-durable medical equipment including provision of exudate management collection system, topical application(s), wound assessment, and instructions for ongoing care, per session; total wound(s) surface area less than or equal to 50 square centimeters	\$	629.00
Negative pressure wound therapy, (eg, vacuum assisted drainage collection), utilizing disposable, non-durable medical equipment including provision of exudate management collection system, topical application(s), wound assessment, and instructions for ongoing care, per session; total wound(s) surface area greater than 50 square centimeters	\$	629.00
	\$	29.00
Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes	\$	159.00
Prosthetic training, upper and/or lower extremity(s), each 15 minutes	\$	139.00
Orthotic(s)/prosthetic(s) management and/or training, upper extremity(ies), lower extremity(ies), and/or trunk, subsequent orthotic(s)/prosthetic(s) encounter, each 15 minutes	\$	192.00
Orthotic(s)/prosthetic(s) management and/or training, upper extremity(ies), lower extremity(ies), and/or trunk, subsequent orthotic(s)/prosthetic(s) encounter, each 15 minutes	\$	192.00
Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes	\$	66.00

DESCRIPTION		CHARGE
Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes	\$	66.00
Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes	\$	66.00
Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes	\$	66.00
Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes	\$	66.00
Medical nutrition therapy; group (2 or more individual(s)), each 30 minutes	\$	44.00
Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)	\$	54.00
Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)	\$	54.00
Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)	\$	54.00
Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)	\$	54.00
Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)	\$	30.00
Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)	\$	28.00
Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)	\$	21.00
Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)	\$	4.00
Handling and/or conveyance of specimen for transfer from the patient in other than an office to a laboratory (distance may be indicated)	\$ \$	10.00
Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and	Ş	359.00
physiological status; initial 15 minutes of intraservice time, patient younger than 5 years of age		
Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that	\$	359.00
the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and	ç	339.00
physiological status; initial 15 minutes of intraservice time, patient age 5 years or older		
Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that	\$	359.00
the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and	Ŷ	555.00
physiological status; initial 15 minutes of intraservice time, patient age 5 years or older		
Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that	\$	300.00
the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and	+	
physiological status; each additional 15 minutes intraservice time (List separately in addition to code for primary service)		
Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that	\$	300.00
the sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and		
physiological status; each additional 15 minutes intraservice time (List separately in addition to code for primary service)		
Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care	\$	349.00
professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient younger than 5 years of		
age		
Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care	\$	349.00
professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient age 5 years or older		
Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care	\$	349.00
professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient age 5 years or older		
	L .	
Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care	\$	280.00
professional performing the diagnostic or therapeutic service that the sedation supports; each additional 15 minutes intraservice time (List separately in		
addition to code for primary service)		
Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care	\$	280.00
professional performing the diagnostic or therapeutic service that the sedation supports; each additional 15 minutes intraservice time (List separately in		
addition to code for primary service)	L ć	247.00
Phlebotomy, therapeutic (separate procedure)	\$	347.00
Phlebotomy, therapeutic (separate procedure)	\$	347.00
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health	\$	261.00
care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting		
problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.		
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: An expanded problem focused	\$	267.00
history; An expanded problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians,	Ŷ	207.00
other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs.		
Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent face-to-face with the patient and/or family.		
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed	\$	279.00
examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care	. 	
professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s)		
are of moderate severity. Typically, 30 minutes are spent face-to-face with the patient and/or family.		
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A	\$	285.00
comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified		
health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the		
presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.		

DESCRIPTION	CHARGE
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family.	\$ 297.00
Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician or other qualified health care professional. Usually, the presenting problem(s) are minimal. Typically, 5 minutes are spent performing or supervising these services.	\$ 261.00
Office or other outpatient visit for the evaluation and management of an established patient, that may not require the presence of a physician or other qualified health care professional. Usually, the presenting problem(s) are minimal. Typically, 5 minutes are spent performing or supervising these services.	\$ 261.00
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.	\$ 267.00
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.	\$ 267.00
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.	\$ 279.00
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.	\$ 279.00
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.	\$ 285.00
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.	\$ 285.00
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.	\$ 297.00
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.	\$ 297.00
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of low severity. Typically, 30 minutes are spent at the bedside and on the patient's hospital floor or unit.	\$ 429.00
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of moderate severity. Typically, 50 minutes are spent at the bedside and on the patient's hospital floor or unit.	\$ 578.00

DESCRIPTION	CHARGE
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.	\$ 855.00
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Medical decision making that is straightforward or of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is stable, recovering or improving. Typically, 15 minutes are spent at the bedside and on the patient's hospital floor or unit.	\$ 164.00
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.	\$ 305.00
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.	\$ 439.00
Hospital discharge day management; 30 minutes or less	\$ 307.00
Hospital discharge day management; more than 30 minutes	\$ 450.00
Inpatient consultation for a new or established patient, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 20 minutes are spent at the bedside and on the patient's hospital floor or unit.	\$ 261.00
Inpatient consultation for a new or established patient, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low severity. Typically, 40 minutes are spent at the bedside and on the patient's hospital floor or unit.	\$ 267.00
Inpatient consultation for a new or established patient, which requires these 3 key components: A detailed history; A detailed examination; and Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 55 minutes are spent at the bedside and on the patient's hospital floor or unit.	\$ 279.00
Inpatient consultation for a new or established patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 80 minutes are spent at the bedside and on the patient's hospital floor or unit.	\$ 285.00
Inpatient consultation for a new or established patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 110 minutes are spent at the bedside and on the patient's hospital floor or unit.	\$ 297.00
Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor.	\$ 228.00
Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; and Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity.	\$ 415.00
Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; and Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity.	\$ 415.00
Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity.	\$ 685.00
Emergency department visit for the evaluation and management of a patient, which requires these 3 key components: A detailed history; A detailed examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of high severity, and require urgent evaluation by the physician, or other qualified health care professionals but do not pose an immediate significant threat to life or physiologic function.	\$ 1,208.00

DESCRIPTION		CHARGE
Emergency department visit for the evaluation and management of a patient, which requires these 3 key components within the constraints imposed by the urgency of the patient's clinical condition and/or mental status: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of high severity and pose an immediate significant threat to life or physiologic function.	\$	1,874.00
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes	\$	2,609.00
Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service)	\$	571.00
Computer-aided detection, including computer algorithm analysis of MRI image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation, breast MRI (List separately in addition to code for primary procedure)	\$	45.00
External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)	\$	375.00
Myocardial strain imaging (quantitative assessment of myocardial mechanics using image-based analysis of local myocardial dynamics) (List separately in addition to code for primary procedure)	\$	284.00
Needle, sterile, any size, each	\$	277.00
Needle, sterile, any size, each	\$	82.00
Sterile water, saline and/or dextrose, diluent/flush, 10 ml		OPEN
Sterile water, saline and/or dextrose, diluent/flush, 10 ml		OPEN
Sterile water, saline and/or dextrose, diluent/flush, 10 ml		OPEN
Catheter, drainage	\$	56.00
Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.)	\$	63.00
Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.)	\$	112.00
Indwelling catheter; specialty type, (e.g., coude, mushroom, wing, etc.), each	\$	75.00
Indwelling catheter; specialty type, (e.g., coude, mushroom, wing, etc.), each	\$	120.00
Intermittent urinary catheter; coude (curved) tip, with or without coating (teflon, silicone, silicone elastomeric, or hydrophilic, etc.), each	\$	45.00
Tubing with integrated heating element for use with positive airway pressure device	\$	91.00
Peak expiratory flow rate meter, hand held	\$	80.00
Cannula, nasal	\$	167.00
Breathing circuits	\$	146.00
Breathing circuits	\$	203.00
Breathing circuits	\$	149.00
Breathing circuits	\$ \$	92.00 306.00
Tissue marker, implantable, any type, each Tissue marker, implantable, any type, each	\$	299.00
Tissue marker, implantable, any type, each	\$	299.00
Tissue marker, implantable, any type, each	\$	397.00
Tissue marker, implantable, any type, each	\$	343.00
Tissue marker, implantable, any type, each	\$	131.00
Tissue marker, implantable, any type, each	\$	305.00
Gastric Band & Dissector	\$	9,961.00
Miscellaneous dialysis supplies, not otherwise specified	\$	509.00
Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing	\$	82.00
Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing	\$	25.00
Contact layer, sterile, 16 sq. in. or less, each dressing	\$	41.00
Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing		OPEN OPEN
adhesive border, each dressing Vacuum drainage collection unit and tubing kit, including all supplies needed for collection unit change, for use with implanted catheter, each	\$	448.00
Artificial saliva, 30 ml	ې ا	448.00 OPEN
Technetium tc-99m sestamibi, diagnostic, per study dose	\$	763.61
Technetium tc-99m sestambi, diagnostic, per study dose	\$	753.00
Technetium tc-99m sestamibi, diagnostic, per study dose	\$	753.00
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries	\$	191.70
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries	\$	189.00
Thallium tl-201 thallous chloride, diagnostic, per millicurie	\$	165.08
Thallium tl-201 thallous chloride, diagnostic, per millicurie	\$	163.00
Technetium tc-99m pertechnetate, diagnostic, per millicurie	\$	2.13
Technetium tc-99m pertechnetate, diagnostic, per millicurie	\$	2.10
Iodine i-123 sodium iodide, diagnostic, per 100 microcuries, up to 999 microcuries	\$	318.44
Iodine i-123 sodium iodide, diagnostic, per 100 microcuries, up to 999 microcuries	\$	314.00
lodine i-131 sodium iodide capsule(s), therapeutic, per millicurie	\$	76.00

DESCRIPTION	CHARGE
Technetium tc-99m exametazime, diagnostic, per study dose, up to 25 millicuries	\$ 5,296.03
Iodine i-131 sodium iodide solution, therapeutic, per millicurie	\$ 46.00
Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries	\$ 187.44
Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries	\$ 185.00
Technetium tc-99m pyrophosphate, diagnostic, per study dose, up to 25 millicuries	\$ 214.07
Technetium tc-99m pyrophosphate, diagnostic, per study dose, up to 25 millicuries	\$ 212.00
Technetium tc-99m pentetate, diagnostic, per study dose, up to 25 millicuries	\$ 187.44
Technetium tc-99m pentetate, diagnostic, per study dose, up to 25 millicuries	\$ 185.00
Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries	\$ 94.79
Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries	\$ 94.00
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries	\$ 291.81
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries	\$ 106.50
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries	\$ 288.00
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries	\$ 105.00
Indium in-111 pentetate, diagnostic, per 0.5 millicurie	\$ 7,218.57
Indium in-111 pentetate, diagnostic, per 0.5 millicurie	\$ 7,117.00
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	\$ 1,731.69
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	\$ 1,708.00
Gallium ga-67 citrate, diagnostic, per millicurie	\$ 90.53
Gallium ga-67 citrate, diagnostic, per millicurie	\$ 90.00
Technetium tc-99m labeled red blood cells, diagnostic, per study dose, up to 30 millicuries	\$ 449.43
Technetium tc-99m labeled red blood cells, diagnostic, per study dose, up to 30 millicuries	\$ 444.00
Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries	\$ 99.05
Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries	\$ 98.00
Technetium tc-99m mertiatide, diagnostic, per study dose, up to 15 millicuries	\$ 1,126.77
Technetium to-99m mertiatide, diagnostic, per study dose, up to 15 millicuries	\$ 1,111.00
Technetium tc-99m pentetate, diagnostic, aerosol, per study dose, up to 75 millicuries	\$ 344.00
Technetium tc-99m pentetate, diagnostic, aerosol, per study dose, up to 75 millicuries	\$ 340.00
Technetium to-99m exametazime labeled autologous white blood cells, diagnostic, per study dose	\$ 6,085.41
Technetium tc-99m exametazime labeled autologous white blood cells, diagnostic, per study dose	\$ 6,000.00 2,730.66
Indium in-111 labeled autologous white blood cells, diagnostic, per study dose Indium in-111 labeled autologous white blood cells, diagnostic, per study dose	\$ 2,730.66
Indium in-111 labeled actologous white blood cens, diagnostic, per study dose	\$ 7,105.68
Indium in-111 pentetreotide, diagnostic, per study dose, up to 6 millicuries	\$ 7,006.00
Injection, gadobenate dimeglumine (multihance), per ml	\$ 9.32
Injection, gadobenate dimeglumine (multihance), per mi	\$ 9.19
Injection, gadobenete amegianme (matchanee), per mil	\$ 7.76
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml	\$ 2.10
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml	\$ 2.10
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml	\$ 3.00
Sodium fluoride f-18, diagnostic, per study dose, up to 30 millicuries	\$ 883.95
Sodium fluoride f-18, diagnostic, per study dose, up to 30 millicuries	\$ 872.00
Injection, gadoxetate disodium, 1 ml	\$ 15.98
Injection, gadoxetate disodium, 1 ml	\$ 16.00
Injection, gadoxetate disodium, 1 ml	\$ 16.00
Injection, gadobutrol, 0.1 ml	\$ 4.26
Injection, gadobutrol, 0.1 ml	\$ 4.20
Injection, gadobutrol, 0.1 ml	\$ 5.00
Gallium ga-68, dotatate, diagnostic, 0.1 millicurie	\$ 281.40
Gallium ga-68, dotatate, diagnostic, 0.1 millicurie	\$ 268.00
Fluciclovine f-18, diagnostic, 1 millicurie	\$ 1,417.50
Fluciclovine f-18, diagnostic, 1 millicurie	\$ 1,418.00
Gastrostomy/jejunostomy tube, standard, any material, any type, each	\$ 595.00
Gastrostomy/jejunostomy tube, standard, any material, any type, each	\$ 120.00
Gastrostomy/jejunostomy tube, standard, any material, any type, each	\$ 180.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,536.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,350.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,689.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 990.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 354.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 324.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 307.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 369.00

DESCRIPTION		CHARGE
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	369.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	66.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	66.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	132.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	65.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ \$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)		
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ \$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	440.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	609.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	639.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	87.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	102.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	491.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	1,684.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	5 133.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	

DESCRIPTION		CHARGE
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	1,335.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	1,696.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	1,185.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	781.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	663.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	5,674.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	688.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	7,289.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	3,750.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	88.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	185.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	391.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	2,829.0
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	445.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	953.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	2,981.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	549.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	932.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	1,178.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	263.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	1,122.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	613.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	66.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	394.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	504.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	331.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	394.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	88.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	824.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	133.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	2,465.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	3,965.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	3,439.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	2,407.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	3,756.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	6,441.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	769.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	2,776.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)		2,337.00
	\$	926.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	511.00 549.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	689.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	714.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	726.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	832.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	689.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	6,813.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	4,107.0
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	4,107.0
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	5,161.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	4,983.0
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	657.0
Anchor/screw for opposing bone to bone or soft tissue-to-bone (implantable)	\$	456.0
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	1,906.0
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	2,586.0
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	140.0
Anchor/screw for opposing bone to bone or soft tissue-to-bone (implantable)	\$	213.0
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	448.0
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	7,101.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	101.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$	843.0
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	Ś	781.0

DESCRIPTION	CHARGE
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,479.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,634.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 5,793.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 445.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 102.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 886.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 500.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 982.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,369.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,527.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,686.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 2,097.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 6,384.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 6,740.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 5,858.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,836.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 934.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 3,685.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 3,632.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 533.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 439.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 767.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,299.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 423.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 168.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 2,301.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,015.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 6,665.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 3,452.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 2,478.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,420.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 2,533.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 823.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,167.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,827.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 414.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,222.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 3,072.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 9,135.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,258.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,827.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 4,183.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 3,657.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 339.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 3,817.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 2,557.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 728.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 533.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 438.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 10,035.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 807.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 113.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,184.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 786.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 4,342.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 8,140.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 15,169.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,420.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 772.00
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	\$ 1,275.00
Brachytherapy needle	\$ 89.00
Brachytherapy source, non-stranded, high dose rate iridium-192, per source	\$ 2,870.00
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)	\$ 2,777.00

DESCRIPTION	CHARGE
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)	\$ 2,422.00
Catheter, balloon dilatation, non-vascular	\$ 1,147.00
Catheter, balloon dilatation, non-vascular	\$ 6,902.00
Catheter, balloon dilatation, non-vascular	\$ 1,033.00
Catheter, balloon dilatation, non-vascular	\$ 7,366.00
Catheter, balloon dilatation, non-vascular	\$ 7,344.00
Catheter, balloon dilatation, non-vascular	\$ 7,344.00
Catheter, balloon tissue dissector, non-vascular (insertable)	\$ 681.00
Catheter, drainage	\$ 1,162.00
	\$ 91.00
-	\$ 51.00
Catheter, drainage	\$ 115.00
Catheter, drainage	\$ 1,468.00
Catheter, drainage	\$ 186.00
Catheter, drainage	\$ 403.00
Catheter, drainage	\$ 456.00
Catheter, drainage	\$ 102.00
	\$ 5,039.00
	\$ 84.00
	\$ 432.00
Catheter, drainage	\$ 2,160.00
	\$ 70.00
Catheter, electrophysiology, diagnostic/ablation, other than 3d or vector mapping, other than cool-tip	\$ 4,170.00
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis)	\$ 713.00
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis)	\$ 490.00
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis)	\$ 131.00
	\$ 1,355.00
	\$ 1,355.00
Catheter, hemodialysis/peritoneal, short-term	\$ 658.00
Catheter, intraspinal	\$ 829.00
Catheter, thrombectomy/embolectomy	\$ 309.00
Catheter, thrombectomy/embolectomy	\$ 268.00
Catheter, thrombectomy/embolectomy	\$ 392.00
	\$ 56.00
	\$ 42.00
Closure device, vascular (implantable/insertable)	\$ 422.00
Event recorder, cardiac (implantable)	\$ 12,145.00
Adhesion barrier	\$ 877.00
Adhesion barrier	\$ 952.00
	\$ 48,975.00
Graft, vascular	\$ 69.00
Guide wire	\$ 388.00
Guide wire	\$ 709.00
Guide wire	\$ 282.00
Guide wire	\$ 431.00
Guide wire	\$ 709.00
Guide wire	\$ 282.00
Guide wire	\$ 394.00
	\$ 50.00
Guide wire	\$ 609.00
Guide wire	\$ 407.00
	\$ 60.00
	\$ 111.00
	\$ 116.00
	\$ 154.00
	\$ 288.00
	\$ 149.00
	\$ 456.00
Guide wire	\$ 132.00
Guide wire	\$ 369.00
Guide wire	\$ 133.00
Guide wire	\$ 971.00
Guide wire	\$ 604.00

uide wire uide wire	\$
	721.00
	\$ 50.00
uide wire	\$ 1,785.00
uide wire	\$ 1,694.00
uide wire	\$ 611.00
uide wire	\$ 1,289.00
uide wire	\$ 130.00
uide wire	\$ 365.00
uide wire	\$ 62.00
uide wire	\$ 1,340.00
uide wire	\$ 50.00
epair device, urinary, incontinence, with sling graft	\$ 5,326.00
int device (implantable)	\$ 1,372.00
int device (implantable)	\$ 244.00
int device (implantable)	\$ 1,625.00
int device (implantable)	\$ 367.00
int device (implantable)	\$ 367.00
int device (implantable)	\$ 3,654.00
int device (implantable)	\$ 1,218.00
int device (implantable)	\$ 2,864.00
int device (implantable)	\$ 2,804.00
int device (implantable)	\$ 1,477.00
int device (implantable)	\$ 4,376.00
int device (implantable)	\$ 4,376.00
int device (implantable)	\$ 4,863.00
int device (implantable)	\$ 1,827.00
int device (implantable)	\$ 1,927.00
int device (implantable)	\$ 642.00
int device (implantable)	\$ 4,376.00
int device (implantable)	\$ 2,640.00
int device (implantable)	\$ 6,395.00
int device (implantable)	\$ 1,346.00
int device (implantable)	\$ 1,320.00
int device (implantable)	\$ 1,372.00
int device (implantable)	\$ 9,117.00
int device (implantable)	\$ 8,466.00
int device (implantable)	\$ 33,418.00
int device (implantable)	\$ 5,863.00
int device (implantable)	\$ 4,376.00
int device (implantable)	\$ 5,227.00
int device (implantable)	\$ 4,183.00
int device (implantable)	\$ 3,858.00
int device (implantable)	\$ 2,533.00
int device (implantable)	\$ 2,917.00
int device (implantable)	\$ 2,843.00
int device (implantable)	\$ 7,892.00
int device (implantable)	\$ 1,218.00
sint device (implantable)	\$ 6,808.00
sint device (implantable)	\$ 2,843.00
vint device (implantable)	\$ 3,858.00
int device (implantable)	\$ 5,685.00
int device (implantable)	\$ 1,625.00
int device (implantable)	\$ 2,843.00
int device (implantable)	\$ 1,016.00
int device (implantable)	\$ 2,843.00
int device (implantable)	\$ 12,913.00
int device (implantable)	\$ 8,120.00
ead, cardioverter-defibrillator, endocardial single coil (implantable)	\$ 15,428.00
ead, neurostimulator (implantable)	\$ 3,780.00
ead, neurostimulator (implantable)	\$ 3,990.00
ead, neurostimulator (implantable)	\$ 5,179.00
	\$ 5,880.00
ead, neurostimulator (implantable)	

DESCRIPTION		CHARGE
Mesh (implantable) (Includes MatriStem [®] Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix [®])	\$	3,222.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	824.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	520.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	520.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	1,564.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	1,795.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	1,761.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	3,272.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	2,290.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®) Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	2,748.00 3,663.00
Mesh (implantable) (includes Matristem* Plastic Surgery Matrix, Wound Care Matrix, Matristem MicroMatrix*) Mesh (implantable) (Includes Matristem* Plastic Surgery Matrix, Wound Care Matrix, Matristem MicroMatrix*)	\$	8,595.00
Mesh (implantable) (Includes Matristern [®] Plastic Surgery Matrix, Wound Care Matrix, Matristern MicroMatrix [®])	\$	11,178.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	824.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	6,964.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	7,153.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	9,886.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	3,633.00
Mesh (implantable) (Includes MatriStem [®] Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix [®])	\$	3,897.00
Mesh (implantable) (Includes MatriStem [®] Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix [®])	\$	4,588.00
Mesh (implantable) (Includes MatriStem [®] Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix [®])	\$	5,034.00
Mesh (implantable) (Includes MatriStem® Plastic Surgery Matrix, Wound Care Matrix, MatriStem MicroMatrix®)	\$	545.00
Ocular device, intraoperative, detached retina		OPEN
Pacemaker, dual chamber, rate-responsive (implantable)	\$	15,022.00
Pacemaker, dual chamber, rate-responsive (implantable)	\$	11,977.00
Pacemaker, dual chamber, rate-responsive (implantable)	\$	14,615.00
Pacemaker, dual chamber, rate-responsive (implantable)	\$	15,224.00
Pacemaker, dual chamber, rate-responsive (implantable)	\$	17,864.00
Pacemaker, dual chamber, rate-responsive (implantable)	\$	14,723.00
Pacemaker, dual chamber, rate-responsive (implantable)	\$	14,723.00
Pacemaker, dual chamber, rate-responsive (implantable)	\$	26,349.00
Pacemaker, dual chamber, rate-responsive (implantable) Pacemaker, dual chamber, rate-responsive (implantable)	\$	14,270.00 17,031.00
Pacemaker, dual chamber, rate-responsive (implantable)	\$	17,031.00
Pacemaker, dual chamber, rate-responsive (implantable)	\$	15,224.00
Pacemaker, dual chamber, rate-responsive (implantable)	\$	15,224.00
Pacemaker, dual chamber, rate-responsive (implantable)	\$	23,527.00
Pacemaker, dual chamber, rate-responsive (implantable)	\$	19,488.00
Pacemaker, single chamber, rate-responsive (implantable)	\$	13,398.00
Pacemaker, single chamber, rate-responsive (implantable)	\$	9,744.00
Pacemaker, single chamber, rate-responsive (implantable)	\$	8,467.00
Pacemaker, single chamber, rate-responsive (implantable)	\$	13,398.00
Pacemaker, single chamber, rate-responsive (implantable)	\$	13,398.00
Patient programmer, neurostimulator	\$	2,455.00
Patient programmer, neurostimulator	\$	4,426.00
Port, indwelling (implantable)	\$	3,126.00
Port, indwelling (implantable)	\$	2,600.00
Port, indwelling (implantable)	\$	3,123.00
Port, indwelling (implantable)	\$	1,727.00
Generator, neurostimulator (implantable), with rechargeable battery and charging system	\$	38,850.00
Generator, neurostimulator (implantable), with rechargeable battery and charging system	\$	39,228.00
Generator, neurostimulator (implantable), with rechargeable battery and charging system	\$	53,773.00
Stent, coated/covered, with delivery system	\$	900.00
Stent, coated/covered, with delivery system	\$	37,960.00
Stent, coated/covered, with delivery system Stent coated/covered with delivery system	\$	5,092.00
Stent, coated/covered, with delivery system Stent, coated/covered, with delivery system	\$	39,381.00
Stent, coated/covered, with delivery system Stent, coated/covered, with delivery system	\$	4,388.00
Stent, coated/covered, with delivery system Stent, coated/covered, with delivery system	\$	4,839.00
	\$	5,547.00 5,606.00
	l S	
Stent, coated/covered, with delivery system Stent, coated/covered, with delivery system		5 672 00
Stent, coated/covered, with delivery system Stent, coated/covered, with delivery system Stent, coated/covered, with delivery system	\$ \$	5,673.00 6,106.00

DESCRIPTION		CHARGE
Stent, coated/covered, with delivery system	\$	7,653.00
Stent, non-coated/non-covered, with delivery system	\$	9,449.00
Stent, non-coated/non-covered, with delivery system	\$	11,403.00
Stent, non-coated/non-covered, with delivery system	\$	144.00
Stent, non-coated/non-covered, with delivery system	\$	900.00
Stent, non-coated/non-covered, with delivery system	\$	4,162.00
Stent, non-coated/non-covered, with delivery system	\$	4,157.00
Stent, non-coated/non-covered, with delivery system	\$	5,465.00
Stent, non-coated/non-covered, without delivery system	\$	6,702.00
Stent, non-coated/non-covered, without delivery system	\$	1,020.00
Vena cava filter	\$	4,362.00
Adapter/extension, pacing lead or neurostimulator lead (implantable)	\$	5,880.00
Adapter/extension, pacing lead or neurostimulator lead (implantable)	\$	812.00
Catheter, guiding (may include infusion/perfusion capability)	\$	49.00
Catheter, guiding (may include infusion/perfusion capability)	\$	341.00
Catheter, guiding (may include infusion/perfusion capability)	\$	1,739.00
Catheter, guiding (may include infusion/perfusion capability)	\$	696.00
Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away	\$ ¢	228.00 388.00
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	\$ \$	388.00 257.00
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	\$ \$	47.00
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	\$	282.00
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	\$	1,928.00
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	\$	407.00
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	\$	504.00
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	\$	329.00
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	\$	346.00
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	\$	346.00
Lead, cardioverter-defibrillator, endocardial dual coil (implantable)	\$	15,428.00
Lead, cardioverter-defibrillator, endocardial dual coil (implantable)	\$	15,428.00
Lead, neurostimulator test kit (implantable)	\$	2,843.00
Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00
Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00
Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00
Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00
Lead, pacemaker, other than transvenous vdd single pass	\$	2,336.00
Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00
Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00
Lead, pacemaker, other than transvenous vdd single pass	\$	2,741.00
Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00
Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00
Lead, pacemaker, other than transvenous vdd single pass	\$	2,124.00
Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00
Lead, pacemaker, other than transvenous vdd single pass	\$	2,741.00
Lead, pacemaker, other than transvenous vdd single pass	\$	2,197.00
Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00
Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00
Lead, pacemaker, other than transvenous vdd single pass Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00 2,124.00
Lead, pacemaker, other than transvenous vod single pass Lead, pacemaker, other than transvenous vod single pass	\$ ¢	1,928.00
Lead, pacemaker, other than transvenous vod single pass Lead, pacemaker, other than transvenous vod single pass	\$ \$	2,124.00
Lead, pacemaker, other than transvenous vod single pass Lead, pacemaker, other than transvenous vod single pass	\$	2,124.00
Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00
Lead, pacemaker, other than transvenous vdd single pass	\$	1,928.00
Stent, non-coronary, temporary, without delivery system	\$	236.00
Stent, non-coronary, temporary, without delivery system Stent, non-coronary, temporary, without delivery system	\$	605.00
Stent, non-coronary, temporary, without delivery system Stent, non-coronary, temporary, without delivery system	\$	217.00
Stent, non-coronary, temporary, without delivery system	\$	206.00
Stent, non-coronary, temporary, without delivery system	\$	512.00
Stent, non-coronary, temporary, with delivery system	\$	696.00
Stent, non-coronary, temporary, with delivery system	\$	563.00
Catheter, occlusion	\$	93.00
Catheter, occlusion	\$	93.00

DESCRIPTION		CHARGE
Catheter, occlusion	\$	319.00
Repair device, urinary, incontinence, without sling graft	\$	1,318.00
Repair device, urinary, incontinence, without sling graft	\$	2,495.00
Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area	\$	1,683.00
Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code for primary procedure)	\$	1,683.00
Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children	\$	5,633.00
Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure)	\$	1,610.00
Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area	\$	1,683.00
Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (list separately in addition to code for primary procedure)	\$	1,683.00
Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children	\$	1,683.00
Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (list separately in addition to code for primary procedure)	\$	1,683.00
Magnetic resonance angiography with contrast, abdomen	\$	1,718.00
Magnetic resonance angiography with contrast, abdomen	\$	1,752.00
Magnetic resonance angiography without contrast, abdomen	\$	1,188.00
Magnetic resonance angiography without contrast, abdomen	\$	1,211.00
Magnetic resonance angiography without contrast followed by with contrast, abdomen	\$	1,987.00
Magnetic resonance angiography without contrast followed by with contrast, abdomen	\$	2,025.00
Magnetic resonance imaging with contrast, breast; unilateral	\$	1,718.00
Magnetic resonance imaging without contrast, breast; unilateral	\$	1,188.00
Magnetic resonance imaging without contrast followed by with contrast, breast; unilateral	\$	1,987.00
Magnetic resonance imaging with contrast, breast; bilateral	\$	1,718.00
Magnetic resonance imaging without contrast, breast; bilateral	\$	1,188.00
Magnetic resonance imaging without contrast followed by with contrast, breast, bilateral	\$	1,987.00
Magnetic resonance angiography with contrast, chest (excluding myocardium)	\$	1,718.00
Magnetic resonance angiography with contrast, chest (excluding myocardium)	\$	1,752.00
Magnetic resonance angiography without contrast, chest (excluding myocardium)	\$	1,188.00
Magnetic resonance angiography without contrast, chest (excluding myocardium)	\$	1,211.00
Magnetic resonance angiography without contrast followed by with contrast, chest (excluding myocardium)	\$	1,987.00
Magnetic resonance angiography without contrast followed by with contrast, chest (excluding myocardium)	\$	2,025.00
Magnetic resonance angiography with contrast, lower extremity	\$	1,718.00
Magnetic resonance angiography with contrast, lower extremity	\$	1,752.00
Magnetic resonance angiography without contrast, lower extremity	\$	1,188.00
Magnetic resonance angiography without contrast, lower extremity	\$ ¢	1,211.00
Magnetic resonance angiography without contrast followed by with contrast, lower extremity Magnetic resonance angiography without contrast followed by with contrast, lower extremity	\$	3,549.00 3,619.00
	\$ ¢	1,718.00
Magnetic resonance angiography with contrast, pelvis Magnetic resonance angiography with contrast, pelvis	\$ \$	1,752.00
Magnetic resonance angiography with contrast, pelvis	\$	1,188.00
Magnetic resonance angiography without contrast, pelvis	\$	1,138.00
Magnetic resonance angiography without contrast, pervise Magnetic resonance angiography without contrast followed by with contrast, pelvis	\$	1,987.00
Magnetic resonance angiography without contrast followed by with contrast, pelvis	\$	2,025.00
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode	\$	1,674.00
recording, when performed, follow-up or limited study	, v	1,07 4.00
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography	\$	1,888.00
Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with	\$	2,695.00
interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with	\$	2,695.00
interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision Magnetic resonance angiography with contrast, spinal canal and contents	\$	1,718.00
Magnetic resonance angiography with contrast, spinal canal and contents	\$	1,752.00

DESCRIPTION		CHARGE
Magnetic resonance angiography without contrast, spinal canal and contents	\$	1,188.00
Magnetic resonance angiography without contrast, spinal canal and contents	\$	1,211.00
Magnetic resonance angiography without contrast followed by with contrast, spinal canal and contents	\$	1,987.00
Magnetic resonance angiography without contrast followed by with contrast, spinal canal and contents	\$	2,025.00
Magnetic resonance angiography with contrast, upper extremity	\$	1,718.00
Magnetic resonance angiography with contrast, upper extremity	\$	1,752.00
Magnetic resonance angiography without contrast, upper extremity	\$	1,188.00
Magnetic resonance angiography without contrast, upper extremity	\$	1,211.00
Magnetic resonance angiography without contrast followed by with contrast, upper extremity	\$	1,987.00
Magnetic resonance angiography without contrast followed by with contrast, upper extremity	\$	2,025.00
Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine		OPEN
Injection, pantoprazole sodium, per vial		OPEN
Injection, pantoprazole sodium, per vial		OPEN
Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity	1	OPEN
Injection, clevidipine butyrate, 1 mg		OPEN
Injection, lacosamide, 1 mg	1	OPEN
Injection, bupivacaine liposome, 1 mg		OPEN
Unclassified drugs or biologics: Nilotinib 200Mg Cap	1	OPEN
Unclassified drugs or biologics: Daratumumab Per 1Mg Inj Unclassified drugs or biologics: Lyrica Uclass Drugs/Bio		OPEN OPEN
Unclassified drugs or biologics: Lyrica Uclass Drugs/Bio Unclassified drugs or biologics: Pregabalin 100Mg Cap		OPEN
Unclassified drugs or biologics: Pregabalin 100kg Cap		OPEN
Unclassified drugs or biologics: Lyrica Uclass Drugs/Bio		OPEN
Unclassified drugs or biologics: Pregabalin 200Mg Cap		OPEN
Unclassified drugs or biologics: Pregadalin 200kg cap Unclassified drugs or biologics: Posaconazole 40Mg/MI Per MI		OPEN
Unclassified drugs or biologics: Lubiprostone 24Mcg Cap		OPEN
Unclassified drugs or biologics: Lapatinib 250Mg Tab		OPEN
Unclassified drugs or biologics: Ranolazine 500Mg Tab		OPEN
Unclassified drugs or biologics: Nilotinib 200Mg Cap	[OPEN
Unclassified drugs or biologics: Rifaximin 200 Mg Tab		OPEN
Unclassified drugs or biologics: Alvimopan 12Mg Caps		OPEN
Unclassified drugs or biologics: Lubiprostone 8Mcg Cap		OPEN
Unclassified drugs or biologics: Buffered Lidocaine 1% Per 1Ml		OPEN
Unclassified drugs or biologics: Idarucizumab Per 2.5 Gm Inj		OPEN
Unclassified drugs or biologics: Sod Benz-Sod Phenylacet Inj		OPEN
Injection, cangrelor, 1 mg		OPEN
aprepitant per 1 mg iv inj		OPEN
rituximab hyal per 10 mg inj		OPEN
Injection, sotalol hydrochloride, 1 mg		OPEN
Injection, conivaptan hydrochloride, 1 mg		OPEN
Injection, durvalumab, 10 mg		OPEN
Injection, edaravone, 1 mg		OPEN
Administration of influenza virus vaccine	\$	132.00
Administration of influenza virus vaccine	\$	132.00
Administration of influenza virus vaccine	\$	132.00
Administration of influenza virus vaccine	\$	132.00
Administration of influenza virus vaccine	\$	132.00
Administration of influenza virus vaccine	\$	132.00
Administration of influenza virus vaccine	\$	132.00
Administration of influenza virus vaccine	\$	132.00
Administration of influenza virus vaccine Administration of influenza virus vaccine	\$	132.00
	\$	132.00
Administration of pneumococcal vaccine	\$	180.00
Administration of pneumococcal vaccine Administration of pneumococcal vaccine	\$ \$	180.00 180.00
Administration of pneumococcal vaccine	\$ \$	180.00
Administration of pneumococcal vaccine Administration of pneumococcal vaccine	1	180.00
Administration of pneumococcal vaccine Administration of pneumococcal vaccine	\$ \$	180.00
Administration of pneumococcal vaccine	\$ \$	180.00
Administration of hepatitis b vaccine	\$ \$	166.00
Administration of hepatitis b vaccine	\$ \$	166.00
Prostate cancer screening; prostate specific antigen test (psa)	\$ \$	144.00
Colorectal cancer screening; flexible sigmoidoscopy	\$ \$	1,895.00

DESCRIPTION		CHARGE
Colorectal cancer screening; colonoscopy on individual at high risk	\$	2,658.00
Diabetes outpatient self-management training services, individual, per 30 minutes	\$	176.00
Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes	\$	80.00
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk	\$	2,658.00
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	\$	117.00
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	\$	117.00
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	\$	117.00
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	\$	117.00
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	\$	157.00
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	\$	157.00
Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening	\$	82.00
Wound closure utilizing tissue adhesive(s) only	\$	167.00
Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring)	\$	47.00
Therapeutic procedures to improve respiratory function, other than described by g0237, one on one, face to face, per 15 minutes (includes monitoring)	\$	60.00
Therapeutic procedures to improve respiratory function or increase strength or endurance of respiratory muscles, two or more individuals (includes	\$	95.00
monitoring)	l ć	1 001 00
Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility Hemodialysis procedure with single evaluation by a physician or other qualified health care professional	\$ \$	1,001.00 432.00
Hemodialysis procedure with single evaluation by a physician of other qualified health care professional	\$	452.00
Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes	\$	66.00
Medical nutrition therapy, reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition, or treatment regimen (including additional hours needed for renal disease), group (2 or more individuals), each 30 minutes	\$	44.00
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to g0204 or g0206)	\$	93.00
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care	\$	57.00
Reconstruction, computed tomographic angiography of aorta for surgical planning for vascular surgery	\$	2,091.00
Reconstruction, computed tomographic angiography of aorta for surgical planning for vascular surgery	\$	2,091.00
Low dose ct scan (ldct) for lung cancer screening	\$	138.00
Low dose ct scan (ldct) for lung cancer screening	\$	138.00
Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous	\$	94.00
Vessel mapping of vessels for hemodialysis access (services for preoperative vessel mapping prior to creation of hemodialysis access using an autogenous	\$	785.00
hemodialysis conduit, including arterial inflow and venous outflow)		
Hospital observation service, per hour	\$	48.00
Hospital observation service, per hour	\$	48.00
Hospital observation service, per hour	\$	48.00
Hospital observation service, per hour	\$	48.00
Hospital observation service, per hour	\$	48.00
Hospital observation service, per hour Direct admission of patient for hospital observation care	\$ \$	48.00 1.00
Direct admission of patient for hospital observation care	\$	1.00
Direct admission of patient for hospital observation care	\$	1.00
Direct admission of patient for hospital observation care	\$	1.00
Direct admission of patient for hospital observation care	\$	1.00
Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation	\$	510.00
Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method	\$	1,266.00
Pulmonary rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day	\$	235.00
Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure)	\$	655.00
Preparation with instillation of fecal microbiota by any method, including assessment of donor specimen	\$	3,128.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	97.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	97.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	267.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	285.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	297.00

DESCRIPTION		CHARGE
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	267.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	285.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	297.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	267.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	285.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	297.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	97.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	164.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	97.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	267.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	285.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	297.00
Hospital outpatient clinic visit for assessment and management of a patient Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00 267.00
	ې ډ	279.00
Hospital outpatient clinic visit for assessment and management of a patient Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	283.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	267.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	285.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	297.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	97.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	267.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	285.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	297.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	267.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	285.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	297.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	97.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	267.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	
Hospital outpatient clinic visit for assessment and management of a patient	\$	297.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	267.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	285.00
Hospital outpatient clinic visit for assessment and management of a patient Hospital outpatient clinic visit for assessment and management of a patient	\$	297.00
	\$	261.00 267.00
Hospital outpatient clinic visit for assessment and management of a patient Hospital outpatient clinic visit for assessment and management of a patient	\$	267.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient Hospital outpatient clinic visit for assessment and management of a patient	\$ \$	285.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	97.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	97.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	267.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	285.00

DESCRIPTION	СН	ARGE
Hospital outpatient clinic visit for assessment and management of a patient	\$	297.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	267.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	285.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	297.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	261.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	267.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	279.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	285.00
Hospital outpatient clinic visit for assessment and management of a patient	\$	297.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily	\$	212.00
stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)		
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily	Ś	80.00
stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	Ŷ	00.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	115.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	424.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	113.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	284.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	166.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	112.00

DESCRIPTION		CHARGE
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	116.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	112.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	281.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	Ş	419.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	261.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	264.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	163.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	116.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	117.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	229.00

DESCRIPTION	CHARGE
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 107.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 109.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 116.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 117.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 126.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 126.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 486.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 486.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 275.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 275.00

DESCRIPTION	CHARGE
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 173.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 173.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 716.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 716.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 164.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 164.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 177.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 177.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 179.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 179.00

DESCRIPTION		CHARGE
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	108.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	108.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	108.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	Ş	110.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	110.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	110.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	66.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	67.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	210.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	46.00

DESCRIPTION	CHARGE
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 67.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 163.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 79.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 76.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 69.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 91.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 69.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 74.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 290.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 142.00

DESCRIPTION		CHARGE
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	136.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	130.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	170.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	Ş	113.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	226.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	370.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	63.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	225.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	207.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	283.00

DESCRIPTION	CHARGE
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 91.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 317.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 439.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 76.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 310.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 597.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 597.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 54.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 325.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 192.00

DESCRIPTION	CHARGE
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 189.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 94.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 63.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 71.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 71.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 70.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 63.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 91.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 330.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 443.00

DESCRIPTION	CHARGE
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 498.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 498.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 177.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 108.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 377.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 1,052.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 134.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 513.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 310.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 598.00

DESCRIPTION		CHARGE
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	116.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	Ş	107.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	94.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	619.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	94.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	243.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	710.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	657.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	629.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$	686.00

DESCRIPTION	CHARGE
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 443.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 443.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 327.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 327.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 46.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 46.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 46.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 46.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 46.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 46.00

DESCRIPTION	CHARGE
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 47.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 47.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 47.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 47.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 47.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 47.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 285.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed)	\$ 339.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	\$ 178.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	\$ 113.00

DESCRIPTION		CHARGE
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	\$	112.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	\$	176.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	\$	109.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	\$	109.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	\$	46.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	\$	80.00
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	\$	629.00
Development of cognitive skills to improve attention, memory, problem solving (includes compensatory training), direct (one-on-one) patient contact, each 15 minutes	\$	95.00
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	\$	1.00
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	\$ \$	1.00 1.00
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting more and a to a status and a to a status at the status at	\$	1.00
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting	\$	1.00
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting	\$	1.00
Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals	\$	1.00
Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting reporting Changing & maintaining body position functional limitation, discharge status, at discharge from therapy or to end reporting	\$ \$	1.00
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals	\$	1.00
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	\$	1.00
Carrying, moving & handling objects functional limitation, discharge status, at discharge from therapy or to end reporting	\$	1.00
Self care functional limitation, current status, at therapy episode outset and at reporting intervals	\$	1.00
Self care functional limitation, current status, at therapy episode outset and at reporting intervals	\$	1.00
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	\$ \$	1.00
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting Self care functional limitation, discharge status, at discharge from therapy or to end reporting	\$ \$	1.00 1.00

DESCRIPTION	СН	IARGE
Self care functional limitation, discharge status, at discharge from therapy or to end reporting	\$	1.00
Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals	\$	1.00
Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	\$	1.00
Other physical or occupational therapy primary functional limitation, discharge status, at discharge from therapy or to end reporting	\$	1.00
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals	\$	1.00
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	\$	1.00
Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting	\$	1.00
Motor speech functional limitation, current status at therapy episode outset and at reporting intervals	\$	1.00
Motor speech functional limitation, discharge status, at discharge from therapy or to end reporting	\$	1.00
Spoken language comprehension functional limitation, current status at therapy episode outset and at reporting intervals	\$	1.00
Spoken language comprehension functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting	\$	1.00
Spoken language comprehension functional limitation, discharge status, at discharge from therapy or to end reporting	\$	1.00
Spoken language expression functional limitation, current status at therapy episode outset and at reporting intervals	\$	1.00
Spoken language expression functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting	\$	1.00
Spoken language expression functional limitation, discharge status at discharge from therapy or to end reporting	\$	1.00
Memory functional limitation, current status at therapy episode outset and at reporting intervals	\$	1.00
Memory functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting	\$	1.00
Memory functional limitation, discharge status at discharge from therapy or to end reporting	\$	1.00
Motor speech functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting	\$	1.00
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)		DPEN
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	0	DPEN
Injection abciximab, 10 mg	0	DPEN
Injection, acetaminophen, 10 mg	0	DPEN
Injection, acetaminophen, 10 mg	0	DPEN
Injection, acetylcysteine, 100 mg	. 0	DPEN
Injection, acyclovir, 5 mg	0	DPEN
Injection, acyclovir, 5 mg	0	DPEN
Injection, adalimumab, 20 mg	0	DPEN
Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)	0	DPEN
Injection, adrenalin, epinephrine, 0.1 mg	1	DPEN
Injection, adrenalin, epinephrine, 0.1 mg	1	DPEN
Injection, adrenalin, epinephrine, 0.1 mg	1	DPEN
Injection, adrenalin, epinephrine, 0.1 mg	1	DPEN
Injection, adrenalin, epinephrine, 0.1 mg	1)PEN
Injection, adrenalin, epinephrine, 0.1 mg	1	OPEN
Injection, adrenalin, epinephrine, 0.1 mg		OPEN
Injection, alatrofloxacin mesylate, 100 mg	1	OPEN
Injection, alatrofloxacin mesylate, 100 mg	1	OPEN
Injection, alemtuzumab, 1 mg	1	OPEN DEN
Injection, alemtuzumab, 1 mg	1	DEN
Injection, amifostine, 500 mg Injection, amifostine, 500 mg	1	OPEN OPEN
Injection, methyldopate hcl, up to 250 mg	1	OPEN OPEN
Injection, alglucosidase alfa, (lumizyme), 10 mg	1	OPEN .
Injection, alpha 1 proteinase inhibitor (human), not otherwise specified, 10 mg		OPEN
Injection, alpha 1 proteinase inhibitor (human), not otherwise specified, 10 mg	1	OPEN
Injection, alprostadil, 1.25 mcg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	1	OPEN
Injection, amikacin sulfate, 100 mg	0	DPEN
Injection, amikacin sulfate, 100 mg	1	DPEN
Injection, aminophyllin, up to 250 mg	1	DPEN
Injection, amiodarone hydrochloride, 30 mg	1	OPEN
Injection, amphotericin b, 50 mg	1	PEN
Injection, amphotericin b, 50 mg	1	DPEN
Injection, amphotericin b lipid complex, 10 mg	1	DPEN
Injection, amphotericin b lipid complex, 10 mg	1	DPEN
Injection, amphotericin b liposome, 10 mg	1	DPEN
Injection, ampicillin sodium, 500 mg	0	DPEN

DESCRIPTION	CHARGE
Injection, ampicillin sodium, 500 mg	OPEN
Injection, ampicillin sodium, 500 mg	OPEN
Injection, ampicillin sodium, 500 mg	OPEN
Injection, ampicillin sodium, 500 mg	OPEN
Injection, ampicillin sodium, 500 mg	OPEN
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	OPEN
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	OPEN
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	OPEN
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	OPEN
Injection, amobarbital, up to 125 mg	OPEN
Injection, succinylcholine chloride, up to 20 mg	OPEN
Injection, hydralazine hcl, up to 20 mg	OPEN
Injection, hydralazine hcl, up to 20 mg	OPEN
Injection, aprotonin, 10,000 kiu	OPEN
Injection, aripiprazole, intramuscular, 0.25 mg	OPEN
Injection, aripiprazole, extended release, 1 mg	OPEN
Injection, azithromycin, 500 mg	OPEN OPEN
Injection, azithromycin, 500 mg	OPEN OPEN
Injection, atropine sulfate, 0.01 mg	OPEN
Injection, atropine sulfate, 0.01 mg Injection, atropine sulfate, 0.01 mg	OPEN
Injection, atropine sulfate, 0.01 mg	OPEN
Injection, atropine sulfate, 0.01 mg	OPEN
Injection, dimercaprol, per 100 mg	OPEN
Injection, baclofen, 10 mg	OPEN
Injection, baclofen, 10 mg	OPEN
Injection, baclofen, 50 mcg for intrathecal trial	OPEN
Injection, basiliximab, 20 mg	OPEN
Injection, belatacept, 1 mg	OPEN
Injection, belatacept, 1 mg	OPEN
Injection, belimumab, 10 mg	OPEN
Injection, belimumab, 10 mg	OPEN
Injection, dicyclomine hcl, up to 20 mg	OPEN
Injection, benztropine mesylate, per 1 mg	OPEN
Injection, benztropine mesylate, per 1 mg	OPEN
Injection, penicillin g benzathine and penicillin g procaine, 100,000 units	OPEN
Injection, penicillin g benzathine and penicillin g procaine, 100,000 units	OPEN
Injection, penicillin g benzathine, 100,000 units	OPEN
Injection, bezlotoxumab, 10 mg	OPEN
Injection, bezlotoxumab, 10 mg	OPEN
Buprenorphine, oral, 1 mg	OPEN
Buprenorphine, oral, 1 mg	OPEN
Injection, bivalirudin, 1 mg	OPEN
Injection, onabotulinumtoxina, 1 unit	OPEN
injection, busulfan, 1 mg	OPEN
injection, busulfan, 1 mg	OPEN
Injection, butorphanol tartrate, 1 mg	OPEN
Injection, c-1 esterase inhibitor (human), berinert, 10 units	OPEN
Injection, c-1 esterase inhibitor (human), berinert, 10 units	OPEN
Injection, c-1 esterase inhibitor (human), cinryze, 10 units	OPEN
Injection, edetate calcium disodium, up to 1000 mg	OPEN
Cinacalcet, oral, 1 mg, (for esrd on dialysis)	OPEN
Injection, calcium gluconate, per 10 ml Injection, calcium gluconate, per 10 ml	OPEN OPEN
Injection, calcium gluconate, per 10 ml	OPEN
Injection, calcium gluconate, per 10 ml	OPEN
Injection, calcium gluconate, per 10 ml	OPEN
Injection, calcium giuconate, per 10 mi Injection, calcitonin salmon, up to 400 units	OPEN OPEN
Injection, calcitonin salmon, up to 400 units	OPEN
Injection, calcitriol, 0.1 mcg	OPEN
Injection, caspofungin acetate, 5 mg	OPEN
Injection, caspolungin acetate, 5 mg	OPEN
Injection, caspofungin acetate, 5 mg	OPEN

DESCRIPTION	CHARGE
Injection, caspofungin acetate, 5 mg	OPEN
Injection, leucovorin calcium, per 50 mg	OPEN
Injection, leucovorin calcium, per 50 mg	OPEN
Injection, leucovorin calcium, per 50 mg	OPEN
Injection, leucovorin calcium, per 50 mg	OPEN
Injection, levoleucovorin calcium, 0.5 mg	OPEN
Injection, levoleucovorin calcium, 0.5 mg	OPEN
Injection, mepivacaine hydrochloride, per 10 ml	OPEN
Injection, mepivacaine hydrochloride, per 10 ml	OPEN
Injection, cefazolin sodium, 500 mg	OPEN
Injection, cefazolin sodium, 500 mg	OPEN
Injection, cefazolin sodium, 500 mg	OPEN
Injection, cefazolin sodium, 500 mg	OPEN
Injection, cefazolin sodium, 500 mg	OPEN
Injection, cefazolin sodium, 500 mg	OPEN
Injection, cefazolin sodium, 500 mg	OPEN
Injection, cefazolin sodium, 500 mg	OPEN
Injection, cefazolin sodium, 500 mg	OPEN
Injection, cefepime hydrochloride, 500 mg	OPEN
Injection, cefepime hydrochloride, 500 mg	OPEN
Injection, cefepime hydrochloride, 500 mg	OPEN
Injection, cefepime hydrochloride, 500 mg	OPEN
Injection, cefoxitin sodium, 1 gm	OPEN
Injection, cefoxitin sodium, 1 gm	OPEN
Injection, cefoxitin sodium, 1 gm	OPEN
Injection, cefoxitin sodium, 1 gm	OPEN
Injection, ceftolozane 50 mg and tazobactam 25 mg	OPEN
Injection, ceftolozane 50 mg and tazobactam 25 mg	OPEN
Injection, ceftriaxone sodium, per 250 mg	OPEN
Injection, ceftriaxone sodium, per 250 mg	OPEN
Injection, ceftriaxone sodium, per 250 mg	OPEN
Injection, ceftriaxone sodium, per 250 mg	OPEN
Injection, ceftriaxone sodium, per 250 mg	OPEN
Injection, ceftriaxone sodium, per 250 mg	OPEN
Injection, ceftriaxone sodium, per 250 mg	OPEN OPEN
Injection, ceftriaxone sodium, per 250 mg	OPEN
Injection, ceftriaxone sodium, per 250 mg	
Injection, sterile cefuroxime sodium, per 750 mg	OPEN OPEN
Injection, sterile cefuroxime sodium, per 750 mg Injection, sterile cefuroxime sodium, per 750 mg	OPEN
Injection, sterile cefuroxime sodium, per 750 mg	OPEN
Injection, seene centroxime sodium, per 750 mg	OPEN
Injection, cefotaxime sodium, per gm	OPEN
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg	OPEN
Injection, caffeine citrate, 5 mg	OPEN
Injection, ceftaroline fosamil, 10 mg	OPEN
Injection, ceftaroline fosamil, 10 mg	OPEN
Injection, ceftazidime, per 500 mg	OPEN
Injection, ceftazidime, per 500 mg	OPEN
Injection, ceftazidime, per 500 mg	OPEN
Injection, ceftazidime, per 500 mg	OPEN
Injection, ceftazidime, per 500 mg	OPEN
Injection, ceftazidime, per 500 mg	OPEN
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug	OPEN
is self administered)	2
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug	OPEN
is self administered)	0. 11
Injection, chloramphenicol sodium succinate, up to 1 gm	OPEN
Injection, chorionic gonadotropin, per 1,000 usp units	OPEN
Injection, clonidine hydrochloride, 1 mg	OPEN
Injection, clonidine hydrochloride, 1 mg	OPEN
Injection, cidofovir, 375 mg	OPEN
Injection, cidofovir, 375 mg	OPEN

DESCRIPTION	CHARGE
Injection, cilastatin sodium; imipenem, per 250 mg	OPEN
Injection, cilastatin sodium; imipenem, per 250 mg	OPEN
Injection, cilastatin sodium; imipenem, per 250 mg	OPEN
Injection, ciprofloxacin for intravenous infusion, 200 mg	OPEN
Injection, ciprofloxacin for intravenous infusion, 200 mg	OPEN
Injection, ciprofloxacin for intravenous infusion, 200 mg	OPEN
Injection, codeine phosphate, per 30 mg	OPEN
Injection, colistimethate sodium, up to 150 mg	OPEN
Injection, colistimethate sodium, up to 150 mg	OPEN
Injection, prochlorperazine, up to 10 mg	OPEN
Injection, prochlorperazine, up to 10 mg	OPEN
Injection, corticorelin ovine triflutate, 1 microgram	OPEN
Injection, corticotropin, up to 40 units	OPEN
Injection, cosyntropin (cortrosyn), 0.25 mg	OPEN
Injection, cosyntropin (cortrosyn), 0.25 mg	OPEN
Injection, crotalidae polyvalent immune fab (ovine), up to 1 gram	OPEN
Injection, cytomegalovirus immune globulin intravenous (human), per vial	OPEN
Injection, cytomegalovirus immune globulin intravenous (human), per vial	OPEN
Injection, daptomycin, 1 mg	OPEN
Injection, daptomycin, 1 mg	OPEN
Injection, darbepoetin alfa, 1 microgram (non-esrd use)	\$ 21.00
Injection, darbepoetin alfa, 1 microgram (non-esrd use)	OPEN
Injection, argatroban, 1 mg (for non-esrd use)	OPEN
Injection, argatroban, 1 mg (for esrd on dialysis)	OPEN
Injection, epoetin alfa, (for non-esrd use), 1000 units	\$ 60.00
Injection, epoetin alfa, (for non-esrd use), 1000 units	OPEN
Injection, epoetin alfa, (for non-esrd use), 1000 units	OPEN
Injection, epoetin alfa, (for non-esrd use), 1000 units	OPEN
Injection, epoetin alfa, (for non-esrd use), 1000 units	OPEN
Injection, epoetin alfa, (for non-esrd use), 1000 units	OPEN
Injection, epoetin alfa, (for non-esrd use), 1000 units	OPEN
Injection, epoetin alfa, (for non-esrd use), 1000 units	OPEN
Injection, decitabine, 1 mg	OPEN
Injection, decitabilite, 1 mg	OPEN
Injection, deferoxamine mesylate, 500 mg	OPEN
Injection, deferoxamine mesylate, 500 mg	OPEN
Injection, denosumab, 1 mg	OPEN
Injection, denosumab, 1 mg	OPEN
Injection, denostinab, 1 mg	OPEN
	OPEN
Injection, methylprednisolone acetate, 20 mg	OPEN
Injection, methylprednisolone acetate, 40 mg	OPEN
Injection, methylprednisolone acetate, 40 mg Injection, methylprednisolone acetate, 40 mg	
	OPEN
Injection, methylprednisolone acetate, 80 mg	OPEN
Injection, methylprednisolone acetate, 80 mg	OPEN
Injection, methylprednisolone acetate, 80 mg	OPEN
Injection, medroxyprogesterone acetate, 1 mg	OPEN
Injection, medroxyprogesterone acetate, 1 mg	OPEN
Injection, testosterone cypionate, 1 mg	OPEN
Injection, dexamethasone sodium phosphate, 1 mg	OPEN
Injection, dexamethasone sodium phosphate, 1 mg	OPEN
Injection, dexamethasone sodium phosphate, 1 mg	OPEN
Injection, dexamethasone sodium phosphate, 1 mg	OPEN
Injection, dexamethasone sodium phosphate, 1 mg	OPEN
Injection, dexamethasone sodium phosphate, 1 mg	OPEN
Injection, dexamethasone sodium phosphate, 1 mg	OPEN
Injection, dexamethasone sodium phosphate, 1 mg	OPEN
Injection, dihydroergotamine mesylate, per 1 mg	OPEN
Injection, dihydroergotamine mesylate, per 1 mg	OPEN
Injection, acetazolamide sodium, up to 500 mg	OPEN
Injection, acetazolamide sodium, up to 500 mg	\$ 558.00
Injection, digoxin, up to 0.5 mg	OPEN
Injection, digoxin, up to 0.5 mg	OPEN

DESCRIPTION	CHARGE
Injection, digoxin, up to 0.5 mg	OPEN
Injection, digoxin immune fab (ovine), per vial	OPEN
Injection, phenytoin sodium, per 50 mg	OPEN
Injection, hydromorphone, up to 4 mg	OPEN
Injection, hydromorphone, up to 4 mg	OPEN
Injection, hydromorphone, up to 4 mg	OPEN
Injection, hydromorphone, up to 4 mg	OPEN
Injection, hydromorphone, up to 4 mg	OPEN
Injection, hydromorphone, up to 4 mg	OPEN
Injection, hydromorphone, up to 4 mg	OPEN
Injection, hydromorphone, up to 4 mg	OPEN
Injection, hydromorphone, up to 4 mg	OPEN
Injection, hydromorphone, up to 4 mg	OPEN
Injection, hydromorphone, up to 4 mg	OPEN
Injection, dexrazoxane hydrochloride, per 250 mg	OPEN
Injection, dexrazoxane hydrochloride, per 250 mg	OPEN
Injection, dexrazoxane hydrochloride, per 250 mg	OPEN
Injection, diphenhydramine hcl, up to 50 mg	OPEN
Injection, diphenhydramine hcl, up to 50 mg	OPEN
Injection, chlorothiazide sodium, per 500 mg	OPEN
Injection, dmso, dimethyl sulfoxide, 50%, 50 ml	OPEN
Injection, methadone hcl, up to 10 mg	OPEN
Injection, methadone hcl, up to 10 mg	OPEN
Injection, dimenhydrinate, up to 50 mg	OPEN
Injection, dipyridamole, per 10 mg	OPEN
Injection, dipyridamole, per 10 mg	OPEN
Injection, dobutamine hydrochloride, per 250 mg	OPEN
Injection, dobutamine hydrochloride, per 250 mg	OPEN
Injection, dolasetron mesylate, 10 mg	OPEN
Injection, dolasetron mesylate, 10 mg	OPEN
Injection, dopamine hcl, 40 mg	OPEN
Injection, dopamine hcl, 40 mg	OPEN
Injection, dopamine hcl, 40 mg	OPEN
Injection, dopamine hcl, 40 mg	OPEN
Injection, dopamine hcl, 40 mg	OPEN
Injection, doxercalciferol, 1 mcg	OPEN
Injection, doxercalciferol, 1 mcg	OPEN
Injection, eculizumab, 10 mg	OPEN
Injection, eculizumab, 10 mg	OPEN
Injection, enfuvirtide, 1 mg	OPEN
Injection, epoprostenol, 0.5 mg	OPEN
Injection, eptifibatide, 5 mg	OPEN
Injection, eptifibatide, 5 mg	OPEN
Injection, ertapenem sodium, 500 mg	OPEN
Injection, ertapenem sodium, 500 mg	OPEN
Injection, erythromycin lactobionate, per 500 mg	OPEN
Injection, erythromycin lactobionate, per 500 mg	OPEN
Injection, estrogen conjugated, per 25 mg	OPEN
Injection, ethanolamine oleate, 100 mg	OPEN
Injection, etidronate disodium, per 300 mg	OPEN
Injection, etanercept, 25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self	OPEN
administered)	
Injection, etanercept, 25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self	OPEN
administered)	
Injection, ferric carboxymaltose, 1 mg	OPEN
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram	OPEN
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram	OPEN
Injection fluconazole, 200 mg	OPEN
Injection fluconazole, 200 mg	OPEN
Injection fluconazole, 200 mg	OPEN
Injection, fomepizole, 15 mg	OPEN
Injection, fosaprepitant, 1 mg	OPEN
Injection, fosaprepitant, 1 mg	OPEN

DESCRIPTION	CHARGE
Injection, foscarnet sodium, per 1000 mg	OPEN
Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	OPEN
Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	OPEN
Injection, gamma globulin, intramuscular, 1 cc	OPEN
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	OPEN
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	OPEN
Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg	OPEN
Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg	OPEN
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	OPEN
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	OPEN
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	OPEN
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	OPEN
Injection, ganciclovir sodium, 500 mg	OPEN
Injection, ganciclovir sodium, 500 mg	OPEN
Injection, hepatitis b immune globulin (hepagam b), intramuscular, 0.5 ml	OPEN
Injection, hepatitis b immune globulin (hepagam b), intramuscular, 0.5 ml	OPEN
Injection, hepatitis b immune globulin (hepagam b), intravenous, 0.5 ml	OPEN
Injection, hepatitis b immune globulin (hepagam b), intravenous, 0.5 ml	OPEN
Injection, garamycin, gentamicin, up to 80 mg	OPEN
Injection, garamycin, gentamicin, up to 80 mg Injection, garamycin, gentamicin, up to 80 mg	OPEN OPEN
	OPEN
Injection, garamycin, gentamicin, up to 80 mg	OPEN
Injection, garamycin, gentamicin, up to 80 mg Injection, garamycin, gentamicin, up to 80 mg	OPEN
	OPEN
Injection, garamycin, gentamicin, up to 80 mg Injection, garamycin, gentamicin, up to 80 mg	OPEN
Injection, glatiramer acetate, 20 mg	OPEN
Injection, gold sodium thiomalate, up to 50 mg	OPEN
Injection, golimumab, 1 mg, for intravenous use	OPEN
Injection, golimumab, 1 mg, for intravenous use	OPEN
Injection, glucagon hydrochloride, per 1 mg	OPEN
Injection, glucagon hydrochloride, per 1 mg	OPEN
Injection, gonadorelin hydrochloride, per 100 mcg	OPEN
Injection, granisetron hydrochloride, 100 mcg	OPEN
Injection, granisetron hydrochloride, 100 mcg	OPEN
Injection, granisetron hydrochloride, 100 mcg	OPEN
Injection, haloperidol, up to 5 mg	OPEN
Injection, haloperidol, up to 5 mg	OPEN
Injection, haloperidol, up to 5 mg	OPEN
Injection, haloperidol decanoate, per 50 mg	OPEN
Injection, haloperidol decanoate, per 50 mg	OPEN
Injection, hemin, 1 mg	OPEN
Injection, hemin, 1 mg	OPEN
Injection, heparin sodium, (heparin lock flush), per 10 units	OPEN
Injection, heparin sodium, (heparin lock flush), per 10 units	\$ 0.
Injection, heparin sodium, (heparin lock flush), per 10 units	OPEN
Injection, heparin sodium, (heparin lock flush), per 10 units	OPEN
Injection, heparin sodium, (heparin lock flush), per 10 units	OPEN
Injection, heparin sodium, (heparin lock flush), per 10 units	OPEN
Injection, heparin sodium, (heparin lock flush), per 10 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN

DESCRIPTION	CHARGE
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, heparin sodium, per 1000 units	OPEN
Injection, dalteparin sodium, per 2500 iu	OPEN
Injection, enoxaparin sodium, 10 mg	OPEN
Injection, enoxaparin sodium, 10 mg	OPEN
Injection, enoxaparin sodium, 10 mg	OPEN
Injection, enoxaparin sodium, 10 mg	OPEN
Injection, enoxaparin sodium, 10 mg	OPEN
Injection, enoxaparin sodium, 10 mg	OPEN
Injection, enoxaparin sodium, 10 mg	OPEN
Injection, enoxaparin sodium, 10 mg	OPEN
Injection, enoxaparin sodium, 10 mg	OPEN
Injection, enoxaparin sodium, 10 mg	OPEN
Injection, enoxaparin sodium, 10 mg	OPEN
Injection, enoxaparin sodium, 10 mg	OPEN
Injection, enoxaparin sodium, 10 mg	OPEN OPEN
Injection, fondaparinux sodium, 0.5 mg Injection, fondaparinux sodium, 0.5 mg	
Injection, fondaparinux sodium, 0.5 mg	OPEN OPEN
Injection, fondaparinux sodium, 0.5 mg	OPEN
Injection, tetanus immune globulin, human, up to 250 units	OPEN
Injection, tetanus immune globulin, human, up to 250 units	OPEN
Injection, hydrocortisone sodium succinate, up to 100 mg	OPEN
Injection, hydrocortisone sodium succinate, up to 100 mg	OPEN
Injection, hydrocortisone sodium succinate, up to 100 mg	OPEN
Injection, hydrocortisone sodium succinate, up to 100 mg	OPEN
Injection, hydrocortisone sodium succinate, up to 100 mg	OPEN
Injection, hydrocortisone sodium succinate, up to 100 mg	OPEN
Injection, diazoxide, up to 300 mg	OPEN
Injection, ibandronate sodium, 1 mg	OPEN
Injection, ibandronate sodium, 1 mg	OPEN
Injection, ibuprofen, 100 mg	OPEN
Injection, ibutilide fumarate, 1 mg	OPEN
Injection, infliximab, excludes biosimilar, 10 mg	OPEN
Injection, infliximab, excludes biosimilar, 10 mg	OPEN
Injection, iron dextran, 50 mg	OPEN
Injection, iron dextran, 50 mg	OPEN
Injection, iron sucrose, 1 mg	OPEN
Injection, iron sucrose, 1 mg	OPEN
Injection, imiglucerase, 10 units	OPEN
Injection, imiglucerase, 10 units	OPEN
Injection, droperidol, up to 5 mg	OPEN
Injection, droperidol, up to 5 mg	OPEN
Injection, propranolol hcl, up to 1 mg	OPEN
Injection, insulin, per 5 units	OPEN
Injection, insulin, per 5 units	OPEN
Injection, insulin, per 5 units	OPEN
Injection, insulin, per 5 units	OPEN
Injection, insulin, per 5 units	OPEN OPEN
Injection, insulin, per 5 units	OPEN OPEN
Injection, insulin, per 5 units Injection, insulin, per 5 units	OPEN
Injection, insulin, per 5 units	OPEN
Injection, insulin, per 5 units	OPEN OPEN
Injection, insulin, per 5 units	OPEN
Injection, insulin, per 5 units	OPEN
Injection, insulin, per 5 units	OPEN
Injection, insulin, per 5 units	OPEN
Injection, insulin, per 5 units	OPEN
Injection, insulin, per 5 units	OPEN

DESCRIPTION	CHARG	iΕ
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, insulin, per 5 units	OPEN	
Injection, interferon beta-1b, 0.25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when	OPEN	
drug is self administered)		
Injection, isavuconazonium, 1 mg	OPEN	
Injection, isavuconazonium, 1 mg	OPEN	
Injection, itraconazole, 50 mg	OPEN	
Injection, kanamycin sulfate, up to 75 mg	OPEN	
Injection, ketorolac tromethamine, per 15 mg	OPEN	
Injection, ketorolac tromethamine, per 15 mg	OPEN	
Injection, ketorolac tromethamine, per 15 mg	OPEN	
Injection, ketorolac tromethamine, per 15 mg	OPEN	
Injection, ketorolac tromethamine, per 15 mg	OPEN	
Injection, ketorolac tromethamine, per 15 mg	OPEN	
Injection, furosemide, up to 20 mg	OPEN	
Injection, furosemide, up to 20 mg	OPEN	
Injection, furosemide, up to 20 mg	OPEN	
Injection, furosemide, up to 20 mg	OPEN	
Injection, furosemide, up to 20 mg	OPEN	
Injection, furosemide, up to 20 mg	\$	5.9
Injection, lepirudin, 50 mg	OPEN	
Injection, leuprolide acetate (for depot suspension), per 3.75 mg	OPEN	
Injection, leuprolide acetate (for depot suspension), per 3.75 mg	OPEN	
Injection, levetiracetam, 10 mg	OPEN	
Injection, levocarnitine, per 1 gm	OPEN	
Injection, levofloxacin, 250 mg	OPEN	
Injection, levofloxacin, 250 mg	OPEN OPEN	
Injection, levofloxacin, 250 mg	OPEN	
Injection, levofloxacin, 250 mg	OPEN OPEN	
Injection, levofloxacin, 250 mg	OPEN	
Injection, levorphanol tartrate, up to 2 mg	OPEN	
Injection, hyoscyamine sulfate, up to 0.25 mg	OPEN OPEN	
Injection, chlordiazepoxide hcl, up to 100 mg	1	
Injection, lidocaine hel for intravenous infusion, 10 mg	OPEN OPEN	
Injection, lidocaine hel for intravenous infusion, 10 mg	OPEN OPEN	
Injection, lidocaine hcl for intravenous infusion, 10 mg Injection, lidocaine hcl for intravenous infusion, 10 mg	OPEN	
	OPEN OPEN	
Injection, lidocaine hcl for intravenous infusion, 10 mg	OPEN	
Injection, linezolid, 200 mg	1	
Injection, Iorazepam, 2 mg	OPEN	
Injection, Iorazepam, 2 mg	OPEN	
Injection, Iorazepam, 2 mg	OPEN OPEN	
Injection, Iorazepam, 2 mg	OPEN	
Injection, mannitol, 25% in 50 ml	OPEN OPEN	
Injection, mannitol, 25% in 50 ml	OPEN	

DESCRIPTION	CHARGE
Injection, meperidine hydrochloride, per 100 mg	OPEN
Injection, meperidine hydrochloride, per 100 mg	OPEN
Injection, meperidine hydrochloride, per 100 mg	OPEN
Injection, meperidine hydrochloride, per 100 mg	OPEN
Injection, meperidine hydrochloride, per 100 mg	OPEN
Injection, meropenem, 100 mg	OPEN
Injection, meropenem, 100 mg	OPEN
Injection, meropenem, 100 mg	OPEN
Injection, methylergonovine maleate, up to 0.2 mg	OPEN
Injection, methylnaltrexone, 0.1 mg	OPEN
Injection, methylnaltrexone, 0.1 mg	OPEN
Injection, midazolam hydrochloride, per 1 mg	OPEN
Injection, midazolam hydrochloride, per 1 mg	OPEN
Injection, midazolam hydrochloride, per 1 mg	OPEN
Injection, midazolam hydrochloride, per 1 mg	OPEN
Injection, midazolam hydrochloride, per 1 mg	OPEN
Injection, midazolam hydrochloride, per 1 mg	OPEN
Injection, milrinone lactate, 5 mg	OPEN
Injection, milrinone lactate, 5 mg	OPEN
Injection, milrinone lactate, 5 mg	OPEN
Injection, morphine sulfate, up to 10 mg	OPEN
Injection, morphine sulfate, up to 10 mg	OPEN
Injection, morphine sulfate, up to 10 mg	OPEN
Injection, morphine sulfate, up to 10 mg	OPEN
Injection, morphine sulfate, up to 10 mg	OPEN
Injection, morphine sulfate, up to 10 mg	OPEN
Injection, morphine sulfate, up to 10 mg	OPEN
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg	OPEN
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg	OPEN
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg	OPEN
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg	OPEN
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg	OPEN
Injection, nalbuphine hydrochloride, per 10 mg	OPEN
Injection, naloxone hydrochloride, per 1 mg	OPEN
Injection, naloxone hydrochloride, per 1 mg	OPEN
Injection, naloxone hydrochloride, per 1 mg	OPEN
Injection, naloxone hydrochloride, per 1 mg	OPEN
Injection, natalizumab, 1 mg	OPEN
Injection, natalizumab, 1 mg	OPEN
Injection, nesiritide, 0.1 mg	OPEN
Injection, nusinersen, 0.1 mg	OPEN
Injection, ocrelizumab, 1 mg	OPEN
Injection, octreotide, depot form for intramuscular injection, 1 mg	OPEN
Injection, octreotide, depot form for intramuscular injection, 1 mg	OPEN
Injection, octreotide, depot form for intramuscular injection, 1 mg	OPEN
Injection, octreotide, depot form for intramuscular injection, 1 mg	OPEN
Injection, octreotide, depot form for intramuscular injection, 1 mg	OPEN
Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg	OPEN
Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg	OPEN
Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg	OPEN
Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg	OPEN
Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg	OPEN
Injection, oprelvekin, 5 mg	OPEN
Injection, oprelvekin, 5 mg	OPEN
Injection, oprelvekin, 5 mg	OPEN
Injection, omalizumab, 5 mg	OPEN
Injection, phenylephrine hcl, up to 1 ml	OPEN
Injection, chloroprocaine hydrochloride, per 30 ml	OPEN
Injection, chloroprocaine hydrochloride, per 30 ml	OPEN
Injection, ondansetron hydrochloride, per 1 mg	OPEN
Injection, ondansetron hydrochloride, per 1 mg	OPEN
Injection, ondansetron hydrochloride, per 1 mg	OPEN
Injection, ondansetron hydrochloride, per 1 mg	OPEN

DESCRIPTION		CHARGE
Injection, palifermin, 50 micrograms		OPEN
Injection, palifermin, 50 micrograms		OPEN
Injection, paliperidone palmitate extended release, 1 mg		OPEN
Injection, paliperidone palmitate extended release, 1 mg		OPEN
Injection, pamidronate disodium, per 30 mg		OPEN
Injection, pamidronate disodium, per 30 mg		OPEN
Injection, pamidronate disodium, per 30 mg		OPEN
Injection, pamidronate disodium, per 30 mg		OPEN
Injection, papaverine hcl, up to 60 mg	_	OPEN
Injection, palonosetron hcl, 25 mcg		OPEN
Injection, palonosetron hcl, 25 mcg		OPEN
Injection, paricalcitol, 1 mcg		OPEN
Injection, paricalcitol, 1 mcg		OPEN
Injection, pegaptanib sodium, 0.3 mg		OPEN
Injection, pegfilgrastim, 6 mg	\$	13,845.00
Injection, pegfilgrastim, 6 mg		OPEN OPEN
Injection, pegfilgrastim, 6 mg Injection, pegfilgrastim, 6 mg		OPEN
Injection, pegloticase, 1 mg		OPEN
Injection, penicillin g procaine, aqueous, up to 600,000 units		OPEN
Injection, penicillin g procaine, aqueous, up to 600,000 units		OPEN
Injection, pentobarbital sodium, per 50 mg		OPEN
Injection, penicilling potassium, up to 600,000 units		OPEN
Injection, penicillin g potassium, up to 600,000 units		OPEN
Injection, penicilling potassium, up to 600,000 units		OPEN
Injection, penicilling potassium, up to 600,000 units		OPEN
Injection, penicillin g potassium, up to 600,000 units		OPEN
Injection, penicillin g potassium, up to 600,000 units		OPEN
Injection, penicillin g potassium, up to 600,000 units		OPEN
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)		OPEN
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)		OPEN
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)		OPEN
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)		OPEN
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)		OPEN
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)		OPEN
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)		OPEN
Pentamidine isethionate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 300 mg		OPEN
Injection, peramivir, 1 mg		OPEN
Injection, promethazine hcl, up to 50 mg		OPEN
Injection, promethazine hcl, up to 50 mg		OPEN
Injection, promethazine hcl, up to 50 mg		OPEN
Injection, promethazine hcl, up to 50 mg		OPEN
Injection, phenobarbital sodium, up to 120 mg		OPEN
Injection, phenobarbital sodium, up to 120 mg		OPEN
Injection, phenobarbital sodium, up to 120 mg		OPEN
Injection, phenobarbital sodium, up to 120 mg		OPEN OPEN
Injection, plerixafor, 1 mg		OPEN
Injection, plerixafor, 1 mg Injection, oxytocin, up to 10 units		OPEN
Injection, oxytocin, up to 10 units	1	OPEN
Injection, oxytocin, up to 10 units		OPEN
Injection, desmopressin acetate, per 1 mcg		OPEN
Injection, desmopressin acetate, per 1 mcg		OPEN
Injection, desmopressin acetate, per 1 mcg		OPEN
Injection, desmopressin acetate, per 1 mcg		OPEN
Injection, tolazoline hcl, up to 25 mg		OPEN
Injection, progesterone, per 50 mg		OPEN
Injection, fluphenazine decanoate, up to 25 mg		OPEN
Injection, fluphenazine decanoate, up to 25 mg		OPEN
Injection, procainamide hcl, up to 1 gm		OPEN
Injection, procainamide hcl, up to 1 gm		OPEN
Injection, propofol, 10 mg		OPEN
Injection, neostigmine methylsulfate, up to 0.5 mg		OPEN

DESCRIPTION		CHARGE
Injection, neostigmine methylsulfate, up to 0.5 mg		OPEN
njection, protamine sulfate, per 10 mg	· · · · · · · · · · · · · · · · · · ·	OPEN
Injection, protamine sulfate, per 10 mg		OPEN
Injection, protirelin, per 250 mcg		OPEN
Injection, pralidoxime chloride, up to 1 gm		OPEN
Injection, phentolamine mesylate, up to 5 mg		OPEN
Injection, metoclopramide hcl, up to 10 mg		OPEN
Injection, metoclopramide hcl, up to 10 mg		OPEN
Injection, metoclopramide hcl, up to 10 mg		OPEN
Injection, quinupristin/dalfopristin, 500 mg (150/350)		OPEN
Injection, ranibizumab, 0.1 mg		OPEN
Injection, ranitidine hydrochloride, 25 mg		OPEN OPEN
Injection, ranitidine hydrochloride, 25 mg		OPEN
Injection, ranitidine hydrochloride, 25 mg Injection, ranitidine hydrochloride, 25 mg		OPEN
Injection, rasburicase, 0.5 mg		OPEN
Injection, rasburicase, 0.5 mg		OPEN
Injection, regadenoson, 0.1 mg		OPEN
Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.)		OPEN
Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.)		OPEN
Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.)		OPEN
Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu		OPEN
Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu		OPEN
Injection, rho d immune globulin, intravenous, human, solvent detergent, 100 iu	\$	67.00
Injection, rho d immune globulin, intravenous, human, solvent detergent, 100 iu		OPEN
Injection, risperidone, long acting, 0.5 mg	· · · · · · · · · · · · · · · · · · ·	OPEN
Injection, risperidone, long acting, 0.5 mg		OPEN
Injection, ropivacaine hydrochloride, 1 mg	· · · · · · · · · · · · · · · · · · ·	OPEN
Injection, ropivacaine hydrochloride, 1 mg		OPEN
Injection, romiplostim, 10 micrograms		OPEN
Injection, romiplostim, 10 micrograms		OPEN
Injection, sincalide, 5 micrograms		OPEN
Injection, sincalide, 5 micrograms	\$	225.00
Injection, sargramostim (gm-csf), 50 mcg	\$	118.00
Injection, sargramostim (gm-csf), 50 mcg		OPEN
Injection, secretin, synthetic, human, 1 microgram		OPEN
Injection, secretin, synthetic, human, 1 microgram		OPEN
Injection, secretin, synthetic, human, 1 microgram		OPEN
Injection, aurothioglucose, up to 50 mg		OPEN
Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg		OPEN
Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg		OPEN
Injection, methylprednisolone sodium succinate, up to 40 mg Injection, methylprednisolone sodium succinate, up to 40 mg		OPEN OPEN
Injection, methylprednisolone sodium succinate, up to 40 mg		OPEN
Injection, methylprednisolone sodium succinate, up to 40 mg		OPEN
Injection, methylprednisolone sodium succinate, up to 40 mg		OPEN
Injection, methylprednisolone sodium succinate, up to 40 mg		OPEN
Injection, methylprednisolone sodium succinate, up to 40 mg		OPEN
Injection, methylprednisolone sodium succinate, up to 40 mg		OPEN
Injection, methylprednisolone sodium succinate, up to 40 mg		OPEN
Injection, methylprednisolone sodium succinate, up to 125 mg		OPEN
Injection, methylprednisolone sodium succinate, up to 125 mg		OPEN
Injection, methylprednisolone sodium succinate, up to 125 mg		OPEN
Injection, streptokinase, per 250,000 iu		OPEN
Injection, alteplase recombinant, 1 mg	\$	176.00
Injection, alteplase recombinant, 1 mg		OPEN
Injection, alteplase recombinant, 1 mg		OPEN
Injection, alteplase recombinant, 1 mg		OPEN
Injection, alteplase recombinant, 1 mg		OPEN
Injection, alteplase recombinant, 1 mg		OPEN
Injection, streptomycin, up to 1 gm		OPEN
Injection, fentanyl citrate, 0.1 mg		OPEN
Injection, fentanyl citrate, 0.1 mg		OPEN

DESCRIPTION	CHARGE
Injection, fentanyl citrate, 0.1 mg	OPEN
Injection, fentanyl citrate, 0.1 mg	OPEN
Injection, fentanyl citrate, 0.1 mg	OPEN
Injection, fentanyl citrate, 0.1 mg	OPEN
Injection, fentanyl citrate, 0.1 mg	OPEN
Injection, fentanyl citrate, 0.1 mg	OPEN
Injection, sumatriptan succinate, 6 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	OPEN
Injection, sumatriptan succinate, 6 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	OPEN
Injection, taliglucerace alfa, 10 units	OPEN
Injection, taliglucerace alfa, 10 units	OPEN
Injection, telavancin, 10 mg	OPEN
Injection, telavancin, 10 mg	OPEN
Injection, tenecteplase, 1 mg	OPEN
Injection, terbutaline sulfate, up to 1 mg	OPEN
Injection, teriparatide, 10 mcg	OPEN
Injection, testosterone enanthate, 1 mg	OPEN
Injection, chlorpromazine hcl, up to 50 mg	OPEN
Injection, chlorpromazine hcl, up to 50 mg	OPEN
Injection, chlorpromazine hcl, up to 50 mg	OPEN
Injection, chlorpromazine hcl, up to 50 mg	OPEN
Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial	OPEN
Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial	OPEN
Injection, tigecycline, 1 mg	OPEN
Injection, tirofiban hcl, 0.25 mg	OPEN
Injection, trimethobenzamide hcl, up to 200 mg	OPEN
Injection, tobramycin sulfate, up to 80 mg	OPEN
Injection, tobramycin sulfate, up to 80 mg	OPEN
Injection, tobramycin sulfate, up to 80 mg	OPEN
Injection, tobramycin sulfate, up to 80 mg	OPEN
Injection, tocilizumab, 1 mg	OPEN
Injection, tocilizumab, 1 mg	OPEN
Injection, thiethylperazine maleate, up to 10 mg	OPEN
Injection, treprostinil, 1 mg	OPEN
Injection, triamcinolone acetonide, preservative free, 1 mg	OPEN
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	OPEN
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	OPEN
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	OPEN
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	OPEN OPEN
Injection, triamcinolone acetonide, not otherwise specified, 10 mg Injection, triamcinolone acetonide, not otherwise specified, 10 mg	OPEN
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	OPEN
Injection, triamcinolone acetonide, not otherwise specified, 10 mg	OPEN
Injection, triamcinolone hexacetonide, per 5 mg	OPEN
Injection, triamcinolone hexacetonide, per 5 mg	OPEN
Injection, trimetrexate glucuronate, per 25 mg	OPEN
Injection, triptorelin pamoate, 3.75 mg	OPEN
Injection, triptorelin pamoate, 3.75 mg	OPEN
Ustekinumab, for subcutaneous injection, 1 mg	OPEN
Ustekinumab, for intravenous injection, 1 mg	OPEN
Injection, diazepam, up to 5 mg	OPEN
Injection, diazepam, up to 5 mg	OPEN
Injection, diazepam, up to 5 mg	OPEN
Injection, diazepam, up to 5 mg	OPEN
Injection, urokinase, 5000 iu vial	OPEN
Injection, iv, urokinase, 250,000 i.u. vial	OPEN
Injection, vancomycin hcl, 500 mg	OPEN
Injection, vancomycin hcl, 500 mg	OPEN
Injection, vancomycin hcl, 500 mg	OPEN
Injection, vancomycin hcl, 500 mg	OPEN
Injection, vancomycin hcl, 500 mg	OPEN
Injection, vancomycin hcl, 500 mg	OPEN

DESCRIPTION	CHARGE
Injection, vancomycin hcl, 500 mg	OPEN
njection, vedolizumab, 1 mg	OPEN
njection, vedolizumab, 1 mg	OPEN
njection, velaglucerase alfa, 100 units	OPEN
njection, verteporfin, 0.1 mg	OPEN
njection, hydroxyzine hcl, up to 25 mg	OPEN
njection, hydroxyzine hcl, up to 25 mg	OPEN
njection, thiamine hcl, 100 mg	OPEN
njection, thiamine hcl, 100 mg	OPEN
njection, pyridoxine hcl, 100 mg	OPEN
njection, pyridoxine hcl, 100 mg	OPEN
njection, vitamin b-12 cyanocobalamin, up to 1000 mcg	OPEN
njection, vitamin b-12 cyanocobalamin, up to 1000 mcg	OPEN
njection, vitamin b-12 cyanocobalamin, up to 1000 mcg	OPEN
njection, phytonadione (vitamin k), per 1 mg	OPEN
njection, phytonadione (vitamin k), per 1 mg	OPEN
njection, phytonadione (vitamin k), per 1 mg	OPEN
njection, voriconazole, 10 mg	OPEN OPEN
njection, voriconazole, 10 mg njection, hyaluronidase, up to 150 units	OPEN
njection, hyaluronidase, up to 150 units	OPEN
njection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units)	OPEN
njection, hyaluronidase, recombinant, 1 usp unit	OPEN
njection, hvaluronidase, recombinant, 1 usp unit	OPEN
njection, magnesium sulfate, per 500 mg	OPEN
njection, magnesium sulfate, per 500 mg	OPEN
njection, magnesium sulfate, per 500 mg	OPEN
njection, magnesium sulfate, per 500 mg	OPEN
njection, magnesium sulfate, per 500 mg	OPEN
njection, magnesium sulfate, per 500 mg	OPEN
njection, magnesium sulfate, per 500 mg	OPEN
njection, magnesium sulfate, per 500 mg	OPEN
njection, magnesium sulfate, per 500 mg	OPEN
njection, magnesium sulfate, per 500 mg	OPEN
njection, magnesium sulfate, per 500 mg	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, potassium chloride, per 2 meq	OPEN
njection, zidovudine, 10 mg	OPEN
njection, ziprasidone mesylate, 10 mg	OPEN
njection, zoledronic acid, 1 mg	OPEN
njection, zoledronic acid, 1 mg	OPEN OPEN
njection, zoledronic acid, 1 mg	OPEN
ijection, zoledronic acid, 1 mg nelarsified drugs er biologist: Sodium Phosphate Ini	OPEN OPEN
nclassified drugs or biologics: Sodium Phosphate Inj	OPEN
Inclassified drugs or biologics: Doxycycline 100Mg Inj Vial	OPEN
Inclassified drugs or biologics: Famotidine Per 20Mg Inj	OPEN
Inclassified drugs or biologics: Ketamine 50Mg	OPEN OPEN
Inclassified drugs or biologics: Ketamine 100Mg Inclassified drugs or biologics: Bupivacaine 0.5% Inj	OPEN OPEN

DESCRIPTION	CHARGE
Unclassified drugs or biologics: Bupivacaine 0.5% Inj	OPEN
Unclassified drugs or biologics: Bupivacaine 0.25% Inj	OPEN
Unclassified drugs or biologics: Bupivacaine 0.75% Inj	OPEN
Unclassified drugs or biologics: Arginine 10% Iv Soln	OPEN
Unclassified drugs or biologics: Tiotropium Bro Inh	OPEN
Unclassified drugs or biologics: Doxycycline 100Mg Inj Vial	OPEN
Unclassified drugs or biologics: Sodium Ion Inj For Tpn	OPEN
Unclassified drugs or biologics: Potassium Ion Inj For Tpn	OPEN
Unclassified drugs or biologics: Phosphate Ion Inj For Tpn	OPEN
Unclassified drugs or biologics: Calcium Ion Inj For Tpn	OPEN
Unclassified drugs or biologics: Acetate Ion Inj For Tpn	OPEN
Unclassified drugs or biologics: Famotidine Per 10Mg Inj	OPEN
Unclassified drugs or biologics: Diltiazem Hcl Per 5Mg Inj	OPEN
Unclassified drugs or biologics: Pramlintide 600Mcg/5MI Inj	OPEN
Unclassified drugs or biologics: Nitric Oxide Per 1 Hour	OPEN OPEN
Unclassified drugs or biologics: Nitric Oxide Per 15 Minutes	OPEN
Unclassified drugs or biologics: Diltiazem Hcl Per 5Mg Inj Unclassified drugs or biologics: Valproate Sodium Per 100Mg	OPEN
Unclassified drugs or biologics: Allopurinol 500Mg Inj Vial	OPEN
Unclassified drugs or biologics: Sildenafil Citrate Per 25 Mg	OPEN
Unclassified drugs or biologics: Bupivacaine 0.125%/Ns Epsoln	OPEN
Unclassified drugs or biologics: Diltiazem Hcl Per 5Mg Inj	OPEN
Unclassified drugs or biologics: Famotidine Per 20Mg Inj	OPEN
Unclassified drugs or biologics: Fecal Specimen	\$ 1,701.00
Edetate disodium, per 150 mg	OPEN
Unclassified drugs or biologics: Thrombin (Recomb) Per 5000U	OPEN
Unclassified drugs or biologics: Thrombin (Recomb) Per 20000U	OPEN
Infusion, normal saline solution, 1000 cc	OPEN
Infusion, normal saline solution, 1000 cc	OPEN
Infusion, normal saline solution, sterile (500 ml = 1 unit)	OPEN
Infusion, normal saline solution, sterile (500 ml = 1 unit)	OPEN
5% dextrose/normal saline (500 ml = 1 unit)	OPEN
5% dextrose/normal saline (500 ml = 1 unit)	OPEN
Infusion, normal saline solution, 250 cc	OPEN
Infusion, normal saline solution, 250 cc	OPEN
5% dextrose/water (500 ml = 1 unit)	OPEN
5% dextrose/water (500 ml = 1 unit)	OPEN
5% dextrose/water (500 ml = 1 unit)	OPEN
5% dextrose/water (500 ml = 1 unit)	OPEN
5% dextrose/water (500 ml = 1 unit)	OPEN
5% dextrose/water (500 ml = 1 unit)	OPEN
5% dextrose/water (500 ml = 1 unit)	OPEN
5% dextrose/water (500 ml = 1 unit) 5% dextrose/water (500 ml = 1 unit)	OPEN
5% dextrose/water (500 ml = 1 unit) 5% dextrose/water (500 ml = 1 unit)	OPEN OPEN
5% dextrose/water (500 ml = 1 unit)	OPEN
5% dextrose/water (500 ml = 1 unit) 5% dextrose/water (500 ml = 1 unit)	OPEN
5% dextrose/water (500 ml = 1 unit)	OPEN
5% dextrose/water (500 ml = 1 unit)	OPEN
5% dextrose/water (500 ml = 1 unit)	OPEN
5% dextrose/water (500 ml = 1 unit)	OPEN
Infusion, dextran 40, 500 ml	OPEN
Ringers lactate infusion, up to 1000 cc	OPEN
Ringers lactate infusion, up to 1000 cc	OPEN
Ringers lactate infusion, up to 1000 cc	OPEN
Ringers lactate infusion, up to 1000 cc	OPEN
5% dextrose in lactated ringers infusion, up to 1000 cc	OPEN
5% dextrose in lactated ringers infusion, up to 1000 cc	OPEN
Hypertonic saline solution, 1 ml	OPEN
Injection, human fibrinogen concentrate, 1 mg	OPEN
Injection, von willebrand factor (recombinant), (vonvendi), 1 i.u. vwf:rco	OPEN
Injection, factor viii (antihemophilic factor, recombinant) (xyntha), per i.u.	OPEN
Injection, von willebrand factor complex (humate-p), per iu vwf:rco	OPEN

DESCRIPTION	CHARGE
njection, von willebrand factor complex (humate-p), per iu vwf:rco	OPEN
actor viia (antihemophilic factor, recombinant), per 1 microgram	OPEN
actor viia (antihemophilic factor, recombinant), per 1 microgram	OPEN
actor viii (antihemophilic factor, human) per i.u.	OPEN
actor viii (antihemophilic factor, human) per i.u.	OPEN
actor viii (antihemophilic factor (porcine)), per i.u.	OPEN
actor viii (antihemophilic factor, recombinant) per i.u., not otherwise specified	OPEN
actor viii (antihemophilic factor, recombinant) per i.u., not otherwise specified	OPEN
actor viii (antihemophilic factor, recombinant) per i.u., not otherwise specified	OPEN
actor viii (antihemophilic factor, recombinant) per i.u., not otherwise specified	OPEN
actor ix, complex, per i.u.	OPEN
njection, factor ix (antihemophilic factor, recombinant) per iu, not otherwise specified	OPEN
njection, factor ix (antihemophilic factor, recombinant) per iu, not otherwise specified	OPEN
ntithrombin iii (human), per i.u.	OPEN
nti-inhibitor, per i.u.	OPEN
nti-inhibitor, per i.u.	OPEN
evonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg	OPEN
ntrauterine copper contraceptive	OPEN
evonorgestrel-releasing intrauterine contraceptive system (skyla), 13.5 mg	OPEN
Contraceptive supply, hormone containing patch, each	OPEN
itonogestrel (contraceptive) implant system, including implant and supplies	OPEN
njection, dexamethasone, intravitreal implant, 0.1 mg	OPEN
Vitomycin, ophthalmic, 0.2 mg	OPEN
Iyaluronan or derivative, hyalgan or supartz, for intra-articular injection, per dose	OPEN
iyaluronan or derivative, euflexxa, for intra-articular injection, per dose	OPEN
Iyaluronan or derivative, euflexxa, for intra-articular injection, per dose	OPEN
Ivaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg	OPEN
Ivaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg	OPEN
iyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg	OPEN
iyaluronan or derivative, gel-syn, for intra-articular injection, 0.1 mg	OPEN
Capsaicin 8% patch, per square centimeter	OPEN
Azathioprine, oral, 50 mg	OPEN
Azathioprine, oral, 50 mg	OPEN
Azathioprine, parenteral, 100 mg	OPEN
Cyclosporine, oral, 100 mg	OPEN
Cyclosporine, oral, 100 mg	OPEN
Cyclosporine, oral, 100 mg	OPEN
Cyclosporine, oral, 100 mg	OPEN
acrolimus, extended release, (envarsus xr), oral, 0.25 mg	OPEN
ymphocyte immune globulin, antithymocyte globulin, equine, parenteral, 250 mg	OPEN
ymphocyte immune globulin, antitrymocyte globulin, equine, parenteral, 250 mg	OPEN
Auromonab-cd3, parenteral, 5 mg	OPEN
	OPEN
acrolimus, immediate release, oral, 1 mg	1
acrolimus, immediate release, oral, 1 mg	OPEN
acrolimus, immediate release, oral, 1 mg	OPEN
acrolimus, immediate release, oral, 1 mg	OPEN
acrolimus, extended release, (astagraf xl), oral, 0.1 mg	OPEN
Aethylprednisolone oral, per 4 mg	OPEN
Aethylprednisolone oral, per 4 mg	OPEN
rednisolone oral, per 5 mg	OPEN
rednisolone oral, per 5 mg	OPEN
rednisolone oral, per 5 mg	OPEN
ymphocyte immune globulin, antithymocyte globulin, rabbit, parenteral, 25 mg	OPEN
rednisone, immediate release or delayed release, oral, 1 mg	OPEN
rednisone, immediate release or delayed release, oral, 1 mg	OPEN
aclizumab, parenteral, 25 mg	OPEN
aclizumab, parenteral, 25 mg	OPEN
yclosporine, oral, 25 mg	OPEN
yclosporine, oral, 25 mg	OPEN
yclosporin, parenteral, 250 mg	OPEN
1ycophenolate mofetil, oral, 250 mg	OPEN
1ycophenolate mofetil, oral, 250 mg	OPEN
Aycophenolate mofetil, oral, 250 mg	OPEN

DESCRIPTION	CHARGE
Mycophenolate mofetil, oral, 250 mg	OPEN
Sirolimus - various dosages	OPEN
Sirolimus - various dosages	OPEN
Tacrolimus, parenteral, 5 mg	OPEN
Everolimus, oral, 0.25 mg	OPEN
Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg	OPEN
Tobramycin, inhalation solution, fda-approved final product, non-compounded, unit dose form, administered through dme, per 300 milligrams	OPEN
Aprepitant, oral, 5 mg	OPEN
Busulfan; oral, 2 mg	OPEN
Busulfan; oral, 2 mg	OPEN
Cabergoline, oral, 0.25 mg	OPEN OPEN
Capecitabine, oral, 150 mg Capecitabine, oral, 150 mg	OPEN
Capecitabine, oral, 500 mg	OPEN
Cyclophosphamide; oral, 25 mg	OPEN
Cyclophosphamide; oral, 25 mg	OPEN
Cyclophosphamide; oral, 25 mg	OPEN
Dexamethasone, oral, 0.25 mg	OPEN
Dexamethasone, oral, 0.25 mg	OPEN
Dexamethasone, oral, 0.25 mg	OPEN
Dexamethasone, oral, 0.25 mg	OPEN
Etoposide; oral, 50 mg	OPEN
Etoposide; oral, 50 mg	OPEN
Gefitinib, oral, 250 mg	OPEN
Antiemetic drug, oral, not otherwise specified	OPEN
Antiemetic drug, oral, not otherwise specified	OPEN
Antiemetic drug, oral, not otherwise specified	OPEN
Melphalan; oral, 2 mg	OPEN
Methotrexate; oral, 2.5 mg	OPEN
Methotrexate; oral, 2.5 mg	OPEN
Injection, doxorubicin hydrochloride, 10 mg	OPEN
Injection, doxorubicin hydrochloride, 10 mg	OPEN
Injection, doxorubicin hydrochloride, 10 mg	OPEN
Injection, doxorubicin hydrochloride, 10 mg	OPEN
Injection, aldesleukin, per single use vial	OPEN
Injection, arsenic trioxide, 1 mg	OPEN
Injection, arsenic trioxide, 1 mg	OPEN
Injection, asparaginase (erwinaze), 1,000 iu	OPEN
Injection, asparaginase (erwinaze), 1,000 iu	OPEN
Injection, asparaginase, not otherwise specified, 10,000 units	OPEN
Injection, asparaginase, not otherwise specified, 10,000 units	OPEN
Injection, atezolizumab, 10 mg Injection, atezolizumab, 10 mg	OPEN OPEN
Injection, atezolizumab, 10 mg Injection, avelumab, 10 mg	OPEN
Injection, aveidinab, 10 mg	OPEN
Injection, azacitidine, 1 mg	OPEN
Injection, azacitume, 1 mg	OPEN
Injection, clofarabine, 1 mg	OPEN
Bcg (intravesical) per instillation	OPEN
Bcg (intravesical) per instillation	OPEN
Injection, belinostat, 10 mg	OPEN
Injection, belinostat, 10 mg	OPEN
Injection, bendamustine hcl (treanda), 1 mg	OPEN
Injection, bendamustine hel (treanda), 1 mg	OPEN
Injection, bendamustine hcl (bendeka), 1 mg	OPEN
Injection, bendamustine hcl (bendeka), 1 mg	OPEN
Injection, bevacizumab, 10 mg	OPEN
	OPEN
Injection, bevacizumab, 10 mg	

DESCRIPTION	CHARGE
Injection, blinatumomab, 1 microgram	OPEN
Injection, blinatumomab, 1 microgram	OPEN
Injection, bleomycin sulfate, 15 units	OPEN
Injection, bleomycin sulfate, 15 units	OPEN
Injection, bortezomib, 0.1 mg	OPEN
Injection, bortezomib, 0.1 mg	OPEN
Injection, brentuximab vedotin, 1 mg	OPEN
Injection, brentuximab vedotin, 1 mg	OPEN
Injection, cabazitaxel, 1 mg	OPEN
Injection, cabazitaxel, 1 mg	OPEN
Injection, carboplatin, 50 mg	OPEN
Injection, carboplatin, 50 mg	OPEN
Injection, carboplatin, 50 mg	OPEN
Injection, carboplatin, 50 mg	OPEN
Injection, carboplatin, 50 mg	OPEN
Injection, carboplatin, 50 mg	OPEN
Injection, carfilzomib, 1 mg	OPEN
Injection, carfilzomib, 1 mg	OPEN
Injection, carmustine, 100 mg	OPEN OPEN
Injection, carmustine, 100 mg Injection, carmustine, 100 mg	OPEN
Injection, cetuximab, 10 mg	OPEN
Injection, cetuximab, 10 mg	OPEN
Injection, cetuximab, 10 mg	OPEN
Injection, cetuximab, 10 mg	OPEN
Injection, cisplatin, powder or solution, 10 mg	OPEN
Injection, cisplatin, powder or solution, 10 mg	OPEN
Injection, cladribine, per 1 mg	OPEN
Injection, cladribine, per 1 mg	OPEN
Cyclophosphamide, 100 mg	OPEN
Cyclophosphamide, 100 mg	OPEN
Injection, cytarabine liposome, 10 mg	OPEN
Injection, cytarabine liposome, 10 mg	OPEN
Injection, cytarabine, 100 mg	OPEN
Injection, cytarabine, 100 mg	OPEN
Injection, cytarabine, 100 mg	OPEN
Injection, cytarabine, 100 mg	OPEN
Injection, cytarabine, 100 mg	OPEN
Injection, dactinomycin, 0.5 mg	OPEN
Injection, dactinomycin, 0.5 mg	OPEN
Dacarbazine, 100 mg	OPEN
Dacarbazine, 100 mg	OPEN
Dacarbazine, 100 mg	OPEN
Dacarbazine, 100 mg	OPEN
Injection, daratumumab, 10 mg	OPEN
Injection, daratumumab, 10 mg	OPEN
Injection, daunorubicin, 10 mg	OPEN
Injection, daunorubicin, 10 mg	OPEN
Injection, daunorubicin, 10 mg	OPEN
Injection, daunorubicin citrate, liposomal formulation, 10 mg	OPEN
Injection, daunorubicin citrate, liposomal formulation, 10 mg	OPEN
Injection, degarelix, 1 mg	OPEN
Injection, degarelix, 1 mg	OPEN OPEN
Injection, denileukin diftitox, 300 micrograms Injection, denileukin diftitox, 300 micrograms	OPEN OPEN
	OPEN
Injection, docetaxel, 1 mg Injection, docetaxel, 1 mg	OPEN
Injection, docetaxel, 1 mg Injection, elotuzumab, 1 mg	OPEN OPEN
Injection, epirubicin hcl, 2 mg	OPEN
Injection, epirubicin hcl, 2 mg	OPEN OPEN
Injection, epirubicin nci, z mg	OPEN
Injection, eribulin mesylate, 0.1 mg	OPEN
Injection, etoposide, 10 mg	OPEN

DESCRIPTION	CHARGE
Injection, etoposide, 10 mg	OPEN
Injection, etoposide, 10 mg	OPEN
Injection, etoposide, 10 mg	OPEN
injection, fludarabine phosphate, 50 mg	OPEN
injection, fludarabine phosphate, 50 mg	OPEN
Injection, fluorouracil, 500 mg	OPEN
Injection, fluorouracil, 500 mg	OPEN
Injection, fluorouracil, 500 mg	OPEN
Injection, fluorouracil, 500 mg	OPEN
Injection, floxuridine, 500 mg	OPEN
Injection, floxuridine, 500 mg	OPEN
Injection, gemcitabine hydrochloride, 200 mg	OPEN
Injection, gemcitabine hydrochloride, 200 mg	OPEN
Injection, gemcitabine hydrochloride, 200 mg	OPEN
Injection, gemcitabine hydrochloride, 200 mg	OPEN
Goserelin acetate implant, per 3.6 mg	OPEN
Goserelin acetate implant, per 3.6 mg	OPEN
Injection, gemtuzumab ozogamicin, 0.1 mg	OPEN
Injection, gemtuzumab ozogamicin, 0.1 mg	OPEN
Injection, irinotecan liposome, 1 mg	OPEN
Injection, irinotecan liposome, 1 mg	OPEN
Injection, irinotecan, 20 mg	OPEN
Injection, irinotecan, 20 mg	OPEN
Injection, ixabepilone, 1 mg	OPEN OPEN
Injection, ixabepilone, 1 mg Injection, ifosfamide, 1 gram	OPEN
Injection, ifosfamide, 1 gram	OPEN
Injection, ifosfamide, 1 gram	OPEN
Injection, ifosfamide, 1 gram	OPEN
Injection, ifosfamide, 1 gram	OPEN
Injection, mesna, 200 mg	OPEN
Injection, mesna, 200 mg	OPEN
Injection, idarubicin hydrochloride, 5 mg	OPEN
Injection, idarubicin hydrochloride, 5 mg	OPEN
Injection, idarubicin hydrochloride, 5 mg	OPEN
Injection, interferon, alfa-2b, recombinant, 1 million units	OPEN
Injection, interferon, alfa-2b, recombinant, 1 million units	OPEN
Injection, interferon, alfa-2b, recombinant, 1 million units	OPEN
Injection, interferon, alfa-2b, recombinant, 1 million units	OPEN
Leuprolide acetate (for depot suspension), 7.5 mg	OPEN
Leuprolide acetate (for depot suspension), 7.5 mg	\$ 3,135.00
Leuprolide acetate (for depot suspension), 7.5 mg	OPEN
Leuprolide acetate (for depot suspension), 7.5 mg	OPEN
Leuprolide acetate (for depot suspension), 7.5 mg	OPEN
Leuprolide acetate (for depot suspension), 7.5 mg	OPEN
Leuprolide acetate, per 1 mg	OPEN
Leuprolide acetate, per 1 mg	OPEN
Histrelin implant (supprelin la), 50 mg	OPEN
Injection, ipilimumab, 1 mg	OPEN
Injection, ipilimumab, 1 mg	OPEN
Injection, mechlorethamine hydrochloride, (nitrogen mustard), 10 mg	OPEN
Injection, mechlorethamine hydrochloride, (nitrogen mustard), 10 mg	OPEN
Injection, melphalan hydrochloride, 50 mg	OPEN
Injection, melphalan hydrochloride, 50 mg	OPEN
Methotrexate sodium, 5 mg	OPEN
Methotrexate sodium, 5 mg	OPEN
Methotrexate sodium, 5 mg	OPEN
Methotrexate sodium, 5 mg	OPEN
Methotrexate sodium, 5 mg	OPEN
Injection, nelarabine, 50 mg	OPEN
Injection, nelarabine, 50 mg	OPEN
Injection, oxaliplatin, 0.5 mg	OPEN
Injection, oxaliplatin, 0.5 mg	OPEN

DESCRIPTION	CHARGE
njection, oxaliplatin, 0.5 mg	OPEN
njection, oxaliplatin, 0.5 mg	OPEN
njection, paclitaxel protein-bound particles, 1 mg	OPEN
njection, paclitaxel protein-bound particles, 1 mg	OPEN
njection, pegaspargase, per single dose vial	OPEN
njection, pegaspargase, per single dose vial	OPEN
njection, paclitaxel, 1 mg	OPEN
njection, paclitaxel, 1 mg	OPEN
njection, pentostatin, 10 mg	OPEN
njection, pentostatin, 10 mg	OPEN
njection, pembrolizumab, 1 mg	OPEN
njection, mitomycin, 5 mg	OPEN
njection, mitomycin, 5 mg	OPEN
njection, mitomycin, 5 mg	OPEN
njection, mitomycin, 5 mg	OPEN
njection, olaratumab, 10 mg	OPEN
njection, mitoxantrone hydrochloride, per 5 mg	OPEN
njection, mitoxantrone hydrochloride, per 5 mg njection, necitumumab, 1 mg	OPEN OPEN
njection, necitumumab, 1 mg	OPEN
njection, nivolumab, 1 mg	OPEN
njection, nivolumab, 1 mg	OPEN
njection, obinutuzumab, 10 mg	OPEN
njection, obinutuzumab, 10 mg	OPEN
njection, ofatumumab, 10 mg	OPEN
njection, ofatumumab, 10 mg	OPEN
njection, panitumumab, 10 mg	OPEN
njection, panitumumab, 10 mg	OPEN
njection, pemetrexed, 10 mg	OPEN
njection, pemetrexed, 10 mg	OPEN
njection, pertuzumab, 1 mg	OPEN
njection, pertuzumab, 1 mg	OPEN
njection, pralatrexate, 1 mg	OPEN
njection, pralatrexate, 1 mg	OPEN
njection, ramucirumab, 5 mg	OPEN
njection, rituximab, 100 mg	OPEN
njection, romidepsin, 1 mg	OPEN
njection, romidepsin, 1 mg	OPEN
njection, streptozocin, 1 gram	OPEN
njection, streptozocin, 1 gram	OPEN
njection, talimogene laherparepvec, per 1 million plaque forming units	OPEN
njection, talimogene laherparepvec, per 1 million plaque forming units	OPEN
njection, temsirolimus, 1 mg	OPEN
njection, temsirolimus, 1 mg	OPEN
njection, thiotepa, 15 mg	OPEN OPEN
njection, thiotepa, 15 mg njection, topotecan, 0.1 mg	OPEN OPEN
njection, topotecan, 0.1 mg	OPEN
njection, topotecan, 0.1 mg	OPEN
njection, ado-trastuzumab emtansine, 1 mg	OPEN
njection, ado nastuzumab enitarisme, i mg	OPEN
njection, trastuzumab, 10 mg	OPEN
njection, valrubicin, intravesical, 200 mg	OPEN
njection, valrubicin, intravesical, 200 mg	OPEN
njection, valrubicin, intravesical, 200 mg	OPEN
njection, vinduciste, 1 mg	OPEN
njection, vinblastine sulfate, 1 mg	OPEN
/incristine sulfate, 1 mg	OPEN
/incristine sulfate, 1 mg	OPEN

DESCRIPTION		CHARGE
Vincristine sulfate, 1 mg		OPEN
Vincristine sulfate, 1 mg		OPEN
Injection, vincristine sulfate liposome, 1 mg		OPEN
Injection, vinorelbine tartrate, 10 mg		OPEN
Injection, vinorelbine tartrate, 10 mg		OPEN
Injection, vinorelbine tartrate, 10 mg		OPEN
Injection, vinorelbine tartrate, 10 mg		OPEN
Injection, fulvestrant, 25 mg		OPEN
Injection, fulvestrant, 25 mg		OPEN
Injection, fulvestrant, 25 mg		OPEN
Injection, fulvestrant, 25 mg		OPEN
Injection, ziv-aflibercept, 1 mg		OPEN
Injection, ziv-aflibercept, 1 mg		OPEN
Injection, porfimer sodium, 75 mg		OPEN
Not otherwise classified, antineoplastic drugs		OPEN
Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf	\$	308.00
Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf	\$	83.00
Tracheostomy speaking valve	\$	272.00
Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only	\$	4,426.00
Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver	\$	325.00
External recharging system for battery (internal) for use with implantable neurostimulator radionequency receiver	\$	3,150.00
External recharging system for battery (internal) for use with implantable neurostimulator, replacement only	\$	8,079.00
	\$	
Prosthetic implant, not otherwise specified	1	1,227.00
Orthotic and prosthetic supply, accessory, and/or service component of another hcpcs "I" code	\$	2,806.00
Screening papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision	\$	59.00
Screening papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision	\$	59.00
Blood (whole), for transfusion, per unit	\$	804.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	804.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Blood, split unit	\$	418.00
Cryoprecipitate, each unit	\$	82.00
Cryoprecipitate, each unit	\$	82.00
Red blood cells, leukocytes reduced, each unit	\$	362.00
Fresh frozen plasma (single donor), frozen within 8 hours of collection, each unit	\$	104.00
Platelets, each unit	\$	942.00
Red blood cells, each unit	\$	151.00
Platelets, leukocytes reduced, each unit	\$	2,426.00
Platelets, pheresis, each unit	\$	953.00
Platelets, pheresis, each unit	\$	953.00
Platelets, pheresis, leukocytes reduced, each unit	\$	975.00
Platelets, pheresis, leukocytes reduced, each unit	\$	987.0
Platelets, pheresis, leukocytes reduced, each unit	\$	987.0
Platelets, pheresis, irradiated, each unit	\$	2,401.0
Platelets, pheresis, in adiated, each unit	\$	2,401.0
Infusion, albumin (human), 5%, 50 ml	, , , , , , , , , , , , , , , , , , ,	OPEN
Infusion, algumin (numan), 5%, 50 ml		OPEN

DESCRIPTION		CHARGE
Plasma, cryoprecipitate reduced, each unit	\$	354.00
Infusion, albumin (human), 5%, 250 ml		OPEN
Infusion, albumin (human), 5%, 250 ml		OPEN
Infusion, albumin (human), 25%, 50 ml		OPEN
Infusion, albumin (human), 25%, 50 ml		OPEN
Infusion, albumin (human), 25%, 50 ml		OPEN
Infusion, plasma protein fraction (human), 5%, 250 ml		OPEN
Granulocytes, pheresis, each unit	\$	4,576.00
Whole blood or red blood cells, leukocytes reduced, frozen, deglycerol, washed, each unit	\$	931.00
Fresh frozen plasma between 8-24 hours of collection, each unit	\$	102.00
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled		OPEN
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	\$	3.00
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	\$	3.00
Catheterization for collection of specimen, single patient, all places of service	\$	47.00
Fern test	\$	44.00
Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time	Ŧ	OPEN
of chemotherapy treatment, not to exceed a 48 hour dosage regimen Chlorpromazine hydrochloride, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time		OPEN
of chemotherapy treatment, not to exceed a 48 hour dosage regimen		ODEN
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen		OPEN
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen		OPEN
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen		OPEN
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen		OPEN
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy]	OPEN
treatment, not to exceed a 48 hour dosage regimen Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy		OPEN
treatment, not to exceed a 48 hour dosage regimen Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy	İ	OPEN
treatment, not to exceed a 48 hour dosage regimen Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy		OPEN
treatment, not to exceed a 48 hour dosage regimen Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy	ĺ	OPEN
treatment, not to exceed a 48 hour dosage regimen		
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen		OPEN
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen		OPEN
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen		OPEN
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time		OPEN
of chemotherapy treatment not to exceed a 48 hour dosage regimen Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time		OPEN
of chemotherapy treatment not to exceed a 48 hour dosage regimen Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of	i	OPEN
chemotherapy treatment, not to exceed a 48 hour dosage regimen Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of		OPEN
chemotherapy treatment, not to exceed a 48 hour dosage regimen Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of	İ	OPEN
chemotherapy treatment, not to exceed a 48 hour dosage regimen		
Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen		OPEN
Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen		OPEN
Promethazine Per 12.5Mg Oral		OPEN
Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen		OPEN

DESCRIPTION		CHARGE
Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen		OPEN
Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen		OPEN
Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of	1	OPEN
chemotherapy treatment, not to exceed a 24 hour dosage regimen Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of		OPEN
chemotherapy treatment, not to exceed a 24 hour dosage regimen Miscellaneous supply or accessory for use with an implanted ventricular assist device	\$	360.00
Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml		OPEN
Injection, fosphenytoin, 50 mg phenytoin equivalent		OPEN
Injection, fosphenytoin, 50 mg phenytoin equivalent		OPEN
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)		OPEN
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)		OPEN
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)		OPEN
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)	\$	35.00
Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per		OPEN
infusion		
Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion		OPEN
Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg		OPEN
Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg		OPEN
Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg		OPEN
Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg		OPEN
Injection, interferon beta-1a, 1 mcg for intramuscular use		OPEN
Injection, interferon beta-1a, 1 mcg for intramuscular use		OPEN
Injection, interferon beta-1a, 1 mcg for subcutaneous use	T	OPEN
Injection, interferon beta-1a, 1 mcg for subcutaneous use	1	OPEN
Cast supplies, short leg cast, adult (11 years +), fiberglass	\$	279.00
Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies)	\$	164.00
Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies)	\$	339.00
Injection, epoetin alfa, 100 units (for ESRD on dialysis)	1	OPEN
Injection, epoetin alfa, 100 units (for ESRD on dialysis)	1	OPEN
Injection, epoetin alfa, 100 units (for ESRD on dialysis)	1	OPEN
Injection, epoetin alfa, 100 units (for ESRD on dialysis)	T	OPEN
Injection, epoetin alfa, 100 units (for ESRD on dialysis)	1	OPEN
Apligraf, per square centimeter	\$	105.00
Oasis wound matrix, per square centimeter	\$	40.00
Dermagraft, per square centimeter	\$	164.00
Dermagraft, per square centimeter	\$	99.00
Alloderm, per square centimeter	\$	175.00
Theraskin, per square centimeter	\$	92.00
Arthroflex, per square centimeter	\$	310.00
Mediskin, per square centimeter	\$	598.00
Puraply or puraply am, per square centimeter	\$	80.00
infliximab dyyb inflectra 10mg	1 2	OPEN
Oral magnetic resonance contrast agent, per 100 ml	\$	58.43
Oral magnetic resonance contrast agent, per 100 ml	\$	59.00
Oral magnetic resonance contrast agent, per 100 ml	\$	60.00
Injection, perflutren lipid microspheres, per ml	\$	758.00
	Ş	
Injection, perflutren lipid microspheres, per ml High osmolar contract material, up to 149 mg/ml iodine concentration, per ml	Ċ	OPEN 0.53
High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml	\$ ¢	0.53
High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml	\$	0.53
High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml	\$ ¢	1.62
High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml	\$	1.62
High osmolar contrast material, 150-199 mg/ml iodine concentration, per ml	\$	0.25
High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml	\$	0.74
High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml	\$	1.62
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml	\$	1.06
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml	\$	24.00
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml	\$	1.06
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	\$	7.23
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	\$	1.10

DESCRIPTION		CHARGE
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	\$	1.10
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	\$	1.10
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	7.23
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.35
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	7.33
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	6.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.10
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$ \$	1.62 1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	ې \$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	\$	1.62
Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg	Ŷ	OPEN
Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg		OPEN
Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg		OPEN
Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg		OPEN
Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg		OPEN
Stat laboratory request (situations other than s3601)		OPEN
Posterior chamber intraocular lens	\$	346.00
Posterior chamber intraocular lens	\$	504.00
Posterior chamber intraocular lens	\$	519.00
Holter Monitor Equipment		OPEN
Paternity Testing/Phleb/Photo	\$	30.00
Paternity Testing/Phleb/Photo	\$	30.00
Paternity Testing/Phleb/Photo	\$	30.00
Room & Care/Bed -Med-Surg/Peds/3B Private	\$	1,212.00
Room & Care/Bed -Med-Surg/Peds/3B Isolation	\$	1,297.00
Room & Care/Bed -Med-Surg/Peds/3B Private Med Justfd	\$	1,212.00
Room & Care/Bed -Med-Surg/Peds/3B Semiprivate	\$	1,115.00
Room & Care/Bed -Med-Surg/Peds/3B Telemetry	\$	1,741.00
Surgical overnight recovery per hour	\$	47.00
Room & Care/Bed -Ortho/Onc/5A Semiprivate	\$	1,115.00
Room & Care/Bed -Ortho/Onc/5A Private	\$	1,216.00
Room & Care/Bed -Ortho/Onc/5A Isolation	\$	1,456.00
Surgical overnight recovery per hour	\$	47.00
Room & Care/Bed -Ortho/Onc/5A Private Med Justfd	\$	1,212.00
Room & Care/Bed -Ortho/Onc/5A Intensive Care	\$	2,407.00
Room & Care/Bed -Psych/7A Psych Semiprivate Room & Care/Bed -Psych/7A Psych Private Med Justfd	\$ ¢	1,321.00 1,321.00
Bridge On Discharge	\$ \$	290.00
Room & Care/Bed -Nursery/D6A	\$	1,211.00
Room & Care/Bed -Nursery/D6A Neonatal Spec Care	\$	7,315.00
Room & Care/Bed -AICU/4A Intensive Care	\$	2,407.00
Room & Care/Bed -AICU/4A Semiprivate	\$	1,115.00
Room & Care/Bed -AICU/4A Isolation	\$	1,456.00
Room & Care/Bed -AICU/4A Private	\$	1,430.00
Room & Care/Bed -AICU/4A Telemetry	\$	1,741.00
Room & Care/Bed -AICU/4A Private Med Justfd	\$	1,212.00
Room & Care/Bed -AICU/4A Cardiac Intensive Care	\$	2,407.00
	\$	1,115.00
Room & Care/Bed -Intm Care Unit/4B Semiprivate		-,00

		CHARGE
Room & Care/Bed -Intm Care Unit/4B Intensive Care	\$	2,407.00
Surgical overnight recovery per hour	\$	47.00
	\$	1,741.00
	\$	1,212.00
	\$	1,212.00
Inpatient CRRT Machine Setup (Davita)	\$	583.00
Inpatient CRRT Machine/24Hr (Davita)	\$	365.00
Inpatient CAPD	\$	432.00
Inpatient CCPD	\$	467.00
Incentive Spirometer Dev (S)	\$	41.00
Heliox Tank	\$	83.00
	\$	92.00
	\$	146.00
Nebulizer Disposable (S)	\$	26.00
Ventilator Mdi Spacer Dev (S)	\$	92.00
Oscillary Vest Supply (S)	\$	675.00
	\$	146.00
Ipv Headset (S)	\$	103.00
	\$	344.00
Micro Pump Device (S)	\$	334.00
	\$	41.00
	\$	41.00
	\$	90.00
	\$	88.00
	\$	92.00
Standard Travel Expense	\$	4.00
Therapist 1/4 Hour - Wp	\$	21.00
Therapist Hour Wp	\$	71.00
	\$	34.00
Pulm Rehab Thr Selfpay/Month	\$	32.00
Pulm Rehab Thr Selfpay/Session	\$	5.00
Flow Vol Loop Bronc Oh Contrct	\$	53.00
Unreturned Sleep Equipment		OPEN
Anesthesia Disbursement time: 000-030 Min	\$	444.00
	\$	506.00
Anesthesia Disbursement time: 091-150 Min	\$	565.00
Anesthesia Disbursement time: 151-210 Min	\$	626.00
Anesthesia Disbursement time: 211-270 Min	\$	687.00
Anesthesia Disbursement time: 271-330 Min	\$	748.00
Anesthesia Disbursement time: 331-390 Min	\$	809.00
	\$	870.00
Anesthesia Disbursement time: 451-510 Min	\$	930.00
Anesthesia Disbursement time: 511-570 Min	\$	992.00
Anesthesia Disbursement time: 571-630 Min	\$	1,052.00
	\$	1,112.00
		OPEN
Anesthesia Disbursement time: Over 690 Min	\$	162.00
Anesthesia Disbursement time: Over 690 Min Nasal Splint	\$	56.00
	, \$	166.00
Nasal Splint Bottle (Disposable)	\$	1,649.00
Nasal Splint Bottle (Disposable) Blade	\$	65.00
Nasal Splint Bottle (Disposable) Blade Laser Endostat	\$	241.00
Nasal Splint Bottle (Disposable) Blade Laser Endostat	\$	83.00
Nasal Splint Bottle (Disposable) Blade Laser Endostat Tube Fluoro Vent Vari Stimulator		83.00
Nasal Splint Bottle (Disposable) Blade Laser Endostat Tube Fluoro Vent Vari Stimulator	\$	131.00
Nasal Splint Bottle (Disposable) Blade Laser Endostat Tube Fluoro Vent Vari Stimulator Carrier (Skin Graft)		
Nasal Splint Bottle (Disposable) Blade Laser Endostat Tube Fluoro Vent Vari Stimulator Carrier (Skin Graft) Carrier (Skin Graft)	\$	65.00
Nasal Splint Bottle (Disposable) Blade Laser Endostat Tube Fluoro Vent Vari Stimulator Carrier (Skin Graft) Carrier (Skin Graft) Tube (Trach) Teflon Felt 019306Ct	\$ \$	
Nasal Splint Bottle (Disposable) Blade Laser Endostat Tube Fluoro Vent Vari Stimulator Carrier (Skin Graft) Carrier (Skin Graft) Tube (Trach) Teflon Felt 019306Ct Operating room time: 241-255 Min	\$ \$ \$	9,394.00
Nasal Splint Bottle (Disposable) Blade User Endostat Tube Fluoro Vent Tube Fluoro Vent Carrier (Skin Graft) Carrier (Skin Graft) Tube (Trach) Tube (Trach) Teflon Felt 019306Ct Operating room time: 241-255 Min Operating room time: 256-270 Min	\$ \$ \$ \$	9,394.00 9,904.00
Nasal Splint Bottle (Disposable) Blade User Endostat Laser Endostat Tube Fluoro Vent Tube Fluoro Vent Carrier (Skin Graft) Carrier (Skin Graft) Carrier (Skin Graft) Tube (Trach) Tube (Trach) Teflon Felt 019306Ct Operating room time: 241-255 Min Operating room time: 256-270 Min Operating room time: 271-285 Min	\$ \$ \$ \$ \$	65.00 9,394.00 9,904.00 10,414.00 10.925.00
Nasal Splint Bottle (Disposable) Blade Laser Endostat Tube Fluoro Vent Carrier (Skin Graft) Carrier (Skin Graft) Carrier (Skin Graft) Tube (Trach) Tube (Trach) Teflon Felt 019306Ct Operating room time: 241-255 Min Operating room time: 256-270 Min Operating room time: 271-285 Min Operating room time: 271-285 Min Operating room time: 286-300 Min	\$ \$ \$ \$ \$ \$	9,394.00 9,904.00 10,414.00 10,925.00
Nasal Splint Bottle (Disposable) Blade User Endostat Laser Endostat Tube Fluoro Vent Tube Fluoro Vent Carrier (Skin Graft) Carrier (Skin Graft) Carrier (Skin Graft) Tube (Trach) Tube (Trach) Teflon Felt 019306Ct Operating room time: 241-255 Min Operating room time: 256-270 Min Operating room time: 271-285 Min	\$ \$ \$ \$ \$	9,394.00 9,904.00 10,414.00

DESCRIPTION		CHARGE
Operating room time: 346-360 Min	\$	12,967.00
Operating room time: 361-375 Min	\$	13,477.00
Operating room time: 376-390 Min	\$	13,988.00
Operating room time: 391-405 Min	\$	14,499.00
Operating room time: 406-420 Min	\$	15,009.00
Operating room time: 421-435 Min	\$	15,519.00
Operating room time: 436-450 Min	\$	16,030.00
Operating room time: 451-465 Min	\$	16,540.00
Operating room time: 466-480 Min	\$	17,050.00
Operating room time: 481-495 Min	\$	17,562.00
Operating room time: 496-510 Min	\$	18,073.00
Operating room time: 511-525 Min	\$	18,583.00
Operating room time: 526-540 Min	\$	19,094.00
Operating room time: 541-555 Min	\$	19,604.00
Operating room time: 556-570 Min	\$	20,114.00
Operating room time: 571-585 Min	\$	20,625.00
Operating room time: 586-600 Min	\$	21,136.00
Blade	\$	4,214.00
Washer Washer	\$	79.00
Washer Tube Medified T	\$	108.00
Tube Modified T	\$	78.00
Stapler (Linear)	\$	362.00
Stapler (Linear)	\$	679.00
Stapler (Linear)	\$	1,570.00
Stapler (Linear)	\$	1,006.00
Endo Clip Applier	\$	658.00
Endopath Veress Needle	\$	116.00
Rod (Syn Ex-Fix) Avitene Jar 110001Ms	\$ \$	955.00
Stapler (Reload)		445.00 578.00
Blade	\$	690.00
Endo Loop O Vicryl Ej10Ggy	\$	79.00
Stapler (Circular)	\$	2,137.00
Stapler (Circular)	\$	2,137.00
Multiclip Applier Er420Gs	\$	530.00
Washer	\$	96.00
Endo Flo Irrigator 0043970Gy	\$	224.00
Cath Bag Con Tube Y	\$	73.00
Operating room time: 000-015 Min	\$	942.00
Operating room time: 016-030 Min	\$	1,453.00
Operating room time: 031-045 Min	\$	1,963.00
Operating room time: 046-060 Min	\$	2,473.00
Operating room time: 061-075 Min	\$	2,984.00
Operating room time: 076-090 Min	\$	3,494.00
Operating room time: 091-105 Min	\$	4,005.00
Operating room time: 106-120 Min	\$	4,515.00
Operating room time: 121-135 Min	\$	5,309.00
Operating room time: 136-150 Min	\$	5,820.00
Operating room time: 151-165 Min	\$	6,330.00
Operating room time: 166-180 Min	\$	6,840.00
Operating room time: 181-195 Min	\$	7,352.00
Operating room time: 196-210 Min	\$	7,863.00
Operating room time: 211-225 Min	\$	8,373.00
Operating room time: 226-240 Min	\$	8,883.00
Operating room time: 601-615 Min	\$	21,646.00
Operating room time: 616-630 Min	\$	22,157.00
Operating room time: 631-645 Min	\$	22,667.00
Operating room time: 646-660 Min	\$	23,177.00
Operating room time: 661-675 Min	\$	23,687.00
Operating room time: 676-690 Min	\$	24,198.00
Operating room time: 691-705 Min	\$	24,709.00
Operating room time: 706-720 Min	\$	25,219.00
Operating room time: 721-735 Min	\$	25,730.00

Operating room time: 726 750 Min	
Operating room time: 736-750 Min	\$ 26,240.00
Operating room time: 751-765 Min	\$ 26,750.00
Operating room time: 766-780 Min	\$ 27,261.00
	\$ 27,773.00
	\$ 28,283.00
	\$ 28,794.00
	\$ 29,304.00
	\$ 29,814.00
	\$ 30,324.00
	\$ 30,835.00
	\$ 31,346.00
	\$ 31,856.00
	\$ 32,367.00
	\$ 32,877.00
	\$ 33,387.00
	\$ 33,898.00
	\$ 34,408.00
	\$ 34,919.00 \$ 25,420.00
	\$ 35,430.00 \$ 35,940.00
	\$ 35,940.00 \$ 36,450.00
	\$ 36,960.00 \$
	\$30,900.00 \$37,471.00
	\$ 37,983.00
	\$ 37,583.00 \$ 38,493.00
	\$ 39,004.00
	\$ 39,514.00
	\$ 40,024.00
	\$ 40,535.00
	\$ 41,045.00
	\$ 41,556.00
	\$ 42,067.00
	\$ 42,577.00
	\$ 43,087.00
	\$ 43,598.00
Operating room time: 1261-1275 Min	\$ 44,108.00
Operating room time: 1276-1290 Min	\$ 44,619.00
Operating room time: 1291-1305 Min	\$ 45,129.00
Operating room time: 1306-1320 Min	\$ 45,640.00
Operating room time: 1321-1335 Min	\$ 46,150.00
	\$ 46,660.00
	\$ 47,171.00
	\$ 47,681.00
	\$ 48,193.00
	\$ 48,704.00
	\$ 49,214.00
	\$ 49,724.00
	\$ 120.00
	\$ 167.00
	\$ 116.00
	\$ 537.00
	\$ 246.00
	\$ 150.00
	\$ 563.00
	\$ 10,162.00 \$ 1,109.00
	\$ 7,448.00 \$ 676.00
	\$ 676.00 \$ 150.00
	\$ 150.00 \$ 549.00
	\$
	\$ 1,102.00
Disposable Cytology Brush	- 437.00

DESCRIPTION		CHARGE
Disposable Tourniquet Cuff 24"	\$	189.00
Recovery room time: 000-030 Min	\$	317.00
Recovery room time: 031-060 Min	\$	633.00
Recovery room time: 061-090 Min	\$	
Recovery room time: 091-120 Min	\$	
Recovery room time: 121-150 Min	\$	1,581.00
Recovery room time: 151-180 Min	\$	
Recovery room time: 181-210 Min	\$	
Recovery room time: 211-240 Min	\$	
Recovery room time: 241-270 Min	\$	2,845.00
Recovery room time: 271-300 Min	\$	
Pre-operative preparation time: 000-030 Min	\$	
Pre-operative preparation time: 031-060 Min	\$	
Pre-operative preparation time: 061-090 Min	\$	
Pre-operative preparation time: 091-120 Min	\$	
Recovery room time: 301-330 Min	\$	
Recovery room time: 331-360 Min	\$	
Recovery room time: 361-390 Min Recovery room time: 391-420 Min	\$	
Recovery room time: 421-450 Min	\$	
Recovery room time: 451-480 Min	\$	
Recovery room time: 481-540 Min	\$	
Recovery room time: 541-600 Min	\$	
Recovery room time: 601-660 Min	\$	
Recovery room time: 661-720 Min	\$	
Pre-operative preparation time: 121-150 Min	\$	
Pre-operative preparation time: 151-180 Min	\$	
Pre-operative preparation time: 181-210 Min	\$	1,776.00
Pre-operative preparation time: 241-270 Min	\$	
Pre-operative preparation time: 211-240 Min	\$	2,028.00
Pre-operative preparation time: 271-300 Min	\$	2,536.00
Pre-operative preparation time: 301-330 Min	\$	2,788.00
Pre-operative preparation time: 331-360 Min	\$	3,042.00
Pre-operative preparation time: 000-030 Min	\$	255.00
Pre-operative preparation time: 031-060 Min	\$	508.00
Pre-operative preparation time: 061-090 Min	\$	762.00
Pre-operative preparation time: 091-120 Min	\$	
Recovery room time: 000-030 Min	\$	
Recovery room time: 031-060 Min	\$	
Recovery room time: 061-090 Min	\$	
Recovery room time: 091-120 Min	\$	1,265.00
Recovery room time: 121-150 Min	\$	
Recovery room time: 151-180 Min	\$	
Recovery room time: 181-210 Min	\$	
Recovery room time: 211-240 Min	\$	
Recovery room time: 241-270 Min	\$	
Recovery room time: 271-300 Min	\$	
Recovery room time: 301-330 Min	\$	
Recovery room time: 331-360 Min		
Recovery room time: 361-390 Min Recovery room time: 391-420 Min	\$	
Recovery room time: 421-450 Min	\$	2,529.00
Recovery room time: 451-480 Min	\$	
Recovery room time: 481-540 Min	\$	
Recovery room time: 541-600 Min	\$	
Recovery room time: 601-660 Min	\$	
Recovery room time: 661-720 Min	\$	
Pre-operative preparation time: 121-150 Min	\$	
Pre-operative preparation time: 151-180 Min	\$	
Pre-operative preparation time: 181-210 Min	\$	
Pre-operative preparation time: 211-240 Min	\$	
Pre-operative preparation time: 241-270 Min	\$	
Pre-operative preparation time: 271-300 Min	\$	

DESCRIPTION		CHARGE
Pre-operative preparation time: 301-330 Min	\$	2,788.00
Pre-operative preparation time: 331-360 Min	\$	3,042.00
Intro Spinal Kit Lvl001	\$	225.00
Gen Neuro Imp Chg Kit Lvl015	\$	3,150.00
Lg Grtr Trochantrc Dvc W/4 Cab	\$	6,019.00
Lg Ext Fix Multi-Pin Clamp	\$	3,314.00
Bit (Drill)	\$	269.00
Reload Ta 90B-4.8	\$	653.00
Electrode (Laproscopic)	\$	177.00
Fiberwire (Ar-7203)	\$	97.00
Helical Blade (456.301)	\$	2,344.00
Stapler (Rectal)	\$	997.00
Stapler (Rotating)	\$	741.00
Patient Care Kit	\$	643.00
Suture Passing Wire Ar-1255-18 Infuse Bone Graft Kit-Small Kt	\$ ¢	306.00
	\$	8,389.00
Infuse Bone Graft Kit-Large Kt Infuse Bone Graft Kit-Large Ii	\$ \$	11,954.00 13,148.00
Knotpusher Fastfix (7209084)	ې \$	13,148.00 538.00
Trocar Bladeless 12Mm & 5Mm	\$ \$	347.00
Trocar Bladeless 12/Min & Swith	ې \$	480.00
Stapler	\$	1,911.00
Stapler (Reload)	\$	713.00
Loop Superpulse Gyrus (744200)	\$	2,694.00
Catheter (Occlusion)	\$	214.00
Bit (Drill)	\$	529.00
Blade Oscillating 2109-109S11	\$	188.00
Suction Irrigation Tubing	\$	252.00
Blade Right Ang Sagittal	\$	116.00
Suture Passer Scorpion	\$	1,452.00
Suture	\$	129.00
Applier Endoclip 5Mm	\$	995.00
Endostitch	\$	1,304.00
Instr Pursestring 45	\$	492.00
O Surgidac	\$	216.00
Stapler (Skin)	\$	212.00
Blade Chisel 25Mm	\$	791.00
Harmonic Scalpel Ace 14S	\$	659.00
Harmonic Scalpel Ace 23P	\$	2,747.00
Harmonic Scalpel Ace 36P	\$	3,290.00
	\$	2,694.00
Greenlight Laserscope	\$	5,068.00
Kit Pleurx Drainage	\$	221.00
Gelport 120Mm	\$	1,941.00
Electrode (Leep)	\$	108.00
Harmonic Wave Instrument	\$	1,809.00
Stapler	\$	1,759.00
Bit (Drill)	\$	886.00 632.00
Bit (Drill)	\$	
Bit (Drill) Bit (Drill)	\$ \$	242.00 489.00
Surgical Postop Support Bra	\$ \$	489.00
Abdominal Binder Postop Supprt	\$	53.00
Bit (Drill)	\$	2,174.00
Bit (Drill)	ډ \$	737.00
Ligasure	\$	1,979.00
Retractor	\$	175.00
Suture 2-0 (Quill)	\$	801.00
Or Misc \$10K & Up Cost		OPEN
Or Misc \$4-10K Cost		OPEN
Or Misc \$2-4K Cost		OPEN
Or Misc \$1-2K Cost		OPEN
Or Misc \$500-1K Cost		OPEN

DESCRIPTION	CHARGE
Or Misc \$200-500 Cost	OPEN
Or Misc \$100-200 Cost	OPEN
Or Misc Under \$100 Cost	OPEN
Device Perm Birth Cntrl	\$ 4,502.00
Scalpel Harmonic Shear Cvd	\$ 2,349.00
Guidewire Drl Tip310.243	\$ 448.00
Bit (Drill)	\$ 277.00
Bit (Drill)	\$ 296.00
Bit (Drill)	\$ 420.00
Bit (Drill)	\$ 281.00
Bit (Drill)	\$ 599.00
Bit (Drill)	\$ 659.00
Bit (Drill)	\$
Bit (Drill)	\$ 1,721.00
Bit (Drill)	\$
Bit (Drill) Bit (Drill)	\$
Bit (Drill)	
Rod Reaming 2.5Mm W/Ball Tip	\$
Rod Offset Tip 351.71S(3 Szs)	\$
Rod Reaming Smooth Tip	\$
Bit (Drill)	\$
Bit (Drill)	\$
Bit (Drill)	\$
Arista Hemost Part Sm0005-Usa	\$
Arista Hemost Part Sm0002-Usa	\$
Dermabond 2.0 Octyl Adhesive	\$
, Bit (Drill)	\$
Drill Bit Cann 6047782-2 Sizes	\$
Dr. Petrick Cds Pack	\$ 748.00
Doppler Flow Probe Exten Cable	\$
Ace Harmnic Crvd Shears Ace36E	\$ 1,902.00
Malyugin Ring	\$ 647.00
Balloon Sinus Infla Dev Bid30	\$ 388.00
Probe Vitrectomy Inf	\$ 696.00
Ace Harmonic Handpiece	\$ 2,181.00
Relieva Hndle Gde Cath,Sdkk01	\$ 396.00
Blade Patella Ream	\$
Cement Mixing Gun	\$ 75.00
Device Novasure Disposable	\$ 3,242.00
Suture Shuttle 45 Deg L	\$
Blade Radnoid 4Mm	\$
Drl Bit J Ltch/Min 1.1-1.5Mm	\$
Lead Cover Boot	\$
Disposable Arth Hip	\$
Forcep Grasper Allig	\$
Pack Lap Chole III	\$
Cylinder Plexur Bone Graft Bane Mill Plade Dien	\$ 4,941.00
Bone Mill Blade Disp Secure Strap 25	\$ 1,527.00 2,677.00
Kyphon Bone Bx Device	\$
Kyphon Express Fx Kit	\$ 14,661.00
Disp Laparoscopic Grasper	\$
Vcare Cup Cervical M/L	\$
Suture Absorbable Level 2	\$ 70.00
Suture Non-Absorbable Lvl 1	\$
Reamer 8Mm Headed Ar-1408	\$
Suture Lasso Left 45 Degree	\$
Kit: Push Lock	\$
Kit Pushlock 2.5 Ar-1926Bc	\$ 1,785.00
Raptor Grasping Device	\$
Reamer Cannulated	\$
Autotome Rx 45	\$ 4,133.00

DESCRIPTION	CHARGE
Trocar Bladeless 11Mm Handle	\$ 383.00
Sut Vicryl 0 J701D	\$ 51.00
Uterine Manipulator 4.5Mm	\$ 109.00
Autotome 39 4519	\$ 976.00
Cann Delivery 301.248	\$ 792.00
Cap End 15Mm 457.010	\$ 8,209.00
Case Graphic Distractor Lrg	\$ 2,914.00
Chip Hemostatic Res 235Cm	\$ 940.00
Device Encore Inflat 6667	\$ 307.00
Graft Aaa Limb Iw1416C105Xh	\$ 16,139.00
Graft Aaa Limb Iw1424C75Xh	\$ 15,936.00
Ndle 19G Flex Expect Slimline	\$ 2,344.00
Plier Bending 329.29	\$ 4,968.00
Pliers Wire Bending 160 391.82	\$ 2,137.00
Protein S Liatest Free	\$ 4,391.00
Spacer Mdi Aerotrach Plus 10	\$ 42.00
Stapler P-R 55.200	\$ 2,964.00
Stein Trapezoid 3.0Cm 1089	\$ 1,147.00 \$ 168.00
Strip Test Cidex Opa Stylet Rigid 0606-0009	\$ 102.00
	\$ 66.00
Sut Vicryl Mesh Vwml	\$ 3,434.00
Tendon Tibialis Post 430340	\$ 6,241.00
Kit I Assist Knee	\$ 4,011.00
	\$ 14,587.00
Sensor Elibra Sm	\$ 2,435.00
Applier Clip Lapr 5Mmx34Cm	\$ 347.00
Bag Retrieval 5Mm Cd003	\$ 204.00
Blade	\$ 674.00
Burr	\$ 139.00
Burr	\$ 555.00
Cable Scope Video Olympus	\$ 8,603.00
Captura Helical Stone Extract	\$ 525.00
Clip Two Hulka	\$ 168.00
Cuff Tourn	\$ 485.00
Cutter Linear Lng Shft	\$ 1,263.00
	\$ 60.00
Drive Direct Clip Appl	\$ 346.00
Elect Laparoscopic Curved	\$ 162.00
Electrode	\$ 594.00
	\$ 339.00
Handpiece Interpulse	\$ 196.00
Hrm Scpl Hand Swtch	\$ 188.00
Instrument Biop Mono	\$ 186.00
	\$ 87.00
Kit Custom Cataract Lewistown	\$ 921.00
Kit Shoulder Suspend Deroyal Lead Intro Single Chamber	\$ 91.00
•	\$ 264.00 \$ 57.00
Meropack Bioresorbable	\$ 438.00
	\$ 76.00
Pack Arthroscopy Glh	\$ 68.00
Pack Fms Flared	\$ 1,142.00
Pack Neuro Back	\$ 173.00
Plug Dome Hole	\$ 391.00
Reload Gold For Echelon	\$ 551.00
Reload Green For Ec60	\$ 551.00
Retractor Alexis Wound Xxs	\$ 157.00
Retriever Suture Hewson	\$ 299.00
Scissor	\$ 306.00
	\$ 65.00
	\$ 2,435.00
Sensor Large Elibra	

D	ESCRIPTION	CHARGE
Stop Acl	\$	136.00
Suture	\$	83.00
Sys Rumi Disp	\$	322.00
System Fix Fios Trocar Cff03	\$	87.00
Tray Chole Endo	\$	176.00
Tray Shoulder Glh	\$	310.00
Trocar Z Thrd Cannul	\$	114.00
Uterine Tip Rumi System	\$	146.00
Wound Clos Vloc 0 Gs21	\$	84.00
Tr Epidural Cath 20G Single	\$	111.00
Cannula Radiofrequency 20Ga	\$	168.00
Cannula Radiofrequency 22Ga	\$	75.00
Cautery L Hook/Ez Blade	\$	181.00
Bivalve Nasal Splint Plastic	\$	94.00
Microvasive'S Rapid Refill Sys	\$	92.00
Rhino Rocket Dsg	\$	48.00
Bill Drill	\$	1,284.00
Cann Radiopaque Marker 20G	\$	73.00
Elect Stat Zoll	\$	76.00
Cuff Tourn Dsp Bldr (Sngl Prt)	\$	226.00
Kit Express li 15/2	\$	8,778.00
Scope Warmer Ps500	\$	268.00
Potassium Phos Inj		OPEN
Potassium Ace Inj		OPEN
Hydrochlorothiazide Tab		OPEN
Methadone 1MI Oral Syringe		OPEN
Pentamidine Per 300Mg Inj		OPEN
Dextrose 50% Inj		OPEN
Sodium Bicarb 8.4% Inj		OPEN
Calcium Chloride 10% Inj		OPEN
Aminocaproic Acid Inj		OPEN
Aminocaproic Acid 500Mg Tab		OPEN
Labetalol Inj		OPEN
Metoprolol Tab		OPEN
Metoprolol Inj		OPEN
Caffeine-Sodium Benzoate Inj		OPEN
Bupivacaine 0.5% Inj		OPEN
Nafcillin Per 2 Gm Inj Emla Cr		OPEN OPEN
Ipatropium 0.02% Inh Soln		OPEN
Bactroban 2% Ex Oint		OPEN
Hycodan Po Syrp		OPEN
Clindamycin Per 300Mg Inj		OPEN
Alprazolam 0.5Mg Tab		OPEN
Ibuprofen Tab		OPEN
Belladonna/Opium Supp		OPEN
Lorazepam Tab		OPEN
Lorazepam Tab		OPEN
Albuterol Inh 17Gm		OPEN
Clotrimazole 1% Cr		OPEN
Bumetanide Inj		OPEN
Lidocaine 2% Ex Gel		OPEN
Acetaminophen Elixir 160Mg 5Ml		OPEN
Acetaminophen Posoln		OPEN
Acetaminophen 320Mg Elixir		OPEN
Potassium Chlor 10% Polig		OPEN
Milk Magnesia Posusp		OPEN
Nacl W/Kcl Ivsoln		OPEN
Potassium Chlor 10% Polig		OPEN
D5Nss With Kcl Ivsoln		OPEN
Ferrous So4 Posoln		OPEN
Chlorpheniramine 4Mg Tab		OPEN
Morphine So4 2Mg/MI Posoln		OPEN

DESCRIPTION	CHARGE
Sodium Chloride 3% Inj	OPEN
Dexamethasone 6Mg Tab	OPEN
Lisinopril 10Mg Tab	OPEN
Potassium Chloride Cap	OPEN
Sodium Thiosulfate 25% Inj	OPEN
Levetiracetam Tab	OPEN
House Antacid Oral	OPEN
Hydroxyzine Tab	OPEN
Nifedipine Cap	OPEN
Felodipine Tab	OPEN
Haloperidol Tab	OPEN
Haloperidol Tab	OPEN
Acetaminophen Tab	OPEN
Acetaminophen Posusp	OPEN
Acetaminophen Posoln	OPEN
Acetaminophen W/Cod Tab	OPEN
Propoxyphene/Apap Tab	OPEN
Nitroglycerin SI Tab	OPEN
Diphenhydramine 2.5Mg/MI Elix Clindamycin Ivsoln	OPEN OPEN
Diazepam 5Mg Tab	OPEN
Prosource Po Pack	OPEN OPEN
Albuterol/Ipratropium Inhsoln	OPEN
Neosporin Ex Oint	OPEN
Bacitracin/Neos/Polymyx Oint	OPEN
Allopurinol Tab	OPEN
Allopurinol Tab	OPEN
Mesna 400Mg Tablet	OPEN
Scopolamine 0.4Mg/MI Inj	OPEN
Bacitracin/Polymixin B Oint	OPEN
Famotidine Inj Per 20Mg	OPEN
Levalbuterol Inh	OPEN
Potasium Chloride 10Meq Tab	OPEN
Hydrocortisone 1% Oint	OPEN
Sodium Chloride 0.9% Inj	OPEN
Sodium Chloride 0.9% Inj	OPEN
Aspirin Chewtab	OPEN
Famotidine Tab	OPEN
Albuterol Inh	OPEN
Ranolazine 500Mg Tab	OPEN
Oxycontin 15Mg Er Tab	OPEN
Rifaximin 200Mg Tab	OPEN
Potassium Phosphate Inj	OPEN
Prochlorperazine Supp	OPEN
Pg Intrfrn Alfa 2B 50Mcg/0.5Ml	OPEN
Famotidine Premix Inj	OPEN
Diph/Dexameth/Met 25/4/10 Supp	OPEN OPEN
Lidocaine-Epi 1%-1:100000 Inj	OPEN
Lidocaine 1% Inj	OPEN
Lidocaine 2% Inj	OPEN
Calcium Carb Chew Tab 750Mg Ciproflexacin Tab	OPEN
Ciprofloxacin Tab Gabapentin 300Mg Cap	OPEN OPEN
Gabapentin 300Mg Cap Sod Chloride 0.9%Flush Inj	OPEN OPEN
Chimeric Monoclonal Antibody	OPEN
Fluconazole 200Mg Tab	OPEN
Fluconazole 200Mg Tab	OPEN
Aztreonam Per 500Mg	OPEN
Nystatin Po Susp	OPEN
Valproate Sodium Inj Per 500Mg	OPEN
Metoprolol Succ XI 25Mg Tab	OPEN
0.45% Normal Saline Ivsoln	OPEN
Ibuprofen 400Mg Tab	OPEN

DESCRIPTION	CHARGE
Verapamil Sr 240Mg Tab	OPEN
Clonidine Tab	OPEN
Torsemide 100Mg Tab	OPEN
Peg-Intrfron Alfa 2B 10Mcg Inj	OPEN
Metoclopramide Tab	OPEN
Atenolol Tab	OPEN
Aspirin 325Mg Tab	OPEN
Felodipine 10Mg Tab	OPEN
Metoprolol 50Mg Tablet	OPEN
Furosemide 40Mg Tab	OPEN
Sucralfate 1Gm Tab	OPEN
Furosemide 20Mg Tabl Ud	OPEN
Ranitidine Tab	OPEN
Atenolol 50Mg Tab	OPEN
Potassium Phosphate Cmpd Inj	OPEN
D5W 0.45%Nss + 20Kcl Ivsoln	OPEN
Posaconazole 17.96Mg/Ml Inj	OPEN
Augmentin 120Mg/Ml Posusp Loperamide 2Mg Cap	OPEN OPEN
Clonidine Tab	OPEN
Gi Cocktail Posusp	OPEN
Non-Formulary Medication	OPEN
Benadryl/Maalox/Lido Posusp	OPEN
Non Formulary Iv	OPEN
Acetaminophen 500Mg Tab	OPEN
Bisacodyl Supp	OPEN
Oxycodone Conc Posoln	OPEN
Morphine Sulfate I.R. Tab	OPEN
Indomethacin Cap	OPEN
Atropine/Diphenox 2.5Mg Tab	OPEN
Lorazepam 0.5Mg Tab	OPEN
Lorazepam 1Mg Tab	OPEN
Levofloxacin 500Mg Tab	OPEN
Methadone 10Mg Tab	OPEN
Morphine Poliq Per 20Mg	OPEN
Morphine Poliq Per 20Mg	OPEN
Leucovorin 5Mg Tab	OPEN
Hydromorphone 2Mg Tab	OPEN
Hydromorphone 4Mg Tablet	OPEN
Acetaminophen Posoln	OPEN
Mannitol 20% Iv Soln	OPEN
Oxycodone 5Mg Cap (Oxy-Ir)	OPEN
Percocet Tab	OPEN
Potassium & Sodium Po4 Pkt	OPEN
Sodium Polysulf Po Susp	OPEN
Metronidazole Inj	OPEN
Oxycodone Po Soln	OPEN
Methadone 5Mg Tab	OPEN
Loratadine 10Mg Tab Tuberculin Ppd Id Soln	OPEN
	OPEN
Fleet Enema Adult Dextrose 10 % Ivsoln	OPEN OPEN
Dextrose 10 % ivsoln Dextrose-Nacl 5-0.45 % ivsoln	OPEN
D5/1/2Nss Per 1000MI	OPEN
Dextrose-Nacl 5-0.2 % Ivsoln	OPEN
Plasma-Lyte 148 lysoln	OPEN
D5W/0.45% Nss + 40Meg Kcl	OPEN
Sterile Water For Inj Ivsoln	OPEN
Sodium Bicarbonate Tab 650Mg	OPEN
Cyclobenzaprine Tab	OPEN
Clindamycin 150Mg Cap	OPEN
Omeprazoel 20Mg Cap	OPEN
Pantopraxole 40Mg Tab	OPEN

DESCRIPTION	CHARGE
Sodium Citrate 4% Inj	OPEN
Fiorcet Tab	OPEN
Alum/Mag Hydrox/Simeth Susp	OPEN
Hydrochlorothiazide 12.5Mg Cap	OPEN
/oriconazole 200Mg Cap	OPEN
Amlodipine 5Mg Tab	OPEN
Azithromycin 500Mg Tab	OPEN
B&O Supp 30Mg	OPEN
Plasmalyte 56/D5W	OPEN
Oxycontin Cr 10Mg	OPEN
Oxycodone Cr 20Mg Tab	OPEN
Oxycodone Cr 40Mg Tab	OPEN
Oxycodone Cr 80Mg Tab	OPEN
Lorazepam Tab	OPEN
Phytonadione 5Mg Tab	OPEN
Acyclovir 400Mg Tab	OPEN
Hyoscyamine SI Tab	OPEN
Thiopental 5Gm lv Kit	OPEN
Hydrochlorothiazide Oretic 25M	OPEN
Hydrochlorothiazide Oretic 50M	OPEN
Cocaine 4% Ex Soln	OPEN
Clorazepate Dip Tab	OPEN
Ephedrine So4 Per 50Mg	OPEN
Erythromycin 200Mg/5MI Susp Ud	OPEN
Erythromycin 250Mg Tab Ud	OPEN
	OPEN
Erythromycin Stearate Erythroc Ascorbic Acid Cecon 50MI S	OPEN
Alcohol Dehyd 99% Amp 1Ml Inj	OPEN
Valproic Acid Depkn 250Mg Cap	OPEN
Vidaylin/F W/Iron Drops 50MI	OPEN
Sodium Bicarbonate Per 1Meq	OPEN
Potassium Phosphate Inj	OPEN
Acetic Acid Irrig 0.25%	OPEN
Cysteine Hcl 50Mg	OPEN
Lidocaine 2% 100Mg/5Ml Inj Syr	OPEN
Dornase Alpha Inh Soln	OPEN
Sodium Chloride Inj	OPEN
Sodium Bicarbonate 4% Inj	OPEN
Sodium Acetate Inj	OPEN
Divalproex Sod Depakote 250Mg	OPEN
Divalproex 500Mg Tab	OPEN
Sodium Phosphate Inj	OPEN
Potassium Phos Inj	OPEN
Potassium Ace Inj	OPEN
Alproazolam Xanax 0.25Mg Tab	OPEN
Zinc So4 Per 1Mg	OPEN
Amino Acid Hbc 7% 1000MI	OPEN
Tromethamine Iv Soln	OPEN
Dermovan Cream 454Gm	OPEN
Lidocaine/Epi 1.5% Inj Amp	OPEN
Hydrochlorothiazide Tab	OPEN
Delsym Liq 90Ml	OPEN
Valpoic Acid Posyrp	OPEN
Sodium Bicarb 4.2% Inj	OPEN
Dextrose 50% Inj	OPEN
Nitroglycerin 5Mg/Ml Inj	OPEN
Nitroglycerin Per 5Mg	OPEN
Potassium Acetate Per 2Meq	OPEN
Benzamycin Gel 23.3 Gm Jar	OPEN
Thiopental Inj	OPEN
Nitroprusside Per 25Mg	OPEN
Triamcinolone Acet 0.1% Lotion	OPEN
Chlordiazepoxide 5Mg Cap	OPEN

DESCRIPTION	CHARGE
Chlordiazepoxide 10Mg Cap	OPEN
Chlordiazepoxide 25Mg Cap	OPEN
Carbamazepine (Dose Varies)	OPEN
rythromycin Ethsuc Ees 400Mg	OPEN
Ammonium Chloride Per 5Meg	OPEN
Adeks Tabs	OPEN
Paregoric Po Liquid	OPEN
Bethanechol Cl 25Mg Tab	OPEN
Pramipexole Tab 0.25Mg	OPEN
Stethescope Bowles Labtron 100	OPEN
Viconazole Nitr Monistat 3 Vag	OPEN
D-Xylose Powd	OPEN
Dermoplast Spray 60Ml	OPEN
Propranolol Hcl Tab 40Mg	OPEN
· -	OPEN
Chothiophate 0.06% Ophth Drop	
istrogen 0.3Mg Tab	OPEN
Conj Estrogen Prem .625 Mg Ta	OPEN
Conjugated Estrogen 0.9Mg Tab	OPEN
Permarin Vagor	OPEN
Conj Estrogen Prem Vag Cr W/O	OPEN
Estrogen 1.25Mg Tab	OPEN
Proprandlol Hcl 20Mg Tab	OPEN
Propranolol 60Mg Tab	OPEN
Methadone Per 10Mg Oral Liq	OPEN
Dapsone Tab 25Mg	OPEN
Propranolol 10Mg Tab Ud	OPEN
Primidone (Doses Vary)	OPEN
Disopyramide 100Mg Cr Cap Ud	OPEN
Propranolol 80Mg Tab Ud	OPEN
Halothane 250MI	OPEN
Vivonex Rtf Poliq	OPEN
Auralgan Otsol	OPEN
Propranolol La 80Mg Cap Ud	OPEN
Propranolol La 120Mg Cap Ud	OPEN
Disopyramide 150Mg Cr Cap Ud	OPEN
Cefadroxil 500Mg Cap	OPEN
Pentamidine Per 300Mg Inj	OPEN
Jltracal Hn Rtf Poliq	OPEN
Dicloxacllin 250Mg Cap	OPEN
Dicloxacillin 62.5Mg/5Ml Susp	OPEN
Choice Dm Rtf Poliq	OPEN
Nafcillin Inj	OPEN
Vetformin 850Mg Tab	OPEN
-	
Pre Pen 0.25 Ml Amp	OPEN
Doxylamine 25Mg Tab	OPEN
actulose 10Gm Pkt	OPEN
actulose 20Gm Pkt	OPEN
abetalol 200Mg Tab	OPEN
Furazolidone 3.3Mg/MI Posp	OPEN
Amoxicillin Polymox 250Mg Cap	OPEN
omustine Po 10Mg	OPEN
omustine Cap	OPEN
omustine Cap	OPEN
Aitotane 500Mg Tab	OPEN
aroxetine Cr 25Mg Tab	OPEN
Dextrose 50% Inj	OPEN
odium Bicarb 8.4% Inj	OPEN
luminum Paste 10% 454Gm	OPEN
Calcium Chloride 10% Inj	OPEN
leph 10 Opoint	OPEN
ugmentin Tab	OPEN
odium Bicarb 10Meq Iv Syringe	OPEN
aroxetine Cr 12.5Mg Tab	OPEN

DESCRIPTION	CHARGE
Trophamine 10% Inj 500Ml	OPEN
Selenium Inj	OPEN
Spectazole Cream 1% 15Gm	OPEN
Spectazole Cream 1% 30Gm	OPEN
Ammonium Lactate Ex Lotn	OPEN
Gentian Violet Solu 2% 30Ml	OPEN
Metformin 500Mg Tab	OPEN
Sufentanil Per 50Mcg	OPEN
Metaproterenol Po Syrp	OPEN
Clonidine Tabs	OPEN
Metaproterenol 5% Inh Sol 30Ml	OPEN
Metaproterenol 5% Inh Sol 10MI	OPEN
Balanced Salt Op Soln	OPEN
Atroptine Op Sol	OPEN
Atroptine Op Sol	OPEN
Carbachol Op Sol	OPEN
Pilocarpine Op Sol	OPEN
Pilocarpine Op Sol	OPEN
Pilocarpine Op Sol Bilocarpine 6% Op Sol 15ML	OPEN
Pilocarpine 6% Op Sol 15Ml Vari-Flavors Lemmon 1Ea	OPEN OPEN
Intensilcal Nutr Supplement	OPEN OPEN
Physostigmine 0.5% Oph Dr 15Ml	OPEN
Homatropine Op Sol	OPEN
Homatropine Op Sol	OPEN
Homatropine Isopto 5% 15MI	OPEN
Maxitrol Op Sol	OPEN
Tropicamide Op Soln	OPEN
Isosorbide Isomatic Soln 220MI	OPEN
Cyclopentolate Hcl 1% 15Ml	OPEN
Trifluoperazine Per 2Mg	OPEN
Zafirlukast 20Mg Tab	OPEN
Tobradex Op Susp	OPEN
Tetracain Op Sol	OPEN
Fluorescein 2% Op Soln	OPEN
Lice Comb	OPEN
Eye Stream Op Soln	OPEN
Proparacaine 0.5% Op Soln	OPEN
Fluorescein 10% Inj	OPEN
Scopolamine 0.25% Op Soln	OPEN
Polyvinyl Alcohol 1.4% Op Soln	OPEN
Cyclopeentolate 1% Op Soln	OPEN
Carbachol 3% Op Soln	OPEN
Natamycin 5% Op Susp	OPEN
Viokase Powder	OPEN
Cyclopentolate 2% Op Soln	OPEN
Naphazoline-Phen Op Soln	OPEN
Maxitrol Op Ointment	OPEN
Tobramycin 0.3% Op Soln	OPEN
Pilocarpine Op Sol 1% 1MI	OPEN
Protain XI Nutr Supplement	OPEN
Levocarnitine Po Soln	OPEN
Cefadroxil Po Susr	OPEN
Betaxolol 0.25% Op Susp	OPEN
Acetazolamide Tab Folic Acid Tab	OPEN OPEN
Folic Acid Tab Trihexyphenidyl (Dose Varies)	OPEN
Trinexyphenidyl (Dose Varies) Trihexyphenidyl (Dose Varies)	OPEN OPEN
Aminocaproic Acid Inj	OPEN
Folic Acid Per 5Mg	OPEN
Trihexyphenidyl Artane 2Mg Tab	OPEN
Trihexyphenidyl Artane 5Mg Tab	OPEN

DESCRIPTION	CHARGE
Acetazolamide 500Mg Sequel 100	OPEN
Golytely 4000Ml	OPEN
Triamcinolone 0.1% Cr	OPEN
Ethambutol Tab	OPEN
Nystatin Po Susp	OPEN
Aminocaproic Acid Po Syrp	OPEN
Pyrazinamide Tab	OPEN
Minocycline 100Mg Cap	OPEN
Methazolamide Tab	OPEN
Loxapine 10Mg Cap	OPEN
Loxapine 25Mg Cap	OPEN
Amoxapine Asendin 100Mg Tab Ud	OPEN
Amoxapine (Doses Vary)	OPEN
Demeclocycline 150Mg Tab	OPEN
Loxapine 5Mg Cap	OPEN
Demeclocycline 300Mg Tab	OPEN
Triamcinolone 0.025% Oint	OPEN
Lithobid 300Mg Sr Tab Ud	OPEN OPEN
Aminocaproic Acid 500Mg Tab Triamcinolone 0.025% Cr	OPEN
Triamcinolone 0.025% Cr	OPEN
Hydralazine Apresoline Hcl 10M	OPEN
Hydralazine Apresoline Hcl 25M	OPEN
Hydralazine Apresoline Hcl 50M	OPEN
Labetalol Inj	OPEN
Inj Nafcillin Sodium 2 Grams	OPEN
Dibucaine 1% Pr Oint	OPEN
Sodium Phosphate Inj	OPEN
Apraclonidine 1% Op Soln	OPEN
Amiloride 5Mg Tab	OPEN
Clorazepate (Doses Vary)	OPEN
Clorazepate 7.5 Mg Tab Ud	OPEN
Hydralazine Tab	OPEN
Scopolamine 1.5Mg Patch	OPEN
Augmentin 125Mg/5Ml Susp 150Ml	OPEN
Augmentin Po Susp	OPEN
Augmentin Tab	OPEN
Methyphenidate 5Mg Tab	OPEN
Carbamazepine Po Susp	OPEN
Carbamazepine Tab	OPEN
Carbamazepine 200Mg Tab Ud	OPEN
Baclofen 10Mg Tab 100	OPEN
Metoprolol Tab	OPEN
Metoprolol Tab	OPEN
Metoprolol Tart Lopressor 100M	OPEN
Imipramine 25Mg Tab Ud	OPEN
Metoprolol Inj	OPEN
Imipramine Tofranil 50Mg Tab	OPEN OPEN
Caffeine-Sodium Benzoate Inj	OPEN
Terbutaline 2.5Mg Tab Ud	OPEN OPEN
Terbutaline 5Mg Tab Carbamazepine 100Mg Xr Tab	OPEN OPEN
Isoproterenol 0.2Mg/MI Inj	OPEN
Isoproterenol 0.5% Inj	OPEN
Mephobarbital 32Mg Tab	OPEN
Mephobarbital S2Mg Tab	OPEN
Norepinephrine Per 1Mg	OPEN
Procaine Per 1MI	OPEN
Procaine Per 1MI	OPEN
Tetracaine 2% Ex Soln	OPEN
Clonidine Tts Patch 0.1Mg	OPEN
Clonidine Tts Patch 0.2 Mg	OPEN
Clonidine Tts Patch 0.3Mg	OPEN

DESCRIPTION	CHARGE
Carbamazepine 200Mg Xr Tab	OPEN
Carbamazepine 400Mg Xr Tab	OPEN
Aethylphenidate 10Mg Tab Ud	OPEN
Bupivacaine It Inj	OPEN
Bupiv/Epi Per 1Ml	OPEN
Cyclopentolate-Phenyl Op Soln	OPEN
idocaine 1% Inj	OPEN
Aineral Oil Sterile	OPEN
iufentanil Inj	OPEN
Apraclonidine 0.5% Op Soln	OPEN
ugmentin 125Mg/5Ml 75Ml	OPEN
Nugmentin 250Mg/5Ml 75Ml	OPEN
nj Nafcillin Sodium 2 Grams	OPEN
nj Nafcillin Sodium 2 Grams	OPEN
moxicillin 250Mg Chew Tab	OPEN
mla Cr	OPEN
ucralfate Po Susp	OPEN
osorbide Mono Xr 60Mg Tab	OPEN
urgicel 2X3	OPEN
urgicel 4X8 (Foil) #1952	OPEN
lovasource Nutr Supplement	OPEN
socalplus Nutr Supplement	OPEN
JItraplus Nutr Supplement	OPEN
eneprotein Po Powd	OPEN
Slycopyrrolate Inj	OPEN
liacin Er 500Mg Tab	OPEN
liacin Er 750Mg Tab	OPEN
litrofurantoin Macrodantin 50M	OPEN
litrofurantoin Macrodantin 100	OPEN
Phenol 1.4%	OPEN
litrofurantoin Po Susp	OPEN
olic Acid/Vit B Comp/Vit C Tb	OPEN
Dantrolene 25Mg Cap	OPEN
alcium Acetate 667 Mg Tab	OPEN
patropium 0.02% Inh Soln	OPEN
efixime 400Mg Tab	OPEN
litrofurazone Solu Drsg 28Gm	OPEN
Depakote 125Mg Sprinkle Cap Ud	OPEN
eractant Inj	OPEN
Iydrocortisone 1% Cr	OPEN
lumazenil Per 0.1Mg	OPEN
lumazenil Per 0.1Mg	OPEN
Carvedilol 25Mg	OPEN
Carvedilol 12.5Mg	OPEN
Carvedilol 6.25Mg Tab	OPEN
urosemide Po Soln	OPEN
Desoximetasone Topicort Cream	OPEN
esoximetasone Topicort Cream	OPEN
entoxifylline Tab	OPEN
arvedilol 3.125Mg	OPEN
urosemide Tab	OPEN
otalol 80Mg Tab	OPEN
efdinir Po Susp	OPEN
otalol Tab	OPEN
otalol 160Mg Tab	OPEN
-	OPEN OPEN
evetiracetam Po Soln	
onisamide 25Mg Cap	OPEN
Comply Nutritional Supp 1000MI	OPEN
evalbuterol Inh Soln	OPEN
evalbuterol Inh Soln	OPEN
Aycophenolate 500Mg Inj	OPEN
egaserod 6Mg Tab	OPEN
Cyanocobalamin Tab	OPEN

DESCRIPTION	CHARGE
Cyanocobalamin Tab	OPEN
Cyanocobalamin Tab	OPEN
Cyanocobalamin Tab	OPEN
Calcium Chloride 10% Inj	OPEN
Lidocaine 2% Inj	OPEN
Dinoprostone Er 10Mg Vag Insrt	OPEN
Foltx Vitamin Tab	OPEN
Sterile Water Inj	OPEN
Sodium Chloride 23.4% Inj	OPEN
Metolazone Po Susp	OPEN
Oxybutynin XI 5Mg Tab	OPEN
Oxybutynin 15Mg XI Tab	OPEN
Mebendazole 100Mg Tab Ud	OPEN
Oxybutynin XI 10Mg Tab	OPEN
Escitalopram Po Soln	OPEN
Ketoconazole (Doses Vary)	OPEN
Ketoconazole Nizoral 200Mg	OPEN
Isosorbide Din Po10Mg Tab B	OPEN
Isosorbide 5Mg Potab Ud	OPEN
Isosorbide SI Tab	OPEN
Isosorbide 40Mg Sa Tab 100	OPEN
Isosorbide 2.5Mg SI Tab	OPEN
Isosorbide Din Po20Mg Tab B	OPEN
Entire Study Meds	OPEN
Beractant Inj	OPEN
Bactroban 2% Ex Oint	OPEN
Warfarin 3Mg Tab Ud	OPEN
Warfarin Tab	OPEN
Warfarin Tab	OPEN
Warfarin 5Mg Tab Ud	OPEN
Warfarin 10Mg Tab Ud	OPEN
Warfarin Tab	OPEN
Warfarin 1Mg Tab Ud	OPEN
Hycodan Po Syrp	OPEN
Benzonatate Caps	OPEN
Warfarin 4Mg Tab Ud	OPEN
Warfarin 6Mg Tab Ud	OPEN
Clindamycin Per 300Mg Inj	OPEN
Clindamycin Per 300Mg Inj Clindamycin ZEMg/EMI Such 100M	OPEN
Clindamycin 75Mg/5Ml Susp 100M	OPEN OPEN
Fluoxymesterone 5Mg Tab Fluoxymesterone 10Mg Tab 100	OPEN
Clindamycin Top/Soln 1% 60Ml	OPEN
Medroxyprogesterone-Doses Vary	OPEN
Bacitracin Im Inj	OPEN
Alprazolam 0.5Mg Tab	OPEN
Hydrocortisone 5Mg Tab	OPEN
Simvaspatin 5Mg Tab	OPEN
Sinvaspatin Sing Tab	OPEN
Cortisone Ace Tab	OPEN
Alprazolam 1Mg Tab	OPEN
Carboprost 250Mg Mcg/Ml Inj	OPEN
Prostine 20Mg Vag Suppos	OPEN
Minoxidil 2.5Mg Tab	OPEN
Hydrocortisone 2Mg/MI Po Susp	OPEN
Attapulgite Po Liqd	OPEN
Cefprozil 250Mg Tab	OPEN
Glyburide 5Mg Tab Ud	OPEN
Ibuprofen Po Susp	OPEN
Panafil-White Ointment 30Gm	OPEN
Ibuprofen Tab	OPEN
Simvastatin 10Mg Tab	OPEN
- ····· ·····	OPEN

DESCRIPTION	CHARGE
Adsorbonac 2% 15Ml Op Soln	OPEN
Adsorbonac 5% 15Ml Op Soln	OPEN
Gatifloxacin 200Mg Tab	OPEN
Gatifloxacin 400Mg Tab	OPEN
Belladonna/Opium Supp	OPEN
Aeperidine 50Mg Tab Ud	OPEN
henobarbital Tab	OPEN
Phenobarbital Tab	OPEN
Aeprobamate 400Mg Tab Udp	OPEN
Neprobamate 200Mg Tab 100	OPEN
Pramipexole Tab 1Mg	OPEN
quagesic Tab	OPEN
Promethazine Per 12.5Mg Oral	OPEN
Promethazine 25Mg Suppos	OPEN
Pramipexole Tab 0.125Mg	OPEN
Risperidone Odt Tab	OPEN
Risperidone Odt Tab	OPEN
Guanabenz (Doses Vary)	OPEN
Risperidone Odt Tab	OPEN
Gelclair Mt Gel	OPEN
ndocyanine Green Inj	OPEN
Guanabenz 8Mg Tab 100	OPEN
Lorazepam Ativan 2Mg Tabs	OPEN
orazepam Tab	OPEN
Numinum Carb 400Mg/5Ml 8360Ml	OPEN
soproterenol 0.2Mg Inj Syr	OPEN
Numinum Hydrox 600Mg Tab Ud	OPEN
Amiodarone Tab	OPEN
Diclofenac 25Mg Ud Tab	OPEN
Diclofenac 50Mg Ud Tab	OPEN
Diclofenac 75Mg Ud Tab	OPEN
Folterodine Er Cap 2Mg	OPEN
Folterodine Er Tab	OPEN
Betamethasone Dip 0.05% Cr	OPEN
Betamethasone Dipr Cr.05% 45Gm	OPEN
Clotrimazole 1% Cr	OPEN
Clotrimazole 1% Exsol	OPEN
Fentanyl 800Mcg Lollipop	OPEN
Betamethasone 0.1% Cr	OPEN
Betamethasone 0.1% Oint	OPEN
/itamin A&D Ex Oint	OPEN
Dxymetazoline 0.05% Na Sol	OPEN
Griseofulvin U/F 500Mg Tab	OPEN
Gentamicin 0.3% Opoint	OPEN
Gentamicin 0.3% Op Sol	OPEN
Betamethasone 0.1% Oint	OPEN
Seaband Wrist Band	OPEN
Betamethasone 0.1% Lotn 60MI	OPEN
Betamethasone 0.1% Cr	OPEN
Entacapone 200Mg Tab	OPEN
Clarithromycin Po Susp	OPEN
ismuth Subsalicylate Po Susp	OPEN
Albuterol Inhaler 17Gm	OPEN
Perphenazine Tab	OPEN
Clotrimazole 1% Sol 30MI	OPEN
Clotrimazole 1% Sol Solvin	OPEN
Albuterol Po Inh	OPEN
Chlorpheniramine 2Mg/5Ml Syr	OPEN OPEN
Amitriptyline Per 10-2 Tab Ud	OPEN
	OPEN OPEN
Amitriptyline Per 25-2 Tab Ud	
Amitriptyline 50-4 Tab	OPEN
Betamethasone 0.5% Lotn	OPEN

DESCRIPTION	CHARGE
/itamin D 50000 U Cap	OPEN
Dihydrotachystrol 0.25Mg/MI Or	OPEN
henylephrine 10% Op Sol	OPEN
Diazoxide Po Susp 50Mg/Ml	OPEN
arapin Inj Sol	OPEN
enofovir 300Mg Tab	OPEN
osinopril 40Mg Tab (Monopril)	OPEN
temifentanil Inj	OPEN
nsulin Syringe 1MI	OPEN
elepaque 500Mg Tab	OPEN
łydroxychloroquine Tab	OPEN
Docusate 100Mg Cap #4	OPEN
Chloroquine 500Mg Tab	OPEN
errous So4 Tabs	OPEN
Albuterol 0.5% Inh	OPEN
Phenylephrine 1% Na Sol	OPEN
Cefuroxime Axetil Ceft 250Mg	OPEN
Cefuroxime Axetil Ceft 500Mg	OPEN
traconazole 100Mg Cap	OPEN
Ziprasidone 20Mg Tab	OPEN
Ziprasidone 60Mg Tab	OPEN
Ziprasidone 80Mg Cap	OPEN
Cisatracurium Per 10Mg	OPEN
idocaine 5% Ex Patch	OPEN
Cafergot Tabs	OPEN
Nortriptyline 75Mg Cap Udp	OPEN
Fiorinal Tab	OPEN
Cisatracurium Inj	OPEN
Thioridazine Tab	OPEN
Thioridazine Tab	OPEN
Chioridazine Tab	OPEN
Thioridazine Tab	OPEN
Chioridazine Tab	OPEN
Fhioridazine 10Mg Tab Ud	OPEN
Thioridazine 200Mg Tab Ud	OPEN
Vethylergonovine 0.2Mg Tab Ud	OPEN
Methysergide 2Mg Tab	OPEN
Bupropion XI 300Mg Tab	OPEN
Bromocriptine Tab	OPEN
Fentanyl Citrate Lolli 600Mcg	OPEN OPEN
Flecainide 50Mg Tab Ud	
Flecainide 100 Mg Tab Ud	OPEN
Fhioridazine 15Mg Tab Ud	OPEN
Burnetanide Tab	OPEN
Bumetanide Inj	OPEN
Dextrose 25% Inj .idocaine 2% Ex Gel	OPEN OPEN
	OPEN
.idocaine 2% Ex Gel Frace Elements Inj	OPEN OPEN
Clorazepate Tab	OPEN OPEN
Jorazepate Tab Jecare Nutrition Supplement	OPEN OPEN
Jacare Nutrition Supplement Dianzapine Per 10Mg Inj	OPEN OPEN
Aetronidazole 500Mg Tab	OPEN OPEN
ediatric Cardioplegia Solutio	OPEN
aphenous Vein Irrigation 250M	OPEN
lydrocortisone Po Susp	OPEN
iyorocortisone Po Susp Ictz/Valsartan Tab	
	OPEN OPEN
aroxetine 40Mg Tab otrel 10/20 Cap	OPEN OPEN
ravastatin 40Mg Tab	OPEN
/aldecoxib 10Mg Tab	OPEN
Omega-3 Fatty Acid Cap Duloxetine 20Mg Cap	OPEN OPEN

DESCRIPTION	CHARGE
Duloxetine 30Mg Cap	OPEN
Duloxetine 60Mg Cap	OPEN
Nafcillin Inj	OPEN
Sertraline Po Conc	OPEN
Memantine Po 5Mg	OPEN
Memantine Po 10Mg	OPEN
Oxcarbazepine Po Susp	OPEN
Quetiapine Tab 200Mg	OPEN
Quetiapine Tab	OPEN
Lubricant Jelly	OPEN
Fretinoin 10Mg Cap	OPEN
_ubricant 5Gm Pkt	OPEN
Povidone-Iodine 5% Op Sol	OPEN
Frypan Blue 0.06 %Op Sol	OPEN
Mesalamine Cap	OPEN
•	l I
/alganciclovir Po Sol	OPEN
actose 20% Po Sol	OPEN
Petrolatum Oint	OPEN
Patanol 0.1% Op Sol	OPEN
Slycerin 50% Per Ml Inj	OPEN
Fravoprost 0.004% Op Sol	OPEN
Hydroxyzine Pam Poper 25 Mg	OPEN
Nitazoxanide Poliq	OPEN
_ubricant Jelly	OPEN
somed Refill Kit #8555	OPEN
Ranitidine Ef Tab	OPEN
Salmeterol Disk Inhal	OPEN
Hydroxyzine Pam Po Per 25 Mg	OPEN
Hydromorphone 12Mg Er Oral	OPEN
Hydromorphone 16Mg Er Oral	OPEN
Hydromorphone 24Mg Er Oral	OPEN
Hydromorphone 32Mg Er Oral	OPEN
Amino Acids 15% Ivsol	OPEN
inezolid Po Sol	OPEN
Acetaminophen Po Sol	OPEN
Acetaminophen Po Sol	OPEN
Acetaminophen W/Cod Po Sol	OPEN
Acetaminophen 320Mg/10Ml El Ud	OPEN
Cascara Aromatic Elixir 5MI	OPEN
Propranolol Po Sol	OPEN
Kaolin-Pectin Susp 30Ml Ud	OPEN
Potassium Chlor 10% Polig	OPEN
Vilk Magnesia Posusp	OPEN
Potassium Chlor 10% Polig	OPEN
D5Nss With Kcl Ivsol	OPEN
Acid Citrate Dex Sod Cit Sol	OPEN
Formaldehyde Exsol	OPEN
Ferrous So4 Po Sol	OPEN
Ascorbic Acid Tab 250Mg Ud	OPEN
Papaverine Hcl Cap Ud 150Mg	OPEN
Pseudoephedrine 60Mg Tab Ud	OPEN
Dihydrotachysterol 0.4Mg Tab	OPEN
Acetaminophen 80Mg Supp	OPEN
Docusate Sod 4Mg/MI Po Syrp	OPEN
Aineral Oil Oral	OPEN
Chlorpheniramine 4Mg Tab Ud	OPEN
Neomycin So4 Tab	OPEN
pecac Syrup 30MI Ud	OPEN
Viethadone 1Mg/MI Po Sol	OPEN
Morphine So4 2 Mg/MI Po Sol	OPEN
Diphenhydramine Po Per 50 Mg	OPEN
viacin (Doses Vary)	OPEN
Aspirin Suppos 600Mg	OPEN

DESCRIPTION	CHARGE
Docusate Sod 50Mg Cap Ud	OPEN
Acetaminophen Supp 120Mg	OPEN
Acetaminophen Supp 650Mg	OPEN
Aspirin Suppos 300Mg	OPEN
Acetaminophen Supp 325Mg Us50S	OPEN
Tocainide (Doses Vary)	OPEN
ocainide Tonocard 600Mg	OPEN
ovastatin (Doses Vary)	OPEN
Bethanechol Tab	OPEN
/alacyclovir 500Mg Caplet Ud	OPEN
/erapamil Posusp	OPEN
ledocromil Po Inh	OPEN
Dexamethasone Op Oint 3.5Gm	OPEN
Dexamethasone 0.1% Op Sol	OPEN
Aethyldopa Tab	OPEN
Aethyldopa 250Mg Tab Ud	OPEN
Airtazapine 15Mg Soltab	OPEN
ithacrynate 50Mg Inj Vial inalapril 5Mg Tab 100	OPEN OPEN
	OPEN OPEN
yproheptadine 2Mg/5Ml Po Syr	
Chlorothiazide Po Susp	OPEN
Chlorothiazide 500Mg Tab Ud	OPEN
Sinemet Tab 10/100	OPEN
Carbidopa-Levodopa Tab	OPEN
Carbidopa-Levodopa Tab	OPEN
inemet 25/250 Tab 100	OPEN
inemet Tab 25/250 Ud	OPEN
nalapril 10Mg Tab	OPEN
inalapril 20Mg	OPEN
Cyclobenzaprine Tab	OPEN
imoptic 0.25% Op Sol	OPEN
imoptic 0.5% Op Sol	OPEN
abetalol Posusp	OPEN
lorfloxacin 400 Mg Tab Ud	OPEN
Aethyldopa 500Mg Tab Ud	OPEN
stradiol Vag Ring 2Mg	OPEN
ethanechol 5Mg Tab Ud	OPEN
inalaprilat 1.25Mg/Ml Inj	OPEN
robenecid Tab	OPEN
inalaprilat Per 1.25Mg	OPEN
inalapril 2.5 Mg Tab	OPEN
hytonadione Tab	OPEN
Benztropine Mesyl Tab	OPEN
Cyproheptadine (Doses Vary)	OPEN
Benztropine 2Mg Tab Ud	OPEN
Acetic Acid Sol 5%	OPEN
isinopril Tab	OPEN
enztropine Mesyl Cogen 1Mg Tb	OPEN
ndomethacin 1Mg Inj Vial	OPEN OPEN
	OPEN OPEN
isinopril 5Mg Tab 100 isinopril 10Mg Tab 100	OPEN OPEN
ndomethacin 50Mg Cap	OPEN
Quinidine So4 300Mg Tab 100'S	OPEN
isinopril 20Mg Tab 100	OPEN
otassium Chloride Cap	OPEN
Clarithromycin 250Mg Tab	OPEN
tomidate Per 2Mg	OPEN
selladonna Alk/Phenobarb Tab	OPEN
Donnatal Extentabs	OPEN
inc So4 Inj	OPEN
Aethocarbamol Tab	OPEN
Aethocarbamol 500Mg Tab Ud	OPEN
Aethocarbamol Tab	OPEN

DESCRIPTION	CHARGE
Donnatal Poelix	OPEN
exofenadine 30Mg Tab	OPEN
Guaifenesin Syrup	OPEN
Guaifenesin 5Ml Ud	OPEN
Suaifenesin 10MI Ud	OPEN
odium Thioso4 25% Inj	OPEN
Suaifenesin-Dm Posyrp	OPEN
Rivastigmine 1.5Mg Cap	OPEN
Guaifenesin Dm 10MI Ud	OPEN
/itamin B Complex W/C Tab Ud	OPEN
Slycopyrrolate 0.2 Mg/Ml Inj	OPEN
Slycopyrrolate 0.02 Mg/Ml Inj	OPEN
Doxapram Per 20Mg	OPEN
iuaifenesin-Cod Posyrp	OPEN
/etoclopramide 1Mg/Ml Syrp	OPEN
Aetoclopramide Tab	OPEN
Aetoclopramide Tab	OPEN
puprofen 400Mg Tab #10	OPEN
livastigmine 3Mg Cap	OPEN OPEN
loasignine Sing Cap Iomipramine 25Mg Cap Ud	OPEN
	OPEN OPEN
Quinidine So4 200Mg Tab Ud	
Quinidine So4 (Doses Vary)	OPEN
Aultiple Vitamin Ud Cap	OPEN
ulfasalazine Tab	OPEN
lunisolide Inh	OPEN
lomipramine 50Mg Cap Ud	OPEN
lydrocortisone Enema	OPEN
evetiracetam 500Mg Tab	OPEN
louse Antacid	OPEN
ripiprazole Posol 1Mg/Ml	OPEN
Suaifen/Hydroco Po 1Ml	OPEN
heophylline Slobid 200Mg	OPEN
heophylline Slo-Bid 100Mg Gyr	OPEN
lydroxyzine 10Mg Tab Ud	OPEN
lydroxyzine Posyrp	OPEN
lydroxyzine 25Mg Tab Ud	OPEN
Chlorpropamide Tab	OPEN
/ivonex Rtf 250Ml Po Supp	OPEN
leomycin Po Sol	OPEN
hiothixene 1Mg Cap Ud	OPEN
hiothixene 5Mg Cap Ud	OPEN
hiothixene 10Mg Cap Ud	OPEN
Doxepin 25Mg Cap Ud	OPEN
Doxepin 50Mg Cap Ud	OPEN
Doxepin 100Mg Cap Ud	OPEN
Prazosin 1Mg Cap Ud	OPEN
razosin 2Mg Cap Ud	OPEN
Prazosin ZMg Cap Ud	OPEN
olysporin Expwd	OPEN
Doxycycline 50Mg Cap	OPEN OPEN
	OPEN OPEN
lifedipine Cap	1
lifedipine Cap	OPEN
oxepin Cap	OPEN
ormaldehyde 2.5% 1Ml	OPEN
onepezil 5Mg Odt Tab	OPEN
ancuronium Per 1Mg	OPEN
lonisamide 100Mg Cap	OPEN
ecuronium 1Mg/Ml Inj	OPEN
ertraline 50 Mg Tab	OPEN
ertraline 100Mg Tab	OPEN
Donepezil 10Mg Odt Tab	OPEN
vicyclomine Cap	OPEN
icyclomine 20Mg Tab Ud	OPEN

DESCRIPTION	CHARGE
Lactulose Posyrp	OPEN
Lactulose Syrup 15Ml Ud	OPEN
Lactulose Syrup 30Ml Ud	OPEN
Cetylpyridinium Mouthwash	OPEN
Menthol Lozenge	OPEN
Clomiphene Tab	OPEN
Desipramine 25Mg Tab Ud	OPEN
Desipramine 50Mg Tab Ud	OPEN
Cepastat Lozenges Bx Of 18	OPEN
Mct Po Oil	OPEN
Bisoprolol-Hctz	OPEN
Nicotine Gum 2Mg	OPEN
Poly Vi Flor .5Mg 50Ml Drop	OPEN
Poly Vi Flor .5Mg Tab W/Iron	OPEN
Poly Vi Flor .5Mg Tab	OPEN
Poly Vi Flor 1Mg Tab 100'S	OPEN
Poly Vi Flor .25Mg 50Ml Drop	OPEN
Poly Vi Flor 1.0Mg Tab W/Iron	OPEN
Potassium Chloride Popwd	OPEN
Acetylcysteine 10% Inh Sol	OPEN
Acetylcysteine 20% Inh Sol	OPEN
Felodipine 2.5Mg Tab	OPEN
Felodipine 5Mg Tab	OPEN
/itamin E Poper 26.6lu/MI	OPEN
	l de la constante de
Docusate 4Mg/MI Syrup	OPEN
Ferrous So4 Po Sol	OPEN
Peri-Colace Syrup	OPEN
Acetylcysteine 20% Inh Sol	OPEN
Haloperidol Tab	OPEN
Haloperidol 2Mg/MI Po Conc	OPEN
Haloperidol Tab	OPEN
Haloperidol Tab	OPEN
Haloperidol 10Mg Tab Ud	OPEN
Acetaminophen Tab	OPEN
Acetaminophen 160Mg/5Ml Elix	OPEN
Acetaminophen Po Sol	OPEN
Acetaminophen W/Cod Tab	OPEN
Ciprofloxacin Po Susp	OPEN
Tolmetin 200Mg Tab 100	OPEN
Pimozide Tab	OPEN
idocaine 20% 10MI VI	OPEN
Glycopyrrolate 1Mg Tab	OPEN
Acetaminophen W/Cod Po Sol	OPEN
Glycopyrrolate 2Mg Tab	OPEN
Slipizide XI 2.5Mg Tab	OPEN
Clozapine 25Mg Tab	OPEN
Clozapine 25 Mg Tab	OPEN
Clozapine 100 Mg Tab	OPEN
Buspirone Tab	OPEN
Buspirone 10Mg Tab 100	OPEN
Ganciclovir 250Mg Cap	OPEN
/itamin E 50lu/MI Drops	OPEN
roduct 3232A Pwd (Oral)	OPEN
Aultivitamin Per 1Ml	OPEN
Aultivitamin Inj	OPEN
Chlorthalidone 100Mg Tab	OPEN
chlorthalidone 50Mg Tab Ud	OPEN
evelamer Cap	OPEN
ibersource Hn	OPEN
chlorthalidone Tab	OPEN
Dra Plus W/Sterile Water Dos V	OPEN
Aidrin Cap	OPEN
Cephalexin Cap	OPEN

DESCRIPTION	CHARGE
odium Morrhuate 5% Inj	OPEN
ancomycin 125Mg Cap Ud	OPEN
ancomycin 250Mg Cap Ud	OPEN
ephalexin Posusp	OPEN
ephalexin 250Mg/5Ml Sp 100Ml	OPEN
enofibrate 48Mg Tab	OPEN
Cephalexin Cap	OPEN
Cordran Oint .05% 15Gm #85	OPEN
rimethoprim Po Sol	OPEN
ropoxyphene/Apap Tab	OPEN
alcitabine Tab	OPEN
/ancomycin 50Mg/MI Or Sol 1Gm	OPEN
operamide Poliq	OPEN
Argestrol Acet Posusp	OPEN
Aethohexital 2.5 Gm VI	OPEN
Aethohexital Inj	OPEN
Jenzoin Tincture	OPEN
alcitabine 0.75Mg Tab	OPEN
ceetohexamide (Doses Vary)	OPEN
cetohexamide (Doses vary)	OPEN
vromatic Elixir	OPEN
Colchicine 0.6Mg Tab 100	OPEN
Emetrol Po Sol	OPEN
Alendronate 10Mg Tab	OPEN
	OPEN
Aethimazole 10Mg Tab Dapsone Tab	OPEN OPEN
odium Chloride Tab	OPEN
Cefaclor 500Mg Cap	OPEN
iulfadiazine 500Mg Tab	OPEN
Agnesium Oxide Hvy 140Mg Cap	OPEN
entanyl 12.5Mcg Transdermal	OPEN
phedrine 25Mg Cap	OPEN
Aisoprostol 200Mcg Tab	OPEN
pratropium/Albuterol Inh	OPEN
Phenytoin Tab	OPEN
Phenytoin 25Mg/MI Po Susp	OPEN
Phenytoin (Doses Vary)	OPEN
/asopressiin Inj	OPEN
orazepam Po Sol	OPEN
Vicotinic Acid Tab	OPEN
Phenobarb Tab	OPEN
Budesonide Nasal Inh 7Gm	OPEN
thosuximide 250Mg Cap	OPEN
Cilostazole 100Mg Tab	OPEN
ranexamic Acid Per 100Mg	OPEN
Cilostazole 50Mg Tab	OPEN
imple Syrup	OPEN
ed Stocking Thigh Length Sm	OPEN
ed Stocking Thigh Length Med	OPEN
ed Stocking Thigh Length Lrg	OPEN
ed Stocking Thigh Length XI	OPEN
ed Stocking Knee Length Sm	OPEN
ed Stocking Knee Length Med	OPEN
ed Stocking Knee Length Lrg	OPEN
ed Stocking Knee Length XI	OPEN
urgicel 6X9	OPEN
Dismolite 1.5Cal Oral	OPEN
Chloramphencl 0.5% Op Sol 15Ml	OPEN
ithium Citrate Posyrp	OPEN
Procanbid 1000Mg	OPEN
rocanald 1000Mg	OPEN OPEN
-	
litroglycerin 0.3Mg Tab 100 litroglycerin 0.6Mg Tab 100	OPEN OPEN

DESCRIPTION	CHARGE
Nitroglycerin SI Tab	OPEN
Procainamide Hcl Pro 250Mg	OPEN
Procainamide Cap	OPEN
Procainamide Sr 500Mg Tab Ud	OPEN
Anusol Supp	OPEN
Hydrocortisone Supp	OPEN
Methenamine Madelamine 500Mg	OPEN
Methenamine 1Gm Pkt	OPEN
Procainamide Sr (Doses Vary)	OPEN
Nefazodone 150Mg Tab	OPEN
Aripiprazole 10Mg Tab	OPEN
Aripiprazole 15Mg Tab	OPEN
Phenazopyridine Tab	OPEN
Nefazodone 100Mg Tab	OPEN
Vefazodone 150Mg Tab	OPEN
Mvi Liq	OPEN
Thrombin 5000U Vial	OPEN
Indapamide 2.5Mg Tab Ud Matropidazala 1% Gal	OPEN OPEN
Metronidazole 1% Gel	OPEN
Metronidazole 0.75% Vaggel	OPEN
Dermabase Oint	OPEN
Diphenhydramine 2.5Mg/MI Elix	OPEN
Chloramphenicol Chloro 250Mg	OPEN
Ethosuximide Po Sol	OPEN
Gentamicin 12Mg/MI Opdrop	OPEN
Witch Hazel/Glycerin Pad	OPEN
Gemfibrozil Tab	OPEN
Nephro Cap	OPEN
Clindamycin Ivsol	OPEN
Dorzolamide 2% Op Sol	OPEN
Clindamycin Ivsol	OPEN
Chloramphencol 1% Opoint 3.5Gm	OPEN
Imiquimod Cr 5%	OPEN
Claritin Reditabs	OPEN
Hydrocortisone 2.5% Rectal Cr	OPEN
Thrombin 1000U Vial	OPEN
Thrombin 10000U Vial	OPEN
Thrombin 20Ku (Topical)	OPEN
Phenytoin Cap	OPEN
Methyrosine 250Mg Cap	OPEN
traconazole 10Mg/MI Po Sol	OPEN
Phenazopyridine Tab	OPEN
Multivitamin Po Sol	OPEN
Naratriptan 1Mg Tab	OPEN
Varatriptan 2.5Mg Tab	OPEN
Pramoxine-Zinc Oxide Oint	OPEN
E.T. Sol 5MI	OPEN OPEN
Flucytosine 250Mg Cap	
Budesonide Inh Sol	OPEN
Nitroglycerin Patch 0.1Mg/Hr	OPEN
Nitroglycerin Patch 0.2Mg/Hr	OPEN
Nitroglycerin Patch 0.3Mg/Hr	OPEN
Vitroglycerin Patch 0.4Mg/Hr	OPEN
Nitroglycerin Patch 0.6Mg/Hr	OPEN
lucytosine 500Mg Cap	OPEN
Neostigmine 15Mg Tab	OPEN
Diazepam Tab	OPEN
Diazepam 5Mg Tab 500	OPEN
Diazepam Tab	OPEN
Diazepam 10Mg Ud	OPEN
rimethoprim 100Mg Tab Ud	OPEN
Sulfamethox-Tmp Tab	OPEN
evophanol 2Mg Tabs Ud	OPEN

DESCRIPTION	CHARGE
Mexiletine 150Mg Cap Ud	OPEN
Vexiletine 200Mg Cap Ud	OPEN
Лexiletine 250Mg Cap Ud	OPEN
sosource 1.5Cal 250MI	OPEN
Diazepam 1Mg/MI Po Sol	OPEN
sotretinoin Accutane 40Mg Cap	OPEN
sotretinoin Accutane 10Mg Cap	OPEN
orprin 800Mg Tab	OPEN
arisoprodol 350Mg Tab	OPEN
aroxetine Tab	OPEN
romote Rth 1000Ml Oral	OPEN
loost Diabetic 240Ml Oral	OPEN
)exmedeomidine Inj	OPEN
rosource Po Pack	OPEN
Iovasource Renal Polig	OPEN
Rosuvastatin 20Mg Tab	OPEN
ource Cf Tab	OPEN
iprofloxacin 0.3% Op Sol	OPEN
npact Glutamine 1000MI Oral	OPEN
aline Nasal Spray	OPEN
Alline Nasal Spray Albuterol/Ipratropium Inh Sol	OPEN
odium Chloride 2% Op Sol	OPEN
iodium Chloride 5% Op Sol	OPEN OPEN
/anco Enema 1500Mg	OPEN
urgicel (Nu-Knit) 3" X 4"	OPEN
Aercaptopurine Tab	OPEN
enofibrate 145 Mg Tab	OPEN
leosporin Op Sol	OPEN
someprazole 40Mg Iv	OPEN
Aquaphor Oint	OPEN
Bacitracin/Neos/Polymyx Oint	OPEN
Bacitracin/Neos/Polymyx Oint	OPEN
Neosporin Ophth Oint 3.5Gm	OPEN
acitra/Neos/Polymyx Gu Irr	OPEN
umatriptan 25Mg Tab	OPEN
umatriptan 50Mg	OPEN
ubdue Choc/Almond Poliq	OPEN
ubdue Orange/Van Poliq	OPEN
igoxin Tab	OPEN
Chlorambucil 2Mg Tab	OPEN
ibrin Sealant Ex Kit	OPEN
protin/Cacl/Fibrn/Thrombn10MI	OPEN
evofloxacin 750 Mg Tab	OPEN
evofloxacin 25Mg/MI Po Sol	OPEN
rocyclidine 5Mg Tab	OPEN
aletra 200Mg-50Mg Tab	OPEN
imtricitabine-Tenofovir Tab	OPEN
odium Hyaluronate Io Sol	OPEN
Cortisporin Oint 15Gm	OPEN
Jacit-Polymx-Hc-Neo Opoint	OPEN
ortisporin Sol Otic 10Ml	OPEN
•	OPEN OPEN
Quetiapine 50Mg Tab	
torvastatin 80Mg Tab	OPEN
yrimethamine 25Mg Tab	OPEN
Aupirocin 2% 0.9Gm Pkt	OPEN
ildenafil 20Mg Tab	OPEN
accharomyces Boulrdi 250Mgcap	OPEN
Iultiple Vitamins W/Minerl Tab	OPEN
Aultiple Vitamins W/Minerals	OPEN
erazosin 1Mg Cap	OPEN
idovudine 10Mg Perml Posyr	OPEN
ctifed Syrup	OPEN
ehydration Po Sol 1000MI	OPEN

DESCRIPTION	CHARGE
Allopurinol Tab	OPEN
Allopurinol Tab	OPEN
Ammonia Inh	OPEN
Mesna 400Mg Tab	OPEN
Sucralfate 1Gm/10MI Posusp	OPEN
Atovaquone Posusp	OPEN
Scopolamine 0.4Mg/Ml Inj	OPEN
Digoxin Tab	OPEN
Bacitracin-Polymyxin B Opoint	OPEN
Thioguanine Tab	OPEN
Polymixin B Inj	OPEN
Neomycin-Polymyxin-Hc Otsusp	OPEN
Bactrim Tab	OPEN
Trifluridine 1% Op Sol	OPEN
Pseudoephedrine Po Syrp	OPEN
Digoxin 0.05Mg/MI Po Sol	OPEN
Bacitracin/Polymixin B Oint	OPEN
Bacitracin/Polymixin B Oint	OPEN
Amyl Nitrate Inh	OPEN
Albuterol 4Mg Tab	OPEN
Triamcinolone Inh	OPEN
Mesalamine 1000Mg Supp	OPEN
Oxcarbazepine 150Mg Tab	OPEN
Cefdinir 300Mg Cap	OPEN
Isradipine 1Mg Perml Po Susp	OPEN
Collodion Flexible	OPEN
Sorbitol 70% Sol	OPEN
Oxyquinolone So4 Vag Gel	OPEN
Pentafluoro/Tetrafluoro Spr	OPEN
Candida Albicans Idsol	OPEN
Vitamin A Per 50000U	OPEN
Famotidine Per 20Mg Inj	OPEN
Permethrin 1% Exlig	OPEN
Famotidine 40Mg/5Ml Po Susp	OPEN
Albuterol Hfa Inh	OPEN
Ciprofloxacin Hc Otsusp	OPEN
Levonorgestrel 2 Tabs	OPEN
Levalbuterol Inh	OPEN
Dorzolamide/Timolol Op Sol	OPEN
Potassium Cl 10Meg Tab	OPEN
Metformin Er 500Mg Tab	OPEN
Ibandronate 150Mg Tab	OPEN
Lansoprazole Solutab	OPEN
Lansoprazole 30Mg Solutab	OPEN
Metformin 750Mg Er Tab	OPEN
Rosuvastatin 40Mg Tab	OPEN
Ferric Subso4 Exsol	OPEN
Flecainide 20Mg/MI Posusp	OPEN
Levothyroxine 175Mcg Tab	OPEN
Levothyroxine 200Mcg Tab	OPEN
Levothyroxine 112Mcg Tab	OPEN
Remifentanyl Per 5Mg Inj	OPEN
Lanthanum Carb 500Mg Tab	OPEN
Saf-Gel Exfgel	OPEN
Peptamen Af Polig	OPEN
Peptamen Af 1000MI Ultrapak	OPEN
Entex La Tab	OPEN
Entex Cap	OPEN
Histoplasmin Idsol	OPEN
Ursodiol (Actigall) 300Mg Cap	OPEN
Rifampin Inj	OPEN
Guaifenesin/Pseu 600-120Tab	OPEN
Propafenone Tab	OPEN

DESCRIPTION	CHARGE
Olmesartan 40Mg Tab	OPEN
Cefprozil 250Mg Per 5Ml Oral	OPEN
Cefprozil 125Mg Per 5Ml Oral	OPEN
Nifedipine Er 30Mg	OPEN
Nifedipine Er 60Mg	OPEN
Nifedipine Er 90Mg	OPEN
Cetacaine Spray 56Gm	OPEN
Lotrel 2.5/10 Tab	OPEN
Lotrel 5/10 Tab	OPEN
Fluvoxamine 100Mg Tab	OPEN
Nicardipine Per 2.5Mg	OPEN
Calcitonin Nasspr	OPEN
Olanzapine 2.5Mg Tab	OPEN
Metoprolol XI 100Mg Tab	OPEN
Ramipril 1.25 Mg Tab	OPEN
Ramipril 2.5Mg Tab	OPEN
Ramipril 5Mg Tab	OPEN
Benazepril 10Mg Tab	OPEN
Benazepril Tab	OPEN
Benazepril 20Mg Tab	OPEN
Rocuronium Inj	OPEN
Rocuronium Inj	OPEN
Calcium Gluconate Gel 25Gm	OPEN
	1
Budesonide Inh Sol	OPEN
Nutren 1.5 1500Ml Ultrapak Tf	OPEN
Nutren 2.0 Polig	OPEN
Nutren 1.0 Poliq	OPEN
Nutren 1.0 1500MI Ultrapak Tf	OPEN
Aveeno Colloidal Oatmeal 454Gm	OPEN
Fluconavole 10Mg Permi Posu	OPEN
Nicardipine 20Mg Tab	OPEN
Nicardipine 30Mg Cap Ud	OPEN
Famciclovir 500Mg Tab	OPEN
Hydrocortisone 1% Cr	OPEN
Hydrocortisone 1% Oint	OPEN
Linezolid 600Mg Tab	OPEN
Glytrol Poliq	OPEN
Glytrol 1500Ml Oral-Ultrapak	OPEN
Succimer 100Mg Cap	OPEN
Probalance Poliq	OPEN
Nutren 1.5 250Ml Tube Feed	OPEN
Probalance 1500Ml Ultrapak Orl	OPEN
Mono Asparte/Glutamte Inj 50Ml	OPEN
Replete Poliq	OPEN
Qualaquin 324Mg Cap Oral	OPEN
Nutren Renal Poliq	OPEN
Trusopt Ocumeter Plus 2% 10MI	OPEN
Replete Ultrapak 1500Ml Oral	OPEN
Travoprost Opth 0.004% 2.5Ml	OPEN
Mastisol Adhesive Liq 4Oz	OPEN
Sodium Chloride 0.9% Inj	OPEN
Sodium Chloride 23.4% Conc Inj	OPEN
Sodium Chloride 0.9% Inj	OPEN
Hyoscyamine SI 0.125Mg Tab	OPEN
Intal Po Inhaler 14.2Gm	OPEN
Aminophyllin 105Mg/5Ml Liq	OPEN
Epinephrine 2.25% Inh Sol	OPEN
Levothyroxine 200Mcg Inj Vial	OPEN
Etidronate Disodium 400 Mg Tab	OPEN
Bacitracin Oint	OPEN
Selegiline 6 Mg/24 Hr Patch	OPEN
Ziprasidone 40 Mg Cap	OPEN
Bupropion Sr 100 Mg Tab	OPEN

DESCRIPTION	CHARGE
Acetylcholine Ophth Sol	OPEN
Captopril 1Mg/MI Po Sol	OPEN
Aspirin 325Mg 2Tabs Ud	OPEN
Aspirin 81Mg Chewable Tab	OPEN
Z.B.T. Baby Powder 4Oz	OPEN
Desmopressin 0.2 Mg Tab	OPEN
Sterile Water For Irrig 1000MI	OPEN
Lanthanum Carb Chew 250Mg Tab	OPEN
Lithium Carbonate 150Mg Tab	OPEN
Chromic Chloride 4Mcg/Ml Inj	OPEN
Ethyl Chloride Topspray	OPEN
Amino Acid 4% Ivsol	OPEN
Fluorescein 1Mg Ophth Strip	OPEN
Fluoxetine Po Sol	OPEN
Fosinopril 10Mg Tab	OPEN
Sevoflurane 250MI VI	OPEN
Magnesium Ion Inj For Tpn	OPEN
Irbesartan 150Mg Tab Olmesartan 20Mg Tab	OPEN OPEN
Fluoride Sod Luride 0.25Mg Tab	OPEN
Fluoride Sod Luride 0.25Mg Tab	OPEN
Fluoride Sod Luride 1.0Mg Tab	OPEN
Chemstrip Bg 25	OPEN
Chemstrip Bg 50	OPEN
Chemstrip Bg Accu-Check li 50	OPEN
Bupropion 100Mg Tab	OPEN
Theophylline 300Mg Gyrocap	OPEN
Bupropion 75 Mg Tab	OPEN
Valcyclovr 50Mg/MI Per 1MI Sus	OPEN
Quinapril 40Mg Tab	OPEN
Irbesartan 300Mg Tab	OPEN
Sitagliptin 100Mg Tab	OPEN
Quinapril Tab	OPEN
Sitagliptin 50Mg Tab	OPEN
Flutamide Po125Mg	OPEN
Theophylline Theodur Tab	OPEN
Theodur 300Mg Sa Tab 100	OPEN
Theodur 450Mg Sa Tab Ud	OPEN
Trimethobenzamide 300Mg Cap	OPEN
Crucial 1000Ml Ultrapk Or Feed	OPEN
Crucial Posusp	OPEN
Verapamil Inj	OPEN
Dexmethylphenidate Ir 5Mg Tab	OPEN
Hyoscyamine 0.125Mg/MI Or Sol	OPEN
Sitagliptin 25Mg Tab	OPEN
Triamcinolone 0.1% Oint	OPEN
Propoxyphene 65Mg Cap	OPEN
Vitamin A Cap 10000 Inter U	OPEN
Ibuprofn Lysne 10Mg/MI 2MI Inj Insuflon Cannula	OPEN
Sodium Chloride 3% Neb For Inh	OPEN OPEN
Famotidine Tab	OPEN
Albuterol Inh	OPEN
Famotidine Tab	OPEN
Silver Sulfadiazine Cr	OPEN
Silver Sulfadiazine Cr	OPEN
Carbamide Perxde 6.5% Otic Sol	OPEN
Oxybutynin Posyrp	OPEN
Fentanyl Cit 100Mcg Buccal Tab	OPEN
Polymyx B/Tmp Op Sol	OPEN
Fentanyl Citrate 200Mcg	OPEN
Napro	OPEN
Advair Diskus 500/50 Po Inh	OPEN

DESCRIPTION	CHARGE
Nitroglycerine 25Mg/250Ml D5W	OPEN
Methylphenidate 54Mg Er Tab	OPEN
Mirtazapine 7.5 Mg Tab	OPEN
Buffered Lidocaine	OPEN
Hydrochlorothiazide 12.5Mg Tab	OPEN
Loestrin 24 Fe Tab	OPEN
Dexmethylphenidate 2.5Mg Tab	OPEN
7% Saline Nebs Inh 4MI	OPEN
Desmopressin 0.025Mg Tab	OPEN
Mesalamine 1200Mg Dr Tab	OPEN
Budesonide Flex 180Mcg Inh	OPEN
Anagrelide 0.5Mg Cap	OPEN
Hc/Neo So4/Polymyx Opth Sol	OPEN
Source Cf Cap	OPEN
Paroxetine 37.5Mg Cr Tab	OPEN
Bupivacaine 0.25% 50Ml Vial	OPEN
Bicitra Po Sol	OPEN
Metaxalone Tab	OPEN
Midodrine 5Mg Tab	OPEN
0.45%+20Meq Kcl 1000Ml Premix Sodium Chl Hyperton 5% Oppint	OPEN OPEN
Sodium Chl Hyperton 5% Opoint L Glutamine Pwd 1Gm	OPEN OPEN
Adhesive Liq Ex Sol	OPEN
Levocabastin 0.05% 5MI	OPEN
Aripiprazole Odt Tab	OPEN
Brinzolamide 1% 10Ml Op Sol	OPEN
Multivitamin & Minerals Per Ml	OPEN
Paroxetine 20Mg Tab	OPEN
Carvedilol Posusp	OPEN
Dantrolene 20Mg Inj Vial	OPEN
Aripiprazole Odt Tab	OPEN
Moricizine 200Mg Tab	OPEN
Moricizine 200Mg Tab	OPEN
Aripiprazole Odt 15Mg Tab	OPEN
Olsalazine 250Mg Cap	OPEN
Moricizine 300Mg Tab	OPEN
Moricizine 300Mg Tab	OPEN
Physostigmine Per 1Mg	OPEN
Alcohol Dehyd 99.5% 5Ml	OPEN
Methsuximide 300Mg Cap	OPEN
Atazanavir 150Mg Cap	OPEN
Methylphenidate 20Mg Er Tab	OPEN
Hydrocortisone 10Mg Tab 100	OPEN
Hydrocortisone 20Mg Tab 100	OPEN
Xphe-Xytr Analog Pwd	OPEN
Efavirenz 600Mg Tab	OPEN
Bunnels Sol Per 1MI	OPEN
Clopidogrel 300Mg Tab	OPEN
Metolazone 2.5Mg Tab Ud	OPEN
Cottonseed Oil Exoil	OPEN
Diclofenac Na 0.1% 2.5MI Opth	OPEN
Betaxolol Opth Sol 0.25% 10MI	OPEN
Chlorhexidine Gluconate Patch	OPEN
Gentamicin 0.1% Cream	OPEN
Aripiprazole Tab Sevoflurane Per MI Inh	OPEN OPEN
Povidone-lodine Oint 1.2Gm	
Povidone-lodine Unit 1.2Gm Cerumenex Otic Drops 6Cc	OPEN OPEN
Trilisate 500Mg Tab	OPEN
Trilisate 500Mg/MI Posusp	OPEN
Desflurane Per MI Inh	OPEN
Trilisate 750Mg Tab Ud	OPEN
Isoflurane Per MI Inh	OPEN

DESCRIPTION	CHARGE
Mesalamine 4Gm/60Ml Enema	OPEN
Chlorhexidine 0.12% Po Sol	OPEN
Oxycontin 15Mg Er Tab	OPEN
Beneprotein Prot	OPEN
Osmolite 1Cal Posusp	OPEN
Hydrochlorothiazide 50Mg Tab	OPEN
Ephedrine 50Mg/1Ml Inj Vial	OPEN
Erythromycin Sterate 250Mg Tab	OPEN
Ascorbic Acid Po Syrp	OPEN
Alcohol Dehyd 98% Ivsol	OPEN
Ciprofloxacin 0.3% Opth Oint	OPEN
Valproic Acid 250Mg Cap	OPEN
Poly-Vi-Flor W/Fe 1Ml Oraldrop	OPEN
Sodium Bicarb 50Meq Inj Vial	OPEN
Potassium Phosphate Inj	OPEN
Naphazoline 0.1% Opth Sol	OPEN
Vasocon A Opth Sol 15MI	OPEN
Vasocidin Opth Sol 10MI	OPEN
Hypromellose 2.5% Opth Sol	OPEN OPEN
Prenatal Vitamin Tab Bingo Crd Tolterodine 2Mg Tab	OPEN OPEN
Tolterodine 2Mg Tab Strong Iodine Sol 8MI	OPEN
Isosource 1.5Cal1500MI Po Fe	OPEN OPEN
Acetic Acid 0.25% Irri 1000MI	OPEN
Osmolite 1Cal 240Ml Ready Feed	OPEN
Promote 240 MI Po Feed	OPEN
Triamcinolo 0.1%/Eucerin 1:1Cr	OPEN
Prochlorperazine Supp	OPEN
Pioglitazone 15Mg Tab	OPEN
Pioglitazone 30Mg Tab	OPEN
Liothyronine Cytomel 5Mcg Tab	OPEN
Pioglitazone 45Mg Tab	OPEN
Topiramate Posusp	OPEN
Dextroamphetamine 5Mg Tab	OPEN
Liothyronine Cytomel 50Mcg Tab	OPEN
Dextroamphetamine 5Mg Tab	OPEN
Dextroa Hetamine 10Mg Spansul	OPEN
Dextroamphetamine Span Cap	OPEN
Dyazide Cap	OPEN
Phenoxybenzamine 10Mg Cap	OPEN
Citalopram Po Sol	OPEN
Lithium Carbonate (Dose Varies	OPEN
Ferrous So4 220Mg/5Cc Elixir	OPEN
Fluphenazine 5Mg/MI Po Conc	OPEN
Budesonide Ec Tabs	OPEN
Tetracaine 0.5% Op Sol	OPEN
Isosource 1.5Cal Posusp	OPEN
Spacer Inhalation Accessory	OPEN
Nitroglycerin Oint 1G	OPEN
Dextroamphetamine 5Mg Cr Tab	OPEN
Trifluoperazine 10Mg/MI Or Con Trifluoperazine 1Mg Tab Ud	OPEN OPEN
Trifluperazine 1Mg Tab Ud	OPEN OPEN
Trifluperazine 5Mg Tab Ud	OPEN OPEN
Oxepa 1000MI Entral Feeding	OPEN
Cadd Cassetts For Flolan 100Ml	OPEN
Trifluperazine 10Mg Tab Ud	OPEN
Diluent For Flolan 50Ml	OPEN
Cimetidine (Doses Vary)	OPEN
Cimetidine (Doses Vary)	OPEN
Cimetidine Inj	OPEN
Cimetidine 400Mg Tab Ud	OPEN
Ext Set Tubing For Flolan	OPEN

DESCRIPTION	CHARGE
Calcium Vitamin D 500Mg-200lu	OPEN
Hydroxurea Posusp	OPEN
Terbinafine 30Gm 1% Cream	OPEN
Ketamine 10Mg/MI 20MI Inj	OPEN
Betadine Irrigation Sol	OPEN
D5Wnss 40Meq Kcl 1000Ml	OPEN
Na Chond/Na Hyalur 0.55-0.5Ml	OPEN
Na Chond/Na Hyaluron 40-30Mg	OPEN
Amphe Salt Combo 12.5Mg Cap	OPEN
Pg Intrfrn Alfa 2B 50Mcg/0.5Ml	OPEN
Famotidine Premix Inj	OPEN
Diph/Dexameth/Met 25/4/10 Supp	OPEN
Naproxyn 500Mg Tab	OPEN
Surgicel 2X14 Hemastat	OPEN
Tetracaine 1% 2MI	OPEN
Liothyronine (Doses Vary)	OPEN
Clopidrogel 5Mg/MI Po Susp	OPEN
Bisoprolol 10Mg Tab	OPEN
Bisoprolol 5Mg Tab	OPEN
Tranylcypromine 10Mg Tab 100 Prochlornerazine SMg Suppos	OPEN OPEN
Prochlorperazine 5Mg Suppos Levofloxacin 0.5% Opth Drp 5Ml	OPEN
Nifedipine Rectal Oint 2% 30MI	OPEN
Erythromycin Opoint	OPEN
Morphine I.R. 30Mg Tab	OPEN
Hydromor 30Mg/Baclofen 1600Mg	OPEN
Creon 12000U Cap	OPEN
Phenyl-Free 2Hp Pwd Ent Feed	OPEN
Rosuvastatin 5Mg Tab	OPEN
Rosuvastatin 10Mg Tab	OPEN
Dipyridamole Posusp	OPEN
Chlorpromazine 100Mg/MI Or Con	OPEN
Ddavp 1.5Mg/Ml Nasal Spray	OPEN
Histamine Po4 Per 0.2Mg	OPEN
Cocaine 4% 4MI/Epi 0.8MI Nasal	OPEN
Aspirin W/Maalox Tab	OPEN
Aspirin 81Mg Ec Tab	OPEN
Infusion Set W/80Micron Filter	OPEN
Mesoridazine Po Sol	OPEN
Estradiol(Climara)Patch 0.1Mg	OPEN
Estradiol(Climara)Patch 0.05Mg	OPEN
Budesonide 1Mg/2Ml Respuls Inh	OPEN
Spironolactone 100Mg Tab	OPEN
Temazepam 7.5Mg	OPEN
Haloperidol 5Mg Tab	OPEN
Lactrase 250Mg Cap	OPEN
Calcium Phosphate Posusp	OPEN
Exenatide 10Mcg Pen Inj	OPEN
Aliskeren 150Mg Tab	OPEN
Collagenase Oint	OPEN
Pyridoxine 12.5Mg Tab	OPEN
Bupivacaine -Epi 0.75% Inj	OPEN
Isosorbide Din 30Mg Tab	OPEN
•	OPEN
	OPEN
	OPEN
	OPEN
	OPEN
· -	OPEN
· · · · · · · · · · · · · · · · · · ·	OPEN OPEN
	OPEN OPEN
	OPEN OPEN
Calmoseptine Oint Indomethacin 50Mg Suppos Oxazepam 15Mg Cap Propranolol 60Mg La Cap Surgiflo Hemastatc Matrx Syrng Nicardipine 20Mg In 200Ml Inf Trolamine Salicylate 10% Cr Etodolac 300Mg Cap Coal Tar Extract 2.5% Exsol Floseal Hemostatic Matrix Kit	10 10 10 10 10 10 10 10 10 10

DESCRIPTION	CHARGE
Polyethylene Glycol Po Powder	OPEN
Lidocaine 1.5% Inj	OPEN
Lidocaine 2% 5Ml Amp	OPEN
Lido/Epi 0.5%-1:200000 Inj	OPEN
Lidocaine-Epi 1%-1:100000 Inj	OPEN
Lido/Epi 0.5%-1:200000 Inj	OPEN
Lidocaine 1% Inj	OPEN
Lidocaine 1% Inj	OPEN
Lidocaine 1% Inj	OPEN
Lidocaine 0.5% Inj	OPEN
Lidocaine-Epi 2%-1:100000 Inj	OPEN
Lidocaine 2% Inj 50Ml Mdv	OPEN
Lidocaine 2% Inj	OPEN
Lidocaine 0.5% Inj	OPEN
Lidocaine 4% Exsol	OPEN
Lidocaine Jelly 2% Gel	OPEN
Lidocaine Viscous 2% Po Sol	OPEN
Lidocaine 5% Oint	OPEN OPEN
Lidocaine 2% Inj	OPEN
Lidocaine 2% Inj	OPEN
Lidocaine 4% Inj Lidocaine/Dextrose 5%-7.5% Inj	OPEN OPEN
	OPEN
Bretylium 500Mg/10Ml Inj Vial Esmolol Per 250Mg	OPEN
Esmolol Per 10Mg	OPEN
Lacosamide 50Mg Tab	OPEN
Calcium Carb (Tums) 750Mg Sf	OPEN
Magnesium L-Aspart Po Pkts	OPEN
Thyroid 30Mg Tab Ud	OPEN
Thyroid 60Mg Tab Ud	OPEN
Advair Diskus 250/50 Po Inh	OPEN
Selegiline Tab	OPEN
Dutasterdie 0.5Mg Caps	OPEN
Cyclosporine 0.5% Opth Sol	OPEN
Cyclosporine 1% Opth Sol	OPEN
Sulfacetamide 10%(Togo Op Sol)	OPEN
Try-Cas-Peru Balsam Oint	OPEN
Cephalexin 250Mg (8) Togo Ed	OPEN
Amoxic 250Mg/5Ml 150Ml Togo Ed	OPEN
Bactrim Ds 4 Tabs Togo Ed	OPEN
Percocet 325/5Mg 6 Tab Togo Ed	OPEN
Alteplase Opth Sol	OPEN
Chlorhexidine 4% Liq	OPEN
Faa 250Ml Liq	OPEN
Niacin 500Mg Tab	OPEN
Progesterone 100Mg Cap	OPEN
Hydro 2.5%/Wh Pet 85:15 Cr	OPEN
Mometasone 50Mcg Inh	OPEN
Nan Popwd	OPEN
Nimodipine 30Mg Cap Ud	OPEN
Ciprofloxacin Tab	OPEN
Ciprofloxacin Tab	OPEN
Ciprofloxacin Tab	OPEN
Domeboro Ot Sol	OPEN
Domeboro Tab Protein 80% Powder 1G	OPEN OPEN
	OPEN OPEN
Trprldne-Pse 1.25-30Mg/5Ml Liq Calcium Carbonate 650Mg Ta1000	OPEN OPEN
Calcium Carbonate 650/0g Ta1000 Amylase/Lip/Pro 6000U Cap	OPEN
Pyridoxine Tab	OPEN
Pyridoxine Tab Pyridoxine 50Mg Tab Ud	OPEN
Isoniazid Tab	OPEN

DESCRIPTION	CHARGE
Lansoprazole 15Mg Cap	OPEN
Oseltamivir 30Mg Caps	OPEN
Oseltamivir 45Mg Caps	OPEN
Sodium Thioso4 10% 10MI	OPEN
Levonorgestrel 1.5Mg Tabs	OPEN
Dronedarone 400Mg Tab	OPEN
Prasugrel 10Mg Tab	OPEN
Acetone Exsol	OPEN
Fansidar Talbet Ud	OPEN
Adderall 5Mg Tab	OPEN
Venlafaxine 50Mg Tab	OPEN
Valsartan 80Mg Cap	OPEN
Bisoprolol-Hctz Tab	OPEN
Nitroglycerin 2% Oint	OPEN
Leflunomide 100Mg Tab	OPEN
Leflunomide 10Mg Tab	OPEN
Leflunomide 20Mg Tab	OPEN
Respigam 50Mg/Ml Vial	OPEN
Tobramycin Beads 6.4 Mm	OPEN OPEN
Fluorometholone 0.1 % Opoint Olanzapine 10Mg Tab	OPEN
Atorvastatin 40Mg Tab	OPEN
Sof-Set For Subg Infusion Pump	OPEN
Tamsulosin 0.4Mg Cap	OPEN
Isoflurane (Forane) 100MI	OPEN
Edrophonium Per 10Mg	OPEN
Cotazym 30-8-30 Cap	OPEN
Phenobarbital 20Mg/5Ml Elix Ud	OPEN
Interlink Secndry Infusion Set	OPEN
Interlink Primary Infusion Set	OPEN
Zolpidem 5Mg Tab	OPEN
Gabapentin 300Mg Cap	OPEN
Flecainide Po Susp 25Mg P/MI	OPEN
Insulin Aspart Per 5 U	OPEN
Vigabatrin 500Mg Pwd Pack	OPEN
Vigabatrin 500Mg Tab	OPEN
Hyaluronate Gv 0.85Ml	OPEN
Sumatriptan 20 Mg/Act Nasol	OPEN
Doxazosin 2Mg Tab	OPEN
Sumatriptan 5 Mg/Act Nasol	OPEN
Lamivudine-Zidovudine Tab	OPEN
Stavudine 20Mg Cap	OPEN
Zinc So4 220Mg Cap	OPEN
To Go Tylenol/Codine 6 Tabs	OPEN
Acamprosate Ec 300Mg Tab	OPEN
Clobetasol 0.5% Cr	OPEN
Glutamine 10Gm Pwd Pkts	OPEN
Paroxetine 10Mg Tab	OPEN
Theophylline Po Sol	OPEN
Sod Chloride 0.9%Flush Inj	OPEN
Temazepam 15Mg Cap Ud Temazepam 30Mg Cap Ud	OPEN OPEN
Temazepam 30Mg Cap 00 Rifaximin 550 Mg Tab	OPEN
Mifaximin 550 Mg Tab Metformin 1000 Mg Tab	OPEN OPEN
Ted Stocking Knee Length Xxl	OPEN
Zanamivir Per 10Mg Inh	OPEN
Amantadine Po Syrp	OPEN
Amantadine Po Syrp Amantadine Cap	OPEN
Oseltamivir 75Mg Tab	OPEN
Oseltamivir 75ivig rab	OPEN
Midodrine 10 Mg Tab	OPEN
Lacosamide 100Mg Tab	OPEN
Aluminum Hydroxide Posusp	OPEN

DESCRIPTION	CHARGE
Psyllium 58.6% Popwd	OPEN
Carbamazepime 100Mg	OPEN
hrombin (Recomb) Spray Appl	OPEN
amoxifen 10Mg Tab 100	OPEN
ed Stocking Knee Length 3XI	OPEN
itodolac XI 400Mg	OPEN
todolac XI 600Mg	OPEN
renatal Rx Vitamin Tab	OPEN
imethicone 40Mg/0.6Ml Dr 30Ml	OPEN
enzocaine 20 % Mtpste	OPEN
ndinavir 400Mg Cap	OPEN
ancreaze 4200U Oral	OPEN
ancreaze 10500U Oral	OPEN
dderall Po Susp	OPEN
ancreaze 16800U Oral	OPEN
laproxen Tab	OPEN
·	OPEN
luconazole 200Mg Tab	
luconazole 100Mg Tab	OPEN
luconazole 50Mg Tab Ud	OPEN
sradipine 2.5 Mg Cap	OPEN
sradipine 5Mg Cap	OPEN
trimonidine 0.2% Op Sol	OPEN
Brimonidine 0.2% Op Sol 10MI	OPEN
imethicone 40Mg Tab	OPEN
riamcinolone Acet Exaers	OPEN
riamcinolone Acet 0.1% Mtpste	OPEN
ztreonam Inj	OPEN
riamcinolone Ace .1% Oint	OPEN
riamcinolone Ace .1% Cr	OPEN
nj Aztreonam 500 Mg	OPEN
Coenzyme Q 30Mg Cap	OPEN
ludrocortisone Tab	OPEN
luphenazine Tab	OPEN
mpicillin Principen 250Mg Cap	OPEN
enicillin Vk 500Mg Tab Ud	OPEN
/itamin E 400 lu Cap	OPEN
Jabumetone 500Mg Tab	OPEN
ritamin E Cap 100 lu	OPEN
lyst-Triamcin Cr	OPEN
Jyst-Triamcin Oint	OPEN
lystatin Cr	OPEN
lystatin Oint	OPEN
amotrigine 25Mg Tab	OPEN
amotrigine 150Mg Tab	OPEN
amotrigine 200Mg Tab	OPEN
Procainamide 250Mg Cap Ud	OPEN
Chloral Hydrate Posyrp	OPEN
enicillin Vk 125Mg/5Ml S100Ml	OPEN
enicilin Vk 125Mg/SMI 5100Ml	OPEN OPEN
•	
enicillin Vk 250Mg/5Ml S200Ml	OPEN
rythromycin 200Mg/5MI S 100Ml	OPEN
rythromycin 200Mg Chew Tab Ud	OPEN
floxacin 0.3% 5MI Op Sol	OPEN
meprazole Posusp	OPEN
luphenazine 5Mg Tab Ud	OPEN
luphenazine 1Mg Tab Ud	OPEN
riamcinolone Ace .1% Oint	OPEN
ancreaze 21000U Oral	OPEN
Chloral Hydrate Posyrp	OPEN
hentermine 30Mg Cap	OPEN
etracycline 250Mg Cap Ud	OPEN
lalcinonide Halog Cr 15Gm	OPEN
Imprenavir 15Mg Posol	OPEN

DESCRIPTION	CHARGE
Amitriptyline Tab 25Mg	OPEN
Anastrozole Po 1Mg	OPEN
Saquniavir 200Mg (Fortovase)Tb	OPEN
Papain-Urea Oint	OPEN
Nadolol Tab	OPEN
Nadolol 80Mg Tab Ud	OPEN
Nystatin Ps Susp	OPEN
Nadolol 20Mg Tab	OPEN
Chlorpromazine Tab	OPEN
Chlorpromazine Tab	OPEN
Phenaphthazine Paper 5Yd	OPEN
Glycerin Adult Supp	OPEN
Glycerin Peds Supp	OPEN
Captopril Tab	OPEN
Chlorpromazine Tab	OPEN
Amoxicillin 125Mg/5Ml 100Ml	OPEN
Amoxicillin 125Mg/5Ml 150Ml	OPEN
Amoxicillin 250Mg/5Ml 100Ml	OPEN
Amoxicillin 250Mg/5Ml 150Ml	OPEN
Captopril 12.5Mg Tab 100	OPEN
Captopril Tab	OPEN
Dipyridamole 25Mg Tab	OPEN
Lamivudine Posol	OPEN
	OPEN OPEN
Talc Sterile	
Dofetilide 250Mcg Caps	OPEN
Dofetilide 500Mcg Caps	OPEN
Advair 100/50 Inhaler	OPEN
Captopril Tab	OPEN
Topiramate 25Mg Tab	OPEN
Topiramate 100Mg Tab	OPEN
Topiramate 200Mg Tab	OPEN
Procainamide Pronestyl 375Mg	OPEN
Metoprolol XI 25Mg Tab	OPEN
Chlorpromazine Tab	OPEN
Nystatin Topical Powder	OPEN
Mineral Oil Heavy	OPEN
0.45% Normal Saline Ivsol	OPEN
Coal Tar Extract 20% Exsol	OPEN
Celecoxib 100Mg Cap	OPEN
Niacin 500Mg Tab	OPEN
Clonidine Posusp	OPEN
Boric Acid Pwd 120Gm	OPEN
Ropinirole 0.25Mg Tab	OPEN
Ropinirole 0.5Mg Tab	OPEN
Ropinirole 1Mg	OPEN
Ropinirole 2Mg	OPEN
Glycerin Exsol	OPEN
Ammonia Aromatic Spirit 30MI	OPEN
Penicillin Vk 250Mg Tab Ud	OPEN
Tetracycline Posusp	OPEN
Menotropins(Repronex)2MI	OPEN
Zolpidem 5Mg Tab	OPEN
Amitriptyline 25Mg Tb Ud	OPEN
0.45% Normal Saline Ivsol	OPEN
lbuprofen 400Mg Tb Ud	OPEN
	OPEN OPEN
Spironolactone 25Mg Tb Ud	
0.9% Normal Saline Irrsol	OPEN
Chlorhexidine 0.12% Posol	OPEN
Amitriptyline 50Mg Tab Ud	OPEN
Diltiazem 30Mg Tb Ud	OPEN
Calan Sr 240Mg Cp Ud	OPEN
Gemfibrozil 600Mg Tb	OPEN
Clonidine Tab	OPEN

DESCRIPTION	CHARGE
Torsemide 100Mg Tab	OPEN
Thiamine 100Mg Tb Ud	OPEN
Trazodone 50Mg Tb Ud	OPEN
Peg-Intrfron Alfa 2B 10Mcg Inj	OPEN
Metoclopramide Tab	OPEN
Atenolol Tab	OPEN
Oxybutynin Chl 5Mg Tb Ud	OPEN
Dilantin 100Mg Cp Ud	OPEN
Trental 400Mg Tb Ud	OPEN
Aspirin 325Mg Tb	OPEN
Soriatane 25Mg Cap	OPEN
Felodipine 10Mg Tab	OPEN
Simvastatin 40Mg Tab	OPEN
Metoprolol Tart 50Mg Tb	OPEN
Furosemide 40Mg Tab	OPEN
Calcitriol Per 0.25Mcg Orl Cap	OPEN
Benztropine Mesyl 1Mg Tb Ud	OPEN
Docusate Sod 100Mg Cp Sucralfate Tab 1Gm	OPEN
	OPEN
Calcitriol Po Sol Eurosemide 20Mg Tab	OPEN OPEN
Furosemide 20Mg Tab Furosemide 80Mg Tab	OPEN OPEN
Folic Acid 1Mg Tb	OPEN
Clinimix/D5W 5/15 1Ml lvsol	OPEN
Timoptic Xe 0.5% 2.5Ml Opgfs	OPEN
Omeprazole 10Mg Cap	OPEN
Acarbose Tab	OPEN
Raloxifene 60Mg	OPEN
Ranitidine Tab	OPEN
Clinimix/D5W 4.25/10 lvsol	OPEN
Levofloxacin 250Mg Tab	OPEN
Naproxen 250Mg Tab	OPEN
Atenolol 50Mg Tab	OPEN
Clinimix/D5W 4.25/5 lvsol	OPEN
Tobramycin (Tobi) Inh Sol	OPEN
Melatonin 1Mg Tab	OPEN
Melatonin 3Mg Tab	OPEN
Saline Nasal Gel 30 Gm	OPEN
Dabigatran Ete 75Mg Caps	OPEN
Dabigatran Ete 150Mg Cap	OPEN
Hyaluronate Sodium Inj	OPEN
Sod Hyaluron/Chondro Inj	OPEN
Voriconazole 1% Op Sol	OPEN
Atripla 600-200-300Mg Tab	OPEN
Raltegravir 400Mg Tab	OPEN
Darunavir Tab	OPEN
Calfactant 3MI Vial	OPEN
Medical Education: level 1 < 14Min	OPEN
Medical Education: level 2 15-29 Min	OPEN
Medical Education: level 3 > 30 Min	OPEN
Sevelamer Tabs	OPEN
Granulex Spray Enlan Blus Ini	OPEN
Enlon-Plus Inj Dextrose 40% Po Gel	OPEN OPEN
	OPEN
Potassium Phosphate Cmpd Inj Sodium Phosphate Cmpd Inj	OPEN
D5W 0.45%Nss + 20Kcl Ivsol	OPEN
Gatifloxacin 0.5% Op Sol	OPEN
Roflumilast Tabs	OPEN
Dextrose 20% lvsol	OPEN
Tramexamic Acid Inj	OPEN
	OPEN
Oxycodone 5 Mg (6) To Go Ed	

DESCRIPTION	CHARGE
Sodium Tetradecyl 1% Inj	OPEN
Sodium Tetradecyl 3% Inj	OPEN
/it D 3 Cholecalciferol Tab	OPEN
Pancrelipase Cap	OPEN
mpact Peptide 1.5 Poliq	OPEN
Hydrocort/Ketocon Cr	OPEN
Jlipristal Tab	OPEN
Amphet-Dextroamphet Xr	OPEN
Ticagrelor Tab	OPEN
Dakins Exsol Full Str	OPEN
Pravastatin Tab	OPEN
Pravastatin Tab	OPEN
Pravastatin Tab	OPEN
Quinapril Tab	OPEN
Dndansetron Per 4 Mg Oral	OPEN
Dndansetron Per 4 Mg Oral	OPEN
Dndansetron Per 4 Mg Oral	OPEN
Dindansetron Per 4 Mg Oral	OPEN
Ondansetron Per 4 Mg Oral	OPEN OPEN
Dndansetron To Go Per 4Mg Pre Cataract Cocktail Op Sol	OPEN
odine Solu Strong Lugol 15Ml	OPEN
Str lodine Sol (Lygol'S) 1Ml	OPEN
Sod Fluoride 1.1 Mg/MI Posol	OPEN
Promethazine 12.5Mg Supp	OPEN
Peptamen Bariatric Polig	OPEN
Sotalol 5Mg/MI Posusp	OPEN
Fluocinolone Ace .025% 15Gm Cr	OPEN
Rivaroxaban Tab	OPEN
luocinolone Ace 0.025% 15Gmoi	OPEN
Cardioplegia Induction Ivsol	OPEN
Cardioplegia Mainten Ivsol	OPEN
Phenobarbital Tab	OPEN
Cardioplegia Reperfus Ivsol	OPEN
Naltrexone 50Mg Tab	OPEN
Clobazam Tab	OPEN
Frypan Blue 0.15% Op Sol	OPEN
Cocaine 4% Op Sol	OPEN
Albuterol Con Per 1Mg Inh Sol	OPEN
Glipizide 5Mg Tab	OPEN
Diphenhydramine Tab	OPEN
Cocaine 10% Op Sol	OPEN
Radial Graft Mixture	OPEN
Eye Multivitamin Tab	OPEN
Coenzyme Q 10Mg Cap	OPEN
olvaptan Tab	OPEN
vacaftor Tab	OPEN
Festosterone Patch	OPEN
Surgiflo Applicator	OPEN
Sentamicin 15Mg/MI Op Sol	OPEN
lifaximin Posusp	OPEN
Caffeine Tab	OPEN
iramadol Er Tab	OPEN
enofibrate Tab	OPEN
Aagnesium Gluconate Po Sol	OPEN
Cinc Gluconate Tab	OPEN
/anilla Tpn Dext 5% lvsol /anilla Tpn Dext 10% lv Sol	OPEN OPEN
/anilla Tpn Dext 10% lv Sol	
Calcium Glubionate Po Syrp	OPEN
Ciprodex Ot Soln	OPEN OPEN
Omni-Stat Nose Bleed Pad	OPEN OPEN
Omni-Stat Granules	OPEN

DESCRIPTION	CHARGE
Aclidinium Bromide Inh	OPEN
Apixaban Tab	OPEN
Hydocodone/Apap Po Liq	OPEN
Nimodipine Po Soln	OPEN
Oral Mucosal Rinse Po Soln	OPEN
Phenol 5% In Peanut Oil Soln	OPEN
Sinus Rinse Adult Hypertonic	OPEN
Sinus Rinse Pediatric	OPEN
Omeprazole Posusp	OPEN
Albendazole Tab	OPEN
Hexaminolevulinate Ir Soln	OPEN
Posaconazole Tab	OPEN
Memantine Er Cap	OPEN
Umeclidinium-Vilanterol Inh	OPEN
Fluticasone -Vilanterol Inh	OPEN
Betamethasone Dip Aug Cr	OPEN
	OPEN
Betamethasone Dip Aug Oint	
Betamethasone Dip Aug Gel Halabatasol Bran Cr	OPEN
Halobetasol Prop Cr Halobetasol Prop Cint	OPEN
Halobetasol Prop Oint	OPEN
Vancomycin 50 Mg/Ml Posoln	OPEN
Ethacrynic Acid Tab	OPEN
Fluticasone-Salm Inh Per Dose	OPEN
Ipratropium Hfa Inh Per Dose	OPEN
Levalbuterolhfa Inh Per Dose	OPEN
Albuterol Hfa Inh Per Dose	OPEN
Ipratr-Albuterol Inh Per Dose	OPEN
Fluticasone Hfa 110 Per Dose	OPEN
Arista Hemostarch Hemostat	OPEN
Arista Hemostat Applicator	OPEN
Rivastigmine Patch	OPEN
Duraseal Spine Sealant	OPEN
Gentamicin Cement	OPEN
Quikclot Combat Gauze	OPEN
Surgicel Snow Hemostat	OPEN
Rufinamide Tab	OPEN
Clobazam 2.5 Mg/Ml Posusp	OPEN
Posaconazole 17.96 Mg/MI Inj	OPEN
Ethanol 24% Posoln	OPEN
Augmentin 120Mg/Ml Posusp	OPEN
Diovan Hct 80/12.5Mg Tab	OPEN
Loperamide 2Mg Cap	OPEN
Clonidine Tab	OPEN
Mineral Oil 50 % Posusp	OPEN
Tiagabine 4Mg Tab	OPEN
Sertraline 25Mg Tab	OPEN
	I
Ivermectin 0.5% Lotion	OPEN
Ascorbic Acid Tab	OPEN
Naloxegol Tab	OPEN
Copper Gluconate 2 Mg Cap	OPEN
Ivabradine Tab	OPEN
Edoxaban Tab	OPEN
Sacubitril-Valsartan Tab	OPEN
Fluticasone Furoate 100Mcg Inh	OPEN
Fluticasone Furoate 200Mcg Inh	OPEN
Fibrin Sealant Patch	OPEN
lloprost Inh	OPEN
Impact Ar Poliq	OPEN
Povidone Iodine Nasal	OPEN
Calcium Acetate Posoln	OPEN
Copper Chloride Inj	OPEN
Ziprasidone Compound Posoln	OPEN
Ambrisentan Tab	OPEN

DESCRIPTION	CHARGE
Theophylline 100 Mg Er Cap	OPEN
Theophylline 200 Mg Er Cap	OPEN
Lidocaine 4% Ex Patch	OPEN
Paliperidone Er Tab	OPEN
Eplerenone Tab	OPEN
Fidaxomicin Tab	OPEN
Fluorescein-Benoxinate Opsoln	OPEN
Phenol 89% Ex Swab	OPEN
Sugammadex Inj	OPEN
Praziquantel Tab	OPEN
Zinc Oxide 12.8 % Oint	OPEN
Zinc Oxide 12.8 % Oint	OPEN
Aluminum Chloride 20% Sol	OPEN
Aluminum Chloride 35% Sol	OPEN
Amphotericin 0.15% Posol	OPEN
Aquaphor/Sugar 2:1	OPEN
Atropine 1Mg/MI Inhltn Solutn	OPEN
Bip Paste	OPEN
Tpn 3&1 Sol 1000MI	OPEN
Tpn 3&1 Sol 3000MI Castellanti Paint-Colorless	OPEN OPEN
Castellanti Paint-Coloriess Cefazolin 5% Op Sol	OPEN
Cholestyramine 50Mg/MI Po Susp	OPEN
Cocaine 10% Op Sol 15Ml	OPEN
Cocaine 4% Op Sol 15MI	OPEN
Modified Dakin'S FI Str 1500MI	OPEN
Dakins Soln 1/2 Strength	OPEN
Dakins Soln 1/4 Strength	OPEN
Decamethasone-Lidocaine-Aquaph	OPEN
Disodium Edetate 0.1% Oph 15Ml	OPEN
Eucerin/Hydrocortisone 1:1 Cr	OPEN
Erythromycin Posusp	OPEN
Estrogen Nasal Sol 30Ml	OPEN
Gentamicin 14Mg/MI Sol 7.1 MI	OPEN
Gentamicin 14Mg/MI Sol 15MI	OPEN
Gi Cocktail Posusp	OPEN
Lactulose Retention Enema	OPEN
10% Lcd In Aquaphor	OPEN
10% Lcd In Aquaphor/Dermovan	OPEN
10% Lcd/Hydrocortisone 1% Cr	OPEN
15% Lcd In Aquaphor	OPEN
Mgw Enema 210MI	OPEN
Nacl 1 Meq/MI Po Sol	OPEN
Neomycin Retention Enema 1%	OPEN
Non-Formulary Medication	OPEN
Pilocarpine 1/16% Op Sol 15Ml	OPEN
Pilocarpine 1/4% Op Sol 15MI	OPEN
Pilocarpine 1/8% Op Sol 15Ml	OPEN
Silvadene/Travase (Doses Vary)	OPEN
Leech	OPEN
Trichloroacetic Acid 80%	OPEN
Tobramycin 14Mg/MI Oph Sol 15M Folic Acid 1Mg/MI Liq	OPEN OPEN
Selenium Tab	OPEN
Procainamide 50Mg/MI Or 240MI	OPEN
Hydrocrt 1%/Cirtri 1% 1:1Cream	OPEN
Metronidazole 50Mg/MI Po Sus	OPEN
Glycopyrrolate Po Sol	OPEN
Jessner'S Sol 100Ml	OPEN
Destrose-Nacl 5-0.45% lvsol	OPEN
Imatinib 100 Mg	OPEN
2&1 Cent/Peripheral Tpn 2000MI	OPEN
2&1 Cent/Peripheral Tpn 3000MI	OPEN

DESCRIPTION	CHARGE
Benadryl/Maalox/Lido Posusp	OPEN
Nonformulary Iv Prep	OPEN
Loxapine 25Mg/MI Po Conc	OPEN
Eucerin/Hydrocort 2.5% 1:1 Cr	OPEN
Midazolam 2.5Mg Perml Po Sol	OPEN
Lidocaine 1% Buff	OPEN
Lurasidone Tab	OPEN
Selexipag Tab	OPEN
Vanilla Tpn 5%Dextrose Ivsoln	OPEN
Vanilla Tpn 10%Dextrose Ivsoln	OPEN
Canagliflozin Tab	OPEN
Empagliflozin Tab	OPEN
Liraglutide Inj	OPEN
Linaclotide 72Mcg Cap	OPEN
Hyoscyamine Poliq	OPEN
Lidocaine 3.5% Op Gel	OPEN
Linagliptin Tab	OPEN
Minocycline 50Mg Cap Moxifloxacin Intravitreal Soln	OPEN OPEN
Acetaminophen 500Mg Tab	OPEN
Bisacodyl 5Mg Tab	OPEN
Bisacodyl Supp	OPEN
Bumetanide 1Mg Tab	OPEN
Carbidopa/Levodopa Cr Tab	OPEN
Diltiazem 60 Mg Tab	OPEN
Metoclopramide Tab	OPEN
Neomycin Tab	OPEN
Verapamil 80Mg Tab	OPEN
Fosfomycin Powder Po	OPEN
Oxycodone Conc Po Sol	OPEN
Clopidogrel Tab	OPEN
Fexofenadine-Pseud Tab	OPEN
Montelukast 5 Mg Chewable	OPEN
Morphine So4 I.R. Tab	OPEN
Montelukast 10 Mg	OPEN
Propranolol 10Mg Tab	OPEN
Nortriptyline 25Mg Cap	OPEN
Glipizide 10Mg Tab	OPEN
Deliver 2.0 Liq 240Ml	OPEN
Percu Stay (Sterile Dressing)	OPEN
Glyburide 2.5Mg Tab	OPEN
Dihydroergot Mesyl Nasol	OPEN
Cosopt Op Sol	OPEN
Brinzolamide 1% Op Susp	OPEN
Carbamazepine 200Mg Er Cap	OPEN
Carbamazepine 300Mg Er Cap	OPEN
Tolterodine 1Mg Tab	OPEN
Repaglinide 0.5Mg Tab	OPEN
Repaglinide 1Mg Tab Repaglinide 2Mg Tab	OPEN
Simvastatin 80Mg Tab	OPEN OPEN
Mupirocin 2% Cream 15Gm	OPEN
Eleview 10 MI Inj	OPEN
Peptamen 1.5 Liq 250MI	OPEN
Ofloxacin 0.3% Otic Sol	OPEN
Metronidazole 1% Cream	OPEN
Indomethacin 25Mg Cap	OPEN
Trazadone 100Mg Tab	OPEN
Tropicamide 1% 3MI Op Sol	OPEN
Phenylephrine 2.5% 2MI Opt Sol	OPEN
Isosorbide Mono Er 30Mg Tab	OPEN
Atropine/Diphenox 2.5Mg Tab	OPEN
Midazolam 2Mg/Ml Po Syrup	OPEN

DESCRIPTION	CHARGE
.orazepam 0.5 Mg Tab	OPEN
orazepam 1Mg Tab	OPEN
evofloxacin 500Mg Tab	OPEN
zithromycin 250Mg Tab	OPEN
isseel Applicator Device	OPEN
antoprazole Po Packet	OPEN
Imeclidinium Inh	OPEN
Aidostaurin Cap	OPEN
imethicone Tab	OPEN
tenolol Tab	OPEN
nsulfon Sq Catheter	OPEN
etrozole 2.5Mg Tab	OPEN
Iortriptyline Po Liq	OPEN
As Contin 15Mg Cr Tab Ud	OPEN
Quinine So4 325Mg Vap 100'S	OPEN
/leperidine 50Mg/5Ml Syrup	OPEN
Aethadone 10Mg Tab 100	OPEN
Dronabinol Cap	OPEN
Aorphine Poliq Per 20Mg	OPEN
Aorphine Poliq Per 20Mg	OPEN
Dronabinol Cap	OPEN
Atropine Sul Opht Oint 1% 3.5G	OPEN
evcovorin Ca 5Mg Tab	OPEN
Aorphine So4 5Mg Suppository	OPEN
Aorphine So4 10Mg Suppository	OPEN
eucovorin 5Mg Tab Ud	OPEN
As Contin 60Mg Sr Tab Ud	OPEN
Aorphine So4 30Mg Sr Tab Ud	OPEN
frythromycin Ats 60MI 2%	OPEN
As Contin 100Mg Cr Tab Ud	OPEN
Vicotine 21Mg Patch	OPEN
Vicotine 14Mg Patch	OPEN
Vicotine 7Mg Patch	OPEN
Cefixime 100Mg Per 5Ml 50Ml Bt	OPEN
Cefixime 100Mg/5Ml 100Ml Bt	OPEN
levirapine 200Mg Tab	OPEN
Velfinavir 250Mg Tab	OPEN
Nelfinavir 50Mg/G Pdr Dsg Vary	OPEN
Ritonavir 80Mg/MI Po Sol	OPEN
Budesonide Inh	OPEN
Cyclosporine Op Sol 0.05%	OPEN
rimethobenzamide 200Mg Supp ientanyl 50Mcg Patch	OPEN
	OPEN
entanyi 100Mcg Patch entanyi 25Mcg/Hr Patch	OPEN OPEN
entanyi 75Mcg Transdermal Sys	OPEN
Clonazepam Tab	
Jonazepam Tab Jonazepam 2Mg Tab	OPEN OPEN
ulfamethoxazole-Tmp Po Susp	OPEN
idrophonium Per 10Mg	OPEN
luorouracil 5 % Cr	OPEN
ulfisoxazole 100Mg/MI Or Susp	OPEN
ulfamethoxazole-Tmp Inj	OPEN
Silycopyrrolate/Formoterol Inh	OPEN
ulfisoxazole 500Mg Tab	OPEN
iotropium Brom 2.5Mcg Act Inh	OPEN
unitriptyline 10Mg Tab Ud	OPEN
witriptyline 75Mg Tab Ud	OPEN
unitriptyline 100Mg Tab Ud	OPEN
vyridostigmine Per 5Mg	OPEN
lyridostigmine Tab	OPEN
istramustine 140Mg Cap	OPEN
Agestrol Acetate Tab	OPEN

DESCRIPTION	CHARGE
Verapamil Sr 120Mg Tab	OPEN
Sulfamethoxazole-Tmp Ds Tab	OPEN
Talc PI Susr	OPEN
Sennosides Po Syrp	OPEN
Povidone-Iodine Oint 30Gm	OPEN
Venlafaxine Xr 150Mg Cap	OPEN
Venlafaxine Xr 37.5Mg Cap	OPEN
Sennosides-Docusate	OPEN
Venlafaxine Xr 75Mg Cap	OPEN
Venlafaxine 100Mg Tab Ud	OPEN
savuconazonium 186 Mg Cap	OPEN
Letermovir Tab	OPEN
Letermovir 20 Mg/Ml Inj	OPEN
Buprenorphine Film Tab	OPEN
Hydrocortisone 2.5% Cr 30Gm	OPEN
Hc 2.5% Creme 1 Lb	OPEN
Defibrotide 80 Mg/MI Inj	OPEN
Drithocreme Hp 1% Cr 50Gm	OPEN
Derma-Smooth Fs Oil 4-Oz .01%	OPEN
Alcophenolate Ec Tab	OPEN
Estradiol 1Mg Tab	OPEN
Granulotion Ex Packets	OPEN
mipramine Tab	OPEN
Crotamitan Nf Eurax Cr 60Gm	OPEN
Methimazole 5Mg Tab	OPEN
/it C (Ascorbic Acid) 500Mg	OPEN
Cyanide Antidote Iv Kit	OPEN
iothyronine Per 10Mcg	OPEN
Modified Dakins 1/8 Str 1500MI	OPEN
Phenobarbital Po Elix	OPEN
Calcium Carbonate Po Susp	OPEN
Festape 1 Box	OPEN
Anakinra 100Mg Inj	OPEN
Zinc Oxide Oint	OPEN
Desflurane 240MI	OPEN
Cocaine Hcl Flakes	OPEN
Acarbose 100Mg Tab	OPEN
rheophylline Cr Tab	OPEN
Spacer For Inhalation	OPEN
Jrea 40% Cream	OPEN
Ketotifen .025% 5MI Ophth	OPEN
Potassium Chloride Po Sol	OPEN
Potassium Iodine Po Sol	OPEN
Sodium Chloride 0.9% 3Ml Nebs	OPEN
Escitalopram 10Mg Tab	OPEN
Escitalpram 20Mg Tab	OPEN
Remifentaryl 1Mg VI(Dsg Varys)	OPEN
evothyroxine Tab	OPEN
Adeks Pediatric Drops	OPEN
Jitrase Mt-12 Cap	OPEN
Diclofenac 0.1% Op Sol 5Ml	OPEN
Pantoprazole 20Mg Tab	OPEN
	OPEN
Jeosynephrine 2.5% Oph Drp 5MI	1
Jeosynephrine 1/4% Nas Sp 15Ml	OPEN
Danazol 100Mg Cap	OPEN
ulfamylon Creme 60Gm	OPEN
hiltiazem Cd 180Mg	OPEN
Divalproex Er Tab	OPEN
Neosynephrine 1/2% Nas Dr 15MI	OPEN
Diltiazem 60Mg Sr Ud	OPEN
Diltiazem 90Mg Tab Sr	OPEN
Diltiazem 120Mg Sr Cap Ud	OPEN
Diltiazem Tab	OPEN

DESCRIPTION	CHARGE
Diltiazem Tab	OPEN
)iltiazem Tab	OPEN
arbamide Peroxide10% Mt Sol	OPEN
viltiazem Cd 300Mg	OPEN
Aesalamine 400Mg Tab	OPEN
Aivacurium Per 2Mg	OPEN
Diltiazem Cd 120Mg Cap	OPEN
Aetaproterenol 20Mg Tabs	OPEN
Dipyridamole Tab	OPEN
Dipyridamole Tab	OPEN
JItracal Liq 960Ml	OPEN
Aminoglutethimide 250Mg Tab	OPEN
luocinonide .05% 15Gm Lidex E	OPEN
luocinonide .05% 30Gm Lidex E	OPEN
Japroxen Tab	OPEN
luocinonide .05% 60Gm Lidex E	OPEN
luocinonide Lidex Gel 15Gm	OPEN
luocinolone Ace 0.01% 20MI	OPEN
inasteride 5Mg Tab	OPEN
laproxen Naprosyn 500 Mg Tab	OPEN
	OPEN OPEN
elbamate Po Susp	
elbamate 400Mg Tab	OPEN
errous Fum-Vit C Tab	OPEN
elbamate 400Mg Ud	OPEN
elbamate 600Mg Tab	OPEN
ntal Neb Sol 20Mg/2Ml Amp	OPEN
/ancomycin 50 Mg/MI Op Sol	OPEN
Docusate Sodium Po Liq	OPEN
ri-Vitamin Po Sol	OPEN
Poly-Vi-Sol Po Sol	OPEN
Cholestyramine 4Gm Pkt	OPEN
Poly-Vi-Sol Chew Tab	OPEN
Cerumenex Otic Drops 12MI	OPEN
Povidone-Iodine Douche 240Mg	OPEN
/erapamil Sr 120Mg Tab	OPEN
iydromorphone 2Mg Tab	OPEN
łydromorphone 4Mg Tab	OPEN
/erapamil Tab	OPEN
/erapamil Hcl 120Mg Tab	OPEN
/erapamil Hcl Per 2.5Mg	OPEN
/erapamil Sr 180Mg	OPEN
/erapamil 180Mg Sr Tab Ud	OPEN
larithromycin 500Mg Tab	OPEN
Risperidone 1Mg/MI Po Sol	OPEN
Beclomethasone Nasal Inh	OPEN
lbuterol 2Mg Tab	OPEN
lbuterol 2Mg/5Ml Syrup	OPEN
lbuterol Sr 4Mg Tab	OPEN
Beclomethasone Na Susp	OPEN
Piperacillin Per 500Mg Inj	OPEN
Imcinonide Cyclocort Oi 15Gm	OPEN
riamcinolone Ace .25% Cr 5Lb	OPEN
iperacillin Per 500Mg Inj	OPEN OPEN
Dxaprozin 600Mg Cap	OPEN
riamcinolone 0.025% 1Lb	OPEN
Acetaminophen Po Sol	OPEN
liboflavin 100Mg Tab	OPEN
olycose Liq 4.2 Oz	OPEN
egaserod 2Mg Tab	OPEN
Nedroxyprogesterone 2.5Mg Tab	OPEN
Vlannitol 20% Iv Soln	OPEN
Dxycodone 5Mg Cap	OPEN
Gabapentin Po Sol	OPEN

DESCRIPTION	CHARGE
Percocet Tab	OPEN
Oxycodone-Apap Po Sol	OPEN
Ezetimibe 10Mg Tab	OPEN
Pyridoxine 100Mg Tab	OPEN
Calamine Lot	OPEN
Valganciclovir Tab	OPEN
Sebulex Shampoo	OPEN
Sebutone Shampoo	OPEN
Valsartan 40Mg Tab	OPEN
Amlodipine 2.5Mg Tab	OPEN
Amlodipine 10Mg Tab	OPEN
Blackwidow Anti Venin Inj	OPEN
Lacri-Sert 5Mg 60/Bx	OPEN
Diflunisal Dolobid 250Mg 60Btl	OPEN
Diflunisal 500Mg Tab Ud	OPEN
Diphenoxylate-Atropine Po Sol	OPEN
Fluvaspatin 20Mg Cap	OPEN
	OPEN
Potassium & Sodium Po4 Pkt	
Neutra Phos K 1.45Gm Conc Cap	OPEN
Amprenavir 150Mg Cap	OPEN
Amprenavir 50Mg Cap	OPEN
Tretinoin Gel 0.25% 15Gm	OPEN
Tretinoin Cr 0.05% 20Gm	OPEN
Levothyroxine 25Mcg Tab	OPEN
Levothyroxine 50Mcg Tab	OPEN
Levothyroxine 75Mcg Tab	OPEN
Levothyroxine 125Mcg Tab	OPEN
Levothyroxine 150Mcg Tab	OPEN
Levothyroxine 100Mcg Tab	OPEN
Sodium Polysulf Po Susp	OPEN
Bupivacaine-Epi Ij Sol	OPEN
Bupivacaine-Epi Ij Sol	OPEN
Loteprednol .5% 5Ml Ophth	OPEN
Bicalutamide 50Mg Tab	OPEN
Citalopram 20Mg Tab	OPEN
Citalopram 40Mg Tab	OPEN
Hyzaar 100/25 Tab	OPEN
Demulen Compact 1/35 139 6X21	OPEN
Demulen Compack Tab 1/50	OPEN
Metronidazole Tab	OPEN
Metronidazole Tab	OPEN
Propantheline Brom Pro-Ban 15M	OPEN
Spironolactone Tab	OPEN
Dimehydrinate 50Mg Tab Ud	OPEN
Disopyramide 150Mg Cap Ud	OPEN
Metronidazole Inj	OPEN
-	
Metolazone Tab	OPEN
Metolazone Tab	OPEN
Galantamine Tab	OPEN
Disopyramide Cap	OPEN
Spironolactone-Hctz Tab	OPEN
Heavy Cream	OPEN
Egg Beaters	OPEN
Galantamine 4Mg Tab	OPEN
Sodium Bicarb Per 1Meq (Oral)	OPEN
Calcium Gluconate Oral/30MI	OPEN
Indigotindisulfonate Na/8Mg	OPEN
Methadone 40Mg Tab	OPEN
Sodium Bicarb For Suctioning	OPEN
Charcoal Activated Po Liqd	OPEN
Insta-Char Liq 50Gm/240Ml	OPEN
Syrpalta 160z	OPEN
Benefiber Po Pack	OPEN

DESCRIPTION	CHARGE
Esmolol 10Mg/MI Ivsol	OPEN
Oxycodone Po Sol	OPEN
Dino Prosprone Cervical Gel	OPEN
Aci-Jel 85Gm Tube	OPEN
Diaphragm Kit Ortho 65Mm	OPEN
Sultrin Vag Cr 78Gm	OPEN
Diaphragm Kit Ortho 75Mm	OPEN
Diaphragm Kit Ortho 85Mm	OPEN
Miconazole 2% Crean 15Gm	OPEN
Miconazole Nitrate 2 % Va Crea	OPEN
Miconazole Nitrate Monistat	OPEN
Methadone 5Mg Tab	OPEN
Sulfasalazine 500Mg En-Tb	OPEN
Debrisan 60Gm	OPEN
Sulfasalazine Tab	OPEN
Sulfasalazine 100Mg/Ml Posu	OPEN
Vontelukast Chew Tab	OPEN
Aspirin Ec Tab	OPEN
Alupent Inhaler 10MI	OPEN
pratropium Hfa Inhaler	OPEN
sotretinoin Po Emulsion	OPEN
Thiothixene 5Mg/MI Poconc	OPEN
Glipizide Tab	OPEN
Glipizide Tab	OPEN
Glipizide XI 5Mg Tab	OPEN
Glipizide XI 10Mg Tab	OPEN
Etioronate Tab	OPEN
Salt	OPEN
Alendronate 5Mg Tab	OPEN
Benzocaine 20 % Ex Aero	OPEN
socal Liq 960MI	OPEN
Isocal Liq 240Ml	OPEN
Boost Plus 240MI	OPEN
Ultracal Lig 240Ml	OPEN
Magnacal Renal	OPEN
Glucose Polymer Po Powd	OPEN
Promod 291Gm	OPEN
Boost High Protein Po Liq	OPEN
Perative 240MI	OPEN
Surgicel 1X2 Fibrillar	OPEN
Rosiglitazone 2Mg Tab	OPEN
Rosiglitazone 4Mg Tab	OPEN
Rosiglitazone 8Mg Tab	OPEN
Risperidone 1Mg Tab	OPEN
	OPEN
Stavudine 40Mg Cap Valacyclovir 1Gm Caplet	OPEN
ketorolac 0.5% 5Ml	OPEN
Loratadine Po Syrp	OPEN
Petrolatum Gel	OPEN
Bacitracin Op Oint	OPEN
Bacitracin Zinc Oint	OPEN
Alendronate 70Mg Tab	OPEN
Alendronate 35Mg Tab	OPEN
Colesevelam 625Mg Tab	OPEN
Celecoxib 200Mg Cap	OPEN
/iokase 325Mg Tab	OPEN
Amylase-Lipase-Protease Cap	OPEN
Amylase-Lipase-Protease Cap	OPEN
Amylase-Lipase-Protease Cap	OPEN
Pancrelipase 250Mg Cap 250'S	OPEN
Amylase-Lipase-Protease Cap	OPEN
Nabumetone 500Mg Tab	OPEN
Etodolac XI 500Mg Tab	OPEN

DESCRIPTION	CHARGE
Lindane 1 % Lotion	OPEN
Lindane 1% Shampoo	OPEN
Camphor-Menthol Lotion	OPEN
Propylene Glycol (Topical)	OPEN
Selenium Sulfide 2.5 % Lotion	OPEN
Chloroform Liq	OPEN
Glycerin Usp Liq	OPEN
Acyclovir 200Mg Cap	OPEN
Atorvastatin 20Mg Tab	OPEN
Baclofen 20Mg Tab	OPEN
Buspirone 15Mg Tab	OPEN
Clonazepam 1Mg Tab	OPEN
Desmopressin Acetate Tab	OPEN
Doxazosin 1Mg Tab	OPEN
Glimepiride 4Mg Tab	OPEN
Lansoprazole 30Mg Cap	OPEN
Lisinopril 2.5Mg Tab	OPEN
Pediazole Po Susp 100Ml	OPEN
Pediazole Po Susp 150MI Loratidine 10Mg Tab	OPEN OPEN
Claritin D 12 Hour Tab	OPEN OPEN
Eucerin Cr	OPEN
Eucerin Cr	OPEN
Triamteren/Hctztab	OPEN
Alcohol Isoproryl 70% 473MI	OPEN
Pilocarpine Hcl 4 % Op Gel	OPEN
Pred Mild 0.12% Op Sol 10MI	OPEN
Prednisolone Ace 1% Opsusp	OPEN
Carboxymethylcellu 1% Op Sol	OPEN
Tears 0.5% Opoint	OPEN
Fml Opht Susp 5Ml	OPEN
Sulfacetamide Sod 10% Op Sol	OPEN
Polyvin Alco-Povidone Op Sol	OPEN
Flurbiprofen 0.03% Oph Sol 2.5	OPEN
Dipivefrin 0.1 % Op Sol	OPEN
Betagan 0.5% Op Sol 5Ml	OPEN
Multivitamin Inj	OPEN
Trace Minerals Inj	OPEN
Iv Fat (Intralipid) 10%	OPEN
Iv Fat (Intralipid) 20%	OPEN
Clarithromycin 250Mg Tab	OPEN
Tuberculin Ppd Id Sol	OPEN
Conjugated Estogens 0.45Mg Tab	OPEN
Prempro 0.45/1.5 Tab	OPEN
Clinitest Tabs 100	OPEN
Occult Blood Vi Strp	OPEN
Wristix Strips 100'S	OPEN
Chemstrip 7L 100'S	OPEN
Albumin (Urine) Test Vi Strp	OPEN
Acetone (Urine) Test Vi Tabs	OPEN
Dextrostix Strips 100'S	OPEN
Glucose Po Liqd Thiopental 1Gm Inj	OPEN OPEN
Benzoyl Peroxide 5% Lotn	OPEN
Benzoyl Peroxide 5% Loth Benzoyl Peroxide 10% Loth	OPEN
Zinc Oxide 40 % Oint	OPEN
Ribavirin 6Mg Vial	OPEN
Fleet Enema Ped	OPEN
Fleet Enema Adult	OPEN
Phospho Soda Flavored Posol	OPEN
n nospho soud nuvorcu r osol	OPEN
Mineral Oil Enema	
Mineral Oil Enema Bisacodyl Enema	OPEN

DESCRIPTION	CHARGE
Blistex Lip Oint	OPEN
Erythromycin Estol 50Mg Susp	OPEN
Pedialyte Po Sol	OPEN
Dextrose 10% Ivsol	OPEN
Dextrose 10% Ivsol	OPEN
Dextrose 10% Ivsol	OPEN
Dextrose-Nacl 5-0.45% Ivsol	OPEN
Miglitol 25Mg Tab	OPEN
Miglitol 50Mg Tab	OPEN
Miglitol 100Mg Tab	OPEN
Efavirenz 200Mg Cap	OPEN
Abacavir 300Mg Tab	OPEN
Paroxetine Po Susp 10Mg/5Ml	OPEN
Celecoxib 100Mg Cap	OPEN
Bethanechol 10Mg Tab	OPEN
Oxazepam 10Mg Cap	OPEN
Ganciclovir 500Mg Cap	OPEN
Olanzepine 5Mg Tab Ud	OPEN
Losartan 25Mg Tab	OPEN
Swim Supporter-Large	OPEN
Swim Supporter-Med	OPEN
Swim Supporter-Small	OPEN
Suspensory-X-Large	OPEN
Suspensory-Large	OPEN
Suspensory-Small	OPEN
Desmopressin Ace 0.01%Na Sol	OPEN
Desmopressin Ace 0.01/Wa Sol	OPEN
Salicylic Acid 2 % Ex Sham	OPEN
Dextrose-Nacl 5-0.45% Ivsol	OPEN
	OPEN
Dextrose-Nacl 5-0.20% Ivsol	OPEN
D5 1/4Nss 250Ml D5 1/4Nss 500Ml	OPEN OPEN
	1
Coccoa Butter Lotion	OPEN
Lactic Acid 86% Sol	OPEN
Normosol 1000MI	OPEN
Cocoa Butter Stick 1.5 Oz	OPEN
Eucerin Lotn	OPEN
Chloral Hydrate 325Mg Suppos	OPEN
Tiagabine 12Mg Tab	OPEN
Nefazodone 50Mg Tab	OPEN
Silver Nitrate Appl	OPEN
Citrate Of Magnesia Po Sol	OPEN
Clobetasol 0.05% Sol	OPEN
Testosterone Tts 5Mg Patch	OPEN
Fentanyl 200Mcg Lollipop	OPEN
Plasma-Lyte 148 Ivsol	OPEN
Miralax Pwd 527Gm	OPEN
Chloral Hydrate 500Mg Suppos	OPEN
Spironolactone/Hctz Po Susp	OPEN
Ora-Plus Po Liq	OPEN
Neosweet Po Sol	OPEN
Silver Protein Mild Powd	OPEN
Aluminum Chloride Crys	OPEN
Alum Ammonium Pwd	OPEN
Anthralin Powder 25 Gm	OPEN
Bismuth Subnitrate Powd	OPEN
Brilliant Green Powder 25Gm	OPEN
Calcium Chloride Powder 500Gm	OPEN
Cherry Po Syrp	OPEN
Citric Acid Powder	OPEN
Hydrocortisone Powder 25Gm	OPEN
iodoform Powd	OPEN
Lactose Powd	OPEN

DESCRIPTION	CHARGE
Sodium Citrate Crys	OPEN
Progesterone Micronized Powd	OPEN
Renacidin Powder 300Gm	OPEN
tesorcinol Crys	OPEN
richloroacetic Acid Cry 125Gm	OPEN
mino Acid 10% Ivsol	OPEN
Dextrose 70 % Ivsol	OPEN
Bacteriostatic .9% 30Ml Inj Vl	OPEN
Clorox Sol	OPEN
aif Set 1 Micron	OPEN
urow'S Sol 1 Pint	OPEN
Addified Burows Sol 1:40 1500	OPEN
at Emulsion 10% Iv Emul	OPEN
at Emulsion 20% lv Emul	OPEN
ithium Carb 450Mg Cr Tab	OPEN
leomycin So4 Powder	OPEN
henol Liq	OPEN
alicylic Acid Powder 500Gm	OPEN
alicylic Acid Powder Sougm lugar Powdered 1Lb	OPEN OPEN
volysorbate 80 Po Liq	OPEN
Jrea Powd	OPEN
Acetic Acid Glacial 2.5 Liters	OPEN
Day Pass Charge	OPEN
mergency Box Replacement Chg	OPEN
Nopurinol Po Susp	OPEN
mphotericin 5Mg/MI Po Sol	OPEN
ethanechol Po Susp	OPEN
affeine Citrate 20Mg/MI Oral	OPEN
erbutaline 1Mg Per Ml Po Su	OPEN
hloroquine 10MI/MI Ped Sol	OPEN
Dantrolene 5Mg/MI Po Susp	OPEN
lucytosine Po Sol	OPEN
łydralazine 1Mg/Ml Sol	OPEN
soniazid Po Syrp	OPEN
etoconazole Po Susp	OPEN
Prazosin 50Mcg/MI Po Sol	OPEN
anitidine 15Mg/Ml Po Liq	OPEN
lifampin Po Susp	OPEN
pironolactone Po Susp	OPEN
'erapamil 2Mg/MI Po Susp	OPEN
inc So4 Po Sol	OPEN
cetylcysteine 10% Op Sol 12MI	OPEN
Disopyramide 100Mg/10MI Or Sus	OPEN
Jeomycin 1Gm/5MI Sol	OPEN
Quinidine 10Mg/MI Po Susp	OPEN
iterile Water For Ir Sol	OPEN
terile Water For Inj Ivsol	OPEN
odium Chloride 0.9 % Ir Sol	OPEN
	OPEN OPEN
odium Chloride 0.9 % Ir Sol	OPEN OPEN
iismuth Subgallate Pwd	
cholestyramine 20% In Aquaphor	OPEN
15W 250Ml & Nitroglycerin 50Mg	OPEN
apain Powder	OPEN
terile Water For Inj Ivsol	OPEN
razodone 10Mg/MI Susp 100MI	OPEN
olyethylene Gly Po Powd	OPEN
'ogurt Doses Vary	OPEN
ofecoxib 25Mg Tab	OPEN
tisperidone 0.5Mg Tab	OPEN
isoprolol-Hctz Tab	OPEN
tavudine 1Mg/Ml Po Sol	OPEN
leviprapine 50Mg/5Ml Po Sol	OPEN
ancrelipase Po Cap	OPEN

DESCRIPTION	CHARGE
Negestrol 20Mg Tab	OPEN
opiramate 15Mg Cap (Sprinkle)	OPEN
spirin-Dipyridamole Cap	OPEN
exofenadine 180Mg Tab	OPEN
lyzaar 50/12.5 Tab	OPEN
odium Bicarbonate 650Mg	OPEN
Dxychlorosene Sodium Powd	OPEN
Budesonide Aq Inhaler	OPEN
Ciprofloxacin 10% Po Susp	OPEN
isperidone .25Mg Tab	OPEN
Quetiapine 100Mg Tab	OPEN
Cyclobenzaprine 10Mg Tab	OPEN
Amoxicillin 500Mg Cap	OPEN
Aisoprostol 100Mcg Tab	OPEN
Digoxin Tab	OPEN
errous So4 325Mg Tab	OPEN
ithium Carbonate 300Mg Tabs	OPEN
/alsartan 160Mg Tab	OPEN
Calcium Carbonate 1250Mg Tab	OPEN
Addafanil 100Mg Tab	OPEN
evetiracetam 250Mg Tab	OPEN
Rehydralyte 240Ml	OPEN
Fobranycin Op Sol	OPEN
	OPEN
Haloperidol 2Mg Tab	
Nitroglycerin 0.8Mg/Hr Patch	OPEN
Nifampin 300Mg Cap	OPEN
Carbamazepine 200Mg Tab	OPEN
Clindamycin 150Mg Cap	OPEN
Sennosides Tab	OPEN
Dmeprazole 20Mg Cap	OPEN
Glimepiride 2Mg Tab	OPEN
Ppn 3 ln 1 1000Ml lvsol	OPEN
2pn 3 ln 1 3000Ml	OPEN
2pn 3 ln 1 2000Ml	OPEN
hrombin 10000U Spray Kit	OPEN
Pseudoephedrine 30Mg Tab	OPEN
Diltiazem Cd 240Mg Cap	OPEN
Pantoprazole 40Mg Tab	OPEN
łydroxyurea Po 500Mg	OPEN
Morphine Sr 20Mg Cap	OPEN
Aorphine Sr 50Mg Cap	OPEN
Norphine Sr 100Mg Cap	OPEN
Norphine 0.15% Topical Gel	OPEN
Dxycodone 15Mg Tab	OPEN
Dxycodone 30Mg Tab	OPEN
ntrasite Gel 15Gm	OPEN
Clobetasol 0.05% Oint	OPEN
Hydrocortisone 1% Lotion	OPEN
Clobetasol 0.05 % Ex Gel	OPEN
Bromocriptine 5Mg Cap	OPEN
opinavir-Ritonavir Cap	OPEN
Divalproex Er Tab	OPEN
lerpecin L Lip Balm	OPEN
odium Citrate 4% Sol Inj	OPEN
Quetiapine 25Mg Tab	OPEN
Doxazosin 4Mg Tab	OPEN OPEN
Dianzapine Diss Tab	OPEN OPEN
Virtazapine Soltab	OPEN
actobacillus Cap	OPEN
lisedronate 5Mg Tab	OPEN
Dxcarbazepine Tab	OPEN
Potassium Bicarb Eff Tab	OPEN
Histamine Phosphate Base	OPEN

DESCRIPTION	CHARGE
Didanosine (Ddi) 50Mg Tab	OPEN
Sevelamer 800Mg Tab	OPEN
Calfactant In Susp	OPEN
Ticlopidine 250Mg Tab Ud	OPEN
Bimatoprost 0.03% Op Sol	OPEN
Fiorcet Tab	OPEN
Glutamine Po Susp 500Mg/MI	OPEN
Ibuprofen Infant Drops	OPEN
Vitamin A 8000lu Cap	OPEN
Modafanil 200Mg Tab	OPEN
Epinephrine Racemic 30MI Inh	OPEN
Drotrecogin 5Mg VI Inj	OPEN
Drotrecogin 20Mg Inj	OPEN
Naproxen Po Susp	OPEN
Fluoxetine 10Mg Cap	OPEN
Nitroglycerin Spray	OPEN
Labetalol 100Mg Ud Tab	OPEN
Olanzapine 10Mg Odt Tab	OPEN
Hydrogen Peroxide Top Sol	OPEN
Oxazepam 30Mg Cap	OPEN
Doxepin 75Mg Cap Ud	OPEN
Ibuprofen 800Mg Tab	OPEN
Leucovorin 25 Mg Tab	OPEN
Magnesium Chloride Tab	OPEN
Prednisolone Acet 1 % Opsusp	OPEN
Ibuprofen 600Mg Tab	OPEN
Fleet Prep Kit	OPEN
Gelatin Pwd 1Gm	OPEN
Gelatin Adsorbable	OPEN
Gelatin Adsorbable	OPEN
Dextrose Chew Tab	OPEN
Hydrocodone/Apap Tab	OPEN
Methylphenidate Hcl Er Tab	OPEN
Methylphenidate Hcl Er Tab	OPEN
Divalproex 125Mg Tab	OPEN
Sensorcaine W/Epi 50Ml Inj	OPEN
Carbachol 0.01 % Io Inj	OPEN
Ciprofloxacin Opth 0.3% 2.5Ml	OPEN
Thermazine 1% 20Gm Cream	OPEN
Lactase Tab	OPEN
Buprenorphine-Nalox SI Tab	OPEN
Acetic Acid/Hc Otic Sol	OPEN
Alcohol Isopropyl	OPEN
Suboxone 8-2Mg Tab	OPEN
Nss Irrigation Sol	OPEN
Hydrophilic Oint 454 Gm	OPEN
Alum/Mag Hydrox/ Simeth Susp	OPEN
Phenylephrine Hcl 2.5 % Op Sol	OPEN
	L
Ferro Sequels Po Tab	OPEN
Tle 3MI Sol	OPEN
Rofecoxib 5Mg/MI Po Susp	OPEN
Hetastarch-Nacl Ivsol	OPEN
Dofetilide 125Mcg Cap	OPEN
Antipyrene/Benzo Otic Sol	OPEN
Hydrochlorthiazide Cap 12.5Mg	OPEN
Nortriptyline 10Mg Cap	OPEN
Labetolol Per 10Mg/Ml	OPEN
Risedronate 35Mg Tab	OPEN
Permethrin 5% Cream	OPEN
Terazosin 5Mg Tab	OPEN
Vecuronium 20Mg Inj VI	OPEN
Pirbuterol Aero Pwd 80 Dose	OPEN
Ferrous Fum-Vit C Tab	OPEN

DESCRIPTION	CHARGE
Voriconazole 200Mg Tab	OPEN
Pilocarpine 0.5% Op Solutn	OPEN
Resource Optisource Po Liq	OPEN
Nutra Recipes (Van)	OPEN
Etodolac 200Mg Cap	OPEN
Tacrolimus 0.03% Oint	OPEN
Tacrolimus 0.1% Oint	OPEN
Misoprospol Tab	OPEN
Fosinopril 20Mg Tab	OPEN
Acyclovir 800 Mg Tab	OPEN
Blue Dye 4MI	OPEN
Mesalamine 500Mg Suppository	OPEN
Acyclovir Po Susp	OPEN
Amlodipine 5Mg Tab	OPEN
Pulmacare Str	OPEN
Pfd 2 Po Powd	OPEN
Azithromycin 500Mg Tab	OPEN
Os 2 Po Powd	OPEN
Peptamen Po Liq	OPEN
Nutrihep Po Liq	OPEN
Peptamen Junior Po Liq	OPEN
Vivonex Plus Po Pack	OPEN
Vivonex Pediatric Po Pack	OPEN
Nutren 1.5 Van	OPEN
Fat Emulsion 50% Po Emul	OPEN
Suplena 240Ml	OPEN
Fluoxetine 20Mg Cap	OPEN
Acebutolol 200Mg Cap	OPEN
Amino Acids Iv 7% 500Ml Inj	OPEN
Lotrel 5/20 Tab	OPEN
B&O Supp 30Mg	OPEN
Clotrimazole-Betameth Cr	OPEN
Cherry Syrup Per Ml	OPEN
Polycitra Po Sol	OPEN
Clavulante/Ticarciln 3.1Mg Inj	OPEN
Tobramycin-Dexa Op Oint	OPEN
Plasmalyte 56/D5W	OPEN
Ferrous Gluconate 300Mg Tab	OPEN
Ferrous So4 Er 1 Tab	OPEN
Flx Col/Lac Acd/Sal Ac Liq15Ml	OPEN
Insulin Syringe Needle Various	OPEN
Lansinoh Oint	OPEN
Minibottles Prep	OPEN
Verapamil Po Susp	OPEN
Oxycontin 10Mg Tab Ud	OPEN
Oxycontin 20Mg Tab Ud	OPEN
Oxycontin 40Mg Tab Ud	OPEN
Oxycontin 80Mg Tab Ud	OPEN
Naproxen Na 275Mg Tab	OPEN
Paroxetine 30Mg Tab	OPEN
Pramipexole Tab 0.5Mg	OPEN
Pyridostigimine Inj	OPEN
Quinapril 20Mg Tab	OPEN
Theophylline Er Tab	OPEN
Tobramycin 0.3 % Op Oint	OPEN
Torsemide 10Mg Tab	OPEN
Torsemide 20Mg Tab	OPEN
Trazodone 150Mg Tab	OPEN
Triamcinolone Acet 0.1 % Cr	OPEN
Trimethobenzmde 100Mg Ped Supp	OPEN
Vitamin D 400lu Tab	OPEN
Zolpidem 10Mg Tab	OPEN
Brompheniramine-Pseud Po Liq	OPEN

DESCRIPTION	CHARGE
Fluvoxamine 50Mg Tab	OPEN
Buspirone Tab	OPEN
Neonatal Tpn Sol	OPEN
Tpn/Ppss Sol 1100MI	OPEN
3 & 1 Tpn Sol 2000Ml	OPEN
Doxycycline 100Mg Cap Ud	OPEN
Ptu 5Mg Per MI Suspension	OPEN
Amiodarone 12.5Mg 500Mg Tritur	OPEN
Desipramine 10Mg Udp Tab	OPEN
Quinidine Gluconate Cr Tab	OPEN
Ursodiol Po Susp	OPEN
Phenytoin Po Susp	OPEN
Pindolol 5Mg Tab Udp	OPEN
Enalapril Tab	OPEN
Lomotil Liq 5Mg Ud	OPEN
Furosemide 10Mg (1/2X20Mg) Tab	OPEN
Primidone 50Mg Tab Ud	OPEN
Tolmetin 200Mg Tab Ud	OPEN
Pyridostigmine Tab	OPEN
Sucralfate Tab	OPEN
Propylthiouracil 50Mg Tab Ud	OPEN
Levothyroxine Tab	OPEN
Reserpine 0.25Mg Tab	OPEN
Cyproheptadine 4Mg Tab Ud	OPEN
Clotrimazole 10Mg Troches Ud	OPEN
Isosorbide 2.5Mg (1/2X5Mg) Tab	OPEN
Maprotiline Tab	OPEN
Phenelzine 15Mg Tab Udp	OPEN
Maprotiline 50Mg Tab Ud	OPEN
Medroxyprogesterone 10Mg Tab U	OPEN
Trilisate 500Mg Tab Ud	OPEN OPEN
Cyclosporine 1% Op Sol	OPEN
Cimetidine 300Mg/5Ml Liq 5Ml U Phenobarbital Elix 30Mg 7.5Ml	OPEN
Sodium Citrate Po Sol 0.3M	OPEN
Colchicine Tab	OPEN
Clonaxepam Tab	OPEN
Chlorothiazide 250Mg Tab Ud	OPEN
Hydralazine Tab	OPEN
Hydrochlorothiazide Tab	OPEN
Isosorbide Dinitrate Cr Tab	OPEN
Mesoridazine 50Mg Tab Ud	OPEN
Minoxidil 10Mg Tab Ud	OPEN
Aporvastatin 10Mg Tab	OPEN
Adapalene 0.1 % Top Gel	OPEN
Donepezil 10Mg Tab	OPEN
Vit D2 Ergocalciferol Cap	OPEN
Oxybutynin Tab	OPEN
Penicillamine 250Mg Tab Ud	OPEN
Procarbazine 50Mg Cap Ud	OPEN
Propantheline Bro Pro-Banthine	OPEN
Clonazepam 100Mcg Per MI Oral	OPEN
Pyridostigmine Cr Tab	OPEN
Sodium Bicarb 325 Mg Tab	OPEN
Thiamine Tab	OPEN
Thioguanine 40Mg Tab Ud	OPEN
Verapamil Tab	OPEN
Maalox/Lidocaine Po Susp	OPEN
Sulindac 200Mg Tab Ud	OPEN
Brilliant Green 5% Liq 30Ml	OPEN
Septra Po Susp 20Ml Ud	OPEN
Cortisone Acetate 5Mg Tab Ud	OPEN
Reserpine 0.1Mg Tab Ud	OPEN

DESCRIPTION	CHARGE
Sulindac 150Mg Tab Ud	OPEN
Digoxin 125Mcg/2.5Ml Elixir Ud	OPEN
Digoxin 250Mcg/5Ml Elixir Ud	OPEN
lidovudine 100Mg Cap Ud	OPEN
Aesoridazine 10Mg Tab Udp	OPEN
orazepam 0.25Mg Udp	OPEN
Phytonadione 5Mg Tab Udp	OPEN
Danazol 200 Mg Cap Udp	OPEN
Rifampin 150Mg Cap Udp	OPEN
Viacin 50Mg Tab	OPEN
Didanosine (Ddi) 100Mg Tab	OPEN
evothyroxinetab	OPEN
Vesoridazine 25Mg Tab	OPEN
ildenafil Po Susp	OPEN
osartan 50Mg	OPEN
imoptic Xe 0.5% Gel 5MI	OPEN
/enlafaxine 75Mg Tab	OPEN
Aesalamine 250Mg Cap	OPEN
amotrigine 100Mg Tab	OPEN
vilocarpine 5Mg Tab	OPEN
riamterene Hctz 37.5/25 Tab	OPEN
	1
Fluticasone Propionate Na Susp	OPEN
Sinemet Cr 25/100 Tab	OPEN
Gabapentin 400Mg	OPEN
nalapril 1Mg/MI Po Liq	OPEN
Aetoprolol XI 50Mg Tab	OPEN
Dxygen Charge (8 Hours)	OPEN
Gabapentin 100Mg Cap	OPEN
Cisapride Susp Dos Var	OPEN
itavudine 30Mg Cap	OPEN
nj Cefotetan Disodium 500 Mg	OPEN
Cefotetan Inj	OPEN
Cefotetan Inj	OPEN
Acyclovir 400Mg Tab	OPEN
Azithromycin Po Susp	OPEN
Azithromycin Po Susp	OPEN
Pyridoxine 10Mg Perml Po Sus	OPEN
Framadol 50Mg Tab	OPEN
imoptic Xe 0.25% Gel 5Ml	OPEN
Salmeterol Po Inh	OPEN
amivudine 150Mg Tab	OPEN
Beclomethasone Po Inh	OPEN
Flutter Mucus Clearance Device	OPEN
Festosterone 2.5Mg Patch	OPEN
/enlafaxine 37.5Mg Tab	OPEN
/enlafaxine Tab	OPEN
.odoxamide 0.1 % Op Sol	OPEN
Pyrazinamide Po Susp	OPEN
Jitrase Mt 20	OPEN
erbinafine 1% Topical Cream	OPEN
Aetronidazole 0.75 % Cr	OPEN
ifabutin 150Mg Cap	OPEN
aquinavir 200Mg Cap	OPEN
lyoscyamine 0.125Mg Tab	OPEN
Cromolyn Sodium 4% Op Sol	OPEN
Cetirizine Tab	OPEN
JItrase Mt 18	OPEN
Baclofen Po Susp	OPEN
Friamcinolone Acet Na Inh	OPEN
exofenadine 60Mg Cap	OPEN
Slynase 1.5Mg Micronized Tab	OPEN
Glyburide 3Mg Tab	OPEN
Slynase 6Mg Micronized Tab	OPEN

DESCRIPTION		CHARGE
Terbinafine 250Mg Tab		OPEN
Latanoprost 0.005% Op Sol		OPEN
Hyoscyamine 0.375Mg Er Cap		OPEN
Fluconazole 40Mg/MI(Dsge Vrys)		OPEN
Amoxicillin-Pot Clavul Tab		OPEN
Risperidone 2Mg Tab		OPEN
Loratadine-Pseudoephedrine Tab		OPEN
Mirtazapine Tab		OPEN
Mirtazapine 15Mg		OPEN
Ritonavir 100Mg Cap		OPEN
Bupropion 150Mg Sr Tab		OPEN
Olanzapine 7.5Mg Tab		OPEN
Acetamino Then 80Mg Cheu Tab		OPEN
Fluticasone Poinh 44Mcg		OPEN
Fluticasone Prop Inh		OPEN
Fluticasone Poinh 220Mcg		OPEN
Adderall 20Mg Tab		OPEN
Adderall 10Mg Tab		OPEN
Mupirocin Calcium 2 % Na Oint		OPEN
Donepezil 5Mg Tab Tizanidine 4Mg Tab		OPEN OPEN
	ć	66.00
Inpatient Medical Nutrition Consult: 008-022 Min Inpatient Medical Nutrition Consult: 053-067 Min	\$	264.00
Inpatient Medical Nutrition Consult: 038-052 Min	\$	198.00
Inpatient Medical Nutrition Consult: 038-032 Min	\$	132.00
Inpatient diabetic education: 008-022 Min	\$	88.00
Inpatient diabetic education: 023-037 Min	\$	175.00
Inpatient diabetic education: 038-052 Min	\$	264.00
Inpatient diabetic education: 053-067 Min	\$	352.00
Inpatient diabetic education: 068-082 Min	\$	440.00
Inpatient Medical Nutrition Consult: 068-082 Min	\$	330.00
Inpatient Medical Nutrition Consult: 083-097 Min	\$	396.00
Inpatient Medical Nutrition Consult: 098-112 Min	\$	462.00
Inpatient Medical Nutrition Consult: 113-127 Min	\$	528.00
Inpatient diabetic education: 083-097 Min	\$	528.00
Inpatient diabetic education: 098-112 Min	\$	616.00
Inpatient diabetic education: 113-127 Min	\$	704.00
Preprd Childbirth	\$	63.00
Refrsh Childbirth	\$	21.00
Breastfeeducation Class	\$	10.00
Parent Basic Skill	\$	32.00
Sibling Class	\$	10.00
Misc Blood Bank		OPEN
Dau Medical Review Officer	\$	54.00
Paternity Testing/Phleb/Photo	\$	30.00
Paternity Testing/Phleb/Photo	\$	30.00
Misc Referred Test		OPEN
Room & Care/Bed -Emergency Dept Psych Semiprivate	\$	1,321.00
Room & Care/Bed -Emergency Dept Intensive Care	\$	2,407.00
Room & Care/Bed -Emergency Dept Private Med Justfd Room & Care/Bed -Emergency Dept Semiprivate	\$	1,056.00
Room & Care/Bed -Emergency Dept Semiprivate Room & Care/Bed -Emergency Dept Isolation	\$	1,115.00 1,297.00
Room & Care/Bed -Emergency Dept Telemetry	\$	1,741.00
Cs Long Arm Splint Adult Fbrgl	\$	270.00
Zero Bill		OPEN
Operating room time: 000-030 Min	\$	1,453.00
Vaginal Delivery Service	\$	3,983.00
Room & Care/Bed -OB/D6A Semiprivate	\$	2,227.00
Room & Care/Bed -OB/D6A Semiphvate	\$	2,227.00
Room & Care/Bed -OB/D6A Isolation	\$	1,056.00
Surgical overnight recovery per hour	\$	47.00
Operating room time: 031-045 Min	\$	7,009.00
Operating room time: 046-060 Min	\$	7,520.00

DESCRIPTION	CHARGE
Operating room time: 061-075 Min	\$ 8,030.00
Operating room time: 076-090 Min	\$ 8,540.00
Operating room time: 091-105 Min	\$ 9,051.00
Operating room time: 106-120 Min	\$ 9,562.00
Operating room time: 121-135 Min	\$ 10,356.00
Operating room time: 136-150 Min	\$ 10,866.00
Operating room time: 151-165 Min	\$ 11,376.00
Operating room time: 166-180 Min	\$ 11,886.00
Operating room time: 181-195 Min	\$ 12,398.00
Operating room time: 196-210 Min	\$ 12,909.00
Operating room time: 211-225 Min	\$ 13,419.00
Operating room time: 226-240 Min	\$ 13,930.00
Recovery room time: 000-030 Min	\$ 734.00
Recovery room time: 031-045 Min	\$ 1,050.00
Recovery room time: 046-060 Min	\$ 1,050.00
Recovery room time: 061-075 Min	\$ 1,367.00
Recovery room time: 076-090 Min	\$ 1,367.00
Recovery room time: 091-105 Min	\$ 1,683.00
Recovery room time: 106-120 Min	\$ 1,683.00
Recovery room time: 121-135 Min	\$ 1,999.00
Recovery room time: 136-150 Min	\$ 1,999.00
Recovery room time: 151-165 Min	\$ 2,315.00
Recovery room time: 166-180 Min	\$ 2,315.00
Venous Access Device	\$ 27.00
Vaginal Dilator Sm Med Large	\$ 83.00
Device Biopsy Localization	\$ 788.00